DISEASE MARKERS IN EXHALED BREATH
NATO Science Series A series presenting the results of scientific meetings supported under the NATO Science Programme.
The series is published by 10s Press and Kluwer Academic Publishers in conjunction with the NATO Scientific Affairs Division. Sub-series
I.
Life and Behavioural Sciences Mathematics, Physics and Chemistry 111. Computer and Systems Sciences IV. Earth and Environmental Sciences V. Science and Technology Policy
II.
10s Press Kluwer Academic Publishers 10s Press Kluwer Academic Publishers 10s Press
The NATO Science Series continues the series of books published formerly as the NATO AS1 Series. The NATO Science Programme offers support for collaboration in civil science between scientists of countries of the Euro-Atlantic Partnership Council. The types of scientific meeting generally supported are “Advanced Study Institutes” and “Advanced Research Workshops”, although other types of meeting are supported from time to time. The NATO Science Series collects together the results of these meetings. The meetings are co-organized by scientists from NATO countries and scientists from NATO’s Partner countries - countries of the CIS and Central and Eastern Europe.
Advanced Study Institutes are high-level tutorial courses offering in-depth study of latest advances in a field. Advanced Research Workshops are expert meetings aimed at critical assessment of a field, and identification of directions for future action. As a consequence of the restructuring of the NATO Science Programme in 1999, the NATO Science Series has been re-organized and there are currently five sub-series as noted above. Please consult the following web sites for information on previous volumes published in the series, as well as detail; of earlier sub-series: http://www.nato.int/science http://www.wkap.nl http://www.iospress.nl http://www.wtv-books.de/nato-pco.htm
-*-
Series I: Life and Behavioural Sciences - Vol. 346
ISSN: 1566-7693
Disease Markers in Exhaled Breath Basic Mechanisms and Clinical Applications
Edited by
Nandor Marczin National Heart and Lung Institute, Imperial College, London, United Kingdom
and
Magdi H. Yacoub National Heart and Lung Institute, Imperial College, London, United Kingdom
/OS
Press Ohmsha
Amsterdam • Berlin • Oxford • Tokyo • Washington, DC Published in cooperation with NATO Scientific Affairs Division
Proceedings of the NATO Advanced Study Institute on Disease Markers in Exhaled Breath 22 June- 1 July 2001 Limin Hersonissou, Crete, Greece © 2002, IOS Press All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior written permission from the publisher. ISBN 1 58603 273 9 (IOS Press) ISBN 4 274 90532 2 C3045 (Ohmsha) Library of Congress Control Number: 2002109991
Publisher IOS Press Nieuwe Hemweg 6B 1013 BG Amsterdam Netherlands fax:+31 206203419 e-mail:
[email protected]
Distributor in the UK and Ireland IOS Press/Lavis Marketing 73 Lime Walk Headington Oxford OX3 7AD England fax:+44 1865750079
Distributor in the USA and Canada IOS Press, Inc. 5795-G Burke Centre Parkway Burke, VA 22015 USA fax:+l 7033233668 e-mail:
[email protected]
Distributor in Germany, Austria and Switzerland IOS Press/LSL.de Gerichtsweg 28 D-04103 Leipzig Germany fax:+49 341 9954255
Distributor in Japan Ohmsha, Ltd. 3-1 Kanda Nishiki-cho Chiyoda-ku, Tokyo 101-8460 Japan fax:+81 332332426
LEGAL NOTICE The publisher is not responsible for the use which might be made of the following information. PRINTED IN THE NETHERLANDS
Preface This monograph contains the contributions of invited speakers and participants at the NATO Advanced Study Institute on Disease Markers in Exhaled Breath: Basic Mechanisms and Clinical Applications, held at the Knossos Royal Village in Crete, Greece, June 22-July 1, 2001. This ASI was designed to summarise and disseminate expert knowledge regarding this rapidly evolving field of lung biology. Breath testing dates from the earliest history of medicine and puzzled brilliant scientific minds including Linus Pauling. It has provided us with powerful techniques of immense medical and commercial applicability such as capnography and ethanol breath testing. Despite this, a wider concept of breath analysis only recently moved from scientific curiosity to clinical reality. The major events responsible for promoting the current knowledge of exhaled breath testing relate to evolution of the idea that molecules such as nitric oxide (NO) and carbon monoxide (CO), previously viewed only as environmental toxicants, are naturally occurring compounds and play a principal role in the normal and pathological regulation of lung function. Furthermore, we have made tremendous progress in our understanding of the biochemistry and molecular biology of disease processes and bioproducts, which are either released from or consumed by the tissues resulting in changes in exhaled breath. Finally, advances in biomedical engineering now allow us to reliably and sensitively identify and quantify these molecules in the parts per billion concentration range and more than 3000 volatile organic compounds (VOCs) at picomolar concentrations. These developments hold enormous promise that analysis of exhaled breath could open a valuable new window onto human metabolism and illuminate its functions in health and disease. Accordingly, analysis of NO, CO and VOCs in exhaled breath has become a primary focus of respiratory research and essential aspect of investigations into many systemic diseases both in the laboratory and in the clinics. These activities are reflected in the rapid expansion of presentations at international meetings, scientific and clinical publications, editorials and recommendations by major respiratory societies. With the rapid expansion of this field, we felt it was timely to organise this institute and to purposefully bring together technical and basic mechanistic aspects of breath analysis through interaction of industry representatives and scientific investigators in order to explore further its potential from basic science to clinical practice. Accordingly, plenary lectures, short oral communications, small group tutorials, poster sessions, lively pro and contra debates and technical discussions were devoted to discuss basic mechanisms underlying production and release to the gas phase of the proposed major disease markers such as NO, CO and VOCs. The remaining daily lectures examined the mechanisms of altered regulation of these molecules and pathways and evidence for the recommendation to use these changes as biomarkers of the broad spectrum of clinical problems. These included acute and chronic lung inflammation with major emphasis on asthma and chronic obstructive pulmonary disease, acute lung injury such as occurring during thoracic organ transplantation and related end stage lung disease, mechanisms of acute and chronic rejection, ischaemia-reperfusion injury and systemic inflammation. It is concluded that NO, CO and VOCs are important molecular players in many of these conditions and analysis of these molecules in the exhaled breath might provide
important insights into pathogenesis, progression and therapeutic responses of patients suffering from these conditions. The tremendous success of the meeting reflects the tireless work of many people. We are especially thankful for the prominent Organising Committee, which consisted of internationally renowned leaders covering expertise on NO, CO and VOCs. The members of the Organising Committee, which included Peter J. Barnes (London), Augustine M.K. Choi (Pittsburgh), Serpil Erzurum (Cleveland), Sergei A. Kharitonov (London) and Charis Roussos (Athens), assisted by the selected Scientific Advisory Panel have been essential in setting the main objectives of the ASI and putting together a stellar cast of lecturers and eminent scientific program. We would like to take this opportunity to thank the members of the Local Organising Committe: Christina Gratsiou, Antonia Koutsoukou, Stylianos Orfanos and Andreas Papapetropoulos for all their hard work. We are also grateful for the help of our close colleagues, Tamas Kovesi and Marianna Imre throughout the meeting and for their editorial assistance. A very special thanks to Ruth Bundy-Marczin for her efficient and meticulous help and passionate support not only during but much before and after the conference. We are especially indebted to Lydia Argyropoulou for working day and night for making sure that every aspect of the organisation was executed smoothly. Finally the organisers would like to salute all speakers and participants for making this event so special and a landmark in the history of dialogues on exhaled breath markers. Nandor Marczin Magdi H. Yacoub
We wish to extend our sincere thanks and gratitude to the following companies for their generous support of this NATO ASI.
SPONSORS
THE SCIENTIFIC AFFAIRS DIVISION OF NATO, Brussels, Belgium ABBOTT LABORATORIES, Greece AIR LIQUIDS HELLAS, Greece AEROCRINE AB, Smidesvagen, Sweden ASTRAZENECA, Prague, Czech Republic BOEHRINGER INGELHEIM, Greece ERICH JAEGER GMBH, Hochberg, Germany GLAXO WELCOME (Allen Pharmaceuticals), Greece LOGAN RESEARCH LTD., Rochester, UK NOVARTIS (HELLAS) A.E.B.E., Athens, Greece PAPAPOSTOLOU, Greece RESPIRATORY RESEARCH INC, Charlottesville, VA, USA START PROMOTION, Milan, Italy SERVIER POLSKA, Warsaw, Poland THE THORAX FOUNDATION, Athens, Greece
This page intentionally left blank
Participants Participantsofofthe theNATO NATOASI ASIononDisease DiseaseMarkers MarkersininExhaled ExhaledBreath, Breath,Greece, Greece,2001 2001
This page intentionally left blank
List of Participants Ian Adcock Thoracic Medicine National Heart and Lung Institute, Imperial College. Dovehouse St London SW3 6LY UNITED KINGDOM
[email protected] Christofer L. Adding, MD, PhD Division of Physiology Departement of Physiology and Pharmacology Von Eulers vag 6 171 77 Karolinska institute! Solna Stockholm SWEDEN T: 08 728 7226 F: 08 33 20 47
[email protected] Veronica Agrenius, MD PhD, Acting chief, Thoracic Medicine, Karolinska Hospital, 17176 Stockholm SWEDEN Ernst Altman Senior Researcher St Petersburg State University St Petersburg RUSSIAN FEDERATION altniaii@ea4603. spb.edu Adam Antczak MD Med. Univ. Lodz, POLAND T: +48 42 6787505 F:+48 42 6782129
[email protected] Zoe Athanasa, MD Resident and Clinical Fellow Asthma and Allergy Center, Pulmonary and Critical Care Department, Medical School, Athens University, Evgenidio Hospital, 20 Papadiarnantopoulou,! 1528, Athens, GREECE T: (301)7236743 F: (301)7242785
Fritz H. Bach, MD Lewis Thomas Professor Harvard Medical School 99 Brookline Ave. Ste. 370D Boston MA. 02215 USA T: (617) 632-1199 F:(617)632-1198 Fritzhbach @ aol .com Beatrix Balint MD Dept. of Thoracic Medicine University of Szeged Deszk, Alkotmany u 36. HUNGARY T:+36-62-271-411 F:+36-62-271-344
[email protected] George Baltopoulos Professor of Critical Care & Pulmonary Diseases Athens University School of Nursing Director, ICU at "KAT" Hospital of Kifissia 2 Nikis Street Kifissia 14561 Athens GREECE T: 00301-6218381 F: 00301-6218381
[email protected] Adam Barczyk Department of Pneumology Silesian Medical Academy ul. Medykow 14 40-752 Katowice POLAND F:+48-32-2523831
[email protected] Peter J Barnes Professor of Thoracic Medicine National Heart and Lung Institute, Imperial College, Dovehouse St London SW3 6LY UK T:0207 351 8174 F: 0207 351 5675
[email protected]
Gunther Becher FILT Lung and Chest Diagnostics Ltd. Robert-Rossle-Str. 10 Haus 79 (Erwin-Negelein-Haus) 13125 Berlin GERMANY T:+49-30-94892114
[email protected] Ion Belenis Head of Dept of Thoracic and Vascular Surgery, Evangelismos Hospital, Athens, GREECE T:+30-17224449 F:+30-17201506
[email protected] Michael J. Berry Ph.D Chief Scientist, Quadrivium LLC, P.O.Box 1421, Pebble Beach, CA 93953. USA T: (831)625-1177 F: (831) 647-1777. MBcrry717 @cs.com Jorge Boczkowski Unite INSERM 408 Faculte X. Bichat BP416 75870 Paris CEDEX 18 FRANCE T:33 1 44856251 F: 33 1 42263330
[email protected] Nigel Bough ton-Smith AstraZeneca R&D Charnwood Discovery BioSceince, Bakewell Road, Loughborough, Leics. L E i l 5RH, UK T:+44 (0)1509 644332 F:+44 (0)1509 645574
[email protected] Ruth Bundy Heart Science Centre Imperial College Harefield Hospital UB9 6JH, Middlesex UNITED KINGDOM T: 44-(0)l 895-823-737 ext 5044 F:44-(0) 1895-828-900 ruth, bundv@ harcfield.nthames.nhs.uk
John D. Catravas, Ph.D. Regents Professor and Director Vascular Biology Center Medical College of Georgia Augusta, GA 30912-2500 USA T: 706-721-6338
F: 706-721-9799
[email protected] Vladimir Cerny, MD, PhD, FCCM Charles University, Faculty of Medicine University Hospital Dept. of Anesthesiology and Intensive Care 500 05 Hradec Kralove CZECH REPUBLIC T: 42 49 583 ext. 2147 or 3218 F: 42 49 583 2022
[email protected] Augustine M.K. Choi, M.D. Professor of Medicine, Chief, Pulmonary, Allery and Critical Care Medicine University of Pittsburgh School of Medicine MUH 628 NW, 3459 Fifth Ave Pittsburgh, PA 15213 USA T: (412) 692-2117 F: (412) 692-2260 pager (412) 958-6054 choiam @ msx. upmc.cdu Alexander G. Chuchalin Academician, Director Institute of Pulmonology, 32/61, 11 -th Parkovaya Street Moscow 105077, RUSSIAN FEDERATION T: +7 095 465 5208 F: +7 095 465 5364 aisanov @ telemed.ru Eric Demoncheaux, PhD Division of Clinical Sciences (CSUH) Section of Medicine and Pharmacology Respiratory Medicine Unit University of Sheffield Medical School Floor F, Beech Hill Road Sheffield, S10 2RX, UK T: 44(0)114 271 2451 F: 44(0)114 271 1711
[email protected] Christiana Dimitropoulou, Ph.D. Department of Pharmacology and Toxicology Medical College of Georgia Augusta, GA 30912-2300 USA T: 706-721-7361 F: 706-721-2347 cd i
[email protected]
Raed A. Dweik, M.D. Staff Physician Pulmonary and Critical Care Medicine Cleveland Clinic Foundation Cleveland, OH, 44195 USA T: 216-445-5763 P: 216-445-8160
[email protected] Serpil C. Erzurum, MD, FCCP Director, Lung Biology Program, Pulmonary and Critical Care Medicine, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue A90, Cleveland, Ohio 44195 USA T: (216)445-5764, F: (216)445-6624
Dr.Cristian Falup-Pecurariu Department of Neurology "Transilvania" University 2200 Brasov ROMANIA cristp@di'urocon.sult.n) Dr. Oana Falup-Pecurariu Assistant, Depart, of Pediatrics "Transylvania" University, Brasov, ROMANIA.
[email protected] Gerasimos S. Filippatos MD Attending Cardiologist Evangelismos Hospital, 28 Doukissis Plakentias 1 1523 Athens GREECE Tel: 30-1-6745222 Fax: 30-1-6745222 geros@compulink,gr Bryan Flaherty, Ph.D. Vice President, Research and Development Natus Medical Inc. USA T: 650-801-7262
[email protected] Ben Gaston, MD. Division oi'Pediatric Respiratory Medicine Box 800386 University of Virginia Charlottesville, VA 22908 USA
[email protected]
Nakos George MD, Director, ICU of University Hospital of loannina loannina GREECE T: + 30651 99353, F:+30 651 99279
[email protected] Gianfranco Giubileo ENEA, Laboratory of Molecular Spectroscopy Via E.Fermi 45, 00044-Frascati(RM), ITALY T: +39-06-94005768 F: +39-06-94005400
[email protected] Liza Goderdzishvili Department of Intensive Care Central Military Hospital Navtlugi St. No 6, 380013, Tbilisi, GEORGIA T: 995 32 962356 F:995 32958016 eli/.aveua
[email protected] Christina Gratziou Head of Asthma and Allergy Center, Pulmonary and Critical Care Department, Medical School, Athens University Evgenidio Hospital, 20 Papadiamantopoulou,! 1528, Athens, GREECE T: (301)7236743 F: (301)7242785
[email protected] Lars E Gustafsson Professor Department of Physiology and Pharmacology Karolinska Institutet 171-77 Stockholm SWEDEN T: 46 8 728 7226 F: 46-8 332 047
[email protected] Nihal El Habashi. MD. Assistant Lecturer, Department of Physiology, Faculty of Medicine, Alexandria University EGYPT
[email protected]
Tryggve Hemmingsson, Project leader Aerocrine AB Smidesvagen 12 S-171 41 SOLNA SWEDEN T: +46 8 629 07 80
F: +46 8 629 07 81
[email protected]
Timothy W Higenbottam, MD MA DSc FRCP Professor Global Clinical Expert, AstraZeneca R&D Charnwood, Clinical Sciences, Bakewell Road, Loughborough, Leics LEI 1 5RH, UK T:+44 (0)1509 644846 F:+44 (0)1509 645563 tim.higenbottam @ astrazeneca.com Markus Hofer MD Fellow, Lung Transplant Program CHOER 19 University Hospital CH-809! Zurich SWITZERLAND T:+41-1-255-1 1 1 1 , markus.holcM @DlM.us/..ch) Marieann Hogman, PhD, Dept of Medical Sciences, Uppsala University, SWEDEN maricann.hognian(°'mcdsci.uu.se
Jiri Homolka,M.D.,Ph.D. Assoc. Professor First Lung Department Foundation Katerinska 19 120 00 Prague 2 CZECH REPUBLIC T/F:+4 20-2-24941500
[email protected] Dr Adriana Hristea National Institute of Infectious Diseases "Prof dr. Matei Bals" 1 Dr. Grozovici Sect 2, 72204 Bucharest ROMANIA
[email protected] Dr Razvan Hristea Institute of Aeronautical Medicine Str M.Vulcanescu nr 88 Bucharest. ROMANIA
[email protected]
John Hunt, MD Division of Pediatric Respiratory Medicine Box 800386 University of Virginia Charlottesville. VA 22908 USA JFH2M@hscmail. nice, virginia.edu Marianna Imre, MD Assistant Professor Dept. Radiology Medical University of Pecs 7643 Pecs, Ifjusag u. 13 HUNGARY
[email protected] Tamas Jilting, MD Assistant Professor Department of Pediatrics The Evanston Hospital Northwestern University Medical School 2650 Ridge Ave. Evanston, IL 60201 USA T: 847-570-1643 F: 847-570-0231
[email protected] Lena Kajland Wilen Marketing Director Aerocrine AB Smidesvagen 12 S-171 41 SOLNA SWEDEN T: +46 8 629 07 80 F:+46 8 629 07 81
[email protected] Miklos KeUermayer Professor, Director Dept.Clinical Chemistry Medical University of Pecs 7643 Pecs, Ifjusag u. 13 HUNGARY T: 36-72-536-122 F: 36-72-536-121
[email protected] Irina A. Kharitonova MD Department of Sleep Disorders, Centre of Medical Rehabilitation of the President of Russian Federation, Poselok Getsena, 143088 Moscow RUSSIAN FEDERATION.
Sergei A. Kharitonov, MD PhD Lecturer, Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, Royal Brompton & Harefield NHS Trust, Dovehouse Street, London SW3 6LY, UK T: +44 020 7352 8 1 2 1 pager 0025 F: +440207351 8126
[email protected] Anastasia Kotanidou Critical Care Department, Evangelismos General Hospital, Medical School, University of Athens, GREECE. akotanicKg'mcd.noa.gr Nick Koulouris MD. PhD. Senior Lecturer in Respiratory Medicine Respiratory Medicine Dept National University of Athens Medical School "Sotiria" Hospital for Diseases of the Chest 152 Mesogion Ave. Athens GR-11527
GREECE"
T: 0030 1 777 8827 F: 0030 1 777 0423 koulniCfl-'.vtre mc.gr Antonia Koutsoukou Critical Care Department, Evangelismos General Hospital, Medical School, University of Athens, GREECE. T: +30-1-7201913 F: +30-1-7244941
[email protected]
Andrew B. Lindstrom, Ph.D. Exposure Methods and Monitoring Branch (MD44) National Exposure Research Laboratory U.S. Environmental Protection Agency Research Triangle Park, NC 2771 1 USA T: 919-541-0551 F: 919-541-3527
[email protected] Ron Logan-Sinclair Director Logan Research Ltd., Unit B2, Spectrum Business Centre, Anthony's Way, Rochester Kent, ME2 4NP. UK. T:+44(0) 1634294900 F: 444(0) 1634294906
[email protected] Stelios Loukidis MD Chest Physician Head of Pneumonology Dept Athens Army General Hospital GREECE T:003018954603 F: 003017494095 ssat@hol.«r Katerina Marathias, M.D. Associate Director Intensive Care Unit Onassis Cardiac Surgery Center 356 Sygrou Ave, Athens GREECE T: (01) 9493000 Beeper #142 F: (01)9493331
v
[email protected] Tamas Kovesi, MD Head of Anaesthetics Dept.Paediatrics Medical University of Pecs 7643 Pecs, Jo/.sel'A. u7 HUNGARY Tamas
[email protected] Dan Laskovvski Cleveland Clinic Foundation, 9500 Euclid Avenue A90 Cleveland, Ohio 44195 USA T: (216)445-5764, F: (216)445-6624
[email protected] Marilcna Lekka Dep. Of Biochemistry, University of loannina, loannina, GREECE
Sadis Matalon, Ph.D. Associate Dean for Post Doctoral Education Alice McNeal Professor of Anesthesiology Professor of Physiology and Biophysics, Pediatrics, Comparative Medicine and Environmental Health, University of Alabama at Birmingham, 940 THT, 619 19th St. S, Birmingham, AL 35249-6810 USA T:(205)-934-4231 F: (205)-934-7437
[email protected]
Karen McRae, MDCM, FRCP Head of Thoracic Anaesthesia, Department of Anaesthesia, The Toronto General Hospital 585 University Ave Toronto, Ontario, M5G 2C4 CANADA T: I 4163405164 F: 1 4163403698 Karen. McraeCq:uhn.on.ca Wolfram Miekisch, PhD Dept. of" Anaesthesia and Intensive Care Med. University Hospital of Rostock, Schillingallee 35 18057 Rostock GERMANY T:+49-381-494 6114, F:+49-381-4946434
[email protected] Manfred Muertz, Ph.D. Institute of Laser Medicine Diisseldorf University, Medical Department GERMANY F:+49-211-811-1374 rnuerlz @ uni-duesscldorl.de
Andreas Papapetropoulos, PhD GP LIVANOS Research Laboratory Ploutarchou 3 10 675 Athens, GREECE T: (301) 721 7467 F: (301)721 94 17
[email protected] Lara Pizurki, PhD GP LIVANOS Research Laboratory Ploutarchou 3 10 675 Athens, GREECE T: (301) 721 7467 F: (301)721 94 17 lara
[email protected] Mieczysiaw Pokorski Professor Dept. of Neurophysiology Medical Research Center ' Polish Academy of Sciences 5, Pawinskiego St. 02-106 Warsaw POLAND mpokorski@medres,cmdik. pan.pl
Pavlos Myrianthefs, MD Attending Physician Athens University School of Nursing, ICU at "KAT" Hospital, Nikis 2, Kifissia, 14561, Athens GREECE T: 00301/6280685 F: 00301/6280702 pavlos myrianlhcfs(fthotmail.com
Victoria PolyakovaPhD, Senior Researcher Institute of Human Ecological Pathology Vasylkivska Street, 45 Kiev, 03022 UKRAINE T: +380 44 266 98 03, 266 98 48 F: +380 44 227 66 13 victoria
[email protected]
Lothar Neumann Produktmanagment Pneumologie ERICH JAEGER GmbH Leibnizstr. 7 D-97204 Hochberg GERMANY T:+49 931/4972-189
[email protected]
Cristina Popescu, MD, Specialist National Institute of Infectious Diseases "Prof dr. Matei Bals" 1 Dr.Grozovici Sect 2, 72204 Bucharest ROMANIA
[email protected]
Stylianos Orfanos, MD., PhD Dept. of Critical Care University of Athens Medical School, Athens, GREECE T: 30-1-7201919
[email protected]
Gabriel A. Popescu, MD, PhD Senior Physician National Institute of Infectious Diseases "Prof dr. Matei Bals" I Dr.Grozovici Sect 2, 72204 Bucharest ROMANIA
[email protected]
Alfred Priftanji Professor UHC "Mother Teresa"; 372, Dibra Sir. Tirana. ALBANIA. T/F: +355 4 224590 pri ftan ji («\san.corn.al Jacques Rami PhD Service d'exploration fonctionnelle respiratoire CHU de Rangueil-Larrey 1 Avenue Jean Poulhes, 31062 Toulouse Cedex, FRANCE T: 33.05.61.32.28.42 (Hospital) F: 33.05.62.88.90.75 (University)
[email protected] Fabio Ricciardolo, MD, PhD Department of Respiratory Disease Ospedali Riuniti di Bergamo Largo Barozzi, 1 24100 Bergamo ITALY T: +39-035-269989 F: +39-035-266825 Trice iardoloCq'ospcdaliriuniti.bergarnu.it Terence H. Risby, Ph.D. Professor of Toxicological Sciences Department of Environmental Health Sciences Johns Hopkins University School of Hygiene and Public Health, 615 North Wolfe Street Baltimore MD 21205 USA T: (410)955-0024 F: (410) 955-0027. Pager: (410) 283-7078
[email protected] Giovanni Rolla, MD Clinical Investigator Dipartimento di Scienze Biomedtche e Oncologia Uinana, Universita di Torino Divisione di Immunologia Clinica e Allergologia Ospedale Mauriziano Umberto I largo Turati 62, 10128 Torino ITALY F: +39011 5682588 i>rolht@mauri/iano.ii
Charis Roussos MD, PhD Professor Critical Care Department. Evagelismos General Hospital 45-47 Ipsilandou Str. Athens 10675 GREECE T: 30-1-72-43-320 F: 30-1-72-16-503 croussos <$ cc.uoa.gr Nikoletta Rovina, M.D. Asthma and Allergy Center, Pulmonary and Critical Care Department, Evgenidio Hospital, University of Athens, Greece, 20, Papadiamantopoulou str. 115 28 Ilisia, Athens, GREECE T: (01)7236743, 7293407-8 F: (01)7242785
[email protected] David Royston Director of Research Consultant Anaesthetist Harefield Hospital UB9 6JH Middlesex UNITED KINGDOM T:44-(0)l895-823-737
[email protected] Mark H. Sanders, M.D. Professor of Medicine and Anesthesiology Chief, Pulmonary Sleep Disorders Program University of Pittsburgh School of Medicine 3459 Fifth Avenue, Suite S-643, Pittsburgh, PA 15213, USA T: 412-692-2880 F: 412-692-2888 Pager 412-393-9437
[email protected] Jochen Schubert Dept. of Anaesthesia and Intensive Care Med. University Hospital of Rostock, Schiliingallee 35 18057 Rostock GERMANY T:+49-381-494 6114, F: +49-3 81-4946434 jochen. schubcrl @mcdi/in.uni-rostock.de Jigme M. Sethi, M.D. Instructor in Medicine, Division of Pulmonary, Allergy and Critical Care Medicine University of Pittsburgh Medical Center 628.2 NW MUH, 3459 Fifth Avenue Pittsburgh, PA 15213 USA T: (412) 692-2210 F: (412)692-2260
[email protected]
Nicolaos M. Siafakas University General Hospital Dept. of Thoracic Medicine POBox 1352 GR-7lllOHeraklion GREECE T: 30-81-392-433 F: 30-81-542-650 sial'akfe 5 mcd.uoc.gr
Miklos Tekeres, MD, PhD Professor, Director Department of Anesthesiology and Intensive Therapy Medical University of Pecs Pecs, HUNGARY F: 36-1-319-1922
[email protected]
Nickolaj F. Starodub Professor, Head of Department of Sensoric and Regulatoric System of Institute of Biochemistry Ukrainian National Academy of Sciences 9 Leontovicha Str.,01030 Kyiv, UKRAINE T: 380-44-229 47 43 F: 380-44-229 63 65
John Timbrell Professor of Biochemical Toxicology (Editor, Biomarkers) Pharmacy Dept. King's College London, Franklin Wilkins Building, Stamford Street London SE1 8WA UK T/F: 020 7848 4789/4881 John.tiinbreIKnfkcl.ac.uk
nstarod lib (g> holinail .com
Werner Steinhauser Marketing Manager Produktmanagment Pneumologie ERICH JAEGER GmbH Leibnizstr. 7 D-97204 Hochberg GERMANY T: +49 93174972-319 DS @jaeger-toennies.com Gregory Stratakos Dept. of Critical Care, University of Athens Medical School, Athens, GREECE
[email protected] Steven Sunshine, Ph.D. CEO Cyrano Sciences, Inc. Pasadena, CA USA T: (626) 744-1700x226 http. //www.cvranosciences.com Camille Taille INSERM U408 Faculte de Medecine Xavier Bichat 16, rue Henri Huchard 75018-Pans FRANCE T: (33) 1 44.85.62.48 F: (33) I 42.26.33.30
[email protected]
Miroslava Tilkian Department of Anaesthesia and Critical Care Plovdiv 4000 "Leonardo da Vinchi" str.66 BULGARIA F:+35932238107 miratil(°) vahoo.co.uk Tatiana Tkacheva, PhD Senior Researcher, Toxicology department Institute of Occupational Health of Russian Academy of Medical Sciences Prosp.Budennogo, 31 Moscow 105275, RUSSIAN FEDERATION T: +7 095 365 1000 F: +7 095 366 0583 latkachcva<3'mtu-nct.ru John Vaughan Division of Pediatric Respiratory Medicine Box 800386 University of Virginia Charlottesville, VA 22908 USA j w v4c (£ Virginia.EDU Gavin Wright Consultant Anaesthetist Harefield Hospital UB9 6JH Middlesex UNITED KINGDOM T:44-(0) 1895-823-737
Magdi Yacoub, FRS British Heart Foundation Professor of Cardiothoracic Surgery National Heart and Lung Institute, Imperial College, Royal Brornpton and Hare field NHS Trust, Harefield Hospital. Harefield, UK UNITED KINGDOM T: 44-1895-823-737 F: 44-1X95-828-901 Carnal Abdel Naser Yamamah Assistant Professor of Pediatrics Department of Clinical Medical Sciences National Research Center, El Tahrir St. Gi/a, EGYPT
[email protected]
Spyros Zakynthinos Dep of Critical Care, University of Athens Medical School, Athens, GREECE
This page intentionally left blank
Contents Preface Sponsors List of Participants
v vii xi
Part I. Introduction to Disease Markers in Exhaled Breath Section 1. Nitric Oxide Regulation of Nitric Oxide Synthases in the Lung, Serpil C. Erzurum Nitric Oxide Production in the Lung and its Regulation by Oxygen, RaedA. Dweik S-Nitrosothiols in Respiratory Biology, Benjamin Gaston Inhibitors of Nitric Oxide Synthase: Experimental Findings and Clinical Implications, Nigel K. Boughton-Smith Inhaled NO as a Replacement Therapy, George J. Baltopoulos and Pavlos M. Myrianthefs Physiology of Exhaled Nitric Oxide, L. Christofer Adding and Lars E. Gustafsson The "Vascular" Origins of Exhaled Nitric Oxide, Tim Higenbottam and Eric Demoncheaux Exhaled NO originates in Airway Epithelium, L. Christofer Adding and Lars Gustafsson NO is Generated via NOS Enzymes, Sergei A. Kharitonov Technical Aspects of Exhaled NO: Investigator Point of View, Sergei A. Kharitonov Technical Aspects of Exhaled Nitric Oxide: Aerocrine Point of View, Lena Kajland-Wilen Section 2. Carbon Monoxide Cytoprotection by Heme Oxygenase / CO in the Lung, Judit K. Sarady, Leo E. Otterbein and Augustine M.K. Choi Role of Heme Oxygenase in Airway Smooth Muscle Contractility, Camille Taille, Michel Aubier and Jorge Boczkowski Exhaled Carbon Monoxide is Produced in the Lungs, Jigme M. Sethi Exhaled Carbon Monoxide is Delivered from Systemic Sources, Nandor Marczin Kinetics of Carbon Monoxide Accumulation in Exhaled Breath, RaedA. Dweik ETCOc: An Indicator of Hemolysis in Neonatal Hyperbilirubinemia, Molly McCarthy and Judith Hall Section 3. Volatile Organic Compounds (VOCs) Volatile Organic Compounds as Exposure Markers, Andrew B. Lindstrom and Joachim D. Pleil Volatile Organic Compounds as Markers in Normal and Diseased States, Terence H. Risbv
3 11 18 24 30 35 49 52 51 62 64
73 79 84 88 93 96
105 } 13
Section 4. The "Living State" The Living State: Intimate Insights through Personal Discoveries, Miklos Kellermayer
\ 25
Part II. Asthma Biology of Asthma, Peter J. Barnes Transcriptional Regulation of Airway Inflammation, Serpil C. Erzurum Molecular Mechanisms of Steroid Actions, Ian M. Adcock and Kazuhiro Ito Nitric Oxide Reactions in the Asthmatic Airway, RaedA. Dweik Regulation of pH in the Human Airway: Mechanisms and Monitoring, John F. Hunt Markers in Exhaled Air and Condensate to Monitor Treatment in Asthma, Sergei A. Kharitonov Extended NO Analysis Applied to Patients with Known Altered Values of Exhaled NO, Marieann Hogman Exhaled Nitric Oxide and Atopy, Christina Gratziou Bradykinin and Exhaled Nitric Oxide in Asthma, Fabio L.M. Ricciardolo and Peter J. Sterk Exhaled NO is an Optimal Marker of Severity and Responsiveness to Therapy in Asthma, Serpil C. Erzurum Superoxide-NO Interactions in Paranasal Sinus Inflammatory Diseases, Jacques Rami
\ 33 143 151 159 167 177 \ 87 191 196 199 202
Part III. Chronic Lung Diseases Biology, Diagnosis and Management of COPD, N.M. Siafakas, G. Chrysofakis and N. Tzanakis ' Disease Markers in COPD: Exhaled Breath vs. Exhaled Condensate, Sergei A. Kharitonov The Biology of Cystic Fibrosis, Tamas Jilling Exhaled Markers in Cystic Fibrosis, Beatrix Balint, Sergei A. Kharitonov, lldiko Horvdth and Peter J. Barnes Lung Cancer Screening by Breath Analysis, Michael J. Berry Nitric Oxide and Rheumatic Diseases, Giovanni Rolla Nitric Oxide in Hepatopulmonary Syndrome, Giovanni Rolla Pathological Changes in the Airways Epithelium of Liquidators of the Chernobyl Catastrophe, Victoria Polyakova
209 218 223 234 242 246 257 261
Part IV. Transplantation Heme Oxygenase-1 and/or Carbon Monoxide can Promote Organ Graft Survival, Miguel P. Soares, Lukas Guenther, Pascal Berberat and Fritz H. Bach Mechanisms of and Clinical Efforts to Minimise Perioperative Lung Injury, /. Gavin Wright and Nandor Marczin Condensate Inflammatory Markers in Lung Transplantation, Karen McRae. Exhaled Nitric Oxide (NO) in Human Lung Ischemia-Reperfusion, Nandor Marczin In Situ Lung Autotransplantation Model in Pigs, E.N. Koletsis, A. Chatzimichalis, K. Kokinis, V. Fotopoulos, I. Bellenis and D. Dougenis
267 274 284 291 300
Pathogenetic Mechanisms Leading to Obliterative Bronchiolitis, Erkki A. Kallio, Jussi M. Tikkanen, Petri K. Koskinen, Karl B. Lemstrom and Magdi Yacoub
304
Part V. ARDS and Oxidative Stress Clinical Pathology of ARD$,Stylianos E. Orfanos, Antonia Koutsoukou, Irene Mavrommati, Ekaterini Psevdi, loanna Korovesi, Anastasia Kotanidou and Charts Roussos Markers of Oxidative Stress in Exhaled Breath Condensate, Adam Antczak Volatile Organic Compounds as Prognostic Markers in ARDS, J.K. Schubert, W. Miekisch, G.F.E. Noldge-Schomburg Do Reactive Oxygen-Nitrogen Intermediates Contribute to the Pathogenesis of ARDS? Judy M. Hickman-Davis, Ian C. Davis, Phillip O'Reilly, Philip McArdle and Sadis Matalon Modulation of Active Alveolar Na+ Transport by Reactive Oxygen-Nitrogen Intermediates, Karin M. Hardiman, Ahmed Lazrak, Vance Nielsen and Sadis Matalon Luteolin Reduces LPS-Induced TNF-a Production and Protects Mice against LPS Toxicity, Angeliki Xagorari, Anastasia Kotanidou, Charis Roussos and Andreas Papapetropoulos Acute Lung Injury in the Setting of Cardiopulmonary Bypass, David Royston Oxidative Stress During Cardiac Surgery in Diabetic Patients, Tamds Kovesi, Ruth Bundy, Ginette Hoare, David Royston and Nandor Marczin
319 333 338
344
354
375
Part VI. New Technological Developments Exhaled Breath Condensate, Gunther Becher Smell as a Diagnostic Tool in the 21st Century: The Portable Electronic Nose, Timothy E. Burch and Steven A. Sunshine Biosensors and Express Biochemical Diagnostics of Some Diseases, Nickolaj F. Starodub, Andrew V. Rebriev and Valentyna M. Starodub Infrared Laser Spectrometer for Real-Time Analysis of Ethane in Exhaled Human Breath, Manfred Miirtz, Hannes Dahnke, Sandra Stry and Peter Hering Methods of Tuneable Diode Laser Absorption Spectroscopy Applied to the Analysis of Exhaled Breath, Gianfranco Giubileo
383 387 391 395 400
Part VII. Industrial Forum Industrial Forum - Aerocrine AB, Tryggve Hemmingsson Biochemical Diagnostics of the Lung with ECoScreen™, L, Neumann and W. Steinhaeusser Portability and Flexibility in Exhaled Breath Condensate Collection, John W. Vaughan
407
Author Index
417
410 41 3
This page intentionally left blank
Part I. Introduction to Disease Markers in Exhaled Breath Section 1. Nitric Oxide
This page intentionally left blank
Disease Markers in Exhaled Breath N. Marciin and M.H. Yacoub (Eds.) /OS Press, 2002
Regulation of Nitric Oxide Synthases in the Lung Serpil C. ERZURUM Pulmonary and Critical Care Medicine Cancer Biology Lerner Research Institute Cleveland Clinic Foundation Cleveland Ohio 44195 U.S.A. Abstract. Exhaled nitric oxide (NO) is derived from endogenous NO synthesis in the lung by nitric oxide synthases (NOS) which convert L-arginine to Lcitrulline and NO. Three NOS isoforms (1 - 3 ) have been identified in the human lung. NOS1 and 3 are dependent on increases in intracellular calcium for enzyme activation while NOS2 is calcium independent. Ail NOS isoforms require oxygen, NADPH, FAD, FMN, tetrahydrobiopterin, and calmodulin for activity. Airway NOS2 expression is responsible for increased exhaled NO in asthma. NOS2 is upregulated by inflammatory cytokines, and produces high levels of NO. Localization of NOS1-3 and regulation of NOS2 is reviewed.
1. Nitric Oxide Synthases Since the finding that endothelium derived relaxing factor (EDRF) is nitric oxide (NO) [1, 2], NO has been shown to be a multifunctional molecule that mediates a number of physiologic processes in almost all vertebrate organ systems, including diverse functions such as smooth muscle relaxation, platelet inhibition, central and autonomic neurotransmission, tumor cell lysis, bacterial killing, and stimulation of hormonal release [3-6]. NO is a diffusible gas that is produced by a group of enzymes known collectively as nitric oxide synthases [NOS, EC 1.14.13.39]. These enzymes convert the amino acid L-arginine to NO and L-citrulline in the presence of oxygen and NADPH as cosubstrates, a reaction that requires several cofactors including FAD, FMN, tetrahydrobiopterin and calmodulin [7]. NO is relatively unstable and rapidly oxidized in solution to the stable metabolic end-products nitrite (NOz") and nitrate (NOs"), which can be used as indirect markers to monitor NO formation [7]. Three isoforms of NOS, which are the products of individual genes [7, 8], have been identified, including 2 constitutive forms [neuronal (nNOS or NOS 1), and endothelial (eNOS or NOS 3) and an inducible form (iNOS or NOS 2) [3, 5, 7]. In general, NOS 1 and 3 are continuously expressed in endothelial and neuronal cells respectively, and are dependent on increases in intracellular calcium to bind calmodulin which results in enzyme activation leading to picomolar levels of NO production [7]. NOS 1 is also found at relatively abundant levels in skeletal muscle [9|.
S.C. Erzurum / Regulation of Nitric Oxide Synthases in the Lung
NOS 2 is regulated at the level of transcription and mRNA stability and is expressed after exposure of cells to specific cytokines and endotoxin [4, 5, 7, 10]. NOS 2 is calcium independent, avidly binding calmodulin even at low calcium concentrations intracellularly, and produces nanomolar levels of NO [7]. NOS 2 has been described in epithelial, endothelial, smooth muscle cells, macrophages, fibroblasts, and neutrophils. Regulation of expression of NOS 2 varies in different cell types, but typically is increased by cytokines such as TNFa, interferon y (IFNy), and interleukin-1 p. NOS 2 expression is decreased by glucocorticoids, transforming growth factor beta (TGFp), platelet derived growth factor, epidermal growth factor, insulin-like growth factor 1, and thrombin [5. 1113]. Regulation of NOS 3 at the level of transcription is less well studied, but the gene is induced by oxygen tension, shear stress, and IFNy [11, 12, 14, 15]. Both NOS 1 and 3 mRNA are increased by estrogens. NOS 3, unlike 1 and 2, is membrane associated due to myristoylation of its amino-terminus end [8]. 2. NO in the lung NO is produced in the human lung, evidenced by NO detectable in the exhaled air of humans (6-8 ppb) and NO metabolites detectable in the airway aspirate and bronchoalveolar lavage fluid from human lungs [3, 16]. NO is recognized to play key roles in virtually all aspects of lung biology and has been implicated in the pathophysiology of lung diseases [17]. NO in the lung is involved in pulmonary neurotransmission, host defense and bacteriostasis, airway and vascular smooth muscle relaxation, pulmonary capillary leak, inflammation, mucociliary clearance, airway mucus secretion and cytotoxicity [3-5]. Cellular sources of NO in the lung include epithelial cells, endothelial cells of pulmonary arteries and veins, inhibitory nonadrenergic noncholinergic neurons, smooth muscle cells, mast cells, mesothelial cells, fibroblasts, neutrophils, lymphocytes, and macrophages [18]. All three NOS isoforms are present in the human lung [3, 18, 19]. Specifically, NOS 1 is located in inhibitory nonadrenergic noncholinergic neurons in the lung, while NOS 3 is found in endothelial cells and the brush border of ciliated epithelial cells [18]. NOS 2 is found in the epithelial cells of the airway [6, 10, 18, 19]. Although NOS 2 may be induced in several types of cells in response to cytokines, endotoxin, or reactive oxygen species, NOS 2 is continuously expressed in normal human airway epithelium at basal airway conditions [19]. Once produced, NO is freely diffusible and enters target cells activating soluble guanylate cyclase to produce guanosine 3', 5'-cyclic monophosphate (cGMP) which mediates the majority of NO effects [7]. NO also diffuses into the airway and can be measured in the gas phase [16]. Potential anatomic sources of NO in exhaled breath include the pulmonary circulation, the lower airways, and the upper airways and paranasal sinuses. NO is formed in high concentrations in the upper respiratory tract (nasopharynx and paranasal sinuses), but several studies have conclusively demonstrated that NO is also produced in the lower respiratory tract [16, 19].
S. C. Erzurum / Regulation of Nitric Oxide Synthases in the Lung
3. Alterations of exhaled NO in lung diseases Alterations in NO levels have been found in pulmonary diseases such as asthma, pulmonary hypertension, bronchiectasis, cystic fibrosis and interstitial lung disease [3]. Exhaled NO is increased in inflammatory airway diseases, such as asthma and upper respiratory tract infections/bronchiectasis, and reflects an increase in NOS 2 activity in airway epithelial cells [3, 17]. Exhaled NO levels are also higher in women with lymphangioleiomyomatosis (LAM) than healthy women, and is related to increased NOS 3 expresion in lesional smooth muscle in the lung [20]. Exhaled NO levels are lower than normal in smoking individuals and the reduction is proportionate to the number of cigarettes currently smoked. Cigarette smoke contains high levels of NO [17], which may dysregulate NOS activity and contribute to the lung injury caused by smoking [21]. There is also evidence that patients with primary pulmonary hypertension (PPH) have lower levels of expression of NOS 3 in pulmonary vascular endothelial cells, and lower levels of exhaled NO [22, 23]. 4. Posttranslational mechanisms regulating NO synthesis Studies identify transcriptional and posttranslational mechanisms regulating NO synthesis in the human airway. NO biosynthesis is regulated at multiple levels in cells, i.e. NOS gene transcription, mRNA processing, protein expression and dimerization, and enzyme reaction kinetics [7]. NO synthesis is dependent upon post-translational modifications to generate active NOS. Specifically, NOSs are synthesized as monomers and must dimerize to generate NO [7]. Recently deletion of regions critical for NOS dimerization due to alternative splicing of the NOS 2 mRNA have been identified [24]. In tissue culture cells, NOS 2 induction by cytokines and endotoxin results in an increase in both constitutively and alternatively spliced mRNA transcripts [24, 25]. Furthermore, enzyme catalyzed NO synthesis involves hydroxylation of arginine to generate N-hydroxyarginine, an enzyme-bound intermediate, which is then converted to citrulline. Intracellular concentration of arginine (several hundred DM) [26 - 29] has been reported to far exceed the Km of the NO synthases (5 - 10 DM) [29]. In this context, it would seem unlikely that arginine is ever rate limiting to the enzyme. However, arginine administration drives NO synthesis in vivo and in cell culture systems [26 - 29]. Independent of substrate effects, arginine may regulate enzyme reaction kinetics through effects on enzyme dimerization or influences on the reduction potential of the enzyme [7]. The kinetics of NO production by NOS 2 in activated macrophages over a range of arginine concentrations reveal a Km for arginine in intact cells of 73 to 150 DM [30, 31]. Intracellular arginine can be increased by de novo synthesis through regeneration from citrulline, or transport from extracellular sources [27 - 29]. Arginine synthetic pathways and transporter systems are induced coordinately with NOS 2 induction in cell cultures. Argininosuccinate synthetase, the rate limiting enzyme in the synthesis of arginine, is induced by endotoxin and IFNy, suppressed by corticosteroids. and generally mirrors NOS induction in vitro [32]. Arginine is present in healthy control airway epithelial cells, but are increased over 3-fold in asthmatic epithelial cells
5.C. Erzurum / Regulation of Nitric Oxide Synthases in the Lung
suggesting coordinate induction of the arginine synthetic pathways and/or cationic ami no acid transporters to support a high rate of NO synthesis in asthma [33]. 5. Transcriptional regulation of NOS 2 Although translational and post-translational mechanisms are important in the regulation of NO synthesis, NOS 2 is subject to predominantly transcriptional regulation [7, 10, 33]. Healthy human airway epithelium in vivo expresses the NOS 2 gene continuously at abundant mRNA levels [10, 19]. The human NOS2 gene is actively transcribed in airway epithelial cells in vivo using run-on transcription analyses [33]. Transcription of the NOS2 gene is at 15% of the transcription rate of yactin, an abundantly expressed mRNA in the airway epithelium [33]. NOS 2 mRNA expression in asthmatic airway epithelium is higher than controls in vivo, but not increased in asthmatics receiving inhaled corticosteroid. Several studies have shown that inhaled or intravenous corticosteroids reduce exhaled NO. In situ analysis of the asthmatic airway suggested that NOS 2 expression is reduced by corticosteroids [34]. In general, mechanisms by which corticosteroids regulate NOS 2 gene expression in vivo are not known. In vitro. glucocorticoids inhibit NOS 2 expression at multiple levels including inhibition of gene transcription, reduction of mRNA translation and increased degradation of NOS 2 protein [35 - 37]. Increased NOS 2 mRNA in asthma, which is downregulated by corticosteroid, supports an association between NOS 2 expression and airway inflammation. Furthermore, although NOS 2 is continuously expressed in airway cells in vivo. expression in control and asthmatic airway epithelial cells placed ex vivo is lost, which substantiates a critical link between airway conditions and/or factors in vivo and NOS 2 expression [10]. Induction of the NOS 2 gene in vitro The molecular basis for induction of the human NOS 2 gene is only partially understood [35, 38, 39]. In contrast, regions in the murine macrophage NOS 2 promotor essential for conferring inducibility of NOS 2 to LPS and IFNyhave been well defined [40, 41]. A nuclear factor kappa B (NF-DB) element at positions -76 to -85 bp relative to the transcription start point binds members of the NF-DB/Rel family of proteins in response to LPS [42], and further upstream an IFN-stimulated response element site binds interferon regulatory factor 1 (IRF-1) upon stimulation of murine macrophage cell line (RAW 264.7 cells) with IFNy [43]. Originally identified as a transcriptional activator of IFN-p as well as IFN inducible genes [44], IRF-1 is essential for NOS2 activation in murine macrophages [43, 45]. Studies suggest that IRF-1 is also important in human NOS 2 gene expression [46, 47]. NOS 2 expression parallels IRF-1 expression, with IRF-1 expression preceding NOS 2 mRNA accumulation. Induction of NOS 2 expression varies in different human cell types, but typically is increased by cytokines [5, 10, 38, 39]. In general, cytokines induce NOS 2 in human cell lines in vitro through transcriptional up-regulation of the gene [35, 38, 39]. The majority of studies on the regulation of NOS 2 expression in lung cells are based on the human lung cancer cell line, A549. For example, the combination of IL-1, TNF and IFNy
5.C. Erzurum /Regulation of Nitric Oxide Synthases in the Lung
1
leads to NOS2 induction in the A549 [10]. In particular, regulation of NOS2 gene expression in A549 requires activation of activator protein-1 (AP-1), which is comprised of c-fos and c-jun proteins [38]. Other studies suggest that NFkB activation and binding to kB DNA elements in the 5' flanking region of the NOS 2 gene plays a role in the cytokine induction of NOS 2 in A549 in vitro [39]. Induction of NOS2 expression in cell lines derived from transformed normal human bronchial epithelial cells, BEAS-2B and BET-1A require multiple cytokines and mediators to activate multiple intracellular signal transduction pathways, including AP-1, and signal transducer and activator of transcription 1 (STAT-1) and/or IRF-1 [46]. Thus, coordinate activation of multiple signaling pathways is necessary for lung cell lines to express NOS2. In contrast, IFNy alone is essential and sufficient for induction of NOS 2 gene expression in primary human airway epithelial cells in vitro [10, 47]. IFNy signaling IFNy signaling to gene expression begins with a specific receptor interaction and oligomerization of receptor chains. This causes a tyrosine phosphorylation cascade, which involves activation of Janus kinases (Jak) 1 and 2, which in turn activate STAT-1. STAT-1 phosphorylation, dimerization and translocation to the nucleus, is followed by binding to regulatory DNA elements to activate transcription of interferon-stimulatedgenes [48]. IFNy leads to STAT1 activation in primary human airway epithelial cells in culture [10, 33, 46, 47], and tyrosine kinase inhibitor abolishes induction of NOS 2 in airway epithelial cells [33]. Activation of signal transducers in vivo important for NOS 2 gene expression Recently, STAT1 activation has been demonstrated in the asthmatic airway by nuclear localization of STAT1 in airway epithelial cells, and demonstration of phosphorylation of STAT1 by western analyses of epithelial cell lysates [49]. The STAT1 activation correlated with induction of IFNy/STATl-stimulated-genes, including IRF-1 which is essential for NOS 2 activation in murine macrophages. Similarly, STAT1 activation quantitated by electrophoretic mobility shift assays is present in controls but increased in asthmatic airway epithelial cell lysates [33]. These data provide strong support for STAT1 activation mediating NOS 2 gene expression in human airway epithelial cells in vivo. 6, Conclusions Multiple mechanisms function coordinately to support NO synthesis in healthy airways, and high level NO synthesis in the asthmatic airway. Human airway epithelium has abundant expression of NOS 2 due to continuous transcriptional activation of the gene in vivo. Increased NOS 2 gene expression in asthmatic airways is associated with increased STAT1 activation, perhaps related to increased cytokines e.g., IFNy. High levels of intracellular arginine may enhance enzyme reaction kinetics and drive NO synthesis.
S.C. Erzurum / Regulation of Nitric Oxide Synthases in the Lung
Taken together, airway epithelial cells have highly efficient NO synthetic machinery which are amplified in airway inflammation. References [I] R.M.J. Palmer, A.G. Gerrige, and S. Moncada. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327( 1987)524-526. [2] L.J. Ignarro, G.M. Buga, K.S. Wood, R. Byrnes, and G. Chaudhuri. Endothelium derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Nail Acad of Sci USA 84 (1987)9265. [3] B. Gaston, J.M. Drazen, J. Loscalzo, and J.S. Stamler. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med 149 (1994) 538. [4] H.H.H. Schmidt, and U. Walter. NO at work. Cell 78 (1994)919. [5] C. Nathan. Nitric oxide as a secretory product of mammalian cells. FASEB J 6 (1992) 3051. [6] F.H. Guo and S.C. Erzurum. Regulation of inducible nitric oxide synthase in human airway epithelium. Environmental Health Perspectives 106 (1998) 1119-1124. [7] D.J. Stuehr and O.W. Griffith. Mammalian nitric oxide synthases. Adv Enzymol Relat Areas Mol Biol 65(1992)287-346. [8] C. Nathan, and Q. Xie. Nitric oxide synthases: Roles, tolls, and controls. Cell 78 (1994) 915. [9] U. Frandsen, M. Lopez-Figueroa, and Y. Hellsten. Localization of nitric oxide synthase in human skeletal muscle. Biochem Biophys Res Commun 227 (1996) 88-93. [10] F. H. Guo, K. Uetani, S. J. Haque, B. R. G. Williams, R. A. Dweik, F. B. J. M. Thunnissen, W. Calhoun, and S. C. Erzurum. Interferon y and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J. Clin. Invest. 100 (1997) 829. [ I I ] B. Gaston, and J.S. Stamler. Nitrogen Oxides. In: Cyrstal RG, West JB eds. The Lung: Scientific Foundations 2d ed. Philadelphia:Lippincott-Raven, 1997; 239-253. [12] C. Nathan, and Q. Xie. Regulation of biosynthesis of nitric oxide. J Biol Chem. 269 (1994) 13725. [13] K. Asano, C.B.E. Chee, B. Gaston, C.M. Lilly, C. Gerard, J.M. Drazen, and J.S. Stamler. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci USA 91 (1994) 10089. [14] N. Kim, Y. Vardi, H. Padma-Nathan, J. Daley, I. Goldstein, and I. Saenez de Tejeda. Oxygen tension regulates the nitric oxide pathway. J Clin Invest 91 (1993) 437. [15] P.W. Shaul, and L.B. Wells. Oxygen modulates nitric oxide production selectively in fetal pulmonary endothelial cells. Am J Respir Cell Mol Biol 11(1994) 432. [16] R.A. Dweik, D. Laskowski, H.M. Abu-Soud, F.T. Kaneko, R. Hutte, D.J. Stuehr, and S.C. Erzurum: Nitric oxide synthesis in the lung: regulation by oxygen through a kinetic mechanism. J Clin Invest 101(1998)660. [17] P. J. Barnes, and M.G. Belvisi. Nitric oxide and lung disease. Thorax 48 (1993)1034. [18] L. Kobzik, D.S. Bredt, C.J. Lowenstein, J. Drazen, B. Gaston, D. Sugarbaker, and J.S. Stamler. Nitric oxide synthase in human and rat lung: immunohistochemical and histochemical localization. Am J. Respir. Cell. Mol. Biol. 9 (1993)371. [19] F. H. Guo, H. R. De Raeve, T. W. Rice, D. J. Stuehr, F. B. J. M. Thunnissen, and S. C. Erzurum. Continuous nitic oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc. Natl. Acad. Sci. USA. 92 (1995) 7809. [20] R.A. Dweik, D. Laskowski, M. Ozkan, C. Farver, and S.C. Erzurum. High Levels of Exhaled Nitric Oxide (NO) Associated with NO Synthase HI Expression in Lesional Smooth Muscle in Lymphangioleiomyomatosis. Am J Resp Cell Mol Biol 24 (2001)414-418. [21] H. Ischiropoulos, M. Ignacio, D. Fisher, A.B. Fisher, and S.R. Thorn. Role of neutrophils and nitric oxide in lung alveolar injury from smoke inhalation. Am J Respir Crit Care Med 150 (1994) 337. [22] A. Giaid, and D. Saleh. Reduced expression of endothelial nitric oxide synthase in patients with pulmonary hypertension. N Engl J Med 333 (1995) 214-221. [23] F.T. Kaneko, Arroliga, A.C., Dweik, R.A., Comhair, S.A., Laskowski, D., Oppedisano, R., Thomassen, M.J., and S.C. Erzurum. Correlation of nitric oxide reaction products to severity of pulmonary hypertension. Am J Respir Crit Care Med. 158 (1998) 917-923.
S.C. Erzurum / Regulation of Nitric Oxide Synthases in the Lung
[24] N. T. Eissa, J. W. Yuan, C. M. Haggerty, E. K. Choo, C. D. Palmer, et al. Cloning and characterization of human inducible nitric oxide synthase splice variants: A domain, encoded by exons 8 and 9, is critical for dimerization. Proc. Nad. Acad. Sci. USA. 95 (1998) 7625. [25] N. T. Eissa, A. J. Strauss, C. M. Haggerty, E. K. Choo, S. C, Chu, and J. Moss. Alternative splicing of human inducible nitric-oxide synthase mRNA. J. Bioi. Chem. 271 (1996) 27184. [26] S. Kurz, and D. G. Harrison. Insulin and the arginine paradox../ Clin. Invest. 99 (1997) 369. [27] M. Hecker, W. C. Sessa, H. J. Harris, E. E. Anggard, and J. R. Vane. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: Cultured endotheliai cells recycle L-citrulline to L-arginine. Proc. Natl. Acad. Sci. USA. 87 (1990) 8612. [28] R. Hammermann, J. Hirschmann, C. Hey, J. Mossner, G. Folkerts, et al. Cationic proteins inhibit Larginine uptake in rat alveolar macrophages and tracheal epithelial cells. Am. J. Respir. Cell Moi Biol. 21(1999) 155. [29] A. R. Baydoun, P. W. Emery, J. D. Pearson, and G. E. Mann. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endotheliai cells. Biochem. Biophy. Res. Commun. 173(1990)940. [30] F. lyengar, D. J. Stuehr, and M. A. Marietta. Macrophage synthesis of nitrite, nitrate, and Nnitrosamines: Precursors and role of the respiratory burst. Proc. Natl. Acad. Sci. USA. 84 (1987) 6369. [31] D. L. Granger, J. B. Hibbs, J. R. Perfect, and D. T. Durack. Metabolic fate of L-Arginine in relation to microbiostatic capability of murine macrophages. J. Clin. Invest. 85 (1990) 264. [32] A. R. Baydoun, P. W. Emery, J. D. Pearson, and G. E. Mann. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endotheliai cells. Biochem. Biophy. Res. Commun. 173(1990)940. [32] Y. Hattori, E. B. Campbell, and S. S. Gross. Argininosuccinate synthetase mRNA and activity are induced by immunostimulants in vascular smooth muscle. J. Biol. Chem. 269 (1994) 9405. [33] F.H. Guo, S.A.A. Comhair, S. Zheng, R.A. Dweik, N.T. Eissa, M.J. Thomassen, W. Calhoun, S.C. Erzurum. Molecular Mechanisms of Increased Nitric Oxide (NO) in Asthma: Evidence for Transcriptional and Post-translational Regulation of NO Synthesis. J Immunol 164 (2000) 5970. [34] D. Saleh, P. Ernst, S. Lim, P. J. Barnes, and A. Giaid. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. FASEBJ. 12 (1998) 929. [35] D. A. Geller, A. K. Nussler, M. D. Silvio, C. J. Lowenstein, R. A. Shapiro, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc. Natl. Acad. Sci. USA. 90 (1993) 522. [36] M.W. Radomski, R. M. J. Palmer, S. Moncada. Glucocorticoids inhibit the expression of an inducible. but not the constitutive, nitric oxide synthase in vascular endotheliai cells. Proc. Natl. Acad Sci. USA. 87(1990) 10043. [37] D. Kunz, G. Walker, W. Eberhardt, J. Pfeiischifter.. Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin 1 p-stimulated mesangial cells: Evidence for the involvement of transcriptional and posttranscriptional regulation. Proc. Natl. Acad. Sci. USA. 93(1996)255. [38] J. Marks-Konczalik, S.C. Chu, and J. Moss. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaBbinding sites. J. Biol. Chem. 273 (1998) 22201. [39] M. E. de Vera, R. A. Shapiro, A. K. Nussler, J. S. Mudgett, R. L. Simmons, S. M. Morris, Jr., T. R. Billiar, and D. A. Geller. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc. Natl. Acad. Sci. USA. 93 (1996)1054. [40] C. J. Lowenstein, E. W. Alley, P. Raval, A. M. Snowman, S. H. Snyder, S. W. Russell, and W. J. Murphy. Macrophage nitric oxide synthase gene: two upstream regions mediate induction by interferon gamma and lipopolysaccharide. Proc. Natl. Acad. Sci. USA. 90 (1993) 9730. [41] Q. W. Xie, R. Whisnant, and C. Nathan.. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J. Exp. Med. 177(1993) 1779. [42] Q. W. Xie, Y. Kashiwabara, and C. Nathan. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269 (1994) 4705.
10
S.C. Erzurum /Regulation of Nitric Oxide Synthases in the Lung
[43] E. Martin, C. Nathan, and Q. W. Xie. Role of interferon regulatory factor 1 in induction of nitric oxide synthase../. Exp. Med 180(1994)977. [44] H. Harada, T. Fujita, M. Miyamoto, Y. Kimura, M. Maruyama, A. Furia, T. Miyata, and T. Taniguchi. Structurally similar but functionally distinct factors, IRF-1 and IRF- 2, bind to the same regulatory elements of 1FN and IFN-inducible genes. Cell. 58 (1989) 729. [45] R. Kamijo, H. Harada, T. Matsuyama, M. Bosland, J. Gerecitano, D. Shapiro, J. Le, S. I. Koh, T. Kimura, S. J. Green, T. W. Mak, T. Taniguchi, and J. Vilcek.. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science. 263 (1994) 1612. [46] K. Uetani. M. Arroliga, and S.C. Erzurum. Double-stranded RNA Dependence of Nitric Oxide Synthase 2 Expression in Human Bronchial Epithelial Cell Lines BET-1A and BEAS-2B. Am J Resp Cell Mol Biol 24 (2001) 720. [47] K. Uetani, M.J. Thomassen, and S.C. Erzurum. Interferon-y Induction of Human Nitric Oxide Synthase 2 (NOS2) through an Autocrine Loop via Respiratory Epithelial Cell-derived Soluble Mediator. Am J Physiol 280 (2001) L1179. [48] S. J. Haque, and B. R. G. Williams. Signal transduction in the interferon system. Semin. Oncol. 25 1998) 14. [49] D. Sampath, M. Castro, D. C. Look, and M. J. Holtzman. Constitutive activation of an epithelial signal transducer and activation of transcription (STAT) pathway in asthma. J. Clin. Invest. 103 (1999) 1353.
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
Nitric Oxide Production in the Lung and its Regulation by Oxygen Raed A. DWEIK Department of Pulmonary and Critical Care Medicine Cleveland Clinic Foundation 9500 Euclid Avenue Cleveland Ohio 44195 U.S.A.
Abstract. Nitric oxide (NO) in exhaled breath is primarily derived from the airway. NO is endogenously synthesized by nitric oxide synthases (NOS) which convert L-arginine to L-citrulline and NO. Three NOS isoforms (type I, II and III) have been identified in the human lung. Oxygen is a substrate for all NOS enzymes and it also regulates NOS expression and the enzyme activity in the iung. Rapid response of endogenous NO in direct proportion to inspired oxygen strongly supports a role for oxygen in regulating NO production in the lung through a kinetic mechanism.
1. Nitric Oxide (NO) in the Lung NO is produced in the human lung, evidenced by NO detectable in the exhaled air of humans (6-8 ppb) and NO metabolites detectable in the airway aspirate and bronchoalveolar lavage fluid from human lungs [1-8]. NO is recognized to play key roles virtually in all aspects of lung biology and has been implicated in the pathophysiology of lung diseases [2, 9-13]. NO in the lung is involved in pulmonary neurotransmission, host defense and bacteriostasis, airway and vascular smooth muscle relaxation, pulmonary capillary leak, inflammation, mucociliary clearance, airway mucus secretion and cytotoxicity [12, 13]. NO is endogenously synthesized by nitric oxide synthases (NOS) which convert L-arginine to L-citrulline and NO. Three NOS isoforms (type I, II and III) have been identified in the human lung [1-5]. NOSI and HI are dependent on increases in intracellular calcium for enzyme activation while NOSH is calcium independent [6]. All NOS isoforms require oxygen, NADPH, FAD, FMN, tetrahydrobiopterin, and calmodulin for activity [6, 7].
12
R.A. Dweik/NO Production in the Lung and its Regulation by Oxigen
2. Source(s) of NO in Exhaled Breath Cellular sources of NO in the lung include epithelial cells, endothelial cells of pulmonary arteries and veins, inhibitory nonadrenergic noncholinergic neurons, smooth muscle cells, mast cells, mesothelial cells, fibroblasts, neutrophils, lymphocytes, and macrophages [2, 3, 12, 13]. All three NOS isoforms are present in the human lung [1,2, 7]. Specifically, NOSI is located in inhibitory nonadrenergic noncholinergic neurons in the lung, while NOSIII is found in endothelial cells and the brush border of ciliated epithelial cells [1, 2, 7]. NOSH is found in the epithelial cells of the airway. Although NOSH may be induced in several types of cells in response to cytokines, endotoxin, or reactive oxygen species, NOSH is continuously expressed in normal human airway epithelium at basal airway conditions [5]. Once produced, NO is freely diffusible and enters target cells activating soluble guanylate cyclase to produce guanosine 3', 5'-cyclic monophosphate (cGMP) which mediates the majority of NO effects [7]. NO also diffuses into the airway and can be measured in the gas phase [8]. Potential anatomic sources of NO in exhaled breath include the pulmonary circulation, the lower airways, and the upper airways and paranasal sinuses [7, 8, 14]. NO is formed in high concentrations in the upper respiratory tract (nasopharynx and paranasal sinuses) [14], but several studies have conclusively demonstrated that NO is also produced in the lower respiratory tract [7, 8]. Studies of gas phase NO in the airway have been helpful in determining the anatomic source(s) of NO in the lung. During a breathhold NO accumulates in bronchiolar gases in an exponential fashion with an initial linear rise, followed by a plateau [8]. The steady state NO levels in the bronchiolar gases of the lung are achieved within seconds. Attainment of steady-state levels indicates a constant rate of production balanced by a constant consumption or scavenging of NO [8. 15]. Since NO is freely diffusible, consumption of NO can occur at different sites within the cell, lung tissue, extracellular fluids, and intravascular compartments. Primary reactions that may consume NO intra- and extracellularly include its reaction with oxygen, superoxide, hemoglobin, another molecule of NO, enzymes containing ironsulfur centers, heme-containing proteins, and thiol proteins [16]. An especially important scavenger of NO in the lung is hemoglobin [8, 15-17]. NO produced in the lungs may diffuse into the lumen of blood vessels where most will be trapped by oxy- and deoxyhemoglobin in red blood cells [15, 17]. The addition of even very small amounts of hemoglobin results in substantial decrease in the steady-state distribution of NO in vitro [15]. Furthermore, bronchoscopic measurements of airway NO in humans reveal that bronchiolar but not alveolar gases accumulate NO during a breath-hold [8]. During an expiratory breath-hold, bronchiolar gases accumulate NO quickly to a plateau. At the end of expiratory breath-hold, complete exhalation to residual volume causes NO levels to decrease rapidly [8]. Near zero NO levels observed at the end of exhalation indicate alveolar gases do not accumulate NO [8]. Studies in rabbits also demonstrate that NO levels in exhaled gases remain after blood circulation was stopped by intravenous injection of air or helium [18] or when blood was replaced by a physiologic buffer [19]. Despite this, at least some of the endogenously produced NO diffuses into the airway and is eliminated via the gas phase.
R.A. Dweik /NO Production in the Lung and its Regulation by Oxigen
13
Thus, while NO levels in the gas phase likely underestimate NO levels in the lung tissue and at pulmonary vascular sites, the gas phase levels reflect in an accurate and qualitative manner the dynamics of NO production and consumption in the lung. The capacity of the blood as a scavenger of NO can be estimated from experiments of isolated perfused lungs [19]. Exhaled NO output from blood-perfused lungs is less than half the amount from buffer-perfused lungs [19] attesting to the large scavenging capacity of the blood in the pulmonary circulation. Exhaled NO levels also increase in rabbits with experimental anemia [20]. A progressive fall in the hematocrit from 30% to 11% by serial isovolemic hemodilution in rabbits causes a significant and parallel increase in expired NO levels [20]. Considering the high diffusibility of NO, the extremely rapid rate of scavenging by hemoglobin, and the rich supply of blood vessels found in the lung, the pulmonary circulation is undoubtedly a significant biologic sink for NO, and not likely to contribute to NO in exhaled breath.
3. Regulation of NO Synthesis by Oxygfen All NOS isoforms require the presence of oxygen for activity [6]. Although it is recognized that oxygen is a substrate for NOS, its effects on regulation of NOS activity are more complex than simple enzyme-substrate interaction [8, 21-25]. One mechanism to explain oxygen's effect on NO levels in the lung is revealed by enzyme kinetic analyses. All NOS are comprised of an oxygenase domain that contains binding domains for iron protoporphyrin IX (heme), tetrahydrobiopterin, and L-arginine, and a reductase domain that contains binding domains for FMN, FAD, and calmodulin [6]. The NOS heme iron participates in catalysis by binding oxygen and catalyzing the oxidation of Larginine [21-25]. NOSI activity is dependent on oxygen concentration (KMO2 400 uM) [21, 22]. When NO is formed during catalysis, it binds to the heme iron in the catalytic site of NOSI and forms an inactive heme iron-NO complex [19, 20]. The rate of decay of the complex is subsequently dependent upon oxygen concentration to enter the active catalytic cycle [19, 20]. Studies of purified NOSH activity in vitro as determined by the rate of NADPH consumption demonstrate that NOSII activity is dependent on molecular oxygen concentrations in the physiologically relevant range (KMO2 135 jaM) [8]. Although the KMO2 of NOSII is lower than that of NOSI, NOSII has also been shown to form heme iron-NO complexes, however studies using scavengers of NO suggest that the mechanism of regulation by NO and oxygen is not similar between the two enzymes [8, 26]. Work utilizing rapid kinetic analysis of the purified NOSIII enzyme in vitro also confirms significant dependence on oxygen [24]. The formation of active NOSIII complex is first order with respect to oxygen, reversible, and follows a simple one-step mechanism. However, decay of the complex is independent of oxygen concentration and occurs via a one- or two-exponential process depending upon co factors or substrate availability [22, 24]. Based on double reciprocal plots of NOSIII activity and oxygen concentration in vitro, the apparent NOSIII KN^ is strikingly low (4 uM) and consistent
14
R.A. Dweik/NO Production in the Lung and its Regulation by Oxigen
with very little heme-NO complex formation in this isoform [24]. oxygen is less likely relevant to NOSIII enzyme activity in vivo.
Taken together,
4. Effect of Oxygen on Exhaled NO As predicted from the above enzyme kinetic studies, changes in inspired oxygen concentration lead to significant changes in exhaled NO. NO in exhaled gases from lungs of anesthetized rabbits ventilated with hypoxic gas mixtures are only modestly reduced using 0.14 or 0.10 FiO2, but decrease markedly using 0.06 FiOi [18]. In addition, ventilation of an isolated neonatal pig lung with 0.075 FiO2 rapidly decreases NO in exhaled gases and NO2~/NO3~ in the recirculating perfusate as compared to ventilation with 0.21 FiO2 [27]. Similarly, exhaled NO levels correlate to oxygen levels in the hypoxic range in humans, decreasing as oxygen levels decrease below ambient air [«]• Interestingly, the effect of hypoxia on NO levels in the airway is primarily a result of airway and alveolar oxygen tension (FiO2) rather than vascular oxygen tension (pO2) [18, 19, 27, 29]. In models of isolated perfused lungs [18, 19], inspired hypoxic gases result in significant decline in NO output from the lung, while vascular hypoxia has no significant effect on NO lung output. The results are similar whether the lungs are perfused with blood or a physiologic buffer. On the other hand, NO metabolites continue to accumulate in the perfusate [29], suggesting a vascular source of NO that may not be affected by oxygen. Differential regulation of lung NO synthesis in response to hypoxia suggests a complex model for NO production in the lung that involves at least 2 different compartments. The airway compartment with predominant NOSH expression in the airway epithelium is capable of rapidly changing NO output depending on inspired oxygen, couples ventilation-perfusion, and thus mediates hypoxic pulmonary vasoconstriction. In contrast, the vascular compartment predominantly expresses NOSIII, which is less affected by changes in oxygen. NOSIII may be responsible for a continuous low level of NO which modulates the effect of high output NO production by NOSH on the pulmonary circulation. In support of this, genetically engineered NOSIII null mice have only a slight increase in pulmonary artery pressures [30], but an exaggerated vasoconstrictive response to hypoxia. Furthermore, NOSIII-null murine lungs have significantly higher NOSII expression than the wildtype mice [30]. Oxygen concentration in intact tissues ranges from 1 to 150 uM [2, 8, 31. 32], with the highest levels found in the lung. Airway epithelial cells are unique in their exposure to oxygen, since above a thin layer of epithelial lining fluid, the airway cells are exposed directly to air containing 21% oxygen. Based upon oxygen solubility and the low differential oxygen gradient between overlying fluid to intracellular endoplasmic reticulum (1-2 uM) [32], the levels of oxygen in airway epithelial cells may actually approach 260 uM. Thus, the KMO2 determined for NOS II, but not NOSIII or NOSI, is well within the physiologic range of oxygen concentrations in lung epithelial cells. Importantly, KMO2 for NO synthesis in the intact human lung (190 uM) is similar to NOSII KMO2 in vitro [8].
R.A. Dweik/ NO Production in the Lung and its Regulation by Oxigen
15
Taken together, these studies support a primary role for NOSII in maintenance of low pulmonary vascular resistance, and in the pulmonary vasoconstrictor response to hypoxia.
5. Regulation of NOS Gene Expression by Oxygen The immediate effects of short-term changes in oxygen concentration on NOS enzymes activity are likely due to the effects of oxygen on NOS enzyme kinetics. However, prolonged hypoxia can have significant effects on the gene expression of the different NOS isoforms [33, 34]. These transcriptional effects may vary among species or among organ systems in the same species. While hypoxia produces a progressive decline in constitutive NOS mRNA levels in bovine pulmonary artery endothelial cells [33, 34, 35], chronic hypoxia upregulates constitutive NOS expression in rabbit hearts [36] and rat lung pulmonary arteries [37]. Chronic hypoxia also increases NOS expression and NOS activity in rat carotid bodies [38].
6. Conclusions NO in exhaled breath is primarily derived from the airway. The pulmonary circulation likely affects exhaled NO levels by acting as a biologic sink that consumes NO and creates a gradient towards the pulmonary circulation. Oxygen regulates NOS expression and the enzyme activity. Rapid response of endogenous NO in direct proportion to inspired oxygen strongly supports a role for NOSII as a biochemical oxygen sensor and critical mediator of ventilation-perfusion coupling in the lung.
References [1] Kobzik, L., D.S. Bredt, C.J. Lowenstein, J. Drazen, B. Gaston, D. Sugarbaker, and J.S. Stamler. Nitric oxide synthase in human and rat lung: immunohistochemical and histochemical localization. Am. J. Respir. Cell. Mol. Biol. 1993; 9:371-377. [2] Gaston, B., J.M. Drazen, J. Loscalzo, and J.S. Stamler. The biology of nitrogen oxides in the airways. Am. J. Respir. Crit. Care Med. 1994; 149:538-551. [3] Guo FH, Uetani K, Haque J, Williams BRG, Dweik RA, Thunnissen FBJM, Calhoun W, Erzurum SC. Interferon-g and interleukin-4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. Journal of Clinical Investigation 1997; 100:829-38. [4] Dweik RA, Guo FH, Uetani K, Erzurum SC. Nitric oxide synthase in the human airway epithelium. Acta Pharmacologica Sinica 1997; 18: 550-2. [5] Guo, F.H., H.R. De Raeve, T.W. Rice, D.J. Stuehr, F.B.J.M. Thunnisssen, and S.C. Erzurum. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc. Natl. Acad. Sci. U.S.A. 1995; 92:7809-7813. [6] Stuehr, D.J., and O.W. Griffith. Mammalian nitric oxide synthases. Adv. Enzymol. Relat. Areas Mol. Biol. 1992; 65:287-346.
16
R.A. Dweik/NO Production in the Lung and its Regulation by Oxigen
[7] Dweik, R.A., Erzurum, S.C. Effects of nitric oxide and cGMP on smooth muscle proliferation. In: LAM and other diseases characterized by smooth muscle proliferation. Moss J, editor. Marcel Dekker, Inc. New York. 1999; 131:333-349. [8] Dweik, R.A., Laskowski, D., Abu-Soud, H.M., Kaneko, F.T., Hutte, R., Stuehr, D.J., Erzurum, S.C. Nitric oxide synthesis in the lung: regulation by oxygen through a kinetic mechanism. Journal of Clinical Investigation 1998; 101: 660-666. [9] Kaneko, F.T., Arroliga, A.C., Dweik, R.A., Comhair, S.A., Laskowski, D., Oppedisano, R., Thomassen, M.J., Erzurum, S.C. Correlation of nitric oxide reaction products to severity of pulmonary hypertension. Am J Respir Crit Care Med. 1998; 158:917-923. [10]Raychaudhuri, B., Dweik, R., Connors, M.J., Buhrow, L.T., Malur, A., Drazba, J., Erzurum, S.C., Kavuru, M.S., Thomassen, M.J. Nitric Oxide blocks NFkB activation in alveolar macrophages in asthma and primary pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology 1999; 21: 311-316. [11] Thomassen, M.J., Raychaudhuri, B., Dweik, R.A., Farver, C., Buhrow, L.T., Malur, A., Hammel, J., Erzurum, S.C., Kavuru, M.S. Effect of segmental allergen challenge on airway nitric oxide, eosinophils, and cytokines in asthmatics. Journal of Allergy and Clinical Immunology 1999; 104:1174-1182. [12] Nathan, C. Nitric oxide as a secretory product of mammalian cells. FASEB. J. 1992; 6:3051-64. [13]Schmidt, H.H.H.W., and U. Walter. NO at work. Cell 1994; 78:919-925. [14]Lundberg, J.O.N., T. Farkas-Szallasi, E. Weitzberg, J. Rinder, J. Lidholm, A. Anggard, T. Hokfelt. J.M. Lundberg, and K. Alving. High nitric oxide production in human paranasal sinuses. Nat. Med. 1995; 1:370-373. [15] Lancaster, J.R. Jr. Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 1994; 91:8137-8141. [16]Wink, D.A., I. Hanbauer, M.B. Grisham, F. Laval, R.w. Nims, J. Laval, J. Cook, R. Pacelli, J. Liebmann, M. Krishna, P.C. Ford, and J.B. Mitchel. Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. Current topics in cellular regulation. 1996; 34:159-187. [17] Goldstein, S., and G. Czapski. Kinetics of nitric oxide autoxidation in aqueous solutions in the absence and presence of various reductants. The nature of the oxidizing intermediates. J. Am. Chem. Soc. 1995; 117:12078-12084. [18]Gustafsson, L.E., A.M. Leone, M.G. Presson, N.P. Wilkund, and S. Moncada. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem. Biophys. Res. Commun. 1991; 181:852-857. [19]Ide, Hiroshi, Nakano, H., Ogasa, T., Osanai, S., Kikuchi, K., and Iwamoto, J. Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide. American Physiological Society. 1999; 8750-7587:1629-1636. [20]Deem, S., Hedges, R.G., McKinney, S., Polissar, N.L., Alberts, M.K., and Swenson, E.R. Mechanisms of improvement in pulmonary gas exchange during isovolemic hemodilution. J Appl Physiol 1999; 87: 132-141. [21] Abu-Soud, H.M., D.L. Rousseau, and D.J. Stuehr. Nitric oxide binding to the heme of neuronal nitricoxide synthase links its activity to changes in oxygen tension. J. Biol. Chem. 1996; 271:32515-32518. [22] Abu-Soud, H.M., J. Wang, D.L. Rousseau, J.M. Fukuto, L Ignarro, and D. J. Stuehr. Neuronal nitric oxide synthase self-inactivates by forming a ferrous-nitrosyl complex during aerobic catalysis. J. Biol. Chem. 1995; 270:22997-23006. [23] Adak, S., Ghosh, S., Wang, Q., and Stuehr, D.J. Molecular Basis for Hyperactivity in Tryptophan 409 Mutants of Neuronal NO Synthase. In Press. [24] Abu-Soud, Husam, M., Ichimori, K., Presta, A., and Stuehr, D.J. Electron Transfer, Oxygen Binding, and Nitric Oxide Feedback Inhibition in Endothelial Nitric Oxide Synthase. In press.. [25] Abu-Soud H.M., R. Gachhui, P.M. Raushel, and D.J. Stuehr. The ferrous-dioxy complex of neuronal nitric oxide synthase: divergent effects of L-arginine and tetrahydrobiopterin on its stability. J. Biol. Chem. 1997; 272:17349-17353. [26] Hurshman, A.R., and M.A. Marietta. Nitric oxide complexes of inducible nitric oxide synthase: spectral characterization and effect on catalytic activity. Biochemistry 1995; 34:5627-5634. [27]Nelin, L.D., C.J. Thomas, and C.A. Dawson. Effect of hypoxia on nitric oxide production in neonatal pig lung. Am. J. Physiol. 1996; 271 :H8-H14.
R. A. Dweik / NO Production in the Lung and its Regulation by Oxigen
17
[28]Tsujino, I., K. Miyamoto, M. Nishimura, H. Shinano, H. Makita, S. Saito, T. Nakano, and Y. Kawakami. Production of nitric oxide (NO) in intrathoracic airways of normal humans. Am. J. Respir. Crit. Care Med. 1996; 154:1370-1374. [29]Grimminger, F., Spriestersbach, R., Weissmann, N., Walmrath, D., and Seeger, W. Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. The American Physiological Society. 1995; 1509-1515. [30]Pagan, K.A., Fouty, B.W., Tyler, R.C., Morris, K.G., Jr., Hepler, L.K., Sato, K., LeCras, T.D., Abman, S.H., Weinberger, H.D., Huang, P.L., McMurtry I.F., and Rodman, D.M. The pulmonary circulation of homozygous eNOS-null mice is hyperresponsive to mild hypoxia. The Journal of Clinical Investigation. 1999; 103:291-299. [31 ]Vanderkooi, J.M., M. Erecinska, and I.A. Silver. Oxygen in mammalian tissue: methods of measurement and affinities of various reactions. Am. J. Physiol. 1991; 260:C1131-1150. [32]Wakita, M., G. Nishimura, M. Tamura. Some characteristics of the fluorescence liftime of reduced pyridine nucleotides in isolated mitochondria, isolated hepatocytes, and perfused rat liver in situ. J. Biochem. 1995; 118:1151-1160. [33]Liao, J.K., J.L. Zulueta, F.S. Yu, H.B. Peng, C.G. Cote, and P.M. Hassoun. Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen. J. Clin. Invest. 1995; 96:2661-2666. [34]Melillo, G., T. Musso, A. Sica, L.S. Taylor, G.W. Cox, and L Varesio. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promotor. J. Exp. Med. 1995; 182:1683-1693. [35]Phelan, M.W., and V. F. Fallen Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J. Cell. Physiol. 1996; 167:469-476. [36]Baker, J.E., Holman, P., Kalyanaraman, B., Griffith, O.W., and Pritchard, K.A., Jr. Adaptation to chronic hypoxia confers tolerance to subsequent myocardial ischemia by increased nitric oxide production. Annals of the New York Academy of Sciences. 1999; 874:236-53. [37] Sato, K., Rodman, D.M., and McMurtry, I.F. Hypoxia inhibits increased ETB receptor-meadiated NO synthesis in hypertensive rat lungs. American Journal of Physiology. 1999; 276 (4 Pt 1):L571-80. [38] Di Giulio, C., Grilli, A., De Lutiis, M.A., Di Natale, F., Sabatino, G., and Felaco, M. Does chronic hypoxia increase rat carotid body nitric oxide? Comparative Biochemistry & Physiology. 1998: 120(2):243-7.
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub(Eds.) 1OS Press. 2002
S-Nitrosothiols In Respiratory Biology Benjamin GASTON University of Virginia, Department of Pediatrics, Pediatric Respiratory Medicine, PO Box 800386, Charlottesville, Virginia 22908 Abstract. S-Nitrosothiol (SNOs) are nitric oxide (NO) -thiol adducts that mediate several cell and organ system signaling pathways relevant to respiration. SNOs are more selective and potent than NO in mediating many respiratory bioactivities, ranging from airway smooth muscle relaxation to regulation of central ventilatory drive [1-3]. Under physiological conditions, SNOs are also more stable and less cytotoxic than are NO and other bioactive nitrogen oxides [3, 4]. Their broad range of bioactivities arises, in part, from their potential to act stereoselectively [2], as nitrosonium (NO*) donors, as nitroxyl (NO') donors or as NO radical donors [5]. Additionally, specific cell systems regulate the bioactivity of SNOs by modifying their synthesis, breakdown and localization [2, 4, 6, 7].
1. Synthesis of S-nitrosothiols. SNOs may be formed by inorganic reactions, particularly in the oxidative environment of the airways. Specifically, NO produced by nitric oxide synthases (NOS) can react with relatively high concentrations of oxygen(O2) and superoxide (O2) - acting as electron acceptors - to S-nitrosylate reduced thiols - present in mM concentrations in the airways - forming extracellular SNOs such as S-nitrosoglutathione (GSNO) [2, 3]. Of note GSNO, was first identified and characterized as an endogenous, bioactive molecule in the airways. Concentrations are 0.1-0.5 uM at baseline and increase to the 1-10 uM range during acute lung inflammation [1]. Low mass, extracellular species such as GSNO are not the only SNOs formed in the lung: S-nitrosylated albumin is also present in the airway lining fluid, and airway epithelial cells, cartilage and inflammatory cells immunostain strongly for endogenously S-nitrosylated proteins under baseline conditions [8]. Synthesis of SNO bonds require an electron receptor. Under inorganic conditions, this acceptor generally represents nitrogen dioxide (NO2), superoxide (O2~) or iron sulfur precursors of iron nitrosyl species [9]. These relatively electropositive species accept an electron from NO radical and form a complex (such as dinitrogen trioxide or an ironnitrosyl species) from which a NO+ equivalent can serve to allow an electrophilic attack on a protein- or low mass- thiol, leaving a proton [4, 5, 9]. This kind of chemistry is also relevant to the organic synthesis of SNOs, where the electrophilic species can include a metal center (for example, in the case of ceruloplasmin [10]) or a redox-based amino acid motif in the primary or tertiary structure of a protein that favors NO transfer to thiol [11]. Among examples of the latter is the S-nitrosylation of the 6-93 cysteine of hemoglobin, which is favored by vicinal amino acids, stabilized during
B. Gaston / S-Nitrosothiols in Respiratory Biology
19
hemoglobin oxygenation and ("R" conformation) and destabilized by deoxygenation of the tetramer (switch to "T"-conformation) [12]. Of note, NO" can also react with more electropositive thiols to accomplish bioactivity [5, 13]. Finally, NOS itself, depending on the local redox environment—particularly including glutathione concentrations and superoxide dismutase activity—can produce S-nitrosomiols [14].
2. Breakdown of S-nitrosothiols. Several enzyme systems regulate the breakdown of GSNO and other Snitrosothiols. These include xanthine/ xanthine oxidase [15], the thioredoxin thyroredoxin reductase system [16], y-glutamyl transpeptidase (GOT), [2, 17] and glutathione peroxidase [18] as recently reviewed [4]. Additionally, Liu and coworkers have shown that glutathione-sensitive formaldehyde dehydrogenase (GS-FDH) tightly regulates intracellular SNO levels in a spectrum of organisms ranging from bacteria to mammals [7]. These enzymes are active in cells of relevance to the respiratory biology - ranging from airway epithelial cells, macrophages and lymphocytes [7, 19] to cells regulating control of breathing [2]. Of note, the catabolic products formed by these enzymes vary widely ( ranging from NO to ammonia) and have a broad spectrum of bioactivities, suggesting that expression of SNO catabolic enzymes may serve not only to regulate the cellular distribution and transnitrosation biochemistry of low-mass and protein SNOs, but also to localize the bioactivity of SNO catabolic products.
3. Bioactivities of S-nitrosothiols. Classically, SNOs exert their bioactivities through transnitrosation reactions, in which the NO group is transferred from one thiol residue to another [4, 5, 20]. During transfer, the target protein is modified through mechanisms ranging from inactivation of an active site thiol (6, 21) to modification of oxygen binding and delivery [22]. In the lung, SNOs have a broad range of functions, ranging from modulation of ventilation-perfusion matching [1,22-24] to alteration of inflammatory cell survival [19, 25]. The mechanisms by which these bioactivities are regulated involve precise control of the composition, compartmentalization and concentration of the SNO pool. Compositional regulation is exemplified by control of minute ventilation at the level of the nucleus tractus solitarius [2] where n-M GSNO levels [26] are only active to stimulate an increase in minute ventilation if activated by GGT to form S-nitrosocysteinyl glycine. An example of regulation of SNO bioactivity by compartmentalization is that of mitochondrial caspases 3 and 9, which are endogenously S-nitrosylated but are denitrosylated and activated with release into the cytosol [6, 19]. Additionally, release of S-nitrosothiols from neurons and epithelial cells into the extracellular space may be involved in nonadrenergicnoncholinergic mediated airway smooth muscle relaxation [27, 28]. The critical relevance of control of concentration is exemplified by increased DNA binding of the nuclear regulatory factor SP1 following exposure to physiological concentrations (nM to low (j.M) of GSNO, with paradoxical inhibition of binding by supraphysiological concentrations (>10 uM) (unpublished observations). Note that the bioactivities of SNOs may be cyclic GMP- dependent or cyclic GMPindependent, depending, in part, on whether the chemical basis for the bioactivity involves homolytic cleavage (to form NO) or transnitrosation reactions. An example is airway smooth muscle relaxation. In guinea pig trachealis, smooth muscle relaxation appears to be primarily cGMP- dependent, whereas in more peripheral airway smooth muscle in
20
B. Gaston / S-Nitrosothiols in Respiratory Biology
humans and other organisms, relaxation is cGMP independent [3, 29-31]. Indeed, for peripheral airway smooth muscle relaxation, the extent to which SNO acts as a "NO donor" - releasing the NO radical - will be the extent to which it loses its bioactivity. In this regard, improved ventilation -perfusion matching associated with certain NO donors such as inhaled ethyl nitrite, inhaled GSNO - and perhaps even inhaled NO - may involve cGMP- independent mechanisms as much as cGMP- dependent mechanisms [8, 23, 32]. It is also important to appreciate that oxygen delivery to the periphery may be regulated by hemoglobin S-nitrosylation. That is, tissue hypoxemia will favor hemoglobin deoxygenation and transfer of the NO group from hemoglobin to anion exchange protein I on the red blood cell membrane, allowing ultimate transfer to - and relaxation - of peripheral vascular smooth muscle [12, 22, 33]. This transfer appears also to favor upregulation of hypoxia-inducible gene through stabilization of hypoxia-inducible factor 1a [34] and to increase minute ventilation through stereoselective neurostimulation [2]. Physiological concentrations of SNOs also affect a variety of other airway epithelial functions. For example, SNOs can modulate the activity of several airway epithelial ion channels [35-38] and increase airway epithelial ciliary beat frequency [39], primarily through cGMP-dependent mechanisms. The role of GSNO in cystic fibrosis (CF) epithelium may be particularly important. GSNO increases the expression and maturation of the CF transmembrane regulatory protein (CFTR) in cells homozygous for AF508, the most common mutation associated with CF [40]. Remarkably, maturation of this protein allows function of CFTR in AF508 homozygous epithelial cells [41]. Further, clinical restoration of normal levels of GSNO in the CF airway [42] is well tolerated and improves oxygenation [32]; there is hope that its long term administration could be of benefit to these patients. Cell signaling by SNOs is of relevance both to baseline respiratory cell signaling and to the pulmonary inflammatory response. Of note in this regard, physiological and supraphysiological concentrations of SNOs often have opposite effects, and levels can be increased or decreased in inflammation, depending on the location and metabolic flux. Examples of cell signaling events mediated by S-nitrosylation chemistry include 1) FAS ligand-signaled denitrosylation of caspases leading to lymphocyte apoptosis [6, 19]; 2) modulation of the expression of cell adhesion molecules, selectin, IL 1 and IL 8 by inhibition of transcription factor NFicB-specifically through S-nitrosylation of the P50 subunit [43-45]; 3) upregulation of HIF-1 binding by stabilization of the subunit HIFl-a [34] likely through S-nitrosylation of critical cysteines in the ubiquitin activation cascade; 4) inhibition of neutrophil NADPH oxidase by S-nitrosylation of the p47phoxsubunit [46]; and 5) inhibition of a variety of glutathione metabolic enzymes [4, 47, 28]. The size, localization and composition of the intracellular SNO pool, as described above, appears to be regulated in a manner loosely analogous to phosphorylation to coordinate the signaling processes. It is not surprising that the determinants of airway SNO concentrations during inflammation are complex. Therapy with NO donors and/or acute inflammation may be associated with high airway SNO levels [1,8,23]. On the other hand, while synthesis may be increased in the severely affected asthmatic airway, catabolism may be accelerated to a greater degree, resulting in high flux and low SNO levels [49, 50]. Low levels may also be found in the airways of patients with CF, where synthesis may be decreased and catabolism increased [42].
B. Gaston /S-Nitrosothiols in Respirator}' Biology
21
4. Summary In conclusion, SNOs are endogenously formed and highly regulated signaling molecules of substantial relevance to respiratory biology. They are present in the lung in physiologically relevant concentrations under normal conditions. They are involved in ventilation-perfusion matching, regulation of peripheral systemic oxygen delivery and central regulation of minute ventilation. Additionally, their cellular localization and metabolism is relevant to a broad range of cell signaling processes, particularly those involved in host defense. Appreciation of this chemistry has led not only to a more comprehensive understanding of the implications of various exhaled nitrogen oxide biomarkers to respiratory disease, but also to the development of new therapies.
Acknowledgment: This work was supported by the NIH/NHLBI: HL 59337. References 1.
2. 3. 4. 5.
6. 7. 8.
9.
10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20.
Gaston, B., et al., Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proceedings of the National Academy of Sciences of the United States of America, 1993. 90(23): p. 10957-61. Lipton, A.J., et al., S-nitrosothiols signal the ventilator/ response to hypoxia. Nature, 2001. 413(6852): p. 171-4. Gaston, B., et al., Relaxation of human bronchial smooth muscle by S-nitrosothiols in vitro. Journal of Pharmacology & Experimental Therapeutics, 1994. 268(2): p. 978-84. Gaston B. Nitric oxide andthiol groups. Biochim Biophys Acta 1999; 1411:323-333. Arnelle, D.R. and J.S. Stamler, NO+, NO, and NO- donation by S-nitrosothiols: implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. Archives of Biochemistry & Biophysics, 1995. 318(2): p. 279-85. Mannick, J.B., et al., S-Nitrosylation of mitochondria! caspases. J Cell Biol, 2001. 154(6): p. 1 1 1 1 6. Liu, L., et al., A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans. Nature. 2001.410(6827): p. 490-4. Lorch, S.A., et al., Immunohistochemical Localization of Protein 3-Nitrotyrosine and Snitrosocysteine in a Murine Model of Inhaled Nitric Oxide Therapy. Pediatric Research June, 2000. 47(6): p. 798-805. Vanin, A.F., I.V. Malenkova, and V.A. Serezhenkov, Iron catalyzes both decomposition and synthesis of S-nitrosothiols: optical and electron paramagnetic resonance studies. Nitric Oxide, 1997. 1(3): p. 191-203. Inoue, K., et al., Nitrosothiol formation catalyzed by ceruloplasmin. Implication for cytoprotective mechanism in vivo. J Biol Chem, 1999. 274(38): p. 27069-75. Perez-Mato, I., et al., Methionine adenosyltransferase S-nitrosylation is regulated by the basic and acidic amino acids surrounding the target thiol. J Biol Chem, 1999. 274(24): p. 17075-9. Jia, L., et al., S-nitrosohaemoglobin: a dynamic activity of blood involved in vascular control. Nature, 1996. 380(6571): p. 221-6. Choi, Y.B., et al., Molecular basis of NMDA receptor-coupled ion channel modulation by Snitrosylation. Nat Neurosci, 2000. 3(1): p. 15-21. Schmidt, H.H., et al., No .NO from NO synthase. Proc Natl Acad Sci USA, 1996. 93(25): p. 14492-7. Trujillo, M., et al., Xanthine oxidase-mediated decomposition of S-nitrosothiols. J Biol Chem, 1998. 273(14): p. 7828-34. Nikitovic, D. and A. Holmgren, S-nitrosoglutathione is cleaved by the thioredoxin system with liberation of glutathione and redox regulating nitric oxide. J Biol Chem, 1996. 271(32): p. 19180-5. Hogg, N., et al., S-Nitrosoglutathione as a substrate for gamma-glutamyl transpeptidase. Biochem J, 1997. 323(Pt2):p. 477-81. Hou, Y., et al., Seleno compounds and glutathione peroxidase catalyzed decomposition of Snitrosothiols. Biochem Biophys Res Commun, 1996, 228(1): p. 88-93. Mannick, J.B., et al., Fas-induced caspase denitrosylation. Science, 1999. 284(5414): p. 651-4. Stamler, J.S., Redox signaling: nitrosylation and related target interactions of nitric oxide. Cell, 1994. 78(6): p. 931-6.
22
21.
22. 23. 24. 25.
26. 27. 28. 29. 30.
31. 32. 33.
B. Gaston / S-Nitrosothiols in Respiratory Biology
Nikitovic, D., A. Holmgren, and G. Spyrou, Inhibition of AP-1 DNA binding by nitric oxide involving conserved cysteine residues in Jun and Fos. Biochemical & Biophysical Research Communications, 1998. 242(1): p. 109-12. Stamler, J.S., et al., Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science, 1997. 276(5321): p. 2034-7. Moya, M.P., et al., S-nitrosothiol repletion by an inhaled gas regulates pulmonary function. PNAS, 2001.98(10): p. 5792-5797. Emery, C.J., Vasodilator action of the S-nitrosothiol, SNAP, in rat isolated perfused lung. Physiological Research, 1995. 44(1): p. 19-24. Hunt J, Fang K, Malik R, Snyder A, Malhotra N, Platts-Mills TAE, Gaston B. Endogenous airway acidification: implications for asthma pathophysiology. Am J Respir Crit Care Med 2000; 161:694699. Kluge, I., et al., S-nitrosoglutathione in rat cerebellum: identification and quantification by liquid chromatography-mass spectrometry. J Neurochem, 1997. 69(6): p. 2599-607. Lilly, C.M., et al., Modulation of vasoactive intestinal peptide pulmonary relaxation by NO in tracheally supervised guinea pig lungs. AmJPhysiol, 1993. 265(4 Pt 1): p. L410-5. Thompson, D.C. and R.J. Altiere, Differential susceptibility of tracheal contraction to nonadrenergic noncholinergic relaxation. J Pharmacol Exp Ther, 1998. 284(1): p. 19-24. Jansen, A., et al., The relaxant properties in guinea pig airways of S-nitrosothiols. Journal of Pharmacology & Experimental Therapeutics, 1992. 261(1): p. 154-60. Bannenberg, G., et al., Characterization of bronchodilator effects and fate of S-nitrosothiols in the isolated perfused and ventilated guinea pig lung. Journal of Pharmacology & Experimental Therapeutics, 1995. 272(3): p. 1238-45. Perkins, W.J., et al., cGMP-independent mechanism of airway smooth muscle relaxation induced by S-nitrosoglutathione. AmJPhysiol, 1998. 275(2 Pt 1): p. C468-74. Snyder A, McPherson ME, Hunt JF, Johnson M, Stamler JS, Gaston B. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med 2002, in press. Pawloski J, Hess D, Stamler J. Export by red blood cells of nitric oxide bioactivity. Nature 2001;409:622-626.
34.
Palmer, L.A., B. Gaston, and R.A. Johns, Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: redox-dependent effect of nitrogen oxides. Molecular Pharmacology, 2000. 58(6): p. 1197-203.
35.
Jain, L., et al., Nitric oxide inhibits lung sodium transport through a cGMP-mediated inhibition of epithelial cation channels. Am J Physiol Lung Cell Mol Physiol, 1998. 274(4): p. L475-484.
36.
Duszyk, M., Regulation of anion secretion by nitric oxide in human airway epithelial cells. Am J Physiol Lung Cell Mol Physiol, 2001. 281 (2): p. L450-457. Kamosinska, B., et al., Role of Inducible Nitric-Oxide Synthase in Regulation of Whole-Cell Current in Lung Epithelial Cells. J Pharmacol Exp Ther, 2000. 295(2): p. 500-505. Kamosinska, B., et al., Nitric oxide activates chloride currents in human lung epithelial cells. American Journal of Physiology, 1997. 272(6 Pt 1): p. LI 098-104. Li, D., et al., Regulation of Ciliary Beat Frequency by the Nitric Oxide-Cyclic Guanosine Monophosphate Signaling Pathway in Rat Airway Epithelial Cells. Am. J. Respir. Cell Mol. Biol., 2000. 23(2): p. 175-181. Zaman, K., et al., S-nitrosoglutathione increases cystic fibrosis transmembrane regulator maturation. Biochem Biophys Res Commun, 2001. 284(1): p. 65-70. Gaston B, A.C., Zaman K, Hunt J, Palmer L, Roomans G., S-Nitrosoglutathione increases expression and activity of deltaF 408 CFTR. Pediatric Pulmonology, 2001. 22 (Supp): p. 193. Grasemann, H.M.D., et al., Decreased levels of nitrosothiols in the lower airways of patients with cystic fibrosis and normal pulmonary function. Journal of Pediatrics December, 1999. 135(6): p. 770-772. Marshall, H.E. and J.S. Stamler, Inhibition of NF-kappa B by S-nitrosylation. Biochemistry. 2001. 40(6): p. 1688-93. Marshall, H.E., K. Merchant, and J.S. Stamler, Nitrosation and oxidation in the regulation of gene expression. FASEBJ, 2000. 14: p. 1-12. delaTorre, A., et al., Endotoxin-mediated S-nitrosylation of p50 alters NF-kappa B-dependent gene transcription in ANA-1 murine macrophages. Journal of Immunology, 1999. 162(7): p. 4101-4108. Park, J.W., Attenuation of p47phox and p67phox membrane translocation as the inhibitory mechanism of S-nitrosothiol on the respiratory burst oxidase in human neutrophils. Biochemical & Biophysical Research Communications, 1996. 220(1): p. 31-5.
37. 38. 39.
40. 41. 42.
43. 44. 45. 46.
B. Gaston / S-Nitrosothiols in Respiratory Biology
47.
48.
49. 50.
Butzer, U., et al., Increased oxidative stress in the RAW 264.7 macrophage cell line is partially mediated via the S-nitrosothiol-induced inhibition of glutathione reductase. FEES Letters, 1999. 445(2-3): p. 274-278. Moellering, D., et al., The induction of GSH synthesis by nanomolar concentrations of NO in endothelial cells: a role for [gammaj-glutamylcysteine synthetase and [gamma]-glutamyl transpeptidase. FEES Letters, 1999. 448(2-3): p. 292-296. Gaston, B., et al., Bronchodilator S-nitrosothiol deficiency in asthmatic respiratory failure The Lancet, 1998.351(9112): p. 1317-1319. Fang K, Johns R, Macdonald T, Kinter Michael, Gaston B. S-Nitrosoglutathione breakdown prevents airway smooth muscle relaxation in the guinea-pig. Am J Physiol Lung Cell Molec Biol 2000;279:L716-L721.
Disease Markers in Exhaled Breath N. Marczin andM.H. Yacoub (Eds.) IOS Press, 2002
Inhibitors of Nitric Oxide Synthase: Experimental Findings and Clinical Implications Nigel K BOUGHTON-SMITH Discovery BioScience, AstraZeneca R&D Charnwood, Loughborough, Leicestershire LEI 1 5RH, U.K. Abstract Inhibitors of nitric oxide synthase (NOS) have been a major tool in investigating the importance of excessive NO and reactive products in the pathology of chronic inflammatory disease and in identifying the potential of selective iNOS inhibitors as potential therapy for these diseases
1. Introduction Excessive NO production occurs in disease states and has been implicated as an important mediator of immune and inflammatory responses and in the pathology of a variety of chronic inflammatory diseases. The role of NO is largely determined by the level and extent of synthesis. Under physiological conditions the levels of intracellular calcium regulates the constitutive NO synthase isoforms (nNOS or NOS-1 and eNOS or NOS-3 ). In contrast, following induction by inflammatory cytokines the activity of inducible NOS (iNOS, NOS-2) is largely controlled by the level of available substrate, Larginine, and produces much greater amounts of NO for longer periods. Excessive NO production following iNOS induction can result in a variety of reactive products which can interact with a number of molecular targets resulting in altered cell function and in some situation in cell death [1].
2. Inhibitors of NOS NOS inhibitors have been a major tool in determining the role of NO in both physiology and pathology [2,3,4,5]. Initially studies used analogues of L-arginine, such as, monomethyl Larginine (L-NMMA) or L-nitroarginine (L-NA) and its methyl ester (L-NAME), which are potent and specific inhibitors of NOS activity. Another inhibitor, which occurs naturally in some disease conditions, is asymm dimethylarginine (L-ADMA). These L-arginine analogues inhibit all the isoforms of NOS with similar potency and are therefore non-selective.
N.K. Boughton-Smith / Inhibitors of Nitric Oxide Synthase
25
Nitric Oxide Synthase inhibitors related to L- arginine R
R'
H
H
L-Arginine
H
CHS
N-Methyl-L-arginine(L-NMMA)
H
N02
N-Nitro-L-arginine(L-NA)
NH
R
S\r i
R.
11
,.
T**-^ ^-^ H
,^C02H IT 1
NH2
CH3CH3
as/mmdimethylarginin^L-ADMA)
Figure 1. Non-Selective Inhibitors of NO synthase
a. Protective Role for NO from Constitutive NOS Removal of endogenous NO by administration of non-selective NOS inhibitors such as L-NMMA and L- NAME potentiates acute intestinal vascular damage produced by endotoxin [5]. Furthermore, inhibition of NOS by the non-selective inhibitors promotes basal neutrophil endothelial adhesion and vascular leakage in the intestinal vasculature [6,7]. In addition, NO donors, a source of exogenous NO, protect against acute intestinal damage produced by endotoxin. These studies suggest that endogenous NO from constitutive NOS has a protective role in the vasculature. The mechanism of protection by NO is probably due to the vasodilator and anti-aggregatory action of NO as well as inhibition of cellular adhesion.
b. Pathological Role for excessive NO from induced NOS in acute inflammation The role of the excessive NO production from iNOS in models of vascular leakage and inflammation has also been investigated using more selective inhibitors of iNOS.
Miscellaneous Nitric Oxide Synthase Inhibitors
CQjH N-(IminoethyI)-L-lysine (L-NIL)
1400W (Glaxo-Wellcome)
2-Amino-4-mcthylpyridine
Figure 2. NO Synthase Inhibitors with some Selectivity for iNOS
26
N. K. Boughton-Smith / Inhibitors of Nitric Oxide Synthase
Examples of inhibitors with some selectivity for iNOS are the weak inhibitor of NOS aminoguanidine (AG) and the more potent inhibitors, N-iminoethyl-L-lysine (L-NIL), 2-amino4-methylpyridine, and the GSK compound 1400W [2,3,4]. Although some of these inhibitors are very potent in-vitro, they have only marginal selectivity in-vivo and at higher doses can produce adverse side effects. These inhibitors have, however, been used extensively as experimental tools to investigate the potential role of iNOS in normal physiology and in inflammatory disease. In contrast to non-selective NOS inhibitors, such as L-NMMA and LNAME which potentiate vascular leakage and oedema formation produced by endotoxin. the selective iNOS inhibitor, 1400W attenuates these effects [8]. Anti-inflammatory activities of NOS inhibitors have been described in a variety of models of acute inflammation in which there is iNOS induction. In zymosan peritonitis the vascular leakage, which is related to iNOS activity and increases in NO, is attenuated by L-NAME. The selective NOS inhibitor L-NIL also reduces oedema produced by carrageenan in the rat paw and air pouch in which increases in iNOS activity have also been detected [9,10,11]. The anti-inflammatory activity of non-selective and selective NOS inhibitors suggests that iNOS induction and the subsequent formation of NO and other reactive breakdown products play an important role in vascular leakage and oedema formation, the hall marks of the acute inflammatory response.
3. Role of iNOS in chronic inflammatory disease a. Role of iNOS in Inflammatory Bowel Disease Increases in iNOS activity and the consequential excessive production of NO and reactive products have been observed in a variety of chronic inflammatory disease. In Ulcerative Colitis (UC) and Crohn's Disease (CD), there are marked increases in iNOS activity in the inflamed colon which are extensively located in the mucosal epithelium. Furthermore, incubation of colonic epithelial cells with appropriate cytokines results in iNOS expression. There are increases in iNOS activity in animal models of IBD including; the TNB model. PG/PS granulomatous colitis, HLA-B27 transgene colitis and a model of colitis in the guinea pig. Inhibitors of NOS are beneficial in these models. In PG/PS granulomatous colitis both LNAME and AG reduce macroscopic inflammation and neutrophil infiltration. Neutrophil infiltration in HLA-B27 transgene colitis is also inhibited by L-NAME or AG. However, whereas AG reduces colonic permeability in this model, the non-selective inhibitor L-NAME increased permeability [12,13]. These results support the concept for a protective role of constitutive NOS and a pathological role for iNOS. The induction of NOS in the colonic mucosa, with the excessive production of NO, a potent vasodilator, may have an important role to play in the mucosal hyperaemia, vascular permeability and colonic mucosal oedema observed in active ulcerative colitis. Excessive NO production may also affect epithelial function and viability in this disease.
b. Role of iNOS in Rheumatoid and Osteoarthritis Induction of iNOS in arthritis results in increased nitrite levels in the synovial fluid, sera and urine from RA and OA patients. The iNOS is expressed in chondrocytes, type A synoviocytes and fibroblasts. Immunoreactive nitrotyrosine in the inflamed synovium indicates that the highly reactive product peroxynitrite, produced by interaction of NO with the
N. K. Boughton-Smith / Inhibitors of Nitric Oxide Synthase
27
superoxide radical( O2-), has been formed. Increase in plasma nitrite and iNOS activity in a variety of RA models including, adjuvant arthritis, collagen induced arthritis, streptococcal cell wall arthritis, and the spontaneous arthritis and nephritis produced in MLR Ipr/lpw mice are related to disease activity. Furthermore, paw swelling, synovial inflammation and cartilage degradation are reduced by L-NAME and L-NMMA and also by L-NIL, a NOS inhibitor with some selectivity for the induced NOS isoform [2,3,4]. In the dog cruciate ligament model of OA there is iNOS induction in the cartilage and L-NIL reduces the cartilage degradation and inflammatory [14]. The excessive formation of NO following iNOS induction may play an important role in arthritis [15]. The local vasodilator actions of NO may contribute to oedema and NO or reactive products may increase vascular leakage. NO may either directly, or through activation of cyclooxygenase-2 (COX2), also contribute to the pain of arthritis. NO inhibits chondrocyte proliferation and induces chondrocyte apoptosis. Furthermore, NO can both reduce proteoglycan synthesis and activate the metalloprotease enzymes, collagenase and stromolysin and thereby enhance cartilage degradation. Excessive NO production may play a role in cartilage destruction in the arthritic joint. NO may play a role in bone resorption since Inflammatory Disease Joint Lung
Pathology
Bowe|
UC
CD
RA
Vasodilatation
+
_|-
4.
OA
ASTHMA COPD _j.
-j_
Vascular Permeability
_j_
.j.
_j_
_j_
_j_
Epithelial Cell Function
,
+
+
Mucus Secretion
+
+
+
r
Mucosal Permeability
+
4-
+
+
Pain
?
?
Impaired Motility
+
+
+
Cartilage Degradation
+
+
Bone Loss/ Remodelling
.
,
T Cell Response
+
+
+
+
enhancement of IL-1(5 induced calverial bone resorption by TNFa is inhibited by L-NMMA [16]
Table 1 Potential role of iNOS in the pathology of chronic inflammatory disease (UC = Ulcerative Colitis; CD = Crohn's Disease; RA = Rheumatoid Arthritis; OA = Osteoathritris, COPD = Chronic Obstructive Pulmonary Disease)
c. Role of iNOS in Asthma Several clinical studies have shown a marked increase in exhaled NO from patients with asthma, which is closely associated with reduced lung function and eosinophil infiltration. Improvements in lung function produced by corticosteriods are accompanied by a concomitant reduction in exhaled NO [17]. The increase in NO is derived from iNOS in the airways and is located predominantly in the bronchial epithelium with some activity in inflammatory cells.
28
N. K. Boughton-Smith / Inhibitors of Nitric Oxide Synthase
Stimulation of bronchial biopsies, primary cultures of epithelial cells or epithelial cell line results in the induction of iNOS mRNA, protein and iNOS enzyme activity [18]. The induction of iNOS is related to the activation of the transcription factor NFicB [19]. Increases in the local production of NO by the bronchial epithelium of asthmatic could increase the permeability or have cytotoxic effects and contribute to loss of function. Increased NO may contribute to hyperaemia, plasma exudation and mucus production and in the imbalance in the T cell response that underlies the immunological basis of asthma [20].
4. Conclusions In chronic inflammatory diseases increased NO following iNOS induction may produce vasodilatation, vascular permeability and oedema. In addition, NO from iNOS may contribute directly to inflammatory pain. Selective inhibitors of iNOS have considerable potential as anti-inflammatory therapy. Since increased NO and reactive products can fundamentally affect cells to produce a loss of function and cell death inhibitors of iNOS also have the potential to restore cell function in chronic inflammatory disease and be disease modifying. The description of the iNOS crystal structure has heralded a new era in the design of novel inhibitors, which have the greater potency, selectivity, specificity and robust pharmacokinetics required to exploit the clinical potential of iNOS inhibition in chronic inflammatory disease.
References 1. 2. 3. 4. 5. 6. 7. 8. 9. 10.
11.
12.
13.
Moncada S, Palmer RMJ, Higgs EA. Nitric Oxide: physiology, pathophysiology and pharmacology Pharmacol. Rev. 1991, 43, 109-141. Cochran, FR, Selph J, Sherman P. Insights into the role of nitric oxide in inflammatory arthritis Med. Res. Rev. 1996, 16, 547-563. Fretland DJ, Connor JR, Pitzele BS, Currie MG, Manning PT. Inhibition of nitric oxide synthase and prospects for therapy in inflammatory diseases. Cur Pharm Design. 1997, 3, 447-462. Boughton-Smith NK, Tinker AC. Inhibitors of nitric oxide synthase in inflammatory arthritis. I Drugs 1998, 1, 321-333. Hutcheson IR, Whittle BJR, Boughton - Smith NK. Role of nitric oxide in maintaining vascular integrity in endotoxin - induced intestinal damage in the rat. Br. J. Pharmacol. 1990, 101,815- 820. Kubes,P. Granger DN. Nitric oxide modulates microvascular permeability. Am. J. Physiol.1992,262. H611-H615. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 4651-465. Garvey EP, Oplinger JA, Furfme ES, Kiff RJ, Laszlo F, Whittle BJR, Knowles RG. 1400W is a slow, tight binding inhibitor of inducible nitric oxide synthase. J. Biol. Chem. 1997, 21,4959-4963. Boughton-Smith NK, Ghelani A. Role of induced nitric oxide synthase and increased NO levels in zymosan peritonitis in the rat. Inflamm. Res. 1995, Suppl 2, S149-S150. Salvamini D, Manning PT, Zweifel BS, Seibert K, Connor J, Currie MG, Needleman P. Dual inhibition of nitric oxide and prostaglandin production contributes to the anti-inflammatory properties if nitric oxide synthase inhibitors. J. Clin. Invest. 1995, 96, 301-308. Salvemini D, Wang Z-Q, Wyatt PS, Bourden DM, Marino MH, Manning PT, Currie MG, Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br..J.Pharmacol. 1996, 118,829-838. Grishham MB, Specian RD, Zimmerman TE. Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of granulomatous colitis. J Pharmacol. Exp. Ther. 1994, 271, 1114-1221. Aiko S, Fuseler J, Grisham MB. Effcet';s of nitric oxide inhibition or sulphasalzine on spontaneous colitis observed in HLA-B27 transgenic rats. J. Pharmacol & Exp. Thera. 1998, 284, 722 -727.
N.K. Boughton-Smith /Inhibitors of Nitric Oxide Synthase
14. Pelletier J-P, Joanovic D, Fernandas JC, Manning P, Connor JR, Currie MG, DiBattista JA, MartelPelletier J. Reduced progression of experimental osteoarthritis in-vivo by selective inhibition of induced nitric oxide synthase. Arth & Rheum. 1998, 41, 1275-1286. 15. Amin, AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr. Opin. Rheumatol. 1998, 10, 263-272. 16. Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin. Nitric oxideia cytokineinduced regulator of bone resorption. J. Bone & Mineral Res. 1995, 10, 1040-1049. 17. Kharitonov SA, Barnes PJ. Exhaled Markers of Pulmonary Disease. Am. J. Crit. Care Med. 2001, 163, 1693-1722. 18. Dweik RA, Comhair SAA, Gaston B, Thunnissen FBJM, Farver C, Thomassen MJ, Kavuru M, Hammel J, Abu-Soud HM, Erzurum SC. NO chemical events in the human airway during the immediate and the late antigen-induced asthmatic response. Proc. Natl. Acad. Sci. USA, 2001, 98, 2622-2627. 19. Adcock IM, Brown CR, Kwon O, Barnes PJ. Oxidative stress induces NFkB DNA binding and inducible NOS mRNA in human epithelial cells. Biochem. Biophys. Res, Comm. 1994, 199, 15181523 20. Barnes J, Liew FY. Nitric oxide and asthmatic inflammation. Immunology Today, 1995, 16, 128-130.
30
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
Inhaled NO as a Replacement Therapy George J. BALTOPOULOS and Pavlos M. MYRIANTHEFS Athens University School of Nursing Intensive Care Unit at K.A.T General Hospital ofKifissia, 2 Nikis Street 14561, Athens Greece Abstract. Nitric oxide, normally produced by the body in small quantities having significant physiologic functions, may express altered production or metabolism dependent on disease process, O2 concentration, L-arginine, and NOS isoforms function. Inhaled NO may cause selective pulmonary vasodilatation reducing PVR, PAP, increasing CO and improving V/Q matching and oxygenation. Inhaled NO replacement therapy may have significant supporting role in several critical illnesses associated with pulmonary hypertension, right ventricular failure and severe hypoxemia. However, data are lacking concerning iNO replacement based on actual NO deficiency due to reduced production or increased consumption during disease process; substrates or NOS deficiency or dysfunction.
1. Introduction Nitric oxide (NO) was first identified in 1987 as the endothelial-derived relaxing factor -EDRF [1,2]. NO is a small, colourless, almost odourless, unstable, highly reactive, gaseous free radical, slightly soluble to water, that is freely diffusible across cell membranes. NO can be found normally in the atmosphere as well as in the environment of industrial areas, smog, heavy traffic areas or cigarette smoke produced from combustion processes [3]. Thus, until about 10 years ago, NO was considered as a highly reactive toxic molecule to the body and an environmental pollutant. Work-place limits for exposure to NO have been set to 25 ppm [4]. NO is also commercially produced for medical purposes in inhaled form. NO rapidly reacts with O2 and superoxide converting respectively to nitrites/nitrates (NO2/NO3~) and peroxynitrite (a well known oxidizing and nitrating species with toxic properties) having a half-life period of 3 to 50 seconds [5, 6]. NO is normally produced in small quantities by the body being an endogenous molecule that has important physiologic functions concerning the cardiovascular, immune and nervous system [7]. There are three isoforms of NO synthases (endothelial, inducible and neuronal) which catalyses the synthesis of NO from the terminal quanidine nitrogen of L-arginine producing also L-citruline. Both eNOS and nNOS are constitutive forms that produce small amounts of NO for short periods of time when stimulated maintaining physiologic functions such as vascular tone and neurotransmission. Contrary, iNOS when stimulated produces large amounts of NO for longer periods of time and is thought to be involved in inflammatory responses and immune defence mechanisms against invading pathogens including bacteria and parasites [8]. NO has been the focus of intense basic and clinical research due to its important role as a mediator in inflammation, as a neurotransmitter and a regulator of vasomotor tone.
G.J. Baltopoulos and P. M. Myrianthefs / Inhaled NO as a Replacement Therapy
31
2. Rational of inhaled nitric oxide replacement therapy In blood NO produced by the endothelium, causes vasodilatation by increasing cyclic guanosine 3', 5' monophosphate (cGMP) which subsequently decreases intracellular calcium in the vascular smooth muscles [3, 7, 8]. The understanding of endogenous NOcGMP pathway and its significant role in the modulation of vascular tone led to the idea of using exogenous inhaled NO as a therapeutic pulmonary vasodilator. This assumption was based on the knowledge that NO rapidly binds to hemoglobin and consequently the vasodilatation would be limited to the pulmonary circulation and not to systemic circulation [5]. There are early data suggesting that supplemental inhaled NO vasodilate the pulmonary circulation in a dose depended fashion, decreasing pulmonary artery pressure (PAP) and pulmonary vascular resistance (PVR) in patients with primary pulmonary hypertension [9], improving ventilation/perfusion (V/Q) matching and oxygenation [6, 10] and increasing right ventricular injection fraction (RVEF) [11]. NO replacement therapy could be beneficial to control pulmonary vascular tone, pressure and resistance and improve arterial oxygenation if NO levels proved to be inadequate or reduced in the lungs due to disease process which means that NO may be inadequately produced or extremely consumed or metabolized to nitrites/nitrates and peroxinitrate, Inhaled NO could be also beneficial in idiopathic or secondary pulmonary hypertension in the presence of pulmonary vasoconstriction and right ventricle dysfunction. Inhaled NO may also be beneficial in acute lung injury because of its properties in mediating diverse antioxitant and anti-inflammatory reactions protecting from hyperoxia induced apoptosis and vascular leakage, down regulating the expression of adhesion molecules and reducing extravasation and tissue accumulation of leukocytes. Potential beneficial uses of iNO in clinical practice are: 1) mild bronchodilatation, 2) improved ventilation/perfusion ratio (V/Q) 3) decreased intrapulmonary shunt, 4) decreased right ventricular pressure (RVP), 4) decreased intracardiac shunt, 5) increased right ventricular ejection fraction (RVEF), 6) decreased pulmonary artery pressure (PAP) 7) decreased pulmonary vascular resistance (PVR), 8) increased cardiac output (CO) and 9) increased arterial oxygen tension (PaOi). Inhaled NO received approval by FDA for clinical use in 1999 for term and near term (older than 34 weeks) neonates with hypoxemic respiratory failure associated with pulmonary hypertension. 3. Deficient formation and excessive consumption of endogenous NO in the lungs NO production requires Oi, NADPH, cofactors, calmodulin, L-arginine, and functional NO synmases isoforms [3, 5, 12, 13]. In the lungs NO is produced from the vasculature by the action of eNOS and from the airways by the action of all three NO synthases isoforms [14]. Oxygen is an essential substrate for NO synthesis by NOS and thus hypoxia may contribute to significant decrease in NO production in the hypoxic lung. Acute hypoxia in terms of low inspired fraction of oxygen (FiO2) in normal humans resulted in significant decrease in exhaled NO when inhaled hypoxic gas was 5 % of oxygen [15] but not when inhaled oxygen was 10 % [15, 16]. Also, chronic hypoxia limits NO production in the lungs [17, 18] despite increased expression of all three NOS isoforms [19, 20, 21]. Same findings in chronically hypoxic rat lungs observed by Sato et al [24] at FiOi of 3 % which were most markedly at FiO2 of 0%. L-arginine substrate deficiency or uptake is also associated with reduced NO production which is reversed by L-arginine supplementation [23] suggesting an additional mechanism of decreased NO production and deficiency in the human body.
32
G.J. Baltopoulos and P.M. Myrianthefs / Inhaled NO as a Replacement Therapy
NO production is also dependent on the presence and function of NOS isoforms and it has been shown that eNOS immunostaining of pulmonary arterial endothelial cells was consistently less in patients who died with ARDS compared to non ARDS patients. On the other hand iNOS expression was higher in alveolar macrophages and airway epithelial cells in patients who died with ARDS compared to non ARDS patients [24]. These data suggest an impaired NOS expression in ARDS contributing to changes in NO levels in human lungs. In patients with chronic pulmonary hypertension iNOS expression is also reduced resulting in reduced NO production [25]. Aikio et al [26] showed that macrophages iNOS expression in neonates with fulminant early-onset pneumonia differed showing an impaired production of NO and peroxynitrite due to immature iNOS production. Steudel et al [27] showed that congenital absence of eNOS results in pulmonary hypertension and in combination with long-term hypoxia to increased right ventricular remodelling. In COPD patients exhaled NO production is reduced and NO production from the airways is lower and inversely related to the development of cor pulmonale [28]. In transplant patients endogenous production of NO by cadaver lung allografts in the perioperative period is significantly diminished following one of three patterns which correlates to clinical behaviour [29]. Recently Sittipunt et al [8] showed that NO and its products accumulates in the lungs before and after onset of ARDS, that iNOS is expressed at high levels in alveolar macrophages during ARDS and that nitration of intracellular and extra cellular proteins occurs in the lungs of ARDS. These data indicate an altered production and metabolism of NO in the lungs of ARDS patients. 4. Possible indications for inhaled NO replacement therapy Possible indications of iNO in perioperative, intensive care and ambulatory patients are listed in table 1. Table 1. Indications, underlying pathophysiology and related literature. Indication Comments Pathophysiology Mitral valve surgery, Coronary artery bypass grafting (CABG) Heart transplantation
Pulmonary hypertension Pre-existing pulmonary hypertension
Left ventricular assist device Lung transplantation
Reperfusion injury
Congenital heart disease surgery
Pulmonary hypertension
ALI/ARDS
Hypoxemia, Pulmonary hypertension Hypoxemia, Pulmonary hypertension
Persistent primary pulmonary hypertension of the newborn, Hypoxic respiratory failure Massive pulmonary embolism COPD Sickle cell disease, acute syndrome Cystic fibrosis
chest
Pulmonary hypertension, RV failure Pulmonary hypertension Infarction, hypoxemia, pulmonary hypertension Reduced expression of iNOS, and exhaled NO
Decreased PVR, improved CO in RV failure [7, 30] protection from RV failure [29, 3 1 ] Prevention of RV failure [32] Prevention from pulmonary hypertension and RV failure [33] Decrease in PVR, increase in cardiac output [34] Improve oxygenation, decrease PVR, [35, 36, 37, 38] Improve oxygenation, decrease PVR [39,40,41,42] Decrease PAP, increase CO [43] Improve oxygenation, decrease PVR [44] Improve oxygenation [45] Reversion of airway obstruction [46]
GJ. Baltopoulos and P.M. Myrianthefs / Inhaled NO as a Replacement Therapy
33
5. Conclusions Inhaled NO therapy could be an assisting-supporting therapeutic measure in several clinical conditions of critical illness in adult and paediatric patients associated with pulmonary hypertension, RV failure and hypoxemia. Despite lack of benefit in terms of outcome, iNO has several certain indications as a rescue therapy in patients non responding to other therapeutic measures. More studies are needed to determine the need of iNO in terms of absolute or relative NO deficiency (decreased production, increased consumption) in these conditions. References [I] RM Palmer, AG Ferrige, S Moncada. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 327:524-526. [2] LJ Ignarro, GM Buga, KS Wood, RE Byrns, G Chaudhuri. Endotheliurn-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Sci USA (1987) 84:9265-9269. [3] W Steudel, WE Hurford, WM Zapol. Inhaled nitric oxide. Basic biology and clinical applications. Anaesthesiology (1999) 91:1090-1121. [4] NIOSH recommendations for occupational safety and health standards. MMWR Morb Mortal Wkly Rep (1998)37:1. [5] E Anggard. Nitric oxide: mediator, murderer, and medicine. Lancet (1994) 343:1199-1206. [6] N Jindal, RP Dellinger. Inhalation of nitric oxide in acute respiratory failure. J Lab Clin Med (2000) 136:21-28. [7] E Haddad, SM Lowson, RA Johns, GF Rich. Use of inhaled nitric oxide perioperatively and in intensive care patients. Anaesthesiology (2000) 92:1821-1825. [8] C Sittipunt, KP Steinberg, JT Ruzinski, et al. Nitric oxide and nitrotyrosine in the lung of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med (2001) 163:503-510. [9] J Pepke-Zaba, TW Higenbottam, AT Dihn-Xuan, D Stone, J Wallwork. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet (1991) 338:1173-1174. [10] Rossaint R, Falke KJ, Lopez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-405. I I 1 ] L Fierobe, F Brunet, J Daihnaut, et al. Effects of inhaled nitric oxide on right ventricular function in adult respiratory distress syndrome. Am J Respir Crit Care Med (1995) 151:1414-1419. [12] CM Hart. Nitric oxide synthesis in the lung. Chest (1999) 115:1407-1414. [13] RA Dweik, D Laskowski, HM Abu-Soud, et al. Nitric oxide synthesis in the lung. J Clin Invest (1998) 101:660-666. [14] TD Le Grass, IF McMurtry. Nitric oxide production in the hypoxic lung. Am J Physiol Lung Cell Mol Physiol (2001) 280:L575-L582. [15] L Schmetterer, K Strenn, J Kastner, H Eichler, M Woltz. Exhaled NO during graded changes in inhaled oxygen in man. Thorax (1997) 52:736-738. [16] I Tsujino, K Miyamoto, M Nishimura, et al. production of nitric oxide in intrathoracic airways of normal humans. Am J Respi Crit Care Med (1996) 154:1370-1374. [17] TC Isaacson, V Hampl, EK Weir, DP Nelson, SL Archer. Increased endothelium-derived NO in hypertensive pulmonary circulation of chronically hypoxic rats. J Appl Physiol (1994) 76:933-940. [18] M Muramatsu, RC Tayler, DM Rodman, IF McMurtry. Trapsigargin stimulates increased NO activity in hypoxic hypertensive rat lungs and pulmonary arteries.. J Appl Physiol (1998) 80:1336-1344. [19] TD Le Grass, C Xue, A Rengasamy, RA Johns. Chronic hypoxia upregulates endothelial and inducibie nitric oxide synthase gene and protein expression in rat lung. Am J Physiol Lung Cell Mol Physiol (1996) 270:L164-L170. [20] TC Resta, RJ Gonzales, WG Dail, TC Sander, BR Walker. Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol Heart Circ Physiol (1997) 272:H806-813. [21] PW Shaul, AJ North, TS Brannon, et al. Prolonged in vivo hypoxia enhances nitric oxide synthase type 1 and type III gene expression in adult rat lung. Am J Respir Cell Mol Physiol (1995) 13:167-174. [22] K Sato, K Nair, J Hiddinga, et al. Hypoxia inhibits ETB receptor mediated NO synthesis in hypertensive rat lungs. Am J Respir Cell Mol Physiol (1999) 276:L571-L581. [23] CD Fike, MR Kaplowitz, LA Rehorst-Paea, LD Nelin. L-arginine increases nitric oxide production in isolated lung of chronically hypoxic newborn pigs. J Appl Physiol (2000) 88:1797-1803. [24] KH Albertine, ZM Wang, JR Michael. Expression of endothelial nitric oxide syntahse, inducibie nitric oxide synthase, and endothelin-1 in lungs of subjects who died with ARDS. Chest (1999) 116:1018-1025.
34
G.J. Baltopoulos and P.M. Myrianthefs / Inhaled NO as a Replacement Therapy
[25] A Giad, D Saleh. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med (1995) 333:214-221. [26] O Aikio, K Vuopala, M-L Pokela, M Hallman. Diminished inducible nitric oxide synthase expression in fulminant early-onset neonatal pneumonia. Pediatrics (2000) 105:1013-1019. [27] W Steudel, M Scherrer-Crosbie, KD Bloch, et al. sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J Clin Invest (1998) 101:2468-2477. [28] E Clini, G Cremona, M Campana, et al. Production of endogenous nitric oxide in COPD and patients with cor pulmonale correlates with echo Doppler assessment. Am J Respir Crit Care Med (2000) 162:446-450. [29] N Marczin, B Riedel, J Gal, J Polak, M Yacoub. Exhaled nitric oxide during lung transplantation. Lancet (1997)350:1681-1682. [30] DA Fullerton, J Jaggers, MM Wollmering, F Piedaule, FL Groer, RC Mclntyre. Variable response to inhaled nitric oxide after cardiac surgery. Ann Thorac Surg (1997) 63:1251 -1256. [31] N Keiler-Jensen, S Lundin, SE Ricksten. Vasodilator therapy after heart transplantation: Effects of inhaled nitric oxide. J Heart Lung Transplant (1995) 14:436-443. [32] M Argenziano, A Choundhri, N Moazami, EA Rose, CR Smith, HR Levin. Randomised, double blind study trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg (1998) 65:340-345. [33] H Date, AN Triantafillou, EP Trulock, MS Pohl, JD Copper, GA Patterson,. Inhaled nitric oxide reduces human allografts dysfunction. J Thorac Cardiovasc Surg (1996) 111:913-919 [34] IA Russel, MS Zwass, JR Fineman, M Balea, K Roine-Rapp, M Brook. The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease. Anaesth Analg (1998) 87:46-51. [35] RP Dellinger, JL Zimmerman, RW Taylor et al Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomised phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med (1998) 26:15-23. [36] S Lundin, H Mang, M Smithies, O Stenqvist, C Frostell. For the European Study Group of Inhaled Nitric Oxide. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. Intensive Care Med (1999) 25:911-919. [37] D Payen, B Vallet and "Group d' Etude du NO dans I' ARDS". Results of the French prospective multicentric randomised double blind placebo controlled trial on inhaded nitric oxide (NO ) in ARDS.Intensive Care Med (1999) SI66. [37] R Ullrich, C Lorber, G Roder et al. Controlled airway pressure therapy, nitric oxide, prone position and extracorporeal membrane oxygenation as components of an intergrated approach to ARDS. Anaesthesiology (1999) 91:1577-1586. [38] E Troncy, JP Collet, S Shapiro, et al. Inhaled nitric oxide in acute respiratory distress syndrome. A pilot randomised controlled study. Am J Respir Crit Care Med (1998) 157:1483-1488. [39] R Clark, T Kueser, M Walker et al for the Clinical Inhaled Nitric Oxide Research Group. Low dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med (2000) 342:469-474. [40] R Smyth. Inhaled nitric oxide treatment for pre-term infants with hypoxic respiratory failure. Thorax (2000)55:S51-S55. [41] The Neonatal Inhaled Nitric Oxide Study Group. Inhaled Nitric Oxide in Full-Term and Nearly Full-Term Infants with Hypoxic Respiratory Failure. N Engl J Med (1997) 336:597-604. [42] D Cornfield, R Maynard, R deRegnier et al. Randomized, controlled trial of low dose of inhaled nitric oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension. Pediatrics (1999) 104:1089-1094. [43] G Capellier, T Jacques, P Balvay, G Blasco, E Belle, F Barale. Inhaled nitric oxide in patients with pulmonary embolism. Intensive Care Med (1997) 23:1089-1092. [44] M Yoshida, O Taguchi, EC Gabazza, T Kobayashi, T Yamakami, H Kobayashi. Combined inhalation of nitric oxide and oxygen in COPD. Am J Respi Crit Care Med (1997) 155:526-529. [45] AM Atz, DL Wessel. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology (1997) 87(4):988-990. [46] MJ Mhanna, T Ferkol, RJ Martin, et al. Nitric oxide deficiency contributes to impairement of airway relaxation in cystic fibrosis mice. Am J Respir Cell Biol (2001) 24 (5):621-626.
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
35
Physiology of Exhaled Nitric Oxide L. Christofer ADDING and Lars E. GUSTAFSSON Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
Abstract. Nitric oxide in exhaled air denotes the ongoing enzymatic production of this "simple" but essential mediator molecule in the respiratory system where it exerts important physiological functions. To appreciate the value of exhaled nitric oxide measurements one must comprehend that nitric oxide in exhaled air does not represent a waste product from systemic sources passively excreted by the blood. Nitric oxide production in the respiratory system is a necessity at birth and continuous throughout life. In fact, post mortem during circulatory arrest in experimental animals airway levels of exhaled nitric oxide increases provided that ventilation of the lungs are maintained. Experimental studies of exhaled nitric oxide show that the enzymatic production of nitric oxide in the lung is a constant process that endure many investigational provocations. However, there are a few intriguing physiological and pathophysiological conditions, pharmacological treatments and other experimental manoeuvres (e.g. stretch, carbon dioxide, inflammation, catecholamines) that per se alter (increase or decrease) the levels of exhaled nitric oxide. These biological observations and clinical findings becomes even more intriguing considering the fact that for some of these alterations in respiratory NO production we do not know if they are beneficial or detrimental. The standard method for measurements of exhaled nitric oxide is based on the highly specific and sensitive chemiluminescence technique and was first described in 1991. However, the method is not without pitfalls and precaution must be taken when interpreting exhaled nitric oxide data. Particular attention should be paid to physiological factors that are known to confound exhaled nitric oxide measurements and consequently predispose for erroneous conclusions. Thus, in this chapter we summarize the fundamental findings of exhaled nitric oxide measurements and give the reader a basic survey of the physiological regulation of exhaled nitric oxide.
1. Introduction Direct measurements of nitric oxide (NO) have been a problem in NO research, due to NO's rapid oxidation in biological tissues with a half-life for NO only of seconds. Several assays have been used that indirectly measure NO production e.g. cGMP, nitrite (NO2") or citrulline conversion, reflecting the effect of NO, NO metabolism or NO synthesis, respectively, see [1]. In 1987 Palmer et al. [2] introduced a chemiluminescence method, originally developed by environmental scientists to detect nitrogen oxides in the atmosphere [3, 4], and direct measurements of NO released from cells could be made. However, the method determined the sum of NO and NO2" in liquid samples from cells or tissues and recovery of NO was dependent on rapid sample acquisition to avoid oxidation. In 1991 Gustafsson and colleagues used this method to analyse lung perfusate during hypoxic
36
L C. Adding and L E. Gustafsson / Physiology of Exhaled NO
conditions to elucidate the role of NO during hypoxic pulmonary vasoconstriction (HPV). During these experiments it was postulated that NO, being a gas with a low solubility in aqueous solution, would escape into the airways and be detectable in exhaled gas. This hypothesis proved to be right and direct evidence for the production of NO in humans was thus presented [5-7]. The discovery of NO in exhaled gas has not only offered a new approach to directly study features of NO metabolism in vivo, but also exhaled NO measurements seem to be a valuable non-invasive diagnostic tool of airway inflammation [8, 9]. Almost 600 studies in the field of exhaled NO research have been published with sometimes opposing results leading to conflicting interpretation. This chapter gives a review of the most important physiological factors that will influence exhaled NO.
2. Chemilummescence measurement of exhaled NO 1. Identity of exhaled NO Measurements of NO in respiratory gas by the chemiluminescence reaction is based on the finding that ozone reacting with NO yields excited NO2 which subsequently emits a photon of preferentially infrared light. The number of emitted photons are thus directly proportional to the original NO abundance, and the photons can be counted by a photomultiplier tube. Many compounds may react with ozone under the emission of light, but when the method employs red filters with a cut-off such that only light with wavelength above 600 nm is measured the method becomes quite specific although not unique to NO. For another substance to elicit chemiluminescence such a substance must be volatile and have chemical properties, not likely to occur in biological systems, that will make it react with ozone [1]. In the initial study [5], the presence of NO in exhalates of humans and guinea pigs was demonstrated by three separate methods including reacting exhaled gas with thioproline and subsequently demonstrating the presence of nitrosothioproline by gas chromatography/mass spectrometry (GcMS). In a later study [7], direct GcMS on exhaled gas was performed using a cooled gas chromatography column to separate NO from other molecules having a mass of 30 and present in normal athmosphere in significant amounts, e.g. ISI5 N 2 , and the presence of NO in exhalates from humans was thus confirmed in the most direct manner. A limitation of this method was that it was not linearly quantitative. Thus, there was therefore a need to evaluate exhaled NO during quantitative chemiluminescence measurements and using physicochemical means to test for its presence. This was initially done in humans and rabbits using a cold trap at -80 C [5]. A later study was done in humans, rats, guinea pigs, and rabbits [10]. Here the methodology employed was to carry exhaled gas through a cold trap cooled to temperatures where other gases than NO would be expected to be frozen out of exhaled gas, finally taking the temperature down where also the NO signal disappeared. The cooling trap consisted of a copper or stainless steel loop, having a configuration allowing counter-current exchange of heat from afferent to efferent limb to ascertain attainment of desired temperatures. Mixtures of dry ice, acetone and liquid nitrogen allowed temperatures of the coil down to -196 C. During these experiments it was verified that the chemiluminescence signal disappeared only when coil temperature was brought below the freezing point for NO, giving a more facile verification that the chemiluminescence signal derives from exhaled NO. Another support for exhaled NO as the cause for chemiluminescence is testing for the possibility to make it disappear by pharmacological inhibition of its biochemical formation.
LC. Adding and L.E. Gustafsson / Physiology of Exhaled NO
37
The chemiluminescence signal of exhalate is inhibited or disappears during administration of NO-synmase (NOS) inhibitors of L-arginine-derivatives type, and the signal can be partially or fully restored by a surplus of the natural substrate for NO formation, L-arginine (see table 1 and 2 for refs.). 2. Interfering compounds during NO measurements The chemiluminescence signal in NO measurement is reduced by water vapor, carbon dioxide and nitrous oxide [11-13]. Therefore sampled exhaled gas should preferably be led into a dehumidifying tube before entering the NO analyzer and a correction of the NO signal for the quenching effect by CO2 is a necessity if large variations of end-tidal CO2 are encountered. Many chemiluminescence analyzers have a cooled PMT tube, and if not adequately insulated this leads to a cooling of the window/filter between the reaction chamber and the PMT tube, causing condensation or even frost and significant loss in signal when measuring in biological, humid, systems. For this and several other reasons, in clinical measurements only clinically approved equipment should be used in a procedure approved by appropriate regulatory authorities, and in experimentation the investigator should be keenly aware of this kind of problem source. Some studies show that atmospheric NO levels may bias exhaled NO measurements so that exhaled NO increases during days with high NO levels in ambient air [14, 15] whereas others have found no such influence of ambient NO [16]. Recent studies suggest that outdoor air pollution per se may increase endogenous exhaled NO in healthy subjects [17, 18]. To exclude these uncertainties in exhaled NO measurements NO-free inspired air should be used when exhaled NO measurements are performed. A proper charcoal filter, using a sufficiently large filter with the right proportions of length to diameter can be used to make NO free air out of ambient air. Although recent data suggest that a charcoal filter does not remove NO from hospital compressed air [19], our own experience shows that this can be achieved [20]. With these considerations, pollutant-induced changes in exhaled NO should, in our view, be taken as biological effect measures and not as interference with the determination method. It is obvious that ventilatory or exhalation flow rates [21-26] and the pulmonary diffusing capacity of NO into the blood [27, 28], the diffusion capacity being 4.5 times that of carbon monoxide [29], influence the concentrations of NO in exhaled gas. This might be of importance when exhaled NO concentration decreases and NO excretion increases during heavy exercise or hyperventilation [30-35]. This phenomenon has recently been reviewed [36]. It might be that this effect is merely due to the relative changes in ventilation which will decrease the NO concentration gradient between the NO producing cells and the capillary blood, thereby decreasing the net diffusion of NO to the blood [28, 33]. Whether these changes in exhaled NO reflect an increased NO synthesis per se, the postulated mechanisms involving stretch- and catecholamine-induced NO formation [37, 38], will be discussed below. 3. Bioactive NO concentrations Once NO formation is completed in any tissue, regardless of the site of formation, NO diffuses in all directions until it reacts with potential target molecules and is further metabolised. Nitric oxide is lipophilic, has a modest solubility in aqueous solution (similar with oxygen) and NO molecules readily diffuse across cell-membranes. However, net
38
L.C. Adding and LE. Gustafsson /Physiology of Exhaled NO
diffusion of NO molecules, from the site of formation, will preferentially occur toward areas where NO concentrations are lowest. Consequently, if NO production and elimination in the respiratory tissue is constant, in time equilibrium of NO concentration with the surroundings would occur. However, in the respiratory system due to ventilation, measurements of NO will not give the absolute tissue concentration of NO, but will only reflect part of it.
Table 1. Physiological factors regulating exhaled endogenous nitric oxide in experimental animals, t (increase) ^(decrease), <-> (unchanged) Condition Acute airway hypoxia
Chronic airway hypoxia Selective gas- phase vs. vascular hypoxia Alveolar/ airway hyperoxia Carbon dioxide inhalation
Gas emboli i.v. pH (acidosis)
Stretch activation (PEEP, NEEP, CNETP, HFOV) Stretch inhibition (CPETP, Gd i.v.) «radrenoceptors ^-adrenoceptors (i.v.) Endothelin A-rec. Germ-free animals Endotoxin (LPS)
Ethanol (i.v.) Adenosine (i.v.) Angiotensin II i.v. Allergen, Histamine, LTC4 inhal.
Species Rabbit
Exh. NO 1
Pig Cat Pig (newborn) Rabbit
1
Rat Rabbit Guinea pig Dog Rabbit/Dog Rabbit Dog Rat Rabbit Guinea pig Rabbit/ guinea pig Horse Rabbit Rat Rat Pig Pig Rat Dog Rabbit Rabbit Guinea pig Guinea pig
T 4
; <-> i i i t t t t t t i i t t <-> «-» t t t i t t t <2 min 4> 10 min
Reference (5, 44) (45, 46) (47-49) (50) (5!) (46)
(52, 53) (12,45,54) (55) (56) (5, 57) (54) (58) (59) (12,45,60) (55,61) (12,61,62)
(63) (38) (64) (10) (65) (65, 66) (64, 67-72) (73) (74) (75) (76) (77-80)
L.C. Adding and L.E. Gustafsson / Physiology of Exhaled NO
Table 2. Factors affecting exhaled nitric oxide in healthy humans, t (increase) ^(decrease), <-> (unchanged). Provocation Acute alveolar hypoxia Post-moderate altitude stay Circadian rythm Menstrual midcycle Pregnancy Physical exercise
Oral NO
; 4 «t t*> <->
Nasal NO <->
<->
Texcretion iconcentr. texcretion ^concentr.
1
Breathhold Cold air inhal./ hypothermia Spirometry Cigarette smokers vs. nonsmokers
T 1 1 4
t
Cessation of smoking Cigarette smoke inhal. Outdoor air pollution Indoor formaldehyde levels Acute ozone inhalation Chronic ozone inhalation Influenza virus (nasal/ vaccination) Asthma; allergen challenge L-Arg p.o./ i.v./ inhal. Nitrovasodilators (i.v.) Dobutamine (i.v.) Corticosteroids (p.o./ nasal) Ethanol (p.o.) Ibuprofen (p.o.) Enalapril (ACE inhibitor p.o.) /?^agonist (inhal.) Prostacyclin (inhal.) Prostaglandin £2 & ¥2°(inhal.) L-NMMA (inhal./ i.v.) L-NAME (inhal./ nasal) Aminoguanidine (inhal.) «r agonists (nasal) Capsaicin (nasal) Histamine (nasal) Papaverin (nasal)
t t t t
Hyperventilation
(30-32, 34)
4
(31,96-106) (107, 108) (109) (110-116)
^>4
(117, 118) (119, 120) (17,18) (121) (122) (123) (124, 125)
4-> t t t t t
t <-»
<-> <->
<->
<-» 4 t <-»
4
<-> 4 1
4 <->
References (81,82) (33) (83) (84, 85) (86-89) (90) (30-35,91-95)
1^
4 •f^ •e> t
(110, 126-128) (129-133) (134, 135) (34) (130, 136) (122, 137) (138, 139) (140) (200) (141-144) (145) (146) (37, 137, 147-151) (152-159) (153) (154, 158, 159) (154) (154) (158,159)
39
40
L C. Adding and LE. Gustafsson /Physiology of Exhaled NO
In general it is the total dose of NO delivered to the site of action which is likely to be responsible for any biological effect [39]. Murad and colleagues found that the half maximal concentration (apparent K.,,.,) of NO required to activate purified soluble guanylate cyclase was in the 1-10 nM range [40]. Therefore, the most important question is, can airway NO concentrations in the ppb range exert biological effects? Indeed, in rabbits half-maximal reversal of pulmonary vasoconstriction by NO synthase inhibition was obtained by inhalation of approximately 15 nM NO gas [41] and other NO inhalation studies show that that NO concentrations below 30 ppb can influence pulmonary circulation [41-43]. Actions of low concentrations of NO are probably favoured by its high affinity for heme (e.g. in guanylate cyclase) which is 10 000-fold that of oxygen.
3. Physiological factors regulating exhaled NO formation 7. Pulmonary blood flow and exhaled NO Nitric oxide is rapidly inactivated by haemoglobin and therefore a major determinant of NO elimination in the airways and alveolus would be the abundance of blood in the pulmonary circulation. However, in animals neither volume loading (160) nor moderate pulmonary artery obstruction (60) and in humans neither modifying pulmonary blood flow by increased gravity (2 G) nor head-out water immersion affected the exhaled NO concentrations (161). Thus, changes in pulmonary blood-flow within physiological range will not alter exhaled NO. Nevertheless, extreme reductions in pulmonary blood flow, due to severe hypovolemic haemorrhage, increase exhaled NO concentrations (Figure 1 and [162]). Also, in patients with atrial septal defect, closure of the defect decreased pulmonary blood flow which was associated with a decrease in exhaled NO [163].
2. Airway hypoxia and exhaled NO Molecular oxygen is a substrate for NOS and it has been shown that oxygen concentrations likely to occur in hypoxic tissue can fall below the Km value for oxygen of type III NOS [164]. Furthermore, a similar value of Km was found when plotting a Lineweaver-Burke diagram between alveolar oxygen tension and exhaled NO in rabbits ex vivo [46]. Thus oxygen availability is necessary for an optimal pulmonary NO production. In accordance, acute hypoxia has been shown to decrease exhaled NO in vivo [5, 33, 48, 82], in perfused lungs [44, 46, 47, 51, 165] and in pulmonary endothelial cells [166, 167]. Doseresponse studies of FIO2 on exhaled NO show that NO production markedly ceases below FIO2 < 5 % [44, 46, 201]. Along similar lines chronic hypoxia in newborn piglets reduced exhaled NO [51] but chronic hyperoxia has not been found to increase exhaled NO [52]. Nitric oxide and oxygen are two powerful vasodilators in the pulmonary circulation. In fact NO can reverse pulmonary vasoconstriction induced by O2-deficiency (HPV) [168, 169] and, likewise, oxygen can reverse pulmonary vasoconstriction induced by NO-deficiency [41, 62]. Therefore, the most efficacious vasoconstriction in the lung occurs when oxygen and NO are not present as is the case for the fetus (whole lung) and in any hypo-ventilated part of a lung. Thus, exhaled NO production is maintained as long as
L, C, Adding and L.E. Gustafsson / Physiology of Exhaled NO
41
90- Start of bleeding 6030-
0
o u H
5 0J
Figure 1. Recording of the effect of haemorrhage (arrow indicates start of bleeding), until circulatory arrest and post-mortem, on exhaled NO production and end tidal carbon dioxide (ETCO2) in an anaesthetized and mechanically ventilated rabbit {in vivo). Shown is also the effect of carbon dioxide inhalation (CO2, black bars) before and after circulatory collapse, Note the marked effect of CO2-inhalation even after circulation ceased.
airway oxygen tensions are high enough, FIO2 > 5 % , [46] to contribute to the oxygenation of blood. In a recent study it was found that the alveolar-to-arterial difference for oxygen was reciprocally correlated with exhaled NO thus favouring the idea of positive relation between exhaled NO and blood oxygenation efficiency [170], However, in dogs a NO synthase inhibitor given by nebulization unexpectedly improved ventilation perfusion ratio thereby disputing the role for endogenous NO promoting ventilation perfusion ratio regulation [56]. These differences could be due to species differences since it seems that in dogs vasodilator prostaglandin is more important than NO during basal conditions [171], In man a clear-cut increase in pulmonary vascular resistance has been demonstrated upon administration of NO synthase inhibitor [148, 172, 173]. 3. Stretch related effects and exhaled NO As mentioned above it has been speculated that an increased flow rate of respiratory gas will induce NO formation in airway epithelial cells, resembling the flow (shear stress) induced NO production in vascular endothelial cells [31]. Electron microscopy studies show that type III NOS is associated with microtubuli of the cilia in bronchial epithelial cells [174], suggesting that epithelial cilia may in some way regulate epithelial NO production. Indeed, there is evidence for increased NO production from airway epithelial cells during increased ciliary activity in response to ^-adrenoceptor stimulation [175].
42
L.C. Adding andLE. Gustafsson /Physiology of Exhaled NO
9
in vivo
buffer perfused lung
6030-
0J
O(N X
20-1
s 2 min
PEEP
PEEP
Figure 2. Recording of the effect of PEEP (black bars) on exhaled NO production and insufflation pressure (IP) in an anaesthetized and mechanichally ventilated rabbit (in vivo, left) and, later in the same animal, during buffer perfusion of the lungs (buffer perfused lungs, right). Note the higher basal levels of exhaled NO in the perfused lung and that the effect of PEEP on exhaled NO is still pronounced though the blood is no longer present.
A recent study in rabbits showed a significant increase in exhaled NO in response to increased time-weighted tidal volume during pressure-controlled inverse ventilation [176]. This study lends support to another even more speculative possibility of a stretch-dependent and breathing-cycle differentiated formation of airway NO, with a rapid activation of NO production and an increased NO release during inspiration, locally yielding very high NO concentrations in well-ventilated (stretched) distal airways and alveoli. This would mean that we profoundly underestimate lower airway NO concentrations when we measure it in the exhaled gas during an active expiration. A stretch-dependent cellular mechanism in the airways would be in accordance with the mechanically stimulated endothelial NO synthesis encountered under physiological conditions [177, 178, 179, 180], and similar stretchresponsive mechanisms influencing NO release have been established in both striated muscle cells and osteoblastic cells of bone [181, 182]. Our group observed that positive end-expiratory pressure (PEEP) in guinea pigs and rabbits increased lower airway NO formation [60]. The mechanism of these PEEP-induced dose-dependent increases of exhaled NO is still not known but the observation has been confirmed in the blood perfused rabbit lung [45]. The authors of the latter study pointed to the possibility that pulmonary capillaries may become compressed by PEEP and lose their blood, resulting in less scavenging of NO by haemoglobin. The interpretation is likely, especially in situations when high PEEP pressures that interfere with pulmonary blood flow are applied [60, 61]. Nevertheless, the effect of PEEP on exhaled NO is still present in saltbuffer perfused lungs in situ, with no haemoglobin present (Figure 2), and therefore reduced capillary blood filling cannot fully subserve as the mechanism involved. The involvement of the vagus nerves [60] and a correlation with changes in functional residual capacity (FRC) [12] led to the suggestion that mechanical stretching of lung tissue might be one underlying
L. C. Adding and L.E. Gustafsson / Physiology of Exhaled NO
43
mechanism modulating exhaled NO in response to PEEP see [6]. In addition we recently demonstrated that the process of high frequency oscillatory ventilation (HFOV), which is mechanically characterized by small amplitudes and a very high frequency of tidal variation, significantly increased intra-airway NO concentrations and total excretion of NO, in both rabbits in vivo and in buffer perfused lung, in comparison with conventional ventilation suggesting an increase of total pulmonary NO production rather than an increased elimination of NO from the respiratory system. The effect of HFOV on exhaled NO production significantly exceeds the PEEP-related FRC effect during conventional ventilation. Therefore the existence of preferentially high frequency stretch-responsive mechanisms which regulate pulmonary NO production seems likely since such a mechanism has been revealed in endothelial cells [183]. A similar mechanism in the lung, the cellular basis of which remains to be shown, could explain all observations made in relation to stretch responses on exhaled NO, provided moderate degrees of PEEP and the alike are considered. Moreover, it would be in agreement with the suggested role of NO during pulmonary vascular adaptation at birth [184] and the recent findings of pulmonary vascular smooth muscle potassium-channels which are sensitive to both stretch and NO [185-187]. Specific stretch-activated channels in the endothelial cell membrane convert the mechanical stimuli into intracellular calcium mobilization in the micromolar range [188, 189] sufficient to activate the NOS [190]. Stretch-activated channels have also been identified in several pulmonary cells, including alveolar, endothelial, smooth muscle and airway epithelial cells [191-195]. For that reason we performed experiments with gadolinium chloride (GdCl3), an inhibitor of stretch-activated channels, and found that GdCl3 significantly inhibited basal and PEEP-induced pulmonary NO production in guineapigs and rabbits [61, 62]. In the latter study GdCl3 induced a major increase in pulmonary vascular resistance and decreased arterial PO2. 4. Effect of Carbon Dioxide on exhaled NO production Inhaled carbon dioxide (CO2) has been shown to inhibit formation of NO in exhaled air of rabbits [12], guinea-pigs [55] and dogs [56]. Furthermore, a specific CO2-dependent regulatory mechanism on pulmonary NO production could be separated from non-specific actions elicited by CO2-inhalation in vivo, e.g. changes in blood pH, sympathetic activation or pulmonary blood flow, in a study with HEPES buffer-perfused lungs [54]. During control conditions we also observed higher concentrations of exhaled NO in HEPES-buffer solution perfused lungs (~ 80 ppb), where no CO2 was added to respiratory gas, than previously reported in bicarbonate-buffer solution perfused lungs (~ 50 ppb) where CO2 was added to the inspired gas to achieve end-tidal CO2 readings within the normal range [44, 45, 196]. These observations support the findings that CO2 exerts an inhibitory effect on pulmonary NO production. Another interesting observation is the rapid and large increase in exhaled NO when blood flow through the pulmonary circulation ceases at the start of buffer-solution perfusion. The common opinion is that the increase in exhaled NO is a consequence of decreased scavenging by haemoglobin due to the reduced pulmonary blood flow. However, inhaled CO, can reverse a major part of the increment in exhaled NO seen post-mortem (Figure 1).
44
L.C. Adding andLE. Gustafsson / Physiology of Exhaled NO
100
0
3
6
9
12
% CO2 in inhaled air Figure 3. Concentration dependence of the inhibitory effect of inhaled CO2 on basal levels (solid circles) and on PEEP-induced formation (open circles) of exhaled lower airway nitric oxide in guinea pigs in vivo. Values are means ± SEM; n=5. *, significant difference (P< 0.05) between the nitric oxide concentration in exhaled tracheal air during inhalation of CO2 and the pre-exposure value; paired t-test. (From (55), with permission).
The inhibitory effect of CO2 on exhaled NO is dependent on the level of stretch (PEEP) applied to the lungs. At a moderately high PEEP, when pulmonary NO production is increased but pulmonary vasculature is yet not compressed by PEEP, CO2 is a more effective inhibitor of NO production (Figure 3) [55]. However, the mechanism whereby inhaled CO2 inhibits pulmonary NO formation is still unknown. It is noteworthy that the concentration response curve is steep in the biologically relevant interval. When high levels of PEEP are applied (10 cm H2O and above) in vivo it is our experience that effects of CO2 are minor, as well as are further effects of PEEP as discussed above. It might well be that under these conditions contribution to exhaled NO from an alveolar macrophage dependent non-calcium dependent component is quite significant, due i.a. to less scavenging from nearby capillary blood hemoglobin, and the responses therefore become blunted. In artificial ventilation systems there might be very significant inherent apparatus auto-PEEP. If this goes unnoticed, it is not surprising that it might be difficult to demonstrate PEEP or CO, effects, on exhaled NO. This might explain some controversies in the literature on PEEP and CO2 effects on exhaled NO. 5. Adrenoceptors and exhaled NO Stimulation of a-adrenoceptors by nasally nebulized methoxamine, an a,-adrenergic agonist, reduced nasally exhaled NO in horses [63]. Likewise, it has been shown that the
LC. Adding andLE. Gustafsson / Physiology of Exhaled NO
45
nasal decongestant, oxymetazolin (a,-adrenergic agonist), significantly lowers the concentrations of NO in the nasal cavities of humans [154, 158, 159]. It is not clear whether these changes in NO occur in response to a reduced local blood flow and/or reduced temperature in the nasal cavity [158] or if a more direct a-adrenergic regulatory effect on the NO synthase is involved. Inhalation of salbutamol (f32-adrenoceptor agonist) does not increase exhaled NO in healthy humans [141, 143] but may increase exhaled NO in asthmatics taking inhaled glucocorticosteroids [142]. A recent in vitro study of cultured tracheal epithelial cells concluded that isoproterenol, an unselective B-adrenoceptor agonist, could stimulate NO production [175] and that the mechanism involved cAMP dependent activation of a
pulmonary arteriole
terminal bronchiole
Poorly ventilated Hypoxia Hypercapnea Low stretch
Well ventilated Oxygen
Pulmonary veins Figure 4. Local regulation of nitric oxide production. Nitric oxide is acting in concert with oxygen to dilate pulmonary arteriole in a well ventilated region. In the poor ventilated region, carbon dioxide accumulates, airway/alveolar hypoxia occurs and stretch is minimal. Therefore nitric oxide production decrease and HPV can fully develop promoting V/Q-matching.
calcium-independent NO-synthase [197]. We have found that adrenaline via p,adrenoceptors stimulates the release of NO into the airways of anaesthetised rabbits [38]. In this study forskolin (an activator of adenylate cyclase), even in concentrations causing profound hypotension and tachycardia, did not stimulate NO production. The lack of effect of an adenylate cyclase stimulator suggests that elevation of cAMP is not a key event in rabbit exhaled NO production. However, administration of the calcium-channel blocker
46
L.C. Adding and LE. Gustafsson /Physiology of Exhaled NO
nimodipine reduced the stimulatory effect on NO production in response to pVadrenoceptor activation. In addition to a pure pharmacological effect of (5-adrenoceptor stimulated NO production we have recently demonstrated a role for endogenous adrenaline released by the adrenals in exhaled NO production and found a correlation between plasma concentrations of adrenaline and exhaled NO [198]. Taken together our data suggest that endogenous adrenaline activates pulmonary [3,-adrenoceptors that in turn stimulate calcium influx without the involvement of cAMP. Indeed, in other systems there is evidence for the existence of fJ,-adrenoceptors with direct G-protein coupling to calcium-channels [199].
4. Summary Together these observations suggest that in well ventilated areas of the lung, where stretch and oxygen tension are optimal, the largest amounts of NO will be synthesized. In poorly ventilated areas of the lung CO2 accumulates, oxygen concentrations are low and the small airways and alveoli collapse or exhibit only minor tidal excursion. These conditions would lead to a deficiency in local pulmonary NO production which may enhance HPV and thereby improve ventilation-perfusion matching (Figure 4). However further studies are needed to elucidate the role of CO2 on local NO production in insufficiently ventilated areas. In considering the role of endogenous NO one should consider methodological aspects such as interfering processes in chemiluminesce NO methodology itself, and also physiological alterations caused by the experimental situation, and in the basic physiology that is altered concomitant with experimental maneuvers. NO is a locally formed vasodilator, smooth muscle relaxant and immune modulator. Application of NO synthase inhibitors may thus not be regarded as identical with apllication of a vasoconstrictor, since the removal of NO will have largest effects in places where its formation is largest. Furthermore, NO synthase inhibition might have effects on relese of mediators or on activities in immune cells, effects some of which may not be instantly apparent.
Acknowledgement Supported by the Swedish MRC (proj no. 7919) and the Swedish Heart-Lung Foundation. References 1. 2. 3. 4. 5. 6. 7. 8. 9.
Archer S: Measurement of nitric oxide in biological models. Faseb J 1993;7:349-60. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endotheliumderived relaxing factor. Nature 1987;327:524-6. Fontijin A SA, Ronco RJ: Homogenous chemiluminescent measurement of nitric oxide with ozone: implications for continuous selective monitoring of gaseous air pollutants. Anal Chem 1970;42:575-579. Downes MJ, Edwards MW, Elsey TS, Walters CL: Determination of a non-volatile nitrosamine by using denitrosation and a chemiluminescence analyser. Analyst 1976; 101:742-8. Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S: Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun 1991; 181:852-7. Gustafsson LE: Exhaled nitric oxide production by the lung, in Zapol W. Bloch K (eds): Nitric oxide and the lung. Basel, Marcel Dekker, 1997, pp 185-201. Leone AM, Gustafsson LE, Francis PL, Persson MG, Wiklund NP, Moncada S: Nitric oxide is present in exhaled breath in humans: direct GC-MS confirmation. Biochem Biophys Res Commun 1994;201:883-7. Barnes P), Kharitonov SA: Exhaled nitric oxide: a new lung function test [editorial]. Thorax 1996;51:233-7. Gustafsson LE: Exhaled nitric oxide as a marker in asthma. Eur Respir JSuppl 1998:26:495-525.
L. C. Adding and L.E. Gustafsson / Physiology of Exhaled NO
10. 11. 12. 13. 14. 15. 16. 17. 18.
19. 20. 21.
22. 23.
24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37.
38. 39.
47
Persson MG, Midtvedt T, Leone AM, Gustafsson LE: Ca(2+)-dependent and Ca(2+)-independent exhaled nitric oxide, presence in germ-free animals, and inhibition by arginine analogues. Eur JPharmacol 1994;264:13-20. van der Mark TW, Kort E, Meijer RJ, Postma DS, Koeter GH: Water vapour and carbon dioxide decrease nitric oxide readings. EurRespirJ 1997;10:2120-3. Stromberg S, Lonnqvist PA, Persson MG, Gustafsson LE: Lung distension and carbon dioxide affect pulmonary nitric oxide formation in the anaesthetized rabbit. Acta Physiol Scand 1997; 159:59-67. Binding N, Muller W, Czeschinski PA, Witting U: NO chemiluminescence in exhaled air: interference of compounds from endogenous or exogenous sources [In Process Citation]. Eur Respir J 2000; 16:499-503. Baraldi E, Azzolin NM, Dario C, Carra S, Ongaro R, Biban P, Zacchello F: Effect of atmospheric nitric oxide (NO) on measurements of exhaled NO in asthmatic children. Pediatr Pulmonol 1998;26:30-4. Corradi M, Pelizzoni A, Majori M, Cuomo A, de' Munari E, Pesci A: Influence of atmospheric nitric oxide concentration on the measurement of nitric oxide in exhaled air. Thorax 1998;53:673-6. Piacentini GL, Bodini A, Vino L, Zanolla L, Costella S, Vicentini L, Boner AL: Influence of environmental concentrations of NO on the exhaled NO test. Am J Respir Crit Care Med 1998; 158:1299-301. Steerenberg PA, Snelder JB, Fischer PH, Vos JG, van Loveren H, van Amsterdam JG: Increased exhaled nitric oxide on days with high outdoor air pollution is of endogenous origin. Eur Respir J 1999; 13:334-7. Van Amsterdam JG, Verlaan BP, Van Loveren H, Elzakker BG, Vos SG, Opperhuizen A, Steerenberg PA: Air pollution is associated with increased level of exhaled nitric oxide in nonsmoking healthy subjects. Arch Environ Health 1999;54:331-5. Thibeault DW, Rezaiekhaligh MH, Ekekezie I, Truog WE: Compressed air as a source of inhaled oxidants in intensive care units. Am J Perinatal 1999; 16:497-501. Schedin U, Norman M, Gustafsson LE, Jonsson B, Frostell C: Endogenous nitric oxide in the upper airways of premature and term infants [see comments]. Acta Paediatr 1997; 86:1229-3 5. Hdgman M, StrOmberg S, Schedin U, Frostell C, Hedenstierna G, Gustafsson E: Nitric oxide from the human respiratory tract efficiently quantified by standardized single breath measurements. Acta Physiot Scand 1997; 159:345-6. Tsoukias NM, George SC: A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 1998;85:653-66. Silkoff PE, McClean PA, Slutsky AS, Furlott HG, Hoffstein E, Wakita S, Chapman KR, Szalai JP, Zamel N: Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am J Respir Crit Care Med I997;155:260-7. Byrnes CA, Dinarevic S, Busst CA, Shinebourne EA, Bush A: Effect of measurement conditions on measured levels of peak exhaled nitric oxide. Thorax 1997;52:697-701. Jorres RA: Modelling the production of nitric oxide within the human airways [In Process Citation]. Eur Respir J 2000; 16:555-60. Kissoon N, Duckworth LJ, Blake KV, Murphy SP, Taylor CL, Silkoff PE: FE(NO): relationship to exhalation rates and online versus bag collection in healthy adolescents. Am J Respir Crit Care Med 2000; 162:539-45. Rimar S, Gillis CN: Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation 1993;88:2884-7. Hyde RW, Geigel EJ, Olszowka AJ, Krasney JA, Forster RE, 2nd, Utell MJ, Frampton MW: Determination of production of nitric oxide by lower airways of humans-theory. J Appl Physiol 1997;82:1290-6. Borland CD, Higenbottam TW: A simultaneous single breath measurement of pulmonary diffusing capacity with nitric oxide and carbon monoxide. Eur Respir J 1989;2:56-63. Iwamoto J, Pendergast DR, Suzuki H, Krasney JA: Effect of graded exercise on nitric oxide in expired air in humans. Respir Physiol 1994;97:333-45. Persson MG, Wiklund NP, Gustafsson LE: Endogenous nitric oxide in single exhalations and the change during exercise. Am Rev Respir Dis 1993; 148:1210-4. Bauer JA, Wald JA, Doran S, Soda D: Endogenous nitric oxide in expired air: effects of acute exercise in humans Lj/e5crl994;55:1903-9. St Croix CM, Wetter TJ, Pegelow DF, Meyer KC, Dempsey JA: Assessment of nitric oxide formation during exercise. Am J Respir Crit Care Med 1999; 159:1125-33. Phillips CR, Giraud GD, Holden WE: Exhaled nitric oxide during exercise: site of release and modulation by ventilation and blood flow. J Appl Physiol 1996;80:1865-71. Chirpaz-Oddou MF, Favre-Juvin A, Flore P, Eterradossi J, Delaire M, Grimbert F, Therminarias A: Nitric oxide response in exhaled air during an incremental exhaustive exercise. J Appl Physiol 1997;82:1311-8. Sheel AW, Road J, McKenzie DC: Exhaled nitric oxide during exercise. Sports Med 1999;28:83-90. Jilma B, Dirnberger E, Eichler HG, Matulla B, Schmetterer L, Kapiotis S, Speiser W, Wagner OF: Partial blockade of nitric oxide synthase blunts the exercise-induced increase of von Willebrand factor antigen and of factor VIII in man. Thromb Haemost 1997;78:1268-71. Adding LC, Agvald P, Artlich A, Persson MG, Gustafsson LE: Beta-adrenoceptor agonist stimulation of pulmonary nitric oxide production in the rabbit. BrJ Pharmacol 1999; 126:833-9. Hobbs AJ, Ignarro LJ: The nitric oxide-cyclic GMP signal transduction system, in Zapol WM, Bloch KD (eds): Nitric oxide and the lung. Basel, Marcel Dekker, 1997, pp 1-57.
48
40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68.
L.C. Adding and LE. Gustafsson / Physiology of Exhaled NO
Murad F: The 1996 Albert Lasker Medical Research Awards. Signal transduction using nitric oxide and cyclic guanosine monophosphate. Jama 1996;276:1189-92 Persson MG, Kalz£n H, Gustafsson LE: Oxygen or low concentrations of nitric oxide reverse pulmonary vasoconstriction induced by nitric oxide synthesis inhibition in rabbits. Acta Physiol Scand 1994; 150:405-11. Gerlach H, Rossaint R, Pappert D, Falke KJ: Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome [see comments]. EurJClin Invest 1993;23:499-502. Lundberg JO, Settergren G, Gelinder S, Lundberg JM, Alving K. Weitzberg E: Inhalation of nasally derived nitric oxide modulates pulmonary function in humans. Acta Physiol Scand 19%; 158:343-7. Grimminger F, Spriestersbach R, Weissmann N, Walmrath D, Seeger W: Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. JAppI Physiol 1995;78:1509-15. Carlin RE, Ferrario L, Boyd JT, Camporesi EM, McGraw DJ, Hakim TS: Determinants of nitric oxide in exhaled gas in the isolated rabbit lung. Am J Respir Crit Care Med \997; 155:922-7. Ide H, Nakano H, Ogasa T, Osanai S, Kikuchi K, Iwamoto J: Regulation of pulmonary circulation by alveolar oxygen tension via airway nitric oxide. JAppl Physiol 1999;87:1629-36. Cremona G, Higenbottam T, Takao M, Hall L, Bower EA: Exhaled nitric oxide in isolated pig lungs. J Appl Physiol 1995;78:59-63. Nelin LD, Thomas CJ, Dawson CA: Effect of hypoxia on nitric oxide production in neonatal pig lung. Am J Physiol 1996,27 \.m-U. Pearl JM, Nelson DP, Wellmann SA, Raake JL, Wagner CJ, McNamara JL, Duffy JY: Acute hypoxia and reoxygenation impairs exhaled nitric oxide release and pulmonary mechanics. J Thorac Cardiovasc Surg 2000; 119:931-8. Toga H, Watanabe T, Okazaki H, Ishigaki M, Noguchi T, Matsuda M, Huang J, Takahashi K, Ohya N, Fukunaga T, et al.: [Effect of endogenous and inhaled nitric oxide on pulmonary microcirculation]. Nihon Kyobu Shikkan GakkaiZasshi 1995;33 Suppl: 184-9. Fike CD, Kaplowitz MR, Thomas CJ, Nelin LD: Chronic hypoxia decreases nitric oxide production and endothelial nitric oxide synthase in newborn pig lungs. Am J Physiol 1998;274:L517-26. Cucchiaro G, Tatum AH, Brown MC, Camporesi EM, Daucher JW, Hakim TS: Inducible nitric oxide synthase in the lung and exhaled nitric oxide after hyperoxia. Am J Physiol 1999;277:L636-44. Bernareggi M, Radice S, Rossoni G, Oriani G, Chiesara E, Berti F: Hyperbaric oxygen increases plasma exudation in rat trachea: involvement of nitric oxide. Br J Pharmacol 1999; 126:794-800. Adding LC, Agvald P, Persson MG, Gustafsson LE: Regulation of pulmonary nitric oxide by carbon dioxide is intrinsic to the lung. Acta Physiol Scand 1999; 167:167-74. Bannenberg GL, Giammarresi C, Gustafsson LE: Inhaled carbon dioxide inhibits lower airway nitric oxide formation in the guinea pig. Acta Physiol Scand 1997; 160:401-5. Brogan TV, Hedges RG, McKinney S, Robertson HT, Hlastala MP, Swenson ER: Pulmonary NO synthase inhibition and inspired CO2: effects on VVQ1 and pulmonary blood (low distribution [In Process Citation). Eur Respir J 2000; 16:288-95. Deem S MS, Polissar NL, Hedges RG, Swenson ER: Hcmodilution during venous gas embolization improves gas exchange, with altering V(AVQ or pulmonary blood flow distributions. Anesthesiology 1999;91:I724-I732. Lee KH, Rico P, Billiar TR, Pinsky MR: Nitric oxide production after acute, unilateral hydrochloric acid-induced lung injury in a canine model. Crit Care Med 1998;26:2042-7. Pedoto A, Caruso JE, Nandi J, Oler A, Hoffmann SP, Tassiopoulos AK, McGraw DJ, Camporesi EM, Hakim TS: Acidosis stimulates nitric oxide production and lung damage in rats. Am J Respir Crit Care Med 1999:159:397402. Persson MG, Lonnqvist PA, Gustafsson LE: Positive end-expiratory pressure ventilation elicits increases in endogenously formed nitric oxide as detected in air exhaled by rabbits. Anesthesiology 1995;82:969-74. Bannenberg GL, Gustafsson LE: Stretch-induced stimulation of lower airway nitric oxide formation in the guinea-pig: inhibition by gadolinium chloride. Pharmacol Toxicol 1997;81:13-8. Adding LC, Bannenberg GL, Gustafsson LE: Gadolinium chloride inhibition of pulmonary nitric oxide production and effects on pulmonary circulation in the rabbit. Pharmacol Toxicol 1998,83:8-15 Mills PC, Martin DJ, Demoncheaux E, Scott C, Casas I, Smith NC, Higenbottam T: Nitric oxide and exercise in the horse. J Physiol (Lond) 1996;495:863-74. Fujii Y, Magder S, Cemacek P, Goldberg P, Guo Y, Hussain SN: Endothelin receptor blockade attenuates lipopolysaccharide-induced pulmonary nitric oxide production. Am J Respir Crit Care Med 2000; 161:982-9. Fujii Y, Goldberg P, Hussain SN: Intrathoracic and extrathoracic sources of exhaled nitric oxide in porcine endotoxemic shock. Chest 1998;! 14:569-76. Metha S JD, Datta P, Levy RD, Magder S: Porcine endotoxemic shock is associated with increased expired nitric oxide. Crit Care Med 1999;27:385-393. Stewart TE, Valenza F, Ribeiro SP, Wener AD, Volgyesi G, Mullen JB, Slutsky AS: Increased nitric oxide in exhaled gas as an early marker of lung inflammation in a model of sepsis. Am J Respir Crit Care Med 1995;! 51:713-8. Stitt JT, Dubois AB, Douglas JS, Shimada SG: Exhalation of gaseous nitric oxide by rats in response to endotoxm and its absorption by the lungs. JAppl Physiol 1997;82:305-16.
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) 1OS Press, 2002
The "Vascular" Origins of Exhaled Nitric Oxide Tim HIGENBOTTAM and Eric DEMONCHEAUX AstraZeneca R&D Charnwood and University of Sheffield Respiratory Medicine Unit
Abstract. The origin of an exhaled gas is a classical physiological question. The biology and chemistry of nitric oxide (NO) is complex. In physiological conditions, NO acts while dissolved in aqueous biological solutions [1]. At high picomolar concentrations, it causes relaxation of vascular smooth muscle [2]. This is a result of activation of intra-cellular soluble guanylyl cyclase that increases the concentration of cyclic guanosine monophosphate (cGMP) which in turn initiates relaxation [1]. The evidence that NO normally regulates pulmonary vascular resistance depends on two observations. Firstly, changes in resistance are seen with inhibition of the endothelial enzyme nitric oxide synthase (eNOS). Secondly, pulmonary vascular disease is associated with changes in NO production.
1. Pulmonary endothelium derived nitric oxide regulates pulmonary vascular resistance and contributes to exhaled nitric oxide In many species, including man but excluding dog and rat, inhibition of endothelium derived NO results in a rise in pulmonary vascular resistance to blood flow [3]. The difference between species is important as it implies that NO is not unique in mammals in determining pulmonary vascular resistance. Other endothelial products, such as prostacyclin, may act to determine the basal vascular tone in the lungs in species such as the rat and possibly the cat. Increased blood flow, as occurs with exercise-induced rise in cardiac output, and increased release of NO, in species where endothelium-derived NO modulates pulmonary vascular resistance, may allow the pulmonary circulation to adapt without a rise in resistance [4]. Nitric oxide is relatively insoluble in aqueous solutions. At one atmosphere over water, only a small fraction of NO will dissolve and less than 5% remains in solution. In the lungs, with the massive surface area of the epithelial surface, NO is likely to be evolved from the aqueous surface liquid of the epithelial surface into the airspace where it can be measured in an exhaled breath [5]. Using an' isolated perfused and ventilated lung (porcine) it is possible to demonstrate that during inhibition of endothelium derived NO release by infusion of a nonspecific inhibitor, both the pulmonary vascular resistance rises and the exhaled NO concentration falls [6]. Furthermore, addition of blood to the lung perfusate reduces exhaled NO concentration, presumably due to reaction between NO with circulating haemoglobin within the red blood cells.
50
T. Higenbottam and E. Demoncheaux / The "Vascular" Origins of Exhaled NO
2. Circulating nitric oxide "donors" can contribute to exhaled nitric oxide When NO gas is dissolved in aqueous solutions under conditions of continuous flow, the dissolved gas concentration rises to a plateau. The amount of NO dissolved is determined by the concentration of gas in the mixture overflowing the solution, the flow rate, the mass transfer characteristics and reaction kinetics. Micromolar concentrations of NO in the gas rapidly lead to nanomolar concentrations of dissolved NO, apparently at steady state, while nitrite quickly reaches micromolar concentrations in solution [2]. Interestingly, nitrite can generate free NO even at physiological pH [2]. This phenomenon is under great scrutiny as it may provide nitrite with an important physiological function as a NO carrier. This may well provide nitrite with an important role in ischaemic injury [7] or in chronic inflammatory disorders such as asthma [8]. Using the isolated perfused and ventilated lung (porcine) addition of nitrite to the perfusate lead to an increase in exhaled NO [2]. This shows that both circulating nitrite and endothelium derived NO may contribute to exhaled NO concentrations.
3. Exhaled nitric oxide and pulmonary vascular disease Measurement of the concentration of NO in collected exhaled air from patients with pulmonary arterial hypertension, a rare disease where there is a loss of up to 80% of the pre-capillary arteries, reveals significantly lower values compared to healthy subjects [9]. In the "explanted" lungs obtained from recipient patients at the time of lung transplant surgery, the release of endothelium derived NO is reduced in both isolated perfused lungs and isolated vascular rings of pulmonary arteries [10, 11]. Similarly in histological studies, immuno-staining for eNOS reveals a reduction in the amount of enzyme in the endothelium in lungs from patients with PPH [12]. The final piece of evidence comes from the measurement of the amount of NO formed from I5N labelled L-arginine which has been used to study NO production in patients with systemic hypertension [13]. This technique confirms a reduction in NO production in PPH patients when compared with age and sex matched healthy subjects [14]These findings link under-expression of NOS with 'under-activity of NO release" from pulmonary endothelium and lower exhaled NO concentrations.
4. Sources of exhaled nitric oxide other than the pulmonary circulation The exhaled air passes from the alveoli through the complex branching system of airways towards the mouth. Once the gas has left the alveolus no further pulmonary circulation derived NO will enter the exhaled air. The alveolar contribution cannot be changed. There is evidence that at high expiratory flow rate, low concentrations of NO are recorded [15]. A rise in NO concentrations at lower flow rates may indicate an important role for the airway epithelial surface as another source of NO [15]. Epithelial cells express the inducible form of NOS even under normal conditions [16]. In asthmatics, NOS expression is greatly increased and is associated with higher exhaled concentrations of NO [17]. Allergen challenge increases exhaled NO and treatment with inhaled steroids reduces the exhaled levels [17].
T. Higenbottam and E. Demoncheaux/The "Vascular" Origins of Exhaled NO
51
These data provide quantitative information on the relative source of NO. In the asthmatic, the airway contributes through iNOS a hundred fold higher amount of exhaled NO than alveolar sources.
References 1. 2.
3. 4. 5.
6. 7. 8. 9. 10.
11.
12. 13. 14.
15. 16.
17.
Moncada, S., and A. Higgs. 1993. The L-arginine-nitric oxide pathway. N Engl J Med 329:20022012. Demoncheaux, E., T. Higenbottam, P. Foster, C. Borland, A. Smith, H. Marriott, S. Akamine, D. Bee, and M. Davies. 2002. Circulating nitrite anions are a directly acting vasodilator and are donors for nitric oxide. Clin Sci (Lond) 102:77-83. Cremona, G., A. Wood, and L. Hall. 1994. Effects of inhibitors of nitric oxide release and action on vascular tone in isolated lungs of pig, sheep, dog and man. J Physiol (Lond) 481.1:185-195. Cremona, G., T. Higenbottam, M. Takao, E. A. Bower, and L. W. Hall. 1997. Nature and site of action of endogenous nitric oxide in vasculature of isolated pig lungs. JAppl Physiol 82:23-31. Demoncheaux, E., M. Maniscalco, S. Roe, G. Cremona, and T. Higenbottam. 1996. Exhaled nitric oxide: origin and physiological meaning. In Nitric oxide and radicals in the pulmonary vasculature (E. Weir, S. Archer and J. Reeves, editors), Futura Publishing Company, Armonk, NY. 427-445. Cremona, G., T. Higenbottam, M. Takao, L. Hall, and E. A. Bower. 1995. Exhaled nitric oxide in isolated pig lungs. JAppl Physiol 78:59-63. Zweier, J. L., P. H. Wang, A. Samouilov, and P. Kuppusamy. 1995. Enzyme-Independent Formation of Nitric-Oxide in Biological Tissues. Nat Med 1:804-809. Hunt, J., and B. M. Gaston. 2001. Endogenous airway acidification: Implications for asthma pathology Am JResp Crit Care Med 163:293-294. Cremona, G., T. Higenbottam, C. Borland, and B. Mist. 1994. Mixed expired nitric oxide in primary pulmonary hypertension in relation to lung diffusion capacity. QJMed 87:547-551. Dinh-Xuan, A. T, Higenbottam, T. W., Clelland, C. A., Pepke-Zaba, J., Cremona, G., Butt, A. Y., Large, S. R., Wells, F. C., and Wallwork, J. 1991. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N EnglJ Med 324:1539-47 Cremona, G., T. W. Higenbottam, E. A. Bower, A. M. Wood, and S. Stewart. 1999. Hemodynamic effects of basal and stimulated release of endogenous nitric oxide in isolated human lungs. Circ 100:1316-21. Giaid, A., and D. Saleh. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N EnglJ Med 333:214-21. Forte, P., M. Copland, L. M. Smith, E. Milne, J. Sutherland, and N. Benjamin. 1997. Basal nitric oxide synthesis in essential hypertension. Lancet 349:837-42. Demoncheaux, E., K. Hall, V. Garner, S. Wharton, A. Spivey, and T. Higenbottam. 2001. Whole body nitric oxide production in patients with pulmonary hypertension. Am J Resp Crit Care Med 163: A116 (abstract) Tsoukias, N. M., Z. Tannous, A. F. Wilson, and S. C. George. 1998. Single-exhalation profiles of NO and CO2 in humans: effect of dynamically changing flow rate. JAppl Physiol 85:642-652. Guo, F. H., De Raeve, H. R., Rice, T. W., Stuehr, D. J., Thunnissen, F. B., and Erzurum, S. C. 1995 Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo Proc NatlAcadSci USA 1995 92:7809-13. Berlyne, G., and N. Barnes. 2000. No role for NO in asthma? Lancet 355:1029-1030.
52
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
Exhaled NO originates in airway epithelium L. Christofer ADDING and Lars E. GUSTAFSSON Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. Abstract. Nitric oxide is a highly reactive molecule and binds in the presence of blood rapidly to haemoglobin with subsequent oxidation to nitrate. The alveolar compartment of the lung is constantly perfused with large amounts of blood and therefore nitric oxide produced in the endothelial or alveolar epithelial regions most likely will be absorbed and inactivated by erythrocytes. Literature data is reviewed and a methodology is presented for measuring NO at high precision in intubated patients. The measurements demonstrate that exhaled NO in normal individuals is almost fully of airway origin, with marked breath-hold accumulation , whereas little or no alveolar accumulation of NO occurs during breath-hold. Airway tissue concentrations of NO are far higher than we presume from normal tidal exhalations, underlining the importance of airway NO formation in respiratory system biology.
1. Concentrations of exhaled NO The first measurements of exhaled NO in laboratory animals clearly demonstrated a local enzyme-dependent NO production within the lower respiratory tract: the animals were tracheotomized and exhaled NO could still be detected after circulatory arrest but not in the presence of an inhibitor of NO synthase, the enzyme responsible for NO production (see Gustafsson 1997). Another fundamental indication is that in salt buffer perfused lungs, when blood is no longer present, there is an immediate and more than two-fold increase in exhaled NO concentration [1-5]. In humans the initial oral measurements of exhaled NO [6] were later suggested to be a mixture of NO emanating from the lower respiratory tract, nasally produced NO [7-9], and NO from salivary NO2" and gastric regurgitation [10, 11]. The relative contribution from respective source depends on the measurement technique, especially the exhaled gas sampling procedure. Continuous oral sampling of exhaled NO using e.g. nose clamp may contain up to 90% nasally derived NO [12, 13] due to backward diffusion from the nose [14] whereas oral single-breath exhaled NO measurements, during plateau phase, are not affected by NO derived from nasal airways [15-18]. Studies of awake humans either intubated [8, 13, 19, 20] or with bronchoscopy [21] have also confirmed the excretion of NO from the lower respiratory tract. To the lower airway NO excretion is added a variable oral mainly non-enzymatic NO production [22]. Nevertheless, the anatomic site and main cell type producing the NO molecules detected in exhaled gas from the lower airways are still a matter of debate. Different volumes of dead-space gas have been sampled, reflecting gas emanating from trachea, bronchi.
L.C. Adding and L.E. Gustafsson / Exhaled NO Originates in Airway Epithelium
53
bronchioles, and respiratory bronchioles, and analyzed for exhaled NO after breath-holding they show significant contribution from distal airways [23, 24]. However, very low NO concentrations are present in alveolar gas in vivo [15, 24-26] due to the rapid scavenging of NO by erythrocytes in the pulmonary capillaries [27] (see also above). In salt buffer perfused lungs end-tidal NO concentrations are very high [1-5] probably reflecting alveolar (endothelial or macrophage) NO production, otherwise rapidly scavenged by haemoglobin. We have experienced that lung-perfusion experiments using buffered salt solutions after a "grace period" inevitably lead to lung oedema formation and that exhaled NO concentrations then markedly decrease. The fluid that accumulates in interstitial tissue and alveoli is likely to have large numbers of oxygen radicals that degrade NO. Furthermore, the fluid in itself may act as a diffusion barrier. Both mechanisms would reduce the amount of endothelial-derived NO in exhaled air. Along similar lines, Cremona et al. [3] demonstrated a decrease in exhaled NO with increasing weight of lungs perfused with salt solution at high outflow pressure. On the other hand, we have observed increased exhaled NO levels during lung oedema formation in vivo, probably due to an increased diffusion barrier and less NO scavenging by erythrocytes (Adding et al., unpublished observations). However, in a recent study by Duplain et al. there was no increase in exhaled NO in subjects who developed high-altitude pulmonary edema [28]. This might be explained by a reduced NOS activity due to the relative hypoxic conditions as previously discussed. In favour of the idea that endothelial derived NO from alveolar regions does not contribute much to exhaled NO in vivo is the observation that infusion of acetylcholine, which massively stimulates endothelial NO production, when administered in concentrations that do not cause airway effects only marginally increases exhaled NO (unpublished observations). However, in the absence of blood (haemoglobin) in the pulmonary circulation, during salt-buffer perfusion acetylcholine infusions will increase exhaled NO concentrations.
2. Measurement of airway and alveolar NO in single breaths in trachea In order to address the question of origin of exhaled NO in vivo we have measured exhaled NO in anesthetized intubated patients undergoing routine surgery (Schedin and Gustafsson, unpublished). We wanted to explore the initial observations [15] that breathhold can markedly increase single-breath NO concentrations in a peak-plateau pattern reaching maximum during the dead space phase of exhalation as determined by CO, exhalation pattern. In the study by Persson et al. [15], breath-hold concentrations typically reached 50 ppb at 30 s of breath-hold, indicating that airway tissue concentrations are higher by at least a factor of 10 as compared with the concentrations during tidal breathing, not to mention the dilute concentrations obtained in artificial ventilation where exhalation gas flows are even higher. We therefore used the Inspiratory Hold feature of a Siemens 900 ventilator and applied it for 5-30 s followed by sampling of exhaled gas into a rapid exhaled CO2 and NO analysis sytem (SBNO, Aerocrine AB, Solna, Sweden) adjusted to give a continuous aspiration of 300 ml/min. The NO and CO2 recordings were presynchronized in the calibration mode of the SBNO system by means of rapid puncture of a membrane behind which a mixture of known concentrations of NO and CO2 were flowing. The response time (t 10-90%) was 0.15 s for NO and approximately 0.25 s for CO2, and detection limit was less than 1 ppb for NO, allowing also determination of alveolar gas
54
L.C. Adding and LE. Gustafsson /ExhaledNO Originates in Airway Epithelium
concentrations when the Inspiratory Hold mode was released. A typical recording is shown in Figure 1. 20 sec 80.0-
NO, vv ppb
60.040.020.0-
C02, %
10:67.5. 5.02.5-
VOL exhal litres
inn
O.s-
2g;8:
ULAA
Ptrach cmH2O 1 264
Time (min:sec) Figure 1. Anesthetized intubated human subject in propofol anesthesia. Synchronized recordings of, from top, exhaled NO, carbon dioxide, exhaled volume in litres, and insufflation pressure. In the left pan of the recordings the typical pressure pattern of volume controlled ventilation can be seen. In the middle part of the recordings gas sampling for NO and COZ was switched to room air at the first arrow (upwards directed) and subsequently an Inspiratory Hold of 10 s was commenced as indicated by the pressure curve. At the second arrow (downwards directed) airway sampling was reinstituted leading to a slow emptying of lungs during 20 more seconds of Inspiratory Hold, leading to a drop in airway pressure beyond spontaneous drop (spontaneous drop, apart from "relaxation", probably being due to alveolar gas diffusions). During Inspiratory Hold sampling a clearcut airway NO peak can be seen during the dead space phase, followed by an "alveolar CO2 plateau", which however is not the true plateau which however becomes evident when the Inspiratory Hold mode is released, the release being denoted by third arrow (downwards directed). The true alveolar CO2 plateau and the "alveolar" NO can be read at the dashed arrows. During this plateau in CO2 it can clearly be seen that NO falls to very low levels, approximately 5 ppb, and then rises again as airflow essentially stops. This low level is only an estimate of alveolar NO concentration, since NO will be admixed to the expired gas during exhalation, from the sources in the airways. Note very low NO concentrations during exhalation in the controlled ventilation mode, also when resumed directly after the inspiratory hold, and identical to the recorded value at the end of the inspiratory hold, indicating that no accumulation of NO occurs in normal alveoli during brief cessation of ventilation.
L.C. Adding and L.E. Gustafsson /ExhaledNO Originates in Airway Epithelium
55
3. Summary Together these observations suggest that nitric oxide in exhaled air mainly emanates from supra-alveolar regions. It can not be argued that true alveolar NO concentrations can be measured directly during single breaths, but an estimate of an upper limit of these can be made. Such estimates should be compared with current methods under development for indirect calculations of alveolar concentrations of NO performed by precise variations in exhalation flow rates [29, 30]. During breath-hold it can be demonstrated in intubated subjects that airway tissue NO concentrations are far higher than determined from single breath exhalation during spontaneous or controlled ventilation. The reproducibility of the exhaled NO concentrations during controlled volume ventilation still suggest that exhalation in the awake state with controlled flow rates gives an excellent estimate of airway NO formation, although it puts a high demand on the flow regulation in the exhaled NO measurement device. In conclusion, exhaled NO is almost exclusively of airway origin. Airway tissue concentrations of NO are far higher than we presume from normal tidal exhalations, confirming our initial observations [1, 15], underlining the importance of airway NO formation in respiratory system biology. Acknowledgement Supported by the Swedish MRC (proj no. 7919} and the Swedish Heart-Lung Foundation. References 1.
2. 3. 4. 5. 6.
7. 8. 9.
10. 11.
Persson MG, Midtvedt T, Leone AM, Gustafsson LE: Ca(2+)-dependent and Ca(2+)-independent exhaled nitric oxide, presence in germ-free animals, and inhibition by arginine analogues. Em J Pharmacol 1994 ;264:13-20. Grimminger F, Spriestersbach R, Weissmann N, Walmrath D, Seeger W: Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J Appl Physiol 1995;78:1509-15. Cremona G, Higenbottam T, Takao M, Hall L, Bower EA: Exhaled nitric oxide in isolated pig lungs. JAppl Physiol 1995;78:59-63. Marczin N, Riedel B, Gal J, Polak J, Yacoub M: Exhaled nitric oxide during lung transplantation [letter]. Lancet 1997;350:1681-2. Adding LC, Agvald P, Persson MG, Gustafsson LE: Regulation of pulmonary nitric oxide by carbon dioxide is intrinsic to the lung. Acta Physiol Scand 1999; 167:167-74. Gustafsson LE, Leone AM, Persson MG, Wiklund NP, Moncada S: Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun 1991;181:852-7. Alving K, Weitzberg E, Lundberg JM: Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respit-J 1993;6:1368-70. Lundberg JO, Rinder J, Weitzberg E, Lundberg JM, Alving K: Nasally exhaled nitric oxide in humans originates mainly in the paranasal sinuses. Acta Physiol Scand 1994; 152:431 -2. Lundberg JO, Farkas-Szallasi T, Weitzberg E, Rinder J, Lidholm J, Anggaard A, Hokfelt T, Lundberg JM, Alving K: High nitric oxide production in human paranasal sinuses. Nat Med 1995;l:370-3. Zetterquist W, Pedroletti C, Lundberg JO, Alving K: Salivary contribution to exhaled nitric oxide. EurRespirJ 1999; 13:327-33. Lundberg JO, Weitzberg E, Lundberg JM, Alving K: Intragastric nitric oxide production in humans: measurements in expelled air. Gut 1994;35:1543-6.
56
12.
13.
14. 15. 16.
17.
18. 19.
20. 21.
22.
23. 24.
25. 26. 27. 28.
29. 30.
L.C. Adding and L.E. Gustafsson / Exhaled NO Originates in Airway Epithelium
Lundberg JO, Weitzberg E, Nordvall SL, Kuylenstierna R, Lundberg JM, Alving K: Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome. Ear Respir J 1994;7:1501-4. Schedin U, Frostell C, Persson MG, Jakobsson J, Andersson G, Gustafsson LE: Contribution from upper and lower airways to exhaled endogenous nitric oxide in humans. Ada Anaesthesia! Scand 1995;39:327-32. Kharitonov SA, Barnes PJ: Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding. Thorax 1997;52:540-4. Persson MG, Wiklund NP, Gustafsson LE: Endogenous nitric oxide in single exhalations and the change during exercise. Am Rev Respir Dis 1993; 148:1210-4. Hogman M, Strdmberg S, Schedin U, Frostell C, Hedenstierna G, Gustafsson E: Nitric oxide from the human respiratory tract efficiently quantified by standardized single breath measurements. Acta Physiol Scand 1997; 159:345-6. Silkoff PE, McClean PA, Slutsky AS, Furlott HG, Hoffstein E, Wakita S, Chapman KR, Szalai JP, Zamel N: Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am J Respir Crit Care Med 1997;! 55:260-7. Suzuki H, Krasney JA: Nitric oxide in single-breath exhalation in humans. Jpn J Physiol 1997;47:335-9. Tsujino I, Miyamoto K, Nishimura M, Shinano H, Makita H, Saito S, Nakano T, Kawakami Y: Production of nitric oxide (NO) in intrathoracic airways of normal humans. Am J Respir Crit Care Merfl996;154:1370-4. Tsujino I, Miyamoto K, Nishimura M, Shinano H, Kawakami Y: Measurement of exhaled nitric oxide concentration using nasal continuous negative pressure. Respirology 1999;4:155-9. Massaro AF, Mehta S, Lilly CM, Kobzik L, Reilly JJ, Drazen JM: Elevated nitric oxide concentrations in isolated lower airway gas of asthmatic subjects. Am J Respir Crit Care Med 1996;153:1510-4. Palm JP, Graf P, Lundberg JO, Alving K: Characterization of exhaled nitric oxide: introducing a new reproducible method for nasal nitric oxide measurements [In Process Citation]. Eur Respir J 2000; 16:236-41. Dillon WC, Hampl V, Shultz PJ, Rubins JB, Archer SL: Origins of breath nitric oxide in humans [see comments]. Chest 1996;! 10:930-8. DuBois AB, Kelley PM, Douglas JS, Mohsenin V: Nitric oxide production and absorption in trachea, bronchi, bronchioles, and respiratory bronchioles of humans. J Appl Physiol 1999:86:15967. Borland C, Cox Y, Higenbottam T: Measurement of exhaled nitric oxide in man. Thorax 1993;48:1160-2. Byrnes CA, Dinarevic S, Busst C, Bush A, Shinebourne EA: Is nitric oxide in exhaled air produced at airway or alveolar level? Eur Respir J 1997; 10:1021 -5. Rimar S, Gillis CN: Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation 1993;88:2884-7. Duplain H, Sartori C, Lepori M, Egli M, Allemann Y, Nicod P, Scherrer U: Exhaled nitric oxide in high-altitude pulmonary edema: role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am J Respir Crit Care Med 2000; 162:221 -4. Tsoukias NM, Tannous Z, Wilson AF, George SC. Single-exhalation profiles of NO and CO2 in humans: effect of dynamically changing flow rate J Appl Physiol. 1998;85:642-52. Hogman M, Holmkvist T, Wegener T, Emtner M, Andersson M, Hedenstrom H, Merilainen P. Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis.Respir Med. 2002;96:24-30
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
57
NO is generated via NOS enzymes Sergei A. KHARITONOV Thoracic Medicine, National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, Dovehouse Street, London SW3 6LY, UK Abstract. The major source of exhaled NO is endogenous NO derived from L-arginine by the enzyme NO synthase (NOS) [1 ].
1. Nitric oxide synthases Two of these enzymes are constitutively expressed and are activated by small rises in intracellular calcium concentration, secondary to cell activation. Neuronal NOS (NOSI, nNOS) is predominantly expressed in neurons and endothelial NOS (NOS3, eNOS) mainly in endothelial cells, although other cell types also express both of these isoforms. A third enzyme is inducible (NOS2, iNOS), has a much greater level of activity and is independent of calcium concentration. NOS2 may be induced by inflammatory cytokines, endotoxin and viral infections and may show increased expression in inflammatory diseases [2-4]. Genetic polymorphisms of all three isoforms of NOS have been detected. Surprisingly, associations have been found between polymorphisms in the NOSI gene and asthma in Caucasian populations [5,6]. In mild asthmatic patients there is a significant association between the length of the AAT repeat polymorphism in intron 20 of the NOSI gene and exhaled NO levels [7]. 2. Cellular sources in airways The cellular source of NO gas in the lower respiratory tract is not yet certain. Studies with perfused porcine lungs suggest that exhaled NO originates at the alveolar surface, rather than from the pulmonary circulation [8], and may be derived from NOS3 expressed in the alveolar walls of normal lungs. Studies in ventilated perfused lungs of guinea pigs show that exhaled NO is reduced during perfusion with calcium-free solutions, suggesting that NO is derived from a constitutive NOS, which is calciumdependent [9]. Airway epithelial cells may express both NOS3 and NOSI and therefore may contribute to NO in the lower respiratory tract [10,11]. There is some expression of NOS2 even in airway epithelial cells from normal subjects [12], and NOS2 appears to be an important isoform contributing to exhaled NO in healthy mice [13]. In inflammatory diseases, such as asthma, it is likely that the increase in exhaled NO reflects further induction of NOS2 in response to inflammatory signals, such as proinflammatory cytokines. Indeed, increased NOS activity has been demonstrated in lung tissue of patients with asthma, cystic fibrosis and obliterative bronchiolitis [14]. In asthmatic patients there is evidence for increased expression of NOS2 in airway epithelial cells [15] and this is likely to be due to increased transcription mediated via the transcription factors STAT-1 and nuclear factor-KB (NF-KB), and increased availability
58
S.A. Kharitonov /NO is Generated via NOS Enzymes
of L-arginine [16,17]. Pro-inflammatory cytokines induce the expression of NOS2 in cultured human airway epithelial cells [18,19] and it is likely that these same cytokines are released in asthmatic inflammation. NOS2 may be expressed in other cell types, such as alveolar macrophages, eosinophils and other inflammatory cells [20]. Further evidence that the increase in exhaled NO is derived from increased NOS2 expression is the observation that corticosteroids inhibit inflammatory induction of NOS2 in epithelial cells [16,21], decrease expression in bronchial biopsies of asthmatic patients [20] and also reduce exhaled NO concentrations in asthmatic patients [22]. 3. Non-enzymatic sources of NO NOS is not the only source of NO in exhaled air and exhaled NO is not therefore a direct measure of NOS activity in the lower respiratory tract. NO reacts with thiolcontaining molecules, such as cysteine and glutathione, to form 5-nitrosoproteins and Snitrosothiols [23]. Approximately 70-90% of NO is released by S-nitrosothiols, which therefore provide a major source of NO in tissues [24]. S-nitrosothiols are potent relaxants of human airways and may play an important role in sequestration, releasing and transportation of NO to its site of action [23]. NO in exhaled air may also be derived from nitrite protonation to form nitrous acid, which releases NO gas with acidification [25]. This pH-related pathway has been implicated in acute asthma, when pH in expired condensate is low [26]. 4. Anatomical origin NO is produced along the entire length of human airways. The conducting airways secrete NO into the lumen, which mixes with alveoli NO during exhalation, resulting in the observed expiratory concentration. The levels of NO derived from the upper respiratory tract (200-1000 ppb) [27-29] and sinuses (1000-30000 ppb) [30] are a hundred-fold higher than exhaled NO measured in the lower respiratory tract (1 -9 ppb) [27,27,28,31-36]. Several factors may contribute to high nasal levels. The paranasal sinuses produce a high level of NO [37]. There is a dense innervation with NOS1immunoreactive nerve fibers around nasal blood vessels [38]. Vasculature-derived NO. however, is not the major source of NO in nasal mucosa, as neuropeptide Y, a powerful vasoconstrictor, reduces nasal blood flow by 37%, but NO by only 7% [39]. There appears to be, constitutive expression of NOS2 [40] and the transcription factor NF-KB in nasal mucosa [41]. Interestingly, the NO outputs from the nostrils are significantlylower on the operated side (site with the reduced NO-generating surface) in patients who have undergone unilateral medial maxillectomy [42]. The source of NO in the lower respiratory tract is also of mixed origin and may be derived from airway and alveolar epithelial cells, which express both NOS3 and NOS1. The contribution of endothelial-derived NO is minimal, as inhaled NOS inhibitors are able to reduce exhaled NO by 40% -70% [43-45] without any effect on the systemic circulation. By contrast, L-NMMA infusion modulates blood pressure and heart rate but has only a minimal effect on exhaled NO [43]. Simultaneous measurement of expired COi and NO demonstrate that exhaled NO precedes the peak value of CO2 (end-tidal), suggesting that NO is derived from airways rather than alveoli [27,46]. Direct sampling via fiberoptic bronchoscopy in normal subjects shows a similar levels of NO in trachea and main bronchi to that recorded at the mouth, thus indicating that there is NO derived from the lower airways [27,36]. Exhaled
S.A. Kharitonov / NO is Generated via NOS Enzymes
59
NO is therefore most likely to be of epithelial rather than endothelial origin, and most NO is derived from airways rather than alveoli. References [1] S.A.Kharitonov, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 163(2001) 1693-1722. [2] P.J.Barnes, Belvisi MG. Nitric oxide and lung disease. Thorax. 48 (1993) 1034-1043. [3] B.Gaston et aL The biology of nitrogen oxides in the airways. Am. J. Respir. Crit. Care. Med. 149 (1994) 538-551. [4] P.J.Barnes. Transcription factors and inflammatory disease. Hosp. Pract. 31 (1996) 93-96. [5] P.S.Gao et al.. Variants of NOS1, NOS2, and NOS3 genes in asthmatics. Biochem. Biophys. Res. Commun. 267 (2000) 761-763. [6] H.Grasemann et aL A neuronal NO synthase (NOS1) gene polymorphism is associated with asthma. Biochem. Biophys. Res. Commun. 272 (2000) 391-394. [7] M.E.Wechsler et al.. Exhaled nitric oxide in patients with asthma. Association with NOS1 genotype. Am. J. Respir. Crit. Care. Med. 162 (2000) 2043-2047. [8] G.Cremona et al.. Exhaled nitric oxide in isolated pig lungs. J. Appl. Physiol. 78 (1995) 59-63. [9] M.G.Persson et al.. Ca2+-dependent and Ca2+-independent exhaled nitric oxide, presence in germfree animals, and inhibition by arginine analogues. Eur J Pharm 264 (1994) 13-20. [10] P.W.Shaul et al.. Endothelial nitric oxide synthase is expressed in cultured human bronchiolar epithelium. J. Clin. Invest. 94(1994) 2231-2236. [11] J.B.Mannick et al.. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell. 79 (1994) 1137-1146. [12] F.H.Guo et al.. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7809-7813. [13] W.Steudel et al.. Exhaled nitric oxide production by nitric oxide synthase-deficient mice. Am J Respir Crit Care Med 162 (2000) 1262-1267. [14] M.G.Belvisi et al.. Nitric oxide synthase activity is elevated in inflammatory lung diseases. Eur J Pharmacol 283 (1995) 255-258. [15] Q.Hamid et al.. Induction of nitric oxide synthase in asthma. Lancet 342 (1993) 1510-1513. [16] F.H.Guo et al.. Molecular mechanisms of increased nitric oxide (NO) in asthma: evidence for transcriptional and post-translational regulation of NO synthesis. J. Immunol. 164 (2000) 59705980. [17] Q.Xie et al.. Role of transcription factor NF-kB/Rel in induction of nitric oxide synthase. J. Biol. Chem. 269 (1994) 4705-4708. [18] K.Asano et al.. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10089-10093. [19] N.A.Chartrain et al.. Molecular cloning, structure, and chromosomal localization of the human inducible nitric oxide synthase gene. J. Biol. Chem. 269 (1994) 6765-6772.
60
S.A. Kharitonov /NO is Generated via NOS Enzymes
[20]
D.Saleh et al.. Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. FASEB.J. 12(1998) 929-937.
[21J R.A.Robbins et al.. Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun 203 (1994) 209-218. [22]
S.A.Kharitonov et al.. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343 (1994) 133-135.
[23] J.S.Stamler et al.. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 444-448. [24]
F.S.Sheu et al.. Direct observation of trapping and release of NO by glutathione and cysteine with electron paramagnetic resonance spectroscopy. Biophys. J. 78 (2000) 1216-1226.
[25] S.J.Klebanoff. Reactive nitrogen intermediates and antimicrobial activity: role of nitrite. Free Radio. Biol. Med. 14(1993) 351-360. [26] J.F.Hunt et al.. Endogenous airway acidification. Implications for asthma pathophysiology. Am J Respir. Crit. Care. Med. 161 (2000) 694-699. [27] S.A.Kharitonov et al.. The elevated level of exhaled nitric oxide in asthmatic patients is mainly derived from the lower respiratory tract. Am. J. Respir. Crit. Care. Med. 153 (1996) 1773-1780. [28] E.Baraldi et al.. Reference values of exhaled nitric oxide for healthy children 6-15 years old. Pediatr. Pulmonol. 27 (1999) 54-58. [29] S.R.Thomas et al.. Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype. Chest. 117 (2000) 1085-1089. [30] J.O.Lundberg, Weitzberg E. Nasal nitric oxide in man. Thorax. 54 (1999) 947-952. [31] C.Borland et al.. Measurement of exhaled nitric oxide in man. Thorax. 48 (1993) 1160-1162. [32] L.E.Gustafsson et al.. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem. Biophys. Res. Commun. 181 (1991) 852-857. [33] K.Alving et al.. Increased amount of nitric oxide in exhaled air of asthmatics. Ear. Respir. J. 6 (1993) 1368-1370. [34] A.F.Massaro et al.. Expired nitric oxide levels during treatment of acute asthma. Am. J. Respir. Crit. Care. Med. 152(1995) 800-803. [35] U.Schedin et al.. Contribution from upper and lower airways to exhaled endogenous nitric oxide in humans. Ada. Physiologica. Scandinavica. 39(1995) 327-332. [36] A.F.Massaro et al.. Elevated nitric oxide concentrations in isolated lower airway gas of asthmatic subjects. Am. J. Respir. Crit. Care. Med. 153 (1996) 1510-1514. [37] J.O.Lundberg et al.. High nitric oxide production in human paranasal sinuses. Nat. Med. \ (1995) 370-373. [38] T.Kondo et al.. Distribution, chemical coding and origin of nitric oxide synthase-con tain ing nerve fibres in the guinea pig nasal mucosa. J. Auton. Nerv. Syst. 80 (2000) 71-79. [39] A.Cervin et al.. Functional effects of neuropeptide Y receptors on blood flow and nitric oxide levels in the human nose. Am. J Respir. Crit. Care. Med. 160 (1999) 1724-1728.
S.A. Kharitonov / NO is Generated via NOS Enzymes
[40] H.Kawamoto et al.. Localization of nitric oxide synthase in human nasal mucosa with nasal allergy. Acta. Otolaryngol. Suppl. (Stockh. ) 539:65-70 (1998) 65-70. [41] I.Ramis et al.. Constitutive nuclear factor-kappaB activity in human upper airway tissues and nasal epithelial cells. Ear. Respir. J. 15 (2000) 582-589. [42] W.Qian et al.. Unilateral nasal nitric oxide measurement after nasal surgery. Ann Oiol Rhinol Laryngol 109 (2000) 952-957. [43]
C.Sartori et al.. Exhaled nitric oxide does not provide a marker of vascular endothelial function in healthy humans. Am. J. Respir. Crit. Care. Med. 160 (1999) 879-882.
[44]
D.H.Yates et al.. Effect of a nitric oxide synthase inhibitor and a glucocorticosteroid on exhaled nitric oxide. Am. J. Respir. Crit. Care. Med 152 (1995) 892-896.
[45]
D.H.Yates et al.. Endogenous nitric oxide is decreased in asthmatic patients by an inhibitor of inducible nitric oxide synthase. Am. J. Respir. Crit. Care. Med 154 (1996) 247-250.
[46]
M.G.Persson et al.. Endogenous nitric oxide in single exhalations and the change during exercise. Am. Rev. Respir. Dis. 148 (1993) 1210-1214.
62
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press. 2002
Technical aspects of exhaled NO: Investigator point of view Sergei A. KHARITONOV Thoracic Medicine, National Heart and Lung Institute, Imperial College and Royal Brompton Hospital, Dovehouse Street, London SW3 6LY, UK Abstract. There has recently been an explosion of interest in the analysis of breath constituents as a way of monitoring inflammation and oxidative stress in the lungs. Here we review the technical aspects of exhaled nitric oxide measurements (NO) in the diagnosis and monitoring of lung disease.
Expiratory flow, soft palate closure, and dead space air may all influence exhaled NO levels. Therefore, exhaled NO is usually determined during single-breath exhalations against a resistance [1,2] to prevent contamination with nasal NO [3,4], or using reservoir collection with discarding of the dead space [5]. However, this method has proven difficult for some children, who may have trouble maintaining a constant flow, and recently a simple flow-driven method for online NO measurements has been developed that does not require active patient co-operation. Recently, single breath analysis of exhaled NO has been successfully performed in the newborn when exhaled air was sampled from the tip of a thin nasal catheter placed in the hypopharynx [6]. The most commonly used method to measure nasal NO is to sample nasal air directly from one nostril using the intrinsic flow of the chemiluminescence analyzer. A novel method of measuring exhaled NO at several exhalation flow rates has recently been described which can used to approximate alveolar and airway NO production [7]. NO is continuously formed in the airways. Mixing during exhalation between the NO produced by the alveoli and the conducting airways, explains its flow dependency and accumulation during a breath-hold [8]. It is therefore important to register the flow rate if NO is expressed as a concentration The flow rate recommended in 1997 by a Task Force of the European Respiratory Society is 10-15 L/min or 167-250 mL/s [1]. Most authors have used about 100 mL/s, but a more recent recommendation from the American Thoracic Society suggests 50 mL/s [9]. Exhaled and nasal NO in healthy subjects is independent of age, gender and lung function [10]. There is no evidence for significant diurnal variation, and exhaled NO measurements are highly reproducible in normal subjects. Different phases of menstrual cycle may influence exhaled NO [11]. There are several major factors, which may change NO levels in normal subjects [10]. Some routinely used tests can transiently reduce exhaled NO, for example repeated spirometry [12], physical exercise [13], sputum induction [14]. Environmental factors, such as NO ozone, chlorine dioxide, are know to increase exhaled NO levels [15]. Habitual factors, such as smoking [16] and alcohol ingestion [17], reduce exhaled NO. Upper respiratory infection significantly increases exhaled NO [18] and nasal NO [19].
S.A. Kharitonov / Technical Aspects of Exhaled NO: Investigator Point of View
63
References [1] S.A.Kharitonov et al.. Exhaled and nasa! nitric oxide measurements: recommendations. Eur. Respir. J. 10(1997) 1683-1693. [2] S.A.Kharitonov et al.. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343 (1994) 133-135. [3] S.A.Kharitonov, Barnes PJ. Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding. Thorax. 52 (1997) 540-544. [4] P.E.Silkoff et al.. Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am. J. Respir. Crit. Care. Med. 155 (1997) 260-267. [5] P.Paredi et al.. Exhalation flow and pressure-controlled reservoir collection of exhaled nitric oxide for remote and delayed analysis. Thorax. 53 (1998) 775-779. [6] A.Artlich et al.. Single Breath Analysis of Endogenous Nitric Oxide in the Newborn. Biol Neonate 79 (2001) 21-26. [7] L.Lehtimaki et al.. Increased bronchial nitric oxide production in patients with asthma measured with a novel method of different exhalation flow rates. Ann Med 32 (2000) 417-423. [8] S.A.Kharitonov et al.. The elevated level of exhaled nitric oxide in asthmatic patients is mainly derived from the lower respiratory tract. Am. J. Respir. Crit. Care. Med. 153 (1996) 1773-1780. [9] Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide in Adults and Children. Am. J. Respir. Crit. Care. Med. 160(1999) 2104-2117. [10] S.A.Kharitonov, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 163 (2001) 1693-1722. [11] S.A.Kharitonov et al.. Peak expiratory nitric oxide differences in men and women: relation to the menstrual cycle. British. Heart. J. 72 (1994) 243-245. [12] A.Deykin et al.. Exhaled NO following repeated spirometry or repeated plethysmography in healthy individuals. Am. J. Respir. Crit. Care. Med. 161 (2000) 1237-1240. [13] C.R.Phillips et al.. Exhaled nitric oxide during exercise: site of release and modulation by ventilation and blood flow. J. Appl. Physiol. 80 (1996) 1865-1871. [14] G.L.Piacentini et al.. Exhaled nitric oxide is reduced after sputum induction in asthmatic children. Pediatr. Pulmonol. 29 (2000) 430-433. [ 15] J.A.Nightingale et al.. Effect of inhaled ozone on exhaled nitric oxide, pulmonary function, and induced sputum in normal and asthmatic subjects. Thorax. 54 (1999) 1061-1069. [16] S.A.Kharitonov et al.. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am. J. Respir. Crit. Care. Med. 152 (1995) 609-612. . [17] D.H.Yates et al.. The effect of alcohol ingestion on exhaled nitric oxide. Eur. Respir. J. 9 (1996) 1130-1133. [ 18] S.A.Kharitonov et al.. Increased nitric oxide in exhaled air of normal human subjects with upper respiratory infections. Eur. Respir. J. (1995) 295-297. [ 19] E.A.Ferguson, Eccles R. Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta. Otolaryngol. 117(1997) 614617.
64
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) 1OS Press, 2002
Technical aspects of exhaled Nitric Oxide: Aerocrine point of view Lena KAJLAND-WILEN Marketing Director, Aerocrine AB, Smidesvagen 12, S-171 41 Solna, SWEDEN
Abstract. It is an honour and a great pleasure to present our views on the technical aspects of NO measurements on behalf of my company Aerocrine. We at Aerocrine have spent considerable effort and thoughts into this exiting topic, which has led to the development of our newly introduced NO analyser NIOX®.
Key points to consider when performing NO measurements are: • What shall you use the achieved NO values for? • Electrical safety measures, MOD approval and CE mark • Handling of ambient NO levels • Dead space handling • Exhaled flow accuracy and stability • Response time • Analyser signal drift • Reproducibility of results • Specifications at different ambient conditions • Calibration gas quality and stability • Potential ozone leakage I will go through each of these points more in detail and let you know how we have solved them in our system, the NIOX device. 1. What shall you use the achieved NO values for? At Aerocrine our goal is to establish NO measurements into routine clinical practise as a non-invasive tool to measure and follow the inflammation status in primarily asthma patients.
L Kajland- Wilen / Technical Aspects of Exhaled NO: Aerocrine Point of View
65
Thus we have spent considerable efforts into design a device that will fit into a busy clinic workflow, to make it easy to use for more than just one instrument specialist.
One single unit consists of computer hardware, the NO analyser, pumps and flow controls. A lot of effort has been spent on the smoothness of software-hardware interaction, and the ease of use for both patients and instructor.
2. Electrical safety measures, MDD approval and CE mark NIOX is the only available NO analyser that is CE marked according to the medical device directive and approved for routine clinical use in Europe. NIOX has been checked for emission of electrical signals and how well it resist outside electrical signal interference. The CE mark means that the electrical safety performance to fit into a clinical setting has been scrutinised by an independent notified body. To ensure good and safe performance in a clinical setting, the CE-mark is a prerequisite. 3. Handling of ambient NO levels As ambient NO levels might be very high, in the range of 500 ppb is not unusual, especially in big cities, it is necessary to flush the lungs with NO free air prior to exhalation. One single deep breath of NO free air should be enough, which is also what the ATS standard says. In NIOX, we use a NO filter to ensure NO free inhalation air, also the whole system is flushed with NO free air between measurements. 4. Dead space handling As many of you know the dead space is the air in the beginning of the exhalation that is not originating from the lower parts of the lung. Dead space can be divided into anatomical dead space, i.e. the patient's upper respiratory tract volume and the instrument dead space, i.e. the tubing's etc from the mouth to the analyser.
66
L Kajland- Wilen / Technical Aspects of Exhaled NO: Aerocrine Point of View
In NIOX we have minimized the instrument dead space by putting the sampling port very close to the mouth, use of a unique NIOX filter and by using a small sample tube diameter and with a fast sample tube flow, 5 ml/sec.
The anatomical dead space in NIOX is handled by; exhalation time, e.g. Vz a second, exhalation volume (patient specific) or based on height of the patient. 5. Exhaled flow accuracy and stability As the NO value in exhaled breath is very flow dependent, which is caused by that NO is primarily released from the bronchial walls, it is of extreme importance to keep the exhalation flow constant and tightly measured during the full exhalation, to ensure reproducible results. NIOX is equipped with a patented and calibrated dynamic flow control that keeps the exhalation at an even 50 ml/second regardless of patient skills. Also the flow is tightly measured with accurate, calibrated flow sensors. During exhalation a pressure indicator guides the patient on how hard to blow. Exhalation pressure may vary between 10 and 30 cm H2O without affecting the constant 50 ml/second flow. If patient does not manage to keep the pressure within these borders an indication, "Pressure out of range" will appear, the same will happen if the flow is not kept within the
L. Kajland-Wilen / Technical Aspects of Exhaled NO: Aerocrine Point of View
67
set limits of 45 to 55 ml/sec and the reading will not be valid. Thanks to this unique flow control even small children can manage an exhaled NO analysis in NIOX. The attractive balloon view also helps. 6. Response time When scrutinizing the performance of an NO analyser it is very important to consider if tests has been performed on the whole system and with exhaled air, or if the data only refers to data measured on the chemiluminoscence analyser level. As most NO analysers uses the same sensor technology, i.e. chemiluminoscence, the performance on the sensor level is similar. More important, as least we think so at Aerocrine, is the prestanda you get in clinical practise. As NIOX is to be used on real patients in real clinical settings, Aerocrine present total system performance data, i.e. the performance that corresponds to what you will see in your practise. At total system level (exhaled air) NIOX give you a lag time of less than 0.8 seconds, a rise time of less than 0.7 seconds and a total response time of 1.5 seconds. The analyser itself though has a response time of less than 200 mseconds.
7. Analyser signal drift Very important is that your NO analyser give you the same value irrespectively of when you measure your patient or how long time ago the device was calibrated. NIOX has a drift of less than 3 ppb over 14 days. This has been achieved by an automatic self test that checks the zero point drift of the NO signal, the flow and the pressure after each patient measurement. If a signal drift is detected the software automatically compensate for it. If the drift is abnormally high a warning message will appear. NIOX only needs to be calibrated twice a month and in the calibration procedure the NO signal, flow and pressure is simultaneously calibrated in a two point calibration. 8. Reproducibility of results As Dr Kharitonov just presented this reproducibility of NO results in NIOX has shown to hold true also in controlled clinical studies where the pooled standard deviation, was less than 2.5 ppb irrespectively when during the day or when during the week the NO
68
L Kajland- Wilen / Technical Aspects of Exhaled NO: Aerocrine Point of View
measurement was done. This shows that our method and control systems hold true, in real clinical settings.
9. Specifications at different ambient conditions Where is your NO analyser placed? What is the temperature fluctuations? Are you at high altitude? Or maybe in a damp environment? As you are to measure a gas these conditions has a very pronounced effect on your results, and the reproducibility of them. Thus ensure that your NO analyser has been tested and proven to work within the environmental conditions that just your lab has. NIOX prestanda has been proven within 15-30 degrees Celsius, between 860 to 1060 heko-pascal and relative humidity of 30-75%. Also ensure you have a dehumidified sample going into the analyser, as the chemiluminoscence sensor technology is know to be very sensitive to the water content in the sample. 10. Calibration gas quality and stability To ensure good reproducible results you need to calibrate. But what are you calibrating with? If the calibration gas value is not controlled sufficiently and proven not to deteriorate or change over time your whole calibration curve might be wrong and as a consequence your data not correct. Moreover it is important to calibrate within a range that well corresponds to your application, if you are to analyse exhaled NO in asthma patients at 50ml/second flow rate, we have concluded 0 to 200 ppb is optimal as most patients have values within this range. The stability over time of the half-empty calibration cylinder is also of outmost importance, the design of the cylinder, the valve and the regulator are all very important for the end result. We moreover have found that how the calibration cylinder was cleaned and how inert the inner walls of it is, has pronounced effect on the deterioration of the calibration gas during the shelf life. Potential ozone leakage As all NO analysers today used chemiluminescence technology, all has an ozone generator which could potentially leak very high and hazardous levels of ozone. In NIOX we have built in a security system in several levels to ensure this cannot happen. Prior to start up of the ozone generator, the software checks that the vacuum pumps are on and that there is pressure in the system. The pressure and the flow in the system are routinely followed up and if below a certain critical value there is an alarm. Also we have built in an ozone sensor into the cabinet inside NIOX that online checks the level of ozone and that alarms in case of a too high value. If the software should crash there is an automatic system shutdown.
L. Kajland- Wilen / Technical Aspects of Exhaled NO: Aerocrine Point of View
We at Aerocrine have a high interest in finding solutions to the technical challenges of NO measurements and work actively together with many highly respected scientists to continually upgrade and improve our NO analysers. We are dedicated to ensure that, in routine clinical practise doctors shall be able to "See more than your asthma patients can tell you" by supplying accurate and reproducible exhaled NO measurements.
This page intentionally left blank
Section 2. Carbon Monoxide
This page intentionally left blank
Disease Markers in Exhaled Breath N. Marczin andM.H, Yacoub (Eds.) fOS Press, 2002
73
Cytoprotection by heme oxygenase / CO in the lung Judit K. SARADY, Leo E. OTTERBEIN and Augustine M. K. CHOI Division of Pulmonary,Allergy and Critical Care Medicine, University of Pittsburgh School of Medicine 3459 5th Avenue, MUH 628, Pittsburgh, PA 15213 , USA
Abstract. The stress inducible gene heme oxygenase-1 (HO-1) provides protection against oxidative stress, although the precise mechanisms by which HO-1 exerts this cytoprotection is not clearly understood. It has been speculated that the by-products of heme catabolism by HO-1, namely bilirubin, ferritin and carbon monoxide (CO) possess important biological functions and may serve as mediators of HO-1 induced cytoprotection. The lung is particularly susceptible to oxidative stress. In this review we summarize the role of HO-1 in oxidant-induced lung injury, and provide evidence that CO may serve as an important mediator of cytoprotection.
It is becoming clear that oxidative stress plays a crucial role in the pathogenesis of many biological processes including aging, atherosclerosis, carcino-genesis, ischemiareperfusion tissue injury as well as many acute and chronic inflammatory diseases [1]. Reactive oxygen species (ROS) including superoxides, hydroxyl radicals and hydrogen peroxide (H2G2), generated from normal cellular respiration, aerobic metabolism and/or respiratory burst of inflammatory and immune cells can cause cellular damage by oxidizing nucleic acids, proteins and membrane lipids [2]. Mammalian systems evolved several enzymatic and non-enzymatic antioxidant defense systems, which eliminate ROS and help to maintain cellular homeostasis. The non-enzymatic systems include the circulative antioxidants, such as glutathione, vitamin E, albumin, transferrin-lactoferrin, bilirubin and ceruloplasmin. Besides the battery of enzymatic mechanisms present to detoxify free radicals including superoxide dismutase (SOD) and glutathione peroxidase, other protective enzymes also exist, designated the stress-response proteins (heat shock protein (HSP)), which include metallothionein (MT) and heme oxygenase-1 (HO-1) [3], 1. Heme oxygenase-1 Heme oxygenase (HO) was originally identified in 1968 by Tenhunen and colleagues [4] as the catalyst of the first and rate-limiting step in the degradation of heme. HO binds with heme, via oxidation cleaves its a-mesocarbon bridge to yield equimolar quantities of
74
J. K. Sarady et al. / Cytoprotection by Heme Oxygenase I CO in the Lung
biliverdin, free iron and CO. Biliverdin is then subsequently converted to bilirubin by biliverdin reductase, while free iron is promptly sequestered into ferritin.(F/g 1)
Ferritin
Biliverdin
Reductase Heme —^«^«^^^ Biliverdin ••••• «•«•«^- Bilirubin
CO Fig 1. Enzymatic reaction of heme oxygenase
Three isoforms of HO have been identified [5,6,7,8]. HO-2 and HO-3 are constitutively synthesized mainly in the brain and testes whilst HO-1 is highly inducible by numerous stimuli [9]. Under physiological conditions HO activity is highest in the spleen where erythrocytes are sequestered and destroyed but its activity has been observed in all organs. Although the main inducer is heme, many non-heme agents including hypoxia [10], hyperoxia [11], endotoxin [12], and ultraviolet A [13] can also induce HO-1 expression. One common feature of these inducers is their capacity to generate ROS. Other studies demonstrated that HO-1 can not only be induced by non-heme agents that cause oxidative stress, but it can function as a cytoprotective molecule against the increased oxidative stress [14,15]. Observations in HO-1 ("} null mice as well as the first HO-1 deficient human [16,17] have also helped to understand the role of HO-1 in maintaining cellular homeostasis.
2. Cytoprotection by HO-1 Although the importance of HO-1 in the host's defense against oxidative stress is well known, the precise mechanisms by which HO-1 provides cytoprotection is still unclear. Recent data however indicate that products of heme catabolism mediate the cytoprotective effects of HO-1. Bilirubin accumulates in the serum of neonates, causing jaundice. In high concentration it is toxic, because it is deposited in the brain resulting in neurotoxicity. Bilirubin however is responsible for the antioxidant activity of human serum [18] and serves as a potent antioxidant in the brain, acting to scavenge peroxyl radicals as efficiently as atocopherol or vitamin E [19]. Free iron with it's two free electrons can generate hydroxyl radicals via the Fenton reaction. Ferritin synthesis is induced by released iron and serves as a reservoir to restrict
J.K. Sarady et al. / Cytoprotection by Heme Oxygenase / CO in the Lung
75
iron from participation in the Fenton reaction. Among others, Balla et al [20] showed that induction of ferritin was cytoprotective in a model of oxidative stress. Carbon monoxide is, after carbon dioxide (CO2) the main atmospheric pollutant, emanating slowly from natural sources as volcanoes or forest fires and quickly as a byproduct of industrial and household activity [9]. Because of numerous lethal accidents caused by CO, for decades it was considered a poisonous gas, a toxic agent. Indeed, by binding to hemoglobin with a greater effect then oxygen, it replaces 62, increases the level of oxyhemoglobin by shifting the dissociation curve to the left and decreases 62 delivery to the cells causing tissue/cell hypoxia or anoxia. It is interesting to note that GO at low concentrations ( less then 0.01 % ) acts as a chemical messenger in neuronal transmission and modulation of vasomotor tone [22, 23] akin to NO. The majority of CO production in the body is derived from HO [22,24]. These effects of CO, just as of NO, are mediated through the activation of guanyl cyclase which cause an increase in the generation of cGMP [25]. CO may also possess anti-inflammatory effects such as the capacity to inhibit platelet activation or aggregation through activation of guanyl cyclase and subsequent generation of cGMP [9]. In recent studies, Otterbein et al. have demonstrated that administration of exogenous HO-1 by gene transfer [26] and exogenous administration of a low concentration of carbon monoxide (CO), protects rats against hyperoxia-induced lung injury [27]. Using a well-established model of LPS-induced endotoxemia both in vivo and in vitro it was also confirmed that HO-1 has potent anti-inflammatory effects which are mediated by CO [28]. Recently investigators [29,30] proposed to use CO as a biological and measurable marker in the exhaled breath of patients as an index of oxidative stress and inflammation.
3. Cytoprotection by HO-l/CO in the lung The lung is a major target organ for injury by ROS. ROS play a vital role in acute and chronic inflammatory lung diseases including ARDS, asthma, interstitial pulmonary fibrosis or emphysema [2]. In addition, patients who require supplemental O2 therapy are even more the "victims" of cellular damage caused by an increased oxidative burden. In order to improve our knowledge about the molecular responses of the lung, several in vitro and in vivo models have been developed to demonstrate the potent cytoprotective effects of HO-1 including endotoxic shock, hypoxia, hyperoxic lung injury or xenotransplantation related tissue rejection [12,26,31] . Studies by Lee and Suttner demonstrated the protective effect of overexpressing HO1 in pulmonary epithelial cells, fibroblasts, macrophages and smooth muscle cells [11] or fetal rat lung cells [32] which showed increased resistance to hyperoxic lung injury. It is interesting to note that high levels of HO-1 expression can be associated with significant cytotoxicity [33], which can be caused by the augmented release of iron from heme. Hyperoxic lung injury represents a model of oxidant-induced lung injury. After hyperoxia, the rat lung exhibits increased level of HO-1 mRNA and protein levels in many cell types, including the bronchoalveolar epithelium, interstitial cells and inflammatory cells [11]. Otterbein et al using exogenous administration of HO-1 by gene transfer could protect the rodents against oxidant-induced tissue injury. Adenoviral gene transfer of HO-1 (Ad5-
76
J. K. Sarady et al. / Cytoprotection by Heme Oxygenase / CO in the Lung
HO-1) into the lungs of rats resulted in increased expression of HO-1 and a marked resistance to hyperoxic lung injury (reduced level of hyperoxia-induced pleural effusion, neutrophil alveolitis and BAL protein leakage) when compared to the untreated controls [26]. Taylor and al. also provided protection from hyperoxic lung injury by intratracheal administration of hemoglobin, a major inducer of HO-1 production [34]. Otterbein examined whether exogenous CO could confer the same cytoprotective effects as exogenous administration of HO-1 via gene delivery [26]. Based on the studies of Stupfel et. al, which showed that rodents and cells tolerated low concentrations (10-500 parts/million) of CO [[36], rats were exposed to hyperoxia in the presence of 250 ppm CO. This dose, which represents one twentieth of the lethal dose of CO in humans and rodents, offered significant protection from hyperoxic lung injury. Lipopolysaccharide (LPS), a constituent of the Gram negative bacterial cell wall can induce many of the pathophysiological changes observed in sepsis following administration to cells or animals. LPS induces high mRNA levels of HO-1 in rat lung tissues which correlate with increased enzyme activity [35]. Pretreatment of rats with hemoglobin resulted in increased HO-1 induction and provided complete protection against subsequent lethal endotoxemia. Tin protoporhyrin, a competitive inhibitor of HO, blocked this protective effect [12]. To test the hypothesis that CO provided cytoprotection against oxidative stress via anti-inflammatory effects, the levels of anti- and pro-inflammatory cytokines were measured. CO inhibited the LPS-induced proinflammatory cytokines tumor necrosis factor (TNF)-a, interleukin (IL)-IP , macrophage inflammatory protein (MlP)-la but augmented the antiinflammatory cytokine IL-10 expression. Examination of the signaling pathways mediating these effects, interesting results have been obtained. In contrast to other model systems such as neuronal and vascular cells, the guanyl cyclase/cGMP pathway was not involved, but the anti-inflammatory effects of CO were dependent on the mitogen activated protein kinase kinase (MKK-3)/ p38 mitogen activated protein kinase pathway [28]. Furthermore, Otterbein et al. , obtained additional supporting evidence for the involvement of the p38 MAPK pathway in the mechanism of CO effects by using a MKK3-deficient mouse model. MKK3 is the major upstream kinase activator of p38. LPS administration resulted in the inhibition of TNF-a in MKK3-deficient mice exposed to air, but no additional inhibition was detected when exposed to CO. At the same time, IL-10 levels were not elevated in the presence of CO as observed in the wildtype littermates. This confirms that inhibition of the MKK3/p38 MAP kinase pathway not only modulated the expression of inflammatory cytokines but also abrogated the COmediated cytoprotection against lung injury [37]. 4. Conclusions HO-1 has been well established as a stress response gene induced by a wide range of agents including heme and non-heme induced cellular stressors such as heavy metals, LPS, hydrogen peroxide, heat shock, cytokines, hypoxia, and hyperoxia. Although the mechanisms by which HO-1 mediates it's cytoprotective effects are still unclear, it seems likely that one or all of the three catalytic by-products of heme catabolism by HO-1, bilirubin, ferritin and CO act to protect the cells and tissues.
J.K. Sarady et al. / Cytoprotection by Heme Oxygenase / CO in the Lung
77
Numerous studies have investigated the cytoprotective effects of HO-1 in the lung, using animal models of sepsis, hypoxia, hyperoxia and xenotransplantation. CO, a poisonous gas when administered at low concentration can mediate the potent cytoprotective effects of HO-1. Otterbein et al demonstrated that CO, when administered exogenously at low concentrations can exert potent anti-inflammatory effects both in vivo and in vitro models of LPS-induced inflammation, hyperoxic lung injury and allergen-induced inflammation [38]. It was also revealed that CO modulated pro- and anti-inflammatory cytokines and the responsible signaling pathways were identified. According to these new discoveries, perhaps in the future, HO-1, either via gene delivery or exogenous administration or CO in low concentration could be considered as a new therapeutic tool.
References [I] Choi AMK, Alam J: Heme oxygenase-1: Function,regulation and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J RespirCell Mol Biol 15: 9-19, 1996. [2] Kinnula VL, Crapo JD, Raivio KO; Biology of disease.Generation and disposal of reactive oxygen metabolites in the lung. Lab Inv 73: 3-19, 1995. [3] Camhi S, Lee PJ, Choi AMK: The oxidative stress response. New Horizons 3: 170-182, 1995. [4] Tenhunen R, Marver HS, Schmid R : the enzymatic conversion of heme to bilirubin by microsomal heme oxygenase . Proc Natl Acad Sci USA 61: 748-755, 1968. [5] Abraham NG, Lin JH, Dunn MW, Schwartzman ML : Presence of human heme oxygenase and NAPH cytochrome P-450 © reductase in human corneal epithelium. Invest Ophtalmol Vis Sci 28: 1464-1472, 1987. [6] Maines MD: Heme oxygenase:function,multiplicity,regulatory mechanisms and clinical implications. FASEB J 2: 2557-2568, 1988. [7] McCoubrey WK, Ewing JF, Maines MD: Human heme-oxygenase 2: characterization and expression of a full- length cDNA and evidence suggesting that the two HO-2 transcripts may duffer by choice of polyadenylation signal. Arch Biochem Biophys 295: 13-20, 1992. [8] McCoubrey WK, Huang TJ, Maines MD: isolation and characterization of a cDNA from the rat brain that encodes hemoprotein heme oxygenase-3. Eur J Biochem 247: 725-732, 1997. [9] Otterbein LE, Choi AMK: Heme oxygenase: colors of defense against celular stress. Am J Physiol Lung Cell Mol Physiol 279: L1029-L1037, 2000. [10] Carraway MS, Ohio AJ, Carter JD, Piantadosi CA: Expression of heme oxygenase-1 in the lung in chronic hypoxia . AM J Physiol Lung Cell Mol Physiol 278: L806-L812, 2000. [ I I ] Lee PJ, Alam J, Sylvester SL, Inamdar N, Ottrebein L, Choi Am: Regulation of heme oxygenase-1 expression in vivo and in vitro in hyperoxic lung injury . Am J Respir Cell Mol Biol 14: 556-568, 1996. [12] Otterbein LE,Sylvester SL,Choi AM: Hemoglobin provides protection against lethal endotoxaemia in rats: the role of heme oxygenase-1. Am J Respir Cell Mol Biol 13: 595-601, 1995. [13] Vile GF, Tyrrel RM: Oxidativ stress resulting from ultraviolet A irradiation of human skin fibroblasts leads to a heme oxygenase- dependant increase in ferritin . J Biol Chem 268: 14678- 14681, 1993. [14] Keyse SM,Tyrrel RM: Heme oxygenase is the major 32 -kDa stress protein induced in human skin fibroblasts by UVA radiation,hydrogen peroxide and sodium arsenite . Proc,Natl.Acad Sci USA 86: 99-103, 1989. [15] Maeshima H,Sato M, Ishikawa K, Katagata Y, Yoshida T: Participation of altered upstream stimulatory factor in the induction of rat heme oxygenase-1 by cadmium. Nucleid Acids Res 24: 2959-2965, 1996. [16] Poss KD, Tonegawa S: Reduced stress defense in heme oxygenase deficient cells. Proc Natl Acad Sci USA 94, 10925- 10930, 1997. [17] Yachie A, Niida Y, Wada T, Irgarashi N, Kaneda H: Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 defiency. J Clinic Invest 103:129-135, 1999. [18] Gopinathan V, Miller NJ, Milner AD, Rice-Evans CA: Bilirubin and ascorbate antioxidant activity in
78
J. K. Sarady el al. / Cytoprotection by Hetne Oxygenase / CO in the Lung
neonatal plasma . FEBS lett 349: 197-200, 1994. [19] Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN: Bilirubin is an anti-oxidant of possible physiological importance . Science 235 :1043-1046, 1987. [20] Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F, Eaton JW, Vercelotti GM: Ferritin: a cytoprotective antioxidant stratagem of endothelium. J Biol Chem 267: 18148- 18153, 1992. [21] Otterbein LE, Chin BY, Otterbein SL, Lowe VC, Fessler HE, Choi AMK: Mechanism of hemoglobininduced protection against endotoxaemia in rats: a ferritin-independent pathway. Am J Physiol Lung Cell Mol Physiol 272: L 268- L275, 1997. [22] Morita T, Perella MA, Lee M, Kourembanas S: Smooth muscle cell -derived carbon monoxide is a regulator of vascualr cGMP. Proc Natl Acad Sci USA 92:1475-1479, 1995. [23] Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snuder SH: Carbon monoxide, a putatuve neural messenger. Science 259:381-384, 1993. [24] Snyder SH, Jaffrey SR, Zakhary R: Nitric oxide and carbon monoxide: paralell roles as neural messengers. Brain Res Rev 2-3: 167-175, 1998. [25] Cardell LO, Lou YP, Takeyama K, Ueki IF, Lausier J, Nadel JA: Carbon monoxide, a cyclic GMP- related messenger involved in hypoxic bronchodilatation in vivo. Pulm Pharmacol Ther 11: 309-315, 1 998. [26] Otterbein LE, Rolls JK, Mantell LL, Cook JL , Alam J, Choi AMK: Exogenous administration of heme oxigenase-1 by gene transfer provides protection against hyperoxia-induced lung injury. J Clin Invest 103. 1047-1054, 1999. [27] Otterbein LE, Mantell LL, Choi AMK: Carbon monoxide provides protection against hyperoxic lung injury Am J Physiol 276:L688-L694, 1999. [28] Otterbein LE, Bach FH, Alam J, Scares M, Lu HT, Wysk M, Davis RJ, Flavell RA, Choi AMK: Carbon monoxide has anti-inlammatory effects involving the mitogen-activated protein kinase pathway . Nat Med 6 , No 4: 422-428, 2000. [29] Horvath I, Donnelly LE, Kiss A, Paredi P, Kharitonov SA, Barnes PJ: Raised levels of exhaled carbon monoxide are associated with an increased expression of heme-oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Thorax 53: 668-672, 1998. [30] Horvath I, Loukides S, Wodehouse T, Khariatonov SA, Cole PJ, Barnes PJ : Increased levels of exhaled carbon monoxide in bronchiectasis: a new marker of oxidative stress. Thorax 53(10):867-70, 1998. [31] Scares MP, Lin Y, Anrather J, Csizmadia E, Takigami E, Sato K, Grey ST, Colvin RB, Choi AM, Poss KD, Bach FH: Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med 4 : 1073-1077, 1998. [32] Suttner DM, Sridhar K, Lee CS, Tomura T, Hansen TN, Dennery PA: Protective effects of transient HO-1 overexpression on susceptibility to oxygen toxicity in lung cells . Am J Physiol Lung Cell Mol Physiol 274:L443-L451, 1999. [33] Suttner DM, Dennery PA: reversal of HO-1 related cytoprotection with increased expression is due to reactive iron. FASEB J 13: 1800-1809, 1999. [34] Taylor JL, Carraway MS, Piantadosi CA: Lung-specific induction of heme-oxygenase-1 and hyperoxic lung injury . Am J Physiol Lung Cell Mol Physiol 274: L 582-L590, 1998. [35] Camhi SL, Alam J, Wiegand GW, Chin BY, Choi AMK: Transcriptional activation of the HO-1 gene by Hpopolysaccharide is mediate 5' distal enhancers: :role of reactive oxygen intermediates and AP-1. Am J RespirCell Mol Biol 18(2): 226-234, 1998. [36] Stupfel M, Bouley G: Physiological and biochemical effects on rats and mice exposed to small concentrations of carbon monoxide for long periods. Ann NY Acad Sci 174: 342-368, 1970. [37] Otterbein LE, Dyck DE, Otterbein SL, Knickelbein R, Davis RJ, Flavell RA, Choi AMK: MKK3 mitogen activated protein kinase pathway mediates carbon monoxide-induced protection against ox idant-induced lung injury (submitted) [38] Chapman JT, Otterbein LE, Elias JA, Choi AM: Carbon monoxide attenuates aeroallergen-induced inflammation in mice. Am J Physiol Lung Cell Mol Physiol 281(1):L209-16, 2001.
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
79
Role of heme oxygenase in airway smooth muscle contractility Camilla TAILLE, Michel AUBIER and Jorge BOCZKOWSKI Ins ti tut National pour la Sante et la Recherche Medicate (INSERM), Unite 408, Faculte de Medecine Xavier Bichat, Paris, France. Abstract. This chapter summarizes data on the role of HO on smooth muscle contractility. The role of the antioxidant properties of HO are discussed.
1. Introduction Reactive oxygen species (ROS) are produced by all aerobic organisms as a consequence of oxygen consumption and cell respiration. They play the role of intracellular mediators at physiological concentrations. However, in stress situations, increasing production of ROS can lead to cellular injury [1]. One interesting biological relevant effect of oxidants, hydrogen peroxide and superoxide anion in particular, is the regulation of cell functions by controlling level of protein phosphorylation. This is modulated by activation of protein kinases or inactivation of protein phosphatases [1, 2]. In smooth muscle cells, level of phosphorylated proteins is critical for cell contraction : phosphorylation of myosin light chain (MLC) allows the myosin ATPase to be activated by actin and, thus the muscle to contract [3]. Different studies have shown that incubation of tracheal rings with exogenous applied oxidative species or with systems generating ROS, such as xanthine/xanthine-oxydase, induce airway smooth muscle hyperresponsiveness to contractile agonists [4-6]. In the same line, in vitro incubation of guinea pig trachea with superoxide dismutase decreases the contractile response to metacholine [7], suggesting a role of ROS produced by structural cells of the airways. However, the role of ROS in the modulation of MLC phosphorylation is unknown. Ubiquity of ROS production explains the need for strong antioxidant cellular systems. Heme oxygenase, the enzyme responsible for heme degradation, is a powerful antioxidant and protective system [8], Two main isoforms, products of different genes, have been identified: heme oxygenase-1 (HO-1), the inducible form (also known as heat shock protein 32), and HO-2, the constitutive form [8]. Degradation of the tetrapyrrolic ring produces carbon monoxide (CO) and biliverdin, reduced by the biliverdin reductase into bilirubin, one of the most important antioxidant molecule of the organism [9]. Whereas modulation of the HO pathway has shown beneficial effects in different pathological situations where oxidative stress is implicated [10], the role of HO in regulating cellular redox status in normal conditions has not been thoroughly investigated. In this chapter, we will report data from different groups and from our laboratory on the role of HO on smooth muscle contractility. We will discuss the role of the antioxidant properties of HO, including bilirubin, and how this property can modulate MLC phosphorylation.
80
C. Tattle" et al. /Role of Herne Oxygenase in Airway Smooth Muscle Contractility
2. Heme oxygenase modulates airway smooth muscle contractility Heme oxygenase is strongly expressed in normal and pathologic human airways, especially in epithelial cells [11], but also in smooth muscle cells [12], parasympathetic ganglia, endothelium and macrophages [13]. If HO is a powerful antioxidant, it is also involved in the control of smooth muscle reactivity. HO-induced relaxation of smooth muscle has been well demonstrated in vessels [14], and gastrointestinal tissues [15]. CO release is the mechanism most frequently implied to explain this effect. Indeed, a pro-relaxant effect of CO has been demonstrated in vascular, intestinal and also bronchial smooth muscle [12, 14, 15]. This effect is related to the binding of CO to the heme moiety of the soluble isoform of guanylate cyclase and formation of the second messenger cGMP [14, 16]. Modulation of smooth muscle cell contraction, the other side of smooth muscle reactivity, by the HO pathway has been investigated in different tissues such as vessels [8. 18], myometrium [19], esophageal sphincter [20] and bronchi [21]. Increasing HO-1 activity in myometrium strips by a short time incubation with hemin, in an experimental protocol quite similar to ours, is able to inhibit contractile response to KC1, whereas SnPP, a HO inhibitor [8], has the opposite effect [19]. CO release has been proposed as a mechanism to explain this effect. On the contrary, Canning and coworkers [21] find that neither HO inhibitors nor the guanylate cyclase inhibitor ODQ, had marked effects on vagally-mediated bronchial contractions. We have evaluated the role of HO in the modulation of airway smooth muscle contraction in isolated guinea pig tracheal rings. In rings with an intact epithelium layer, 1 hour incubation with hemin (20 uM), an HO inductor or with tin protoporphyrin IX (SnPP, 10 uM), significantly decreased and increased contractile response to carbachol and histamine, respectively. The effect of hemin was reversed by SnPP. These modulations disappeared in epithelium-denuded tracheal rings, suggesting that epithelial HO modulated the contractility of the underlying smooth muscle. This phenomenon could be related to the low level of expression of HO-1 and HO-2 in tracheal smooth muscle as compared to the epithelium. Airway epithelium is not only exposed to exogenous oxidative damage but is also an important source of oxygen and nitrogen species thus explaining the need for a local strong antioxidant system [22]. Catalase for example, is more strongly expressed in epithelial than in smooth muscle cells [23]. Our results are in agreement with this data, thus confirming the protective role of epithelia against oxidants-induced contraction. We next investigated the role of the CO-cGMP pathway in mediating the contractile effect of HO. This was performed by evaluating the effect of the selective inhibitor of the soluble guanylate cyclase inhibitor ODQ, on the contractile response to carbachol of hemin or vehicle-treated tracheal rings. These experiments showed that ODQ did not interfere with the effect of hemin, suggesting that a role of CO-cGMP was unlikely in the decreased contractility induced by hemin. Although we ruled out the participation of CO-related production of cGMP in airway smooth muscle contraction, we do not exclude that CO can modulate airway reactivity in the present experimental model by a cGMP-independent mechanism. These might involve modulation of potassium channels [24] or kinase activity [25], as demonstrated in other tissues.
C. Taille et al. / Role ofHeme Oxygenase in Airway Smooth Muscle Contractility
81
3. Antioxidant properties of heme oxygenase and smooth muscle contractility Since the CO-cGMP pathway is not involved in the effect of HO, a role of the antioxidant properties of this system can be postulated. Indeed, ROS can potentiate smooth muscle contractility by different mechanisms : they are considered as intracellular messengers involved in control of calcium channel sensitivity, mitochondrial respiration or activation of protein-tyrosine kinases and inhibition of protein-tyrosine phosphatases [reviewed in (1), all features involved in muscular contraction. Among them, phosphorylation of the MLC is actually the key event for initiating smooth muscle contraction by modifying the conformation of myosin, and regulation of amount of phosphorylated/dephosphorylated protein is critical for the cellular physiology. Lopez-Ongil and coworkers [26] showed recently that exogenous hydrogen peroxide increased the amount of phosphorylated MLC and increased contraction of endothelial cells. Therefore, we next investigated the role of ROS in mediating the effects of HO on airway smooth muscle contractility. Initially, we evaluated if HO modulated ROS production in our model. This was performed by measuring SOD-inhibable lucigenin-dependent chemilumiscence in epithelium intact trachea! rings. Superoxide anion production was not affected by carbachol or by histamine, but it was significantly increased by SnPP. The effect of SnPP was suppressed by the antioxidants PEG-SOD plus PEG-Catalase. Superoxide anion production was significantly reduced by hemin, and this effect of was reversed by SnPP. In agreement with these results, PEG-SOD plus PEG-Catalase suppressed the increased contractility induced by SnPP, thus showing that the antioxidant properties of HO are involved in its effects on airway smooth muscle contraction. 4. The role of bilirubin Having demonstrated the involvement of the antioxidant properties of HO in its effects on airway smooth muscle contraction, we were interested in the role of bilirubin, since this molecule has been known to possess strong antioxidant properties for a long time. Bilirubin is able to scavenge different oxygen and nitrogen species and to inhibit production of superoxide by the NAD(P)H oxidase [9]. Different studies have shown that bilirubin decreased vascular or gastric smooth muscle contractility [27, 28]. For example, Colpaert and coworkers [27], showed that bilirubin potentiated the relaxant effect of nitric oxide in gastric smooth muscle with a similar potency than other antioxidants such as urate or glutathione. We investigated the effect of bilirubin on ROS production and contractility of guinea pig tracheal rings. We found that 10 nM of bilirubin significantly decreased spontaneous ROS production and suppressed the increased production induced by SnPP. This effect was accompanied by a suppression of the increased contractility induced by SnPP. Moreover, modulating the redox status of airway smooth muscle by hemin, SnPP, antioxidants or bilirubin, modulated the level of phosphorylated MLC. Indeed, Western blot analysis of phosphorylated MLC in airway smooth muscle showed that the basal level was significantly increased by SnPP and significantly reduced by PEG-SOD plus PEG-Catalase, hemin, or bilirubin. Furthermore, PEG-SOD plus PEGCatalase and bilirubin abrogated the increase in phosphorylated MLC induced by SnPP.
82
C. Tattle et al. /Role ofHeme Oxygenase in Airway Smooth Muscle Contractility
5. Conclusion This chapter reviews evidence that the HO pathway, especially bilirubin, controls smooth muscle reactivity by decreasing ROS-dependent phosphorylation of the MLC. These data support the interest for antioxidant therapy in inflammatory diseases associated with an enhanced contractile response of smooth muscle, such as asthma. References 1. Gabbita SP, Robinson KA, Stewart CA, Floyd RA, Hensley K. Redox regulatory mechanisms of cellular signal transduction. Arch Biochem Biophys. 376: 1-13, 2000 2. Barrett W, DeGnores J, Keng Y, Zhang Z, Yim M and Chock P. Roles of superoxide radical anion in signal transduction mediated by reversible regulation of protein-tyrosine phosphatase IB. J Biol Chem. 274 : 34543-34546, 1999 3. Pfitzer G. Regulation of myosin phosphorylation in smooth muscle. J Appl Physiol. 91:497-503, 2001 4. Szarek J and Schmidt N. Hydrogen peroxide-induced potentiation of contractile responses in isolated rat airways. Am. J. Physiol. 258:L232-L237, 1990 5. Sadeghi-Hashjin G, Henricks PA, Folkerts G, Muis T, Garssen J, Nijkamp FP. Role of the epithelial layer in the generation of superoxide anion by the guinea-pig isolated trachea. Mediators Inflamm. 7:35-40, 1998 6. Katsumata U, Miura M, Ichinose M, Kimura K, Takahashi T, Inoue H and Takishima T. Oxygen radicals produce airway constriction and hyperresponsiveness in anesthetized cats. Am. Rev. Respir. Dis. 141:11581161,1990 7. De Boer J, Pouw F, Zaagsma J and Meurs H. Effects of endogenous superoxide and nitric oxide on cholinergic constriction of normal and hyperreactive guinea pig airways. Am J Respir Crit Care Med. 158:1784-1789, 1998 8. Maines MD. The heme oxygenase system : a regulator of second messenger gases. Anna Rev Pharmacol Toxicol. 37:517-554, 1997 9. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 235:1043-6, 1987 10. Choi AMK, A lam J. Heme oxygenase-1 : function, regulation and implication of a novel stress-inductible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol. 15:9-19, 1996 11. Lim S, Groneberg D, Fischer A, Gates T, Caramori G, Mattos W, Adcock I, Barnes PJ, Chung KF. Expression of heme oxygenase isoenzymes 1 and 2 in normal and asthmatic airways: effect of inhaled corticosteroids. Am J Respir Crit Care Med. 162:1912-1918, 2000 12. Kinhult J, Uddman R, Cardell LO. The induction of carbon monoxide-mediated airway relaxation by PACAP 38 in isolated guinea pig airways. Lung. 179: 1-8, 2001 13. Horvath I, Donnelly LE, Kiss A, Paredi P, Kharitonov SA, Barnes P. Raised levels of exhaled carbon monoxide are associated with an increased expression of heme oxygenase-1 in airway macrophages in asthma : a new marker of oxidative stress. Thorax. 53:668-672, 1998 14. Motterlini R, Gonzales A, Foresti R, Clark JE, Green CJ, Winslow RM. Heme oxygenase-1-derived carbon monoxide contributes to the suppression of acute hypertensive responses in vivo. Circ Res. 83:568-77, 1998 15. Rattan S, Chakder S. Influence of heme oxygenase inhibitors on the basal tissue enzymatic activity and smooth muscle relaxation of internal anal sphincter. J Pharmacol Exp Ther. 294:1009-10, 2000 16. Rattan S, Chakder S. Inhibitory effect of CO on internal anal sphincter: heme oxygenase inhibitor inhibits NANC relaxation. Am J Physiol. 265:G799-804, 1993 17. Caudill TK, Resta TC, Kanagy NL, Walker BR. Role of endothelial carbon monoxide in attenuated vasoractivity following chronic hypoxia. Am J Physiol. 275:RI025-R1030, 1998 18. Duckers HJ, Boehm M, True AL, Yet SF, San H, Park JL, Clinton Webb R, Lee ME, Nabel GJ, Nabel EG. Heme oxygenase-1 protects against vascular constriction and proliferation. Nat Med. 7:693-8, 2001 19. Acevedo CH, Ahmed A. Hemeoxygenase-1 inhibits human myometrial contractility via carbon monoxide and is upregulated by progesterone during pregnancy. J Clin Invest. 101:949-955, 1998 20. Ny L, Larsson B, Aim P, Ekstrom P, Fahrenkrug J, Hannibal J, Andersson KE. Distribution and effects of pituitary adenylate cyclase activating peptide in cat and human lower oesophageal sphincter. Br J Pharmacol. 116:2873-80, 1995 21. Canning BJ, Fischer A. Localization of heme oxygenase-2 immunoreactivity to parasympathetic ganglia oh human and guinea pig airways. Am J Respir Cell Mol Biol. 18:279-285, 1998
C. Tattle et al. /Role of Herne Oxygenase in Airway Smooth Muscle Contractility
83
22. Yamada N, Yamaya M, Okinaga S, Lie R, Suzuki T, Nakayamam K, Yamaguchi T, Itoyama Y, Sekizawa K, Sasaki H. Protective effects of heme oxygenase-1 against oxidant-induced injury in the cultured human tracheal epithelium. Am J Respir Cell Mol Biol. 21 : 428-435, 1999 23. Asano T, Hattori T, Tada T, Kajikuri J, Kamyia T, Saitoh M, Yamada Y, Itoh M, Itoh T. Role of the epithelium in opposing H2O2-induced modulation of acetylcholine-induced contractions in rabbit intrapulmonary bronchiole. Br JPharmacol. 132: 1271-1280,2001 24. Wang R, Wu L, Wang Z. The direct effect of carbon monoxide on KCa channels in vascular smooth muscle cells. Pflugers Arch, 434:285-291, 1997 25. Brouard S, Otterbein LE, Anrather J, Tobiasch E, Bach FH, Choi AM, Scares MP. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med. 192:1015-26, 2000 26. Lopez-Ongil S, Torrecillas G, Perez-Sala D, Gonzalez-Santiago L, Rodriguez-Puyol M, Rodriguez-Puyol, D. Mechanisms involved in the contraction of endothelial cells by hydrogen peroxide. Free Radic Biol Med. 26:501-510, 1999 27. Bomzon A, Gali D, Better OS, Blendis LM. Reversible suppression of the vascular contractile response in rats with obstructive jaundice. J Lab Clin Med. 105 :568-572, 1985 28. Colpaert EE, Lefebvre RA. Influence of bilirubin and other antioxidants on nitrergic relaxation in the pig gastric fundus. Br J Pharmacol. 129 :1201-1211, 2000
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub(Eds.) IOS Press, 2002
Exhaled Carbon Monoxide is Produced in the Lungs Jigme M. SETHI Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, 3459 Fifth Avenue, Pittsburgh, PA 15213 Abstract. Carbon monoxide is produced endogenously by the degradation of heme in the reaction catalyzed by heme oxygenase, and is exhaled by the lungs. Heme oxygenase is highly induced in lung tissue by a variety of stressors, potentially accounting for the increase in exhaled carbon monoxide. In inflammatory diseases of the lung, levels of exhaled carbon monoxide are elevated, and return to normal with topical treatment of the disease, suggesting local production of carbon monoxide in the lung.
1. Introduction Endogenous production of carbon monoxide (CO) in humans was reported in 1949[1], but only in 1967 did it become clear that the gas was produced by the catabolism of hemoglobin [2]. Tenhunen, in 1968, identified heme oxygenase (HO) as the enzyme responsible for this reaction [3], and as might be expected, HO is abundantly present in the liver and spleen. For many years, it was assumed that HO was merely a catabolic enzyme, liberating iron for reutilization in heme synthesis, and biliverdin and bilirubin for excretion via the biliary tract. Similarly, it was believed that CO was also merely a waste product, eliminated almost exclusively by exhalation. The error of this assumption became clear when it was discovered that HO-1, the inducible isoform, is strongly upregulated by a variety of cellular stressors, including heavy metals, oxidizing agents, cytokines, ultraviolet radiation, and inflammatory byproducts [4], and that this upregulation has a cytoprotective, anti-oxidant, and anti-inflammatory role [5]. Admittedly, during basal conditions, the CO derived from heme degradation is definitely eliminated by exhalation, but the more complex issue of the origin of the elevated levels of CO in patients with lung inflammation has not been resolved. Where does this increased CO come from? Does it reflect exaggerated systemic heme turnover during inflammatory states, or is it possible that it is locally produced in inflamed lung? Three lines of evidence support the stance that the exhaled CO in inflammatory states originates from the lung: HO-1 mRNA, protein, and activity are all upregulated in lung tissue in numerous animal models of lung injury, confirming the capacity of the lung to produce CO locally in response to inflammatory injury; CO levels are elevated in the exhaled breath of patients with predominantly pulmonary inflammation; and finally, evidence that CO may actually be added to the systemic circulation by the lungs.
J,M. Sethi /Exhaled Carbon Monoxide is Produced in the Lungs
85
2. Data from animal studies When rats are given intra-tracheal hemoglobin, increased HO-1 protein can be demonstrated by western blotting of lung homogenates as well as by immunocytochemical staining of alveolar epithelium in intact lung tissue. This increase represents functional HO-1 protein confirmed by assays of HO-1 enzymatic activity [6]. Similarly, progressively increased staining for HO-1 is noted in alveolar epithelium and macrophages over the 24, hours following intra-tracheal instillation of LPS into rat lungs [7]. Peak induction of lung HO-1 protein and enzymatic activity is seen at one day after exposure of rats to hypoxic conditions, and in this model, immunochemical staining for HO-1 is concentrated in alveolar macrophages and smooth muscle cells of the arterioles by day 21 [8]. 3. Data from lung-limited diseases in humans Exhaled CO levels are significantly elevated over non-smoking control subjects in patients suffering from an upper respiratory tract infection, and these levels decline to baseline with recovery from this purely respiratory tract-limited ailment in 3 weeks [9]. Exhaled CO levels are also elevated in patients with bronchiectasis, as compared to healthy, non-smoking subjects [10]. In adult patients with cystic fibrosis, exhaled CO levels are elevated during exacerbations of pulmonary disease and decline to normal after treatment with antibiotics. During these exacerbations, levels of exhaled CO have been noted to be highest in the subset of patients with the most reduction of FEV^ from baseline [11]. Most importantly, exhaled CO levels are lower in the subset of patients with cystic fibrosis who have been treated with inhaled steroids, a class of drugs that exert their anti-inflammatory effects predominantly via local intra-pulmonary deposition [12]. Similar data in asthmatics also suggests intra-pulmonary production of CO. In asthmatics exposed to an inhaled allergen challenge, both immediate and late phase reductions of FEVt are accompanied by temporally linked increases in exhaled CO levels [13]. Untreated asthmatics have higher levels of exhaled CO than control subjects or asthmatics treated with inhaled steroids [14], and indeed, the elevated levels of exhaled CO correspond to the severity and duration of the reduction in peak expiratory flow rates in asthmatic subjects experiencing an exacerbation [15]. After initiation of a course of oral steroids for asthmatic exacerbations, exhaled CO levels return to normal with the same time course as improvement in peak flow rates. Finally, the resolution of sputum eosinophilia in asthmatics treated with inhaled steroids is tightly correlated to simultaneous reduction in elevated levels of CO in the exhaled breath [14]. In light of this clinical data, it would not be surprising to note that sputum macrophages from asthmatic patients, but not normal subjects, show increased HO-1 protein expression by western blotting [16].
86
J.M. Sethi/Exhaled Carbon Monoxide is Produced in the Lungs
4. Confirmatory studies Confirmatory proof of pulmonary production of CO comes from the observation that exhaled CO concentrations rose dramatically in each of 4 subjects who inhaled 2 mL doses of 1CT4 M hemin, a potent inducer of HO-1 [16]. In a small study of critically ill. mechanically ventilated patients, arterial levels of carboxyhemoglobin were higher than mixed-venous carboxyhemoglobin levels, suggesting net pulmonary addition of CO to the systemic circulation under these conditions [17]. 5. Conclusion While there cannot be any doubt that in basal conditions CO derived from heme breakdown in the reticulo-endothelial system is eliminated from the body by exhalation, the evidence outlined above does confirm the ability of the lung to produce CO locally, in inflammatory conditions characterized by marked up-regulation of heme oxygenase. There can be no doubt that locally produced CO represents a major component of the increased concentration of exhaled CO noted in humans with purely pulmonary diseases, in which there should be no reason for increased delivery of CO to the lungs from the circulation. References 1. 2. 3. 4. 5.
6. 7. 8. 9. 10. 11. 12.
Sjorstrand, T. Endogenous formation of carbon monoxide in man under normal and pathological conditions. Scand. J. Clin. Lab. Invest. 1: 201-214; 1949. Coburn, RF; Williams, WJ; White, P; Kahn, SB. Production of carbon monoxide from hemoglobin in vivo. J. Clin. Invest. 46:346-356; 1967 Tenhunen, R; Marver, HS; Schmid, R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc. Natl. Acad. Sci. USA. 61(2):748-55; 1968. Applegate, LA;Luscher, P;Tyrrell, RM. Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res. 51(3): 974-8; 1991. Sethi, JM; Choi, AMK. Heme oxygenase -1 in Acute Lung Injury, pp 119-132,/w Molecular Biology of Acute Lung Injury. Wong, HR; Shanley, TP (eds.). The Molecular and Cellular Biology of Critical Care Medicine. Clark, RSB; Carcillo, JA (series eds.).KIuwer Academic Publishers. Boston;2001. Taylor, JL;Carraway, MS; Piantadosi, CA. Am. J. Physiol. Lung Cell. Mol. Physiol.274(4):L582590; 1998. Carraway, MS; Ohio, AJ; Taylor, JL; Piantadosi, CA. Am. J. Physiol. Lung Cell. Mol. Physiol.275(3):L583-592;1998 Carraway, MS; Ohio, AJ; Carter, JD; Piantadosi, CA. Am. J. Physiol. Lung Cell. Mol. Physiol. 278(4):L 806-812;2000 Yamaya, M; Sekizawa, K; Ishizuka, S; Monma, M; Mizuta, K; Sasaki, H. Am. J. Respir. Crit. CareMed. 158:311-4; 1998. Horvath, I; Loukides, S; Wodehouse, T; Kharitonov, SA; Cole,PJ; Barnes, PJ. Thorax 53(10):86770; 1998. Antuni, JD; Kharitonov, SA; Hughes, D; Hodson, ME;Margaret, E;Bames PJ. Thorax 55(2)13842; 2000. Paredi,P; Shah, PL; Montuschi,P; Hodson, ME; Kharitonov, SA; Barnes, PJ. Thorax 54(10):91720; 1999.
J.M. Sethi / Exhaled Carbon Monoxide is Produced in the Lungs
13. 14. 15. 16. 17.
87
Paredi,P; Leckie, MJ; Horvath, I; Allegra, L; Kharitonov, SA; Barnes, PJ. Eur. Respir. J. 13:4852; 1999. Zayasu, K; Ohrui,T; Sekizawa,K; Yamaya, M; Fukushima, T; Sasaki, H; Takishima,T. Am. J. Respir. Crit. Care Med. 156:1140-3; 1997. Yamara, M; Sekizawa,K; Ishizuka, S; Monma, M;Sasaki,H. Eur. Respir. J. 13:757-60; 1999. Horvath, I; Donnelly, LE; Kiss, A; Paredi, P; Kharitonov, SA; Barnes, PJ.Thorax.53(8):66872;1998. Meyer, J; Prien, T;van Aken, H; Bone, H-G; Waurick, R; Theilmeier, G; Booke, M. Biochem. Biophys. Res. Com. 244:230-2; 1998.
88
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub(Eds.) IOS Press, 2002
Exhaled Carbon Monoxide is Delivered from Systemic Sources Nandor MARCZIN Department of Anaesthetics, Royal Brompton and Harefield Hospital and Department of Cardiothoracic Surgery, Faculty of Medicine, National Heart and Lung Institute, Imperial College, Heart Science Centre, Harefield Hospital, Harefield, United Kingdom Abstract. Similarly to exhaled nitric oxide (NO), exhaled carbon monoxide (CO) appears to be a promising non-invasive tool to assess lung inflammation in a variety of conditions [1]. However, the origin and determinants of exhaled CO remains controversial. Particularly, the magnitude of local airway production of CO and contribution from delivery from the pulmonary and systemic circulation has not been established. We have addressed these issues by investigating exhaled NO and CO in patients undergoing cardiac surgery. Here, the dynamically changing ventilation and pulmonary blood flow parameters have provided interesting insights into the influence of ventilation and blood flow on gaseous concentrations of CO. The data show that measured concentrations significantly depend on ventilation settings and on pulmonary blood flow. A large proportion of exhaled CO appear to originate from systemic circulation suggesting that this fraction should be taken into consideration before exhaled CO is widely accepted as a marker of pulmonary inflammation.
1. Objectives and study design We have measured exhaled CO and NO in anesthetized intubated patients" undergoing routine open heart surgery, which provides a good opportunity to test the influence of different ventilation maneuvers and dynamically changing pulmonary blood flow on CO and NO concentrations in the gas phase. Since breath holding maneuvers have been particularly useful in delineating characteristics of exhaled gases by showing accumulation of exhaled gases in the airway dead space and by demonstrating changes in concentrations in alveolar gases following breath holding [2,3 and Chapter 8 by Adding and Gustafsson in this volume], we performed these measurements in order to delineate alveolar vs. main airway CO concentrations. In order to investigate influence of pulmonary blood flow on exhaled CO we have studied the influence of PEEP, institution of cardiopulmonary bypass and cardiac arrest. During all these maneuvers, CO was compared to characteristics of CO2, a gas molecule largely derived from systemic sources. 2. Methods Breath to breath measurements of exhaled gas concentrations in the lower airways were performed using a real-time, computer-controlled and integrated system (Logan Research
N. Marczin /Exhaled CO is Delivered from Systemic Sources
89
Ltd. 2000 and 3000 series) [4]. Inspired and expired samples for analysis of CO, NO and CO2 were continuously withdrawn at a flow rate of 150 ml/minute directly from the main lower airways through a thin Teflon sampling tube positioned within the endotracheal tube. Since detected concentration of exhaled gases depends on both the production rate and ventilation parameters, ventilation was normally standardized for inspired gas (100% 02), tidal volume (5 ml/kg), respiratory rate (10/min) and inspiratory and expiratory ratio (1:2). To eliminate the influence of positive end expiratory pressure on gas phase NO, PEEP was set to zero. 3. Alveolar vs. main airway CO concentrations during breath-hold Figure 1 shows representative traces of gas phase CO, NO and CO2 during normal ventilation cycles and during different types of breath-holding. The traces demonstrate that both end-expiratory and end-inspiratory breath-holding results in accumulation of CO, NO and CO2 in the gas phase. The first respiratory manoeuvre following the release of breath-holding allows us to derive information regarding relative gas concentrations between the alveoli and main airways. Figure 1 left panel shows that following expiratory breath-hold the first inspiration delivered by the Servo 900D ventilator is an inspiration of 100% O2- Since this inspired gas does not contain CO, NO and CO2 , it is expected that this gas dilutes gases accumulated in the main airway during breath-holding and as a consequence, CO, CO2 and NO concentrations would decrease after release of
Figure 1. Characteristics of exhaled gases following end-expiratory (left panel) and end-inspiratory (right panel) breath hold. Downwards arrows above the flow trace indicate the start of breath-hold.
breath hold. Upward arrow in the left panel indicates that this is indeed the case. Interestingly, the first expiration depicts different characteristics of NO and CO. In the case of NO, the trace during the first expiration after breath holding does not appear to be any different from the expiratory pattern of NO before breath-holding. However, exhaled CO and CO2 following breath holding appear to be increased when compared to prior breath holding. Following end-inspiratory breath-holding and during the first spontaneous expiration by the patients, alveolar gases dilute the gases accumulated in the airway dead space during breath-holding. Since alveolar gas is rich in CO2, main airway CO2 levels appear to rise further upon release of inspiratory breath hold (upwards arrow, right hand panel). If concentrations of CO and NO were higher in the alveoli than in the airways, a similar pattern to CO2 should be seen, and if alveolar CO and NO equals airway NO, the
90
N. Marczin /Exhaled CO is Delivered from Systemic Sources
mixing should not change the detected concentrations. However, it is obvious that NO concentrations rapidly fall during the first exhalation, whereas CO levels appear to rise. This provides clear evidence that despite accumulation of high concentrations of NO in the lower airways, NO concentrations in the alveoli remains very low during breathholding. This suggests the existence of a mechanism that continuously removes NO from the alveoli. Contrary, it appears that the behaviour of CO is similar to CO2 suggesting that alveolar concentrations of CO are high and that measured concentrations during tidal ventilation and breath holding underestimate true alveolar CO concentrations. Thus, there should be mechanisms that continuously enrich alveoli with CO. Pulmonary blood flow can be postulated to fulfil both of these functions ie., delivery of CO to alveoli from systemic sources and uptake of NO delivered from the airways. This might also explain why exhaled CO and CO2 but not NO is higher during the subsequent breaths after the breath holding period. CO and CO2 appear to accumulate in the systemic circulation during apnoea and it might take several breaths for the blood concentrations of these gases to return to baseline. In contrast, pulmonary blood flow has extreme capacity to take up inhaled NO. Thus one single respiratory cycle is likely to be sufficient to restore exhaled NO concentrations to pre-breath holding levels. 4. Influence of pulmonary blood flow The hypothesis that exhaled CO is influenced by pulmonary blood flow was tested by evaluating the influence of a) PEEP, b) cardiopulmonary bypass and c) cardiac arrest on exhaled gases. Influence of PEEP Ventilation with Positive End Expiratory Pressure is frequently employed in anaesthetic practice. Among other physiological changes the principle events during PEEP application are changes in shear forces, recruitment of alveoli and a reduction of capillary' blood flow. Interestingly, PEEP has been shown to dramatically influence exhaled NO concentrations and this argument has been used to support airway origin and the role of shear forces in regulation of airway production of NO [5,6]. We have reasoned that PEEP might similarly affect exhaled CO concentrations and that PEEP induced alterations in exhaled CO might provide insights into origin of exhaled CO. In particular, a PEEP-induced increase on exhaled CO would suggest a local shear stress mediated production in the lungs, whereas a decrease would imply reduced delivery by the decreased pulmonary blood flow. As shown in Figure 2, application of 10cmH20 PEEP produced and immediate change in exhaled gases. Whereas exhaled NO rose dramatically, there was a detectable decrease in expired CO and COi concentrations. Thus, similarly to breath holding, PEEP also produce a differential effect on exhaled CO and NO concentrations and in this respect, too, CO appears to mimic CO2 exhalation profile. These data confirm in humans previous observations on animals regarding the influence of PEEP on exhaled NO [5,6] and are also consistent with CO delivered from systemic sources.
N. Marczin /Exhaled CO is Delivered from Systemic Sources
Figure 2. Influence of PEEP on exhaled CO, NO and CO2 concentrations.
Influence ofCPB We reasoned that upon instrumentation of CPB when the entire output of the right ventricle is diverted away from the pulmonary circulation, the reduction of pulmonary arterial blood flow should affect capillary blood volume despite bronchial arterial blood flow. This is consistent with everyday experience of reduced pulmonary artery pressures during CPB. As shown in figure 3. institution of CPB indeed results in an immediate decline in expired COi as a reflection of decreased pulmonary blood flow. One can appreciate that NO exhibits a different pattern and that gaseous concentration of NO appears to increase following CPB. In addition, CPB is associated with about 50% reduction of expired CO.
Figure 3. Influence of CPB on exhaled concentrations of CO, NO and CO2 Influence of cardiac arrest
In similar experiments during cadaveric organ donor harvesting we had the opportunity to evaluate the influence of cardiac arrest on exhaled CO. In this procedure, during preparation for liver perfusion, the inferior vena cava was drained resulting in progressive decrease in venous return to the heart leading to cardiac arrest. With ventilation parameters maintained we could observe the influence of complete reduction of pulmonary blood flow on exhaled gases. During this procedure we observed that
92
N. Marczin /Exhaled CO is Delivered from Systemic Sources
similarly to COi, exhaled CO decreased to 10% of its original value, whereas little change in exhaled NO occurred. 5. Conclusions These simple experiments in humans demonstrate that in most experimental situations the behavior of exhaled CO was similar to CO2 and distinct from that of NO. Different lines of evidence suggest that at least in the patients studied a significant amount (up to 90%) of exhaled CO originated from the systemic circulation and was dependent on pulmonary blood flow. These observations might have important implications regarding the use of exhaled CO as a marker of airway inflammation. As discussed in the preceding chapter by Sethi, lung inflammation might contribute to exhaled CO through increased expression of heme oxygenase. However, any local CO production by the lung has to overcome the considerably high CO "noise" from systemic sources before producing a measurable effect on exhaled CO. This high noise obviously lessens the value of exhaled CO as a non-invasive marker in moderate degree of lung inflammation. Another important implication of the presented data is that alterations in exhaled CO may not represent changes in CO production in the lung but might be due to changes in systemic CO production and delivery to the alveoli by pulmonary blood flow. In particular, changes in pulmonary blood flow should be taken into considerations especially since lung inflammation can dramatically alter pulmonary vascular resistance and cardiac output. Acknowledgements This work has been supported by a MRC Clinician Scientist Fellowship to Dr. Nandor Marczin. References [1]
Horvath I, Donnelly LE, Kiss A, Paredi P, Kharitonov SA, Barnes PJ: Raised levels of exhaled carbon monoxide are associated with an increased expression of heme-oxygenase-1 in airway macrophages in asthma: a new marker of oxidative stress. Thorax 53: 668-672, 1998.
[2]
Persson MG, Wiklund NP, Gustafsson LE: Endogenous nitric oxide in single exhalations and the change during exercise. Am Rev Respir Dis 1993; 148:1210-4.
[3]
Marczin N, Riedel B, Royston D, Yacoub M. Exhaled nitric oxide in patients undergoing cardiothoracic surgery: A new diagnostic tool?. In. Matalon S and Sznajder Jl eds. Acute Respiratory Distress Syndrome: Cellular and Molecular Mechanisms and Clinical Management. New York Plenum Press, 1998: 365-374.
[4]
Marczin N, Riedel B, Gal J, Polak J, Yacoub M. Exhaled nitric oxide during lung transplantation. Lancet 1997; 350(9092): 1681-1682.
[5]
Carlin RE, Ferrario L, Boyd JT, Camporesi EM, McGraw DJ, Hakim TS. Determinants of nitric oxide in exhaled gas in the isolated rabbit lung. Am J Respir Crit Care Med 1997; 155:922-927.
[6]
Persson MG, Lonnqvist PA, Gustafsson LE. Positive end-expiratory pressure ventilation elicits increases in endogenously formed nitric oxide as detected in air exhaled by rabbits. Anesthesiology 1995; 82(4):969-974.
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub(Eds.) JOS Press, 2002
93
Kinetics of Carbon Monoxide Accumulation in Exhaled Breath Raed A. DWEIK Department of Pulmonary and Critical Care Medicine Cleveland Clinic Foundation 9500 Euclid Avenue Cleveland Ohio 44195 U.S.A. Abstract. CO is an endogenously generated gas that may play important physiological roles. It is synthesized by heme oxygenases which degrade heme to biliverdin and CO. There are several lines of evidence to support an interaction between NO and CO suggesting potential physiologic and pathophysioiogic implications for this interaction. Whether CO in exhaled breath comes from the circulation or is locally produced in the lung remains the subject of considerable controversy. The relationship of CO to airway inflammation is not clear either.
1. Carbon monoxide (CO) CO is an endogenously generated gas that may play important physiological roles. CO is synthesized by heme oxygenases which degrade heme to biliverdin and CO. Two principal isozymes of heme oxygenase have been identified, a constitutive isoform heme oxygenase -2 and an inducible isoform heme oxygenase -1, which is expressed at a low basal level in vascular endothelial and smooth muscle cells and is induced by heavy metals, oxidative stress, inflammatory mediators and oxidized low density lipoproteins. Like NO, CO modulates platelet aggregation, smooth muscle relaxation, and intracellular cGMP levels, but CO has a much lower affinity (by a 100 fold) for soluble guanylyl cyclase than NO [1-4]. 2. CO - NO interaction There are several lines of evidence to support the interaction between NO and CO suggesting potential physiologic and pathophysioiogic implications for this interaction. It is unknown whether the two messengers converge or exhibit reciprocal feedback regulation and this may well depend on the particular organ system [4-12].
94
R. A. Dweik I Kinetics of CO Accumulation in Exhaled Breath
There is dual expression of heme oxygenase and NOS in cells of several organ systems particularly those that require neural (brain, peripheral nerves) or smooth muscle regulation (the liver sinusoids, the intestine, uretheral sphincter, uterus, and pulmonary and systemic vessels). At physiologically and environmentally relevant levels, CO can directly affect endogenous NO levels and NOS activity. While high levels of CO inhibit NOS activity and NO generation, lower concentrations of CO induce release of NO from the intracellular pool and, therefore, increase endogenous NO levels. NO, endogenously produced or exogenously administered, affects heme oxygenase expression in vascular smooth muscles. Both NO and NO donors are capable of inducing heme oxygenase -1 protein expression, in a mechanism that depends on the de novo synthesis of RNA and protein. Molecular oxygen is essential for biosynthesis of both NO and CO. Oxygen levels in the physiologic range affect the endogenous production of both gases. Thus both NO and CO may act as oxygen sensors. Under normoxia, basal levels of NO and CO may act as amplifiers of molecular oxygen and keep the sensory discharge low. During hypoxia, decreased synthesis of NO and CO may contribute in part to the augmentation of sensory discharge. Some CO effects, like apoptotic cell death following exposure to relatively high concentrations of CO, appear to be mediated by nitric oxide [4-14]. 3. CO in exhaled breath CO in exhaled breath may be increased due to airway inflammation and subsequent induction of heme oxygenase in the airway in different lung diseases [3, 1316]. If CO is produced in the inflamed airway by HO-1; we expect that inflammation resulting from an experimental allergen challenge would result in an increase of CO in exhaled breath of atopic asthmatic individuals. Recently the interrelationship of four different exhaled gases [CO, NO, COz, and 02] was evaluated in asthma during an asthmatic response induced by Ag challenge [3]. Baseline exhaled NO is significantly increased in the asthmatics as compared to healthy controls and increases further following Ag challenge. In contrast to NO, however, baseline exhaled CO levels were similar to control individuals. Furthermore, CO levels did not increase over time after Ag challenge. Rather, CO levels decreased immediately after Ag, with levels tending to be lower even 1 h after Ag. Interestingly, there were similarities between the alterations in CO and CO2 a gas that is derived from diffusion into the lung. Exhaled O2 did not change significantly with Ag challenge. If CO is produced primarily within the lung and airways, the decrease of CO immediately after Ag may be related to increased consumption by lung tissue or hemoglobin. Alternatively if exhaled CO is primarily derived by diffusion from the bloodstream, decrease of CO may be due to decreased diffusion into the conducting airway.
R.A. Dweik / Kinetics of CO Accumulation in Exhaled Breath
95
References [I] OtterbeinLE. BachFH. Alam J. Scares M. Tao Lu H. Wysk M. Davis RJ. Flavell RA. Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nature Medicine. 6(4):422-8, 2000 Apr. [2] Wang R.Resurgence of carbon monoxide: an endogenous gaseous vasorelaxing factor. [Review] [ 102 refs] Canadian Journal of Physiology & Pharmacology. 76(1):1-15, 1998 Jan. [3] Khatri SB, Ozkan M, McCarthy K, Laskowski D, Hammel J, Dweik RA, Erzurum SC. Alterations in Exhaled Gas Profile during Allergen-induced Asthmatic Response. Am J Respir Crit Care Med. 2001; 164:1844-1848. [4] Foresti R. Motterlini R.The heme oxygenase pathway and its interaction with nitric oxide in the control of cellular homeostasis. [Review] [139 refs]Free Radical Research. 31(6):459-75, 1999 Dec, [5] Sharma VS. Magde D. Activation of soluble guanylate cyclase by carbon monoxide and nitric oxide: a mechanistic model.Methods. 19(4):494-505, 1999 Dec. [6] Prabhakar NR.NO and CO as second messengers in oxygen sensing in the carotid body. [Review] [39 refs]Respiration Physiology. 115(2): 161-8, 1999 Apr 1. [7] Snyder SH. Jaffrey SR. Zakhary R.Nitric oxide and carbon monoxide: parallel roles as neural messengers. [Review] [66 refs]Brain Research - Brain Research Reviews. 26(2-3): 167-75, 1998 May. [8] Hartsfield CL. Alam J. Cook JL. Choi AM.Regulation of heme oxygenase-1 gene expression in vascular smooth muscle cells by nitric oxide.American Journal of Physiology. 273(5 Pt 1):L980-8, 1997 Nov. [9] Durante W. Kroll MH. Christodoulides N. Peyton KJ. Schafer AI.Nitric oxide induces herne oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells.Circulation Research. 80(4):557-64, 1997 Apr, [10]Abu-Soud HM. Wu C. Ghosh DK. Stuehr DJ.Stopped-flow analysis of CO and NO binding to inducible nitric oxide synthase.Biochemistry. 37(11):3777-86, 1998 Mar 17. [ I I ] Huang LE. Willmore WG. Gu J. Goldberg MA. Bunn HF.Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. Journal of Biological Chemistry. 274(13):9038-44, 1999 Mar 26. [ 12] Thorn SR. Fisher D. Xu YA. Notarfrancesco K. Ischiropoulos H. Adaptive responses and apoptosis in endothelial cells exposed to carbon monoxide.Proceedings of the National Academy of Sciences of the United States of America. 97(3): 1305-10, 2000 Feb 1. [13] Laskowski D, Ozkan M, Erzurum SC, Dweik RA. Validation of an analyzer to measure exhaled carbon monoxide levels in the part per billion range. Am J Respir Crit Care Med, 2000; 161: A851. [14] Ozkan M, Laskowski D, Dweik RA. High levels of carbon monoxide in patients with Chronic Beryllium Diseases. ChestlQQQ; 118:2535. [15] Ozkan M, Laskowski D, Erzurum SC, Dweik RA. Differences in Exhaled Carbon Monoxide and Nitric Oxide in Alveolar and Airway Inflammation. Am J Respir Crit Care Med2QOl; 163:A714. [16] Acharya SS, Laskowski D, Erzurum SC, Dweik RA. Exhaled Carbon Monoxide Levels in Ventilated Patients. Am J Respir Crit Care Med 2001; A899.
96
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
ETCOc — An Indicator of Hemolysis in Neonatal Hyperbilirubinemia Molly MCCARTHY and Judith HALL Natus Medical Inc., 1501 Industrial Road, San Carlos, CA USA. 94070-4111 Abstract. Of the 4 million neonates born each year in the United States, 60 percent will develop clinical jaundice. The risk factors for normal, or physiologic jaundice, and pathologic jaundice are well-defined and documented. However, it remains difficult to differentiate the etiology of jaundice in routine clinical situations. Therefore, careful monitoring of neonates is important to prevent the potentially toxic effects of bilirubin. Neonatal hyperbilirubinemia results from increased production and/or decreased elimination of bilirubin. Bilirubin production can be exacerbated by several factors, including prematurity, blood group incompatibility, breakdown of extravascular blood, the shorter red cell lifespan associated with newborns, maternal diabetes, and unknown factors associated with ethnicity. Identification of the presence or absence of hemolysis is necessary to establish an effective care plan for each neonate. Understanding the relationship between bilirubin production and carbon monoxide (CO) is important in the management of neonatal jaundice. The catabolism of hemoglobin (Hgb) results in the equimolar formation of CO and bilirubin. End-tidal carbon monoxide corrected for room air (ETCOc) is an indicator of Hemolysis and bilirubin production. An elevated ETCOc identifies the neonate who is a high producer of bilirubin, even before the onset of hyperbilirubinemia, and can aid the clinician in establishing a differential diagnosis of the underlying causes of hyperbilirubinemia. Conversely, the ability to rule out elevated bilirubin production, when applied in conjunction with American Academy of Pediatrics recommendations, may provide the clinician with sufficient information to safely discharge the infant at an earlier hour.
1. Bilirubin Production, Transport and Excretion Catabolism of the red blood cell (RBC) produces bilirubin. The life span of the RBC averages 70 to 90 days in the neonate, a much shorter time period than observed in older children and adults who have a RBC life span of 120 days. Moreover, the rate of bilirubin production in premature infants exceeds that of term neonates [1]. Therefore, in caring for the pre-term or term neonate, it is imperative to consider all parts of the bilirubin pathway, including production, transport, and elimination. Figure 1 illustrates this process. Bilirubin production begins with the formation of RBCs in the bone marrow (Figure 1, Step I). The majority of bilirubin is produced during the catabolism of circulating RBCs, with a small proportion produced from ineffective erythropoiesis [2]. Hgb is released from the RBC during catabolism. The degradation of Hgb by heme oxygenase and biliverdin reductase results in the formation of bilirubin and CO (Figure 1, Step II). This bilirubin, in its unconjugated form, immediately combines with available plasma albumin for transport to the liver (Figure 1, Step III) [2,3]. Because albumin is the mechanism for transporting the bilirubin, neonates who have
M. McCarthy and J. Hall / ETCOc: An Indicator of Hemolysis
insufficient albumin to bind the bilirubin are at greater risk for hyperbilirubinemia. Once the albumin releases the unconjugated bilirubin into the liver, the hepatic cell membrane absorbs and conjugates the bilirubin (Figure 1, Step IV) [4]. Bilirubin excretion (Figure 1, Step V) begins as the conjugated bilirubin is released from the liver into the bile duct and intestine. In the intestine, the conjugated bilirubin is converted into a highly soluble substance, urobilinogen. Urobilinogen is released in the intestine and excreted as stercobilin in the feces [5]. A small percentage of urobilinogen is transported to the kidneys and excreted in the urine. Some of the conjugated bilirubin may be converted back into unconjugated bilirubin which is absorbed into the blood through the intestinal mucosa and transported to the liver for re-excretion. This pathway constitutes the enterohepatic circulation of bilirubin.
Figure 1: Normal Pathways of Bilirubin Production, Transport and Excretion Some portions of Figure I are adapted with permission from Gartner LM, Hollander M. Disorder s of bilurubin metabolism In Assali NS, editor: Pathophysiology of Gestation, 3rd ed., New York, NY: Academic Press; 1972:273.
2. Hemolysis and Carbon Monoxide Approximately 85 percent of endogenous CO is a byproduct of heme catabolism [3]. Figure 2 illustrates the process of hernolysis and production of endtidal carbon monoxide (ETCO) in detail. The degradation of heme results in the equimolar formation of bilirubin and of CO.I3J CO binds to circulating RBCs and can be measured as carboxyhemoglobin (COHb) in the blood. COHb dissociates in the lungs and CO is excreted in the breath continuously. Thus, total bilirubin production can be estimated from COHb or by ETCO. A fraction
97
98
M. McCarthy and J. Hall / ETCOc: An Indicator ofHemolysis
of ETCO is derived from the ambient CO. Therefore, to accurately reflect the rate of bilirubin production, ETCO should be corrected for room air (ETCOc). This is particularly true in neonatal jaundice where CO levels, measured in parts per million (ppm), are very low. The COHb measurement does not differentiate exogenous CO from breath CO. Therefore it is not possible, to estimate a precise endogenous CO level from a COHb reading.
Hemotysis Breakdown of Red Blood Cells (RBCs)
Environmental Carbon Monoxide (CO)
Hcme CataboUsm Endogenous CO Source
Exposure Exogenous CO Source
Carbon Monoxide (CO)
(COHb) Biliary Excretion
Pulmonary Excretion End-Tidal CO (ETCO)
Figure 2: Hemolysis and Production of End Tidal Carbon Monoxide Some portions of Figure 2 are adapted with permission from V reman HJ. Mahoney JJ, Stevenson DK. Carbon monoxide and carboxyhemoglobin. Adv Pediutr 1995:42:303-334. Si Louis: Mosby, 1995
3. The Impact of Early Discharge The emergence of managed care has resulted in cost containment strategies impacting the care of neonates due to early discharge [6]. The clinical management of neonatal jaundice is especially affected by early discharge (defined as less than 72 hours) because the bilirubin level will continue to rise even after the newborn has left the hospital setting, placing neonates at risk for readmission to the hospital for evaluation and treatment of jaundice [7,8]. The AAP Committee on Fetus and Newborn recommends that a total serum bilirubin (TSB) be performed on any neonate noted to be jaundiced in the first 24 hours following birth. The practice parameter also recommends a follow-up visit on day 2 or 3 of life for the neonate discharged less than 48 hours after birth [9]. This follow-up may involve a TSB. A 1997 study conducted by Stevenson and Vreman demonstrated significant interlaboratory variability of TSB measurements performed at 14 laboratories [10]. Therefore, under-or over-estimation of the serum bilirubin value may occur and can lead to the omission of needed therapy or erroneous clinical information in some neonates [7].
M. McCarthy and J. Hall/ETCOc: An Indicator of Hemolysis
4. Clinical Management of Jaundice and Hyperbilirubinemia In routine clinical situations, it remains difficult to differentiate the etiology of neonatal jaundice. Neonatal jaundice and hyperbilirubinemia develop in response to the increased production and/or decreased elimination of bilirubin. The identification and incorporation of these causative factors assists in establishing a differential diagnosis and cost-effective plan of care. A study conducted in 1990 at the University of California, San Francisco, estimated that about $25 million is spent annually on routine hyperbilirubinemia evaluations by hospitals in the United States [11]. Tests commonly recommended as part of a bilirubin workup include TSB, blood group and type, direct Coombs' test, reticulocyte count and RBC morphology (blood smearing). Frequent measurement of the TSB level has been the mainstay of anticipatory management of transitional bilirubinemia. However, the TSB level does not differentiate jaundice caused by high bilirubin production (high rate of hemolysis) from that caused by limited elimination. Similarly, transcutaneous bilirubin (TcB) analysis provides an index of the bilirubin level but does not require a blood sample. The intensity of yellow color in the subcutaneous tissue and skin is measured, correlating to the serum bilirubin concentration [12]. Despite the convenience of TcB measurement, the accuracy of such devices is noted to be complicated by skin pigmentation, gestational age, and birth weight [13]. As with the TSB, the TcB measurement is unable to identify the factors contributing to the bilirubin level, i.e., production (hemolysis) versus elimination. The direct Coombs' test determines if the red blood cells are coated with antibodies and may be predisposed to hemolysis, but does not prove the presence of hemolysis or its magnitude [13,14]. The reticulocyte count indicates RBC production by the bone marrow and thus an elevated level may signify that the marrow is releasing an increased number of reticulocytes in the circulation. However, it is not a direct measure of hemolysis and may be a response to anemia from other causes. The blood smear, which reveals variations in erythrocyte size, shape, color and intracellular content, is the least reliable measure of hemolysis and cannot be used to measure the magnitude of red cell breakdown. ETCOc accurately reflects the rate of bilirubin production. Elevated production may be associated with higher risk. In the Nigerian population studied by Slusher et al, neonates with a high rate of bilirubin production were more likely to develop bilirubin toxicity when compared to neonates having a low production rate [15]. The ability to measure ETCOc and apply this information has been limited by the lack of a simple, rapid, non-invasive test to assess the rate of hemolysis [16]. Recently instrumentation became available to measure ETCOc and assist the clinician in detecting the presence or absence of hemolysis. The AAP practice parameter calls upon the clinician to determine the presence or absence of hemolysis in the jaundiced newborn, in order to establish an effective care plan for neonatal hyperbilirubinemia [17]. Despite the value and clinical contribution provided by other tests, only the ETCOc measurement can provide an estimate of the rate of hemolysis. The relationship between ETCOc and TSB is currently under investigation in a multi-center, international clinical trial. Understanding the relationship between bilirubin production and bilirubin excretion is essential in predicting the jaundice trajectory for an individual newborn. Figure 3 was formulated in conjunction with DK
100
M. McCarthy and J. Hall / ETCOc: An Indicator ofHemolysis
Figure 3: Potential Diagnoses in the Neonate Using ETCOc and TSB * Ethnicities include Chinese, Korean, Japanese, Aleut, Navajo, Pima. **Related to breast feeding, meconium plug, meconium ileus, Hirschprung's, etc. ***Ifenhanced elimination exists, individual with increased production may not exhibit elevated TSB.
Stevenson, MD, AA Fanaroff, MD, and MJ Maisels, MD (October 1998). It suggests points to consider when predicting the path of jaundice in the newborn.
M. McCarthy and J. Hall / ETCOc: An Indicator of Hemolysis
101
5. Conclusions Neonatal hyperbilirubinemia results from increased production and/or decreased elimination of bilirubin. Catabolism of heme results in equimolar parts of bilimbin and CO. Understanding the relationship between bilirubin production and CO is important in the management of neonatal jaundice. ETCOc is an indicator of hemolysis and bilirubin production which can be used to assist clinicians in several ways: • ETCOc identifies high bilirubin producers, even before the onset of jaundice, allowing the clinician to carefully plan in-patient and post-discharge care. • ETCOc enables the clinician to detect a newborn at risk for the development of hyperbilirubinemia due to the overproduction of bilirubin before the onset of jaundice. • ETCOc identifies the rate of hemolysis, assisting the clinician in establishing a differential diagnosis based on a normal or elevated rate of bilirubin production. • ETCOc permits more judicious use of invasive blood tests, phototherapy treatments, extended hospitalizations, home or office visits, and even exchange transfusions. This vital clinical information can be used to devise safe, cost-effective clinical pathways for neonates discharged from the hospital at an early age. References [1] [2] [3] [4]
[5]
[6] [7] [8] [9] [10]
WJ Cashore. Bilirubin metabolism and toxicity in the newborn. In: Pollin RA, Fox WW, eds. Fetal and Neonatal Physiology Isted. Philadelphia, PA: WB Saunders Company; 1992:11601164 CO Frank, BS Turner, et al. Jaundice. In: Frank CG, Merenstein GB, eds. Handbook of Neonatal Intensive Care 3rd ed. Philadelphia, PA: Mosby Year Book; 1993: 272-286 HJ Vreman, JJ Mahoney, DK Stevenson. Carbon monoxide and carboxyhemoglobin. Adv Pediatr. 1995;42:303-334 P Rosenthal. Bilirubin metabolism in the fetus and neonate. In: Pollin RA, Fox WW, eds. Fetal and Neonatal Physiology Isted. Philadelphia, PA: WB Saunders Company; 1992:11541159 Erslev AJ, Beutler E. Production and destruction of erythrocytes. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology 5th ed. New York, NY: McGraw-Hill; 1995:425-441 C Catz, JW Hanson, et al. Summary of workshop: early discharge and neonatal hyperbilirubinemia. Pediatrics.. 1995; 96(4):743-745 DK Stevenson, HJ Vreman. Carbon monoxide and bilirubin production in neonates. Pediatrics. 1997;100(2):252-254 D Bratlid. Criteria for treatment of neonatal jaundice. J Perinatal 1996;!6(3)Part 2:S83-S88 American Academy of Pediatrics, Committee on Fetus and Newborn. Practice parameter: management of hyperbilirubinemia in the healthy term newborn. Pediatrics. 1994;94(4):558565 HJ Vreman, J Verier, et al. Interlaboratory variability of bilirubin measurements. Ciin Chem.
102
[11] [12] [13]
[14] [15] [16] [17]
1996;42(6):869-873 TB Newman, MJ Easter I ing, et al. Laboratory evaluation of jaundice in newborns. Am J Dis Child. 1990; 144:364-368 Smith DW, Inguillo D, Martin D, et al. Use of noninvasive tests to predict jaundice in fullterm infants: preliminary studies. Pediatrics. 1985;75(2): 278-280 V Bhutan!, L Johnson, G Gourley, et al. Non-invasive measurement of total serum bilirubin by multi-wavelength spectral reflectance by Bilicheck™ in newborn patients. Pediatr Res. 1998;43:167A Y Uetani, H Nakamura, O Okamoto O, et al. Carboxyhemoglobin measurements in the diagnosis of ABO hemolytic disease. Ada Paediatr Jpn. \ 989;31 (2): 172-176 DW Smith, AO Hopper, SM Shahin, et al. Neonatal bilirubin production estimated from endtidal carbon monoxide concentration-/Pediatr Gastroenterol Nutr. 1984;3(1):77-80 TM Slusher, HJ Vreman, DW McLaren, et al. Carboxyhemoglobin predicts bilirubin-related morbidity and mortality in infants. Pediatr Res. 1993;33:237A A Strocchi, S Schwartz, M Ellefson, et al. A simple carbon monoxide breath test to estimate erythrocyte turnover. J Lab Clin Med. 1992;120(3):392-399
Section 3. Volatile Organic Compounds (VOCs)
This page intentionally left blank
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
! 05
Volatile Organic Compounds as Exposure Markers Andrew B. Lindstrom and Joachim D. Pleil U. S. Environmental Protection Agency, National Exposure Research Laboratory, MD-44, Research Triangle Park, NC 27711, USA Abstract. Alveolar breath sampling and analysis can be extremely useful in exposure assessment studies involving volatile organic compounds (VOCs). Over recent years scientists from the US Environmental Protection Agency's National Exposure Research Laboratory have developed and refined an alveolar breath collection and analysis technique called the Single Breath Canister (SBC) method which has been applied in a wide range of investigations. This review covers the development of this breath collection technique in the laboratory and the application of this methodology in a range of field studies. Together these studies show how exhaled breath analysis can be used to clearly demonstrate recent exposures to VOCs, to determine compound-specific uptake and elimination kinetics, and to assess the relative importance of various exposure routes (i.e., dermal, ingestion, inhalation) in multipathway scenarios. Specific investigations covered in this overview include: an assessment of exposures related to the residential use of contaminated groundwater; exposures to gasoline and fuel additives at self-service gas stations; swimmers' exposures to trihalomethanes; and occupational exposures to jet fuel vapors. This work has been funded wholly by the United States Environmental Protection Agency. It has been subjected to Agency review and approved for publication.
1. Introduction Breath collection and analysis has been historically useful as a noninvasive technique to help diagnose illness and determine exposures to xenobiotic compounds. This utility is based on the fact that compounds present in the blood will partition into the breath at the blood/alveolus interface and will be eliminated (like carbon dioxide) during exhalation. Perhaps the best known example of this diagnostic practice is the use of exhaled breath analysis by law enforcement officials to determine whether a driver has been operating a motor vehicle under the influence of ethyl alcohol (i.e., the breathalyzer test). This paper summarizes the development of the Single Breath Canister (SBC) method of exhaled breath collection and analysis that was introduced by the US Environmental Protection Agency (USEPA) in the 1990's. We discuss the utility of this method in the context of human exposure assessment and demonstrate how this technique could be used in clinical settings to evaluate disease, metabolism, or changes in physiology. USEPA's interest in the use of breath sampling as an exposure assessment technique began with the Total Exposure Assessment Methodology (TEAM) studies of the 1980's. The TEAM studies were a series of population-based exposure assessment investigations designed to evaluate the most basic aspects of pollutant exposure. As part of these investigations, breath and blood samples were collected from study subjects to help determine which sampling methodology would be most useful in determining exposures.
106
A.B, Lindstrom and J.D. Pleil / Volatile Organic Compounds
While these early breath collection and analysis techniques were cumbersome, it quickly became apparent that breath sampling was a clean, noninvasive method that could provide more accurate information than traditional blood analysis for many volatile organic compounds (VOC). Given this potential utility we set about to develop a simplified breath collection technique that could be coupled with state of the art laboratory analysis to provide a powerful exposure assessment tool for many VOCs. With the SBC method [1,2], an evacuated 1 L stainless steel canister is outfitted with a small (5 cm length) Teflon tubing stub (see Figure 1). After a normal exhalation (eliminating the deadspace portion of a breath) the sample subject places the end of the Teflon collection tube in his mouth and opens the canister valve to fill it with one liter of the expiratory reserve (Figure 2). Because the canister is initially evacuated (< 50 /^m Hg) the sample is collected until the canister comes to atmospheric pressure. The subject then closes the sample valve and is free to resume normal activities. Unlike other end-tidal breath collection devices, these canisters are extremely durable and no special precautions are needed when shipping samples back to the laboratory. Moreover, most VOCs remain stable in these canisters for periods of 30 days or longer without any appreciable degradation.
Figure 1. Single Breath Canister
Figure 2. Exhaled Breath Collection
Once collected, samples are analyzed using gas chromatography/mass spectrometry (GC/MS) techniques based on the EPA Method TO-14 protocol using a Model 3550A Cryogenic Concentrator (Graseby Nutech, Smyrna, GA). This front end concentrator is also an autosampler for canisters and is used in this mode to perform up to 16 unattended analyses. The analytical system used for most of the work discussed below was an ITS40 (Magnum) GC-MS ion trap instrument (Finigan MAT, San Jose, CA). Specifically, a 50 ml aliquot of sample is cryogenically focused at -165°C in a primary trap, then heated and transferred in a helium stream to a secondary trap and refocused at -190°C on a 0.53 mm precolumn. The precolumn is then rapidly ramped to 150°C and the analytes injected in a sharp plug onto a XTI-5 30 m x 0.25 mm i.d. 1 /*m phase analytical column (Restek Corp., Bellefonte, PA). The oven temperature profile is -50°C 2 min hold, ramp to 220°C at 10°C/min, 8 min hold. Tentative identification of each analyte is made using conventional mass spectral libraries, and conclusive identification is assured by injection of authentic
A.B. Lindstrom and J.D. Pleil / Volatile Organic Compounds
107
standards and verification of both retention times and mass spectra. Because contaminant concentrations in the breath are directly related to levels in the blood and other tissues, breath analysis has been used in an increasing number of exposure assessment studies to: confirm that specific exposures have taken place; help assess the importance of different routes of exposure (e.g., proportion of dermal vs. inhalation routes); to establish uptake and elimination kinetics; and to demonstrate the relationships between particular personal activities and their corresponding body burdens (e.g., smoking and increased levels of benzene and other aromatics in the breath and blood). A model presented in Wallace et al. [3] can be used to help interpret the postexposure breath elimination data. The original model takes the form: C, = A,e- k " + A 2 e k 2 t + / P 1 C a i r
(1)
where C, is the contaminant concentration in the blood at any time t; A, 2 are complex constants, each a function of the contaminant concentrations and other physiological variables in two hypothetical body compartments; k{ is the exponent associated with the ilh term; t is the time in minutes; / is the fraction of the parent compound exhaled at equilibrium; Pj is the unitless blood/breath partition coefficient; and Cair is the ambient air concentration of the contaminant. By dividing this equation through by P! we can estimate the alveolar breath concentration at any time t: CalVeo,ar = M- kl! +
fl2ek2t+/Cair
(2)
where Calveolar is the alveolar breath concentration at any time during the elimination; the coefficients (Q) represent the contributions from both unknown body compartments; the inverse of the exponential term (1/kj) represents the residence time (TJ) of the compound in the ith compartment (i.e., the time that it takes the concentration to fall to 1/e (~ 0.37) of its original value); and finally, the half-life of the compound in compartment i is equal to (In 2)/kj. If the elimination series is collected in an environment where the background level of the contaminant is essentially 0 (e.g., outdoors, in many cases), the last term in equations 1 & 2 becomes 0, simplifying elimination calculations. With the appropriate blood/breath partition coefficient, the alveolar breath concentration can be used to determine the concentration of the contaminant in the blood at any time during the elimination phase: ^--blood
=
^-alveolar X Pj X U
(3)
where Cbtood = the concentration of the contaminant in the bloodstream 0-tg/L); Calveolar = the concentration of the contaminant in the breath (/*g/m3); Pj = to the unitless blood breath partition coefficient; U = units conversion factor (1 m3/1000 L). If the subject is moved to an area with little or no background contaminant levels immediately after the exposure, the modeled breath values at the Y-intercept (i.e., t = 0) can be used with equation (2) to estimate the maximum blood levels of the contaminant resulting from the exposure. Integrating the area under the elimination curve also provides an alternative measure of total absorbed dose: the resulting quantity in jug-min/m3 can be multiplied by the breathing rate (nrVmin) to establish the total mass (jig) of contaminant that leaves the body via exhalation. If it is known what proportion of the compound will be eliminated in this manner (e.g., -10% for trichloroethylene), the unmetabolized mass can be divided by this fraction to provide an indirect estimate of total absorbed dose.
108
A.B. Undstrom andJ.D. Pleil / Volatile Organic Compounds
2. Experimental 2.1 Exposures Via Contaminated Groundwater In the first example of the utility of the SBC method we show how it can be used to confirm and quantify exposures to compounds that would otherwise be extremely difficult to measure directly in blood. The solvent trichloroethylene (TCE) has become a common groundwater contaminant in the US. Once underground it is subject to an iron-mediated reductive dehalogenation process (Figure 3) that leads to the formation of vinyl chloride (VC), a potent human carcinogen.
-c
CI
.CI
H \ C:
cr
CI
Trichloroethylene
H \ Cc
c CI
C CI
Vinyl Chloride
cis-1,2-Dichloroethene
Figure 3. Transformation of Trichloroethylene in Groundwater
If TCE contaminates well water and gives rise to VC, both compounds can often be measured hi residences using the contaminated water. Showering and bathing are of particular concern in such circumstances due to the likelihood of simultaneous inhalation and dermal exposures. Figure 4 is a VC in breath elimination profile collected from an individual after taking a 10 min shower in TCE and VC contaminated water [4]. Because VC has such a low boiling point (-14°C) and high vapor pressure (2,660 mm Hg @ 25°C) it is extremely unlikely that conventional blood-based biomonitoring techniques would be able to confirm exposures to this potent carcinogen. On the other hand, SBC samples collected shortly after the shower coupled with cryogenic preconcentration and GC\MS analysis conclusively demonstrate this exposure.
8-
G) O C
O O
0
A A
j
A""-...
2-
0
A
5
10
15
20
25
30
35
40
Time (min) Calveolar = 6.54 X 6° 38t + 5.14 X e° °5 l Figure 4. Vinyl Chloride in Breath After a 10 min Shower With Contaminated Well Water
A.B. Lindstrom andJ.D.Pleil/ Volatile Organic Compounds
109
2.2 Exposure to Motor Vehicle Fuels In the next example we show how the SBC method can clearly differentiate between two individuals who were putatively exposed to the same atmosphere. In this experiment two individuals stood side by side while refueling an automotive vehicle at a conventional service station [5]. After refueling, the study subjects walked away from the service station together and breath samples were then colleted from them on a periodic basis for more than 1 hour. The gasoline used in this process contained 15% methyl tertiary butyl ether (MTBE) by volume. MTBE is an oxygenate added to gasoline in the US to help reduce the formation of carbon monoxide in vehicle exhaust. In the elimination profile below (Figure 5) one can see that one individual's exhaled MTBE in breath was more than two times higher than the other subject despite the fact that both stood side by side during the refueling process. These data suggest that even within the same microenvironment, personal differences in uptake and metabolism can greatly affect an individual's ultimate exposure. The SBC method can thus be used to more accurately quantify an internalized dose and therefore reduce exposure misclassification bias in epidemiologic investigations.
1 UUU -
A Pumper D Observer
o"^
o 800- 5, J3-
c jo
A A
600-
A
"(0
•4-*
'A
400-
"A..
o
c o
o
200-
\,
'""""*""---..
°MX^__D_______^^
~~
n.
0
10
20
""
D— 30
A
.— Q 40
50
60
70
Time (min) 0 240 * + 410 e-ao2° * + (0.7 x 12.3) pumper = 443 e '
^observer = 221 e"° 517 l + 1 19 e 0 ' 025 * + (0.7 X 12.3) Figure 5. Elimination of MTBE in Breath Following Motor Vehicle Refueling 2.3 Breath Analysis to Determine the Route of Exposure One important aspect of using breath as a biomarker of exposure is the concept of the/value during uptake. Simply put, if an individual is exposed to a constant level of a VOC in the air he breaths, the concentration of the VOC in his exhaled breath will rise during the exposure and eventually reach an equilibrium with the surrounding atmosphere (Figure 6). The equilibrium concentration of exhaled breath is always a fraction (hence f) of the surrounding atmosphere because the body will always have some ability to metabolize or sequester the external dose. Each individual compound has its own characteristic/value generally ranging between 0.1 to 0.9 depending on the physical
110
A.B. Lindstrom and J.D. Pleil / Volatile Organic Compounds
characteristics of the compound and the human body's ability to internalize it. The concept of the/value can be important because it helps to apportion exposures between various routes (e.g., dermal, inhalation, or ingestion) as illustrated in the example below. Ambient Concentration
f value
c o •J= CO 4= 0)
Exhaled Breath Concentration
o o O
Time (min) Figure 6. Fraction of Ambient Concentration (/) Eliminated at Equilibrium When water supplies are treated with chlorine to reduce or eliminate bacterial contamination a number of potentially hazardous disinfection byproducts are formed (e.g., trihalomethanes). To assess the potential trihalomethane exposures associated with recreational swimming we designed an experiment to measure exhaled chloroform and bromodichloromethane in two individuals engaged in vigorous swim training [6]. Both study subjects provided exhaled breath samples before, during, and after their regular two hour swim training workout while pool water and natatorium air samples were collected for analysis. With long-term indoor chloroform levels measured at 147 Mg/m3 and an/value for chloroform of approximately 0.14, the highest exhaled breath concentration that we would expect from an inhalation only exposure would be - 21 //g/m3 ( = 0.14 x 147 Aig/m3). The post-exposure breath elimination profiles (Figure 7) however indicate concentrations that were much higher than 21 //g/m3, suggesting that inhalation alone did
Male Female
50
100
150
200
Time (Min) C m a i e = m e' 0 5 0 9 t + 107e-° 027t + 45.8e- 0004t C fema .e = 153 e-° 75° ' + 104 e-° °43 ' + 49.7 e'0 °05 '
Figure 7. Elimination of Chloroform in Breath Following Swimming Training
A.B. Lindstrom and J.D. Pleil/ Volatile Organic Compounds
\ 11
not account for the exposure monitored. In fact, if a three compartment model is fitted to these data, breath levels at the very beginning of the elimination phase (the Y axis) are over 260 jug/m3 for both individuals, suggesting that over 90% of the exposure occurred was via the dermal pathway. Considering that blood vessels in the skin dilate during exercise to help dissipate excess heat, it seems likely that the chloroform from the surrounding water was able to diffuse into the skin during this period of intensive physical activity to ultimately give a higher portion of the total dose than the inhalation route. 2.4 Exposure to Complex Mixtures: JP-8 Jet Fuel US and NATO led forces use more than 4.5 billion gallons of JP-8 jet fuel annually. While most is used as jet fuel for the various air forces, JP-8 is also used in heaters, stoves, tanks, generators, and many other types of support equipment. This widespread use leads to a large number of potential exposure scenarios [7], often involving personnel engaged in critical or sensitive operations (e.g., maintenance of sophisticated aircraft and weaponry). Work place protection programs are in place to minimize potential exposures, but anecdotal reports of health effects associated with exposures (including adverse skin reactions) have now raised concerns over the widespread use. Initial studies conducted with laboratory animals suggest potential neurological and immunological effects are associated with high level exposures but effects with humans remain unclear. To obtain a better understanding of the acute health effects associated routine exposure to JP-8 fuel, the US Air Force recently conducted the field phase of an epidemiological investigation involving over 300 personnel exposed to jet fuel at various Air Force bases across the US [8]. Exposures were assessed using a range JP-8 biomarkers measured in blood, breath, and urine samples. Outcome measures of effect included measures of immune and neurological function. Preliminary results indicate that exhaled breath measurements were particularly well suited to determining the exposure of the study subjects. Figure 8 A below shows a typical total ion chromatogram from a breath sample of a maintenance worker before his work shift, while in Figure 8. B we have the same worker's post-shift breath sample. Note that the post shift sample clearly indicates the C9 - C12 alkane signature pattern of JP-8 exposure.
Figure 8. A. Total Ion Chromatogram of Breath Sample Before Exposure to JP-8
112
A.B. Lindstrom andJ.D. Pleil / Volatile Organic Compounds 25% Acetone
Isoprene
800 0640
1,200 1000
1.600 1320
1000 1640
2,400 2000
2^00 2320
Scans, time (min/min, sec/sec) Figure 8. B. Total Ion Chromatogram of Breath Sample After Exposure to JP-8 3. Conclusions
The SBC method of exhaled breath collection and analysis as outlined above is particularly well suited for exposure assessment studies involving xenobiotic VOCs. The sample collection method is simple and adaptable to a wide range of potential applications. Once collected, samples are stable and easily transported to the laboratory for GC/MS analysis. Two stage cryogenic trapping ensures that even the most volatile VOCs are collected efficiently. When properly applied the SBC method can be used to clearly demonstrate recent exposures to VOCs, link specific activities to a recently incurred body burden of xenobiotic materials, determine compound-specific uptake and elimination kinetics, and to assess the relative importance of various routes (i.e., dermal, ingestion, inhalation) in multipathway exposure scenarios. References [1] J.D. Pleil and A.B. Lindstrom, Collection of a single alveolar exhaled breath for volatile organic compound analysis, American Journal of Industrial Medicine, 28 (1995) 109-121. [2] J.D. Pleil and A.B. Lindstrom, Measurement of volatile organic compounds in exhaled breath as collected in evacuated electropolished canisters, Journal of Chromatography B: Biomedical Applications, 665 (1995) 271-279. [3] L.A. Wallace, E.D. Pellizzari, and S. Gordan, A linear model relating breath concentrations to environmental exposures: application to a chamber study of four volunteers exposed volatile organic chemicals, Journal of Exposure Analysis and Environmental Epidemiology, 3 (1993) 75-102. [4] A.B. Lindstrom and J.D. Pleil, A methodological approach for exposure assessment studies in residences using volatile organic compound contaminated water, The Journal of the Air & Waste Management Association, 48 (1996) 1058-1066. [5] A.B. Lindstrom and J.D. Pleil, Alveolar breath sampling and analysis to assess exposures to methyl tertiary butyl ether (MTBE) during motor vehicle refueling, The Journal of the Air & Waste Management Association, 46 (1996) 676-682. [6] A.B. Lindstrom, J.D. Pleil, and D.C. Berkoff, Alveolar breath sampling and analysis to assess trihalomethane exposures during competitive swimming training, Environmental Health Perspectives, 105(6) (1997) 636-642. [7] J.D. Pleil, L.B. Smith, and S.D. Zelnick, Personal exposure to JP-8 jet fuel vapors and exhaust at air force bases, Environmental Health Perspectives, 108(3) (2000) 183-92. [8] http://sg-www.satx.disa.mil/iera/rsh/IndustrialHygiene/fuels.html
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
113
Volatile Organic Compounds as Markers in Normal and Diseased States Terence H. RISBY Johns Hopkins Medical Institutions Baltimore Maryland 21205, USA
Abstract The concept that blood, urine, and other body fluids and tissues can be sampled and analyzed to yield clinical information for diagnosis of disease states or to monitor therapy is the foundation of modern clinical diagnosis and medical practice. The use of breath as a collectable sample has not received similar clinical use mainly due to the low concentrations (ppm to ppb) of marker molecules in breath. Recent advances in on-line concentration and the development of sensitive analytical techniques have suggested that the use of exhaled breath to study disease processes should now be re-examined. The analysis of exhaled breath has major advantages since it is non-invasive, represents minimal risk to personnel collecting the samples, and can be sampled often. Currently, a number of marker molecules have been identified in breath that can be used to identify disease, disease progression, or to monitor therapeutic intervention. It is expected that this list will soon increase dramatically based upon the available novel analytical instrumentation. Already, the collection and analysis of breath is ideally suited for population-based studies since no special storage conditions are necessary before subsequent analysis in the laboratory. This work was partially supported by NIH Grant P01-HL56091.
1. Introduction The ability to exchange carbon dioxide with oxygen is essential for most life forms. In animals, this gas exchange occurs at the alveolar-capillary membrane in the respiratory tract. Oxygen and carbon dioxide are passively transported from blood to breath or vice versa and the diffusion of these gases is governed by their concentration gradients across the alveolar-capillary membrane. Any additional molecule present in the blood or in the inspiratory air will also pass into the breath or blood respectively. The only requirement for this transport is that the molecule must exhibit a significant vapor pressure. The molecular profile of breath will be the product of the composition of the inspiratory air and volatile molecules that are present in the blood. Cells or tissues in the nose, sinuses, airway and the gastrointestinal tract may also contribute molecules to exhaled breath. The bulk matrix of breath is a mixture of nitrogen, oxygen, carbon dioxide, water vapor and the inert gases. The remainder of breath (<0.000001%) is a mixture of as many as 500 different compounds. These molecules have both endogenous and exogenous sources, however, the concentration is often higher when the origin is exogenous. The concept that breath contains molecules originating from normal or abnormal physiology has its origins in the writings of Hippocrates, the father of medicine. For example, detection of the presence of water vapor in breath has been used as a noninvasive monitor of mortality for thousands of years. Additionally, distinctive breath odors have been used as indications of diseases such as uncontrolled diabetes, liver disease, renal failure or dental disease [for review see 1-3]. However, the use of odors of breath for clinical diagnosis can be confounded by the characteristic odors that result from the ingestion of such materials as garlic, onions, fish, spices, mints, and ethanol.
114
T.H. Risby / Volatile Organic Compounds as Markers
The identification and quantification of molecules present at trace concentrations in breath has a much more limited history. Other chapters in this book describe how breath can be used to estimate actual exposure to xenobiotic compounds in environmental or occupational settings or to study the pathophysiology of exhaled nitric oxide or carbon monoxide. This chapter will be limited to the discussion of those molecules that have been found in human breath whose biochemical pathways are known or whose biochemical pathways can be postulated. Molecules of unknown biochemical origins have the potential to be artifactual and using them to identify disease or disease processes could bring the field of breath analysis and human disease into disrepute. 1.1 Definition of exhaled breath Breath can be sampled from any human subject from the neonate to the elderly with relative ease, minimum invasion and multiple times. The easiest way to obtain a representative sample of breath is from a paralyzed human subject whose breathing is supported mechanically. For all human subjects the composition of breath varies extensively over the breathing cycle as a result of normal pulmonary physiology. The initial portion of a breath cycle originates from the conducting airway (anatomic dead-space) and the composition of this gas is determined almost exclusively by the composition of the inhaled gas. The remainder of the breath consists of mixed expired gas and alveolar gas. In human subjects at rest, approximately 80% of the gas that is in contact with the capillaryalveolar membrane is exchanged with each breath. The gas in contact with this membrane will contain about 5% carbon dioxide. If a human subject is breathing normally, then the concentration of carbon dioxide at the end of the breath (end-tidal), the concentration of carbon dioxide in arterial blood (pCO2) and their ratio will remain constant from breath to breath. Changing the tidal volume and/or breathing frequency will increase or decrease these concentrations. The rate of alveolar ventilation is controlled by the arterial blood concentration of carbon dioxide. Hypo- or hyperventilation will, by definition, change the composition of exhaled breath and in turn the arterial blood concentration. Variations in tidal volume or breathing frequencies are particularly important when sampling breath from human subjects breathing spontaneously since any method of breath sampling will make the subject conscious of their breathing patterns and the potential to change breathing patterns is increased. For spontaneously breathing subjects it is preferable to sample multiple breaths in order to ensure that the analysis of the collected breath is representative. 1.2 Real-time monitors versus breath profiles Until recently, only inhalation anesthetics, oxygen and carbon dioxide could be monitored in real-time. Clinically these monitors are used to display trends for the status of the patient and do not provide information on individual breaths. However, advances in monitor technology have changed this limitation and specific breath molecules can now be monitored in real-time. In order to improve the precision to which these novel breath molecules can be measured, protocols have been established whereby the mouth pressure, flow rate or carbon dioxide are monitored and/or controlled during the time of measurement. The major advantage of real-time monitors is that the analysis of a single breath can be repeated to ensure that the measurement is representative of the breath for the study subject. Unfortunately, not all breath molecules can be determined specifically in real-time and therefore most breath analyses are performed on samples of collected breath. There are basically two approaches to breath collection: i.) sampling end-tidal breath, and ii) sampling total breath for a single breath or for a defined period of time (usually 1 minute). i.) Collection of end tidal breath requires that the subject is breathing at rest and that the breath sample is collected when the concentration of carbon dioxide reaches a plateau (end tidal). This approach requires that this portion of breath is representative of all previous and subsequent breaths during resting or relaxed breathing. End-tidal breath sampling will produce samples with the highest concentration of molecules if the molecules of interest are derived from exchange at the alveolar-capillary membrane. Moreover, end-
T.H. Kisby / Volatile Organic Compounds as Markers
115
tidal breath has the lowest concentrations of room air contaminants. The volume of an endtidal breath sample is only a fraction (<30%) of the tidal volume of a single breath. ii.) Collection of total breath for a single breath or for a defined period of time has been the method that has been used most extensively. Our laboratory has collected breath from 500g premature neonates to normal and diseased adults for defined time periods. The implicit assumption of this approach is that if breath is collected over a period of time, concentrated and analyzed, then the analytical result reflects the average concentration of breath molecules in exhaled breath over the period of sampling. By definition, the concentrations of breath molecules in total collected breath are diluted by the physiologic and anatomic dead space ventilation that contains room air and therefore, it is necessary to collect samples of room air and correct for background contamination. However, the sample does represent the average or integration of all the breaths collected during the sampling period and is less susceptible to spurious breaths. Based upon our experience, the coefficient of variation for the analysis of successive timed breath samples for a given individual is less than 3%. Recently a breath-sampling device for adolescent and adult subjects that continuously measures and records the gas flow, concentration of carbon dioxide and mouth pressure as a function of time during breath collection has been developed. After collection, the tidal volume, breathing frequency, end tidal concentration of carbon dioxide for each breath, minute ventilation, and average concentration of exhaled carbon dioxide are calculated for the period of breath collection. Breath collected by either approach must be taken to the laboratory for concentration and analysis. Most published studies have collected total exhaled breath in inert gas sampling bags and analysis is performed as soon as possible after collection. The requirements for gas sampling bags are that they must be inert and not adsorb breath molecules. These bags should have a volume that corresponds to at least twice the amount of breath collected thereby minimizing any back-pressure from the collected gas that could restrict the exhalation of the study subject. Similarly, the inlet to the sampling bag should have sufficient dimensions to minimize any pressure drop across the inlet. Recently, evacuated polished stainless steel cylinders (SUMMA) or thermal desorption tubes packed with adsorbents have been used to collect breath. These devices collect known volumes of the exhaled breath at controlled flow rates. The advantages of these latter devices are that the subject experiences no resistance to breathing and the collected breath samples can be easily transported from the sampling site to the laboratory. Our laboratory has pioneered the use of thermal desorption tubes to collect breath for subsequent automated analysis. This research was performed in collaboration with a commercial manufacturer of specialty carbon adsorbents (Supelco Corporation, Bellefonte, Pennsylvania, USA). A number of thermal desorption tubes were examined and glass thermal desorption tubes packed with equal amounts of a graphitized carbon (Carbopack X), and two carbon molecular sieves (Carboxen-1018, Carboxen-1021) were found to be the optimum tube design for our breath studies to date. The three adsorbents are separated by glass wool. The graphitized carbon has a nitrogen surface area of 240 m2/g, density of 0.41 g/ml, and a pore volume restricted to the meso range (pore diameter 20 nm) of 0.62 ml/g. The carbon molecular sieve, Carboxen-1018, has a nitrogen surface area of 700 m2/g, density of 0.6 g/ml and a pore volume restricted to the micro range (pore diameter 0.6 nm) of 0.352 ml/g. The carbon molecular sieve, Carboxen-1021, has a nitrogen surface area of 650 m /g, density of 0.3 g/ml and a pore volume restricted to micro range (pore diameter 0.5 nm) of 0.35 ml/g. Carbopack X is the weaker adsorbent, Carboxen-1018 is the intermediate adsorbent, and Carboxen 1021 is the stronger adsorbent. When breath is sampled it passes through the bed of graphitized carbon first and then through the two beds of carbon molecular sieves in order of increasing adsorptive strength. The breath samples collected in the thermal desorption tubes are analyzed by twostage thermal desorption capillary gas chromatography with a variety of detection systems. The collected breath is thermally desorbed in the opposite direction to the flow used during breath collection to ensure the removal of the sample. In our laboratory we use a fused silica open tubular column (0.32 mm) wall coated with a thick film (5fj.ni) of cross-linked bonded dimethyl silicone (60 m) to separate molecules found in exhaled breath, with the following temperature protocol: isothermal at 35°C for 10 min., 35-200°C at 5°C/min., isothermal at 200°C for 10 min. If non-selective detectors, such as a flame ionization detector or an electron impact mass spectrometric detector, are used, this separation protocol
116
T.H. Risby / Volatile Organic Compounds as Markers
produces a breath molecular profile for breath markers from methane through tetradecane with excellent resolution. Selective breath molecular profiles can also be obtained by the use of detectors such as flame photometric detector (selective to sulfur-containing compounds) or thermionic specific detector (selective to nitrogen-containing compounds). Selective detectors have the advantage of simplifying the resulting separation. 1.3 Expressing breath analysis data The concentration of breath markers can be expressed in concentration units (ppm, ppb or pmol/1) but this information does not permit intersubject comparisons to be made. Therefore, the concentration data are converted to generation rates by the measurement of the minute ventilation (1/min) and subsequently corrected for body weight (pmol/kg min). Data could be corrected by body surface area (nmol/m min) and these are the units that are used clinically by most anesthesiologists. More recently, an additional correction has been made for anatomic, physiologic, and instrumental dead space based upon the concentration of exhaled carbon dioxide. During collection, the end-tidal concentration and average concentration of carbon dioxide over each breath are quantified and recorded. After the breath sample has been collected the average values for these measurements during breath collection can be made. The average end-tidal concentration of carbon dioxide and the average concentration of carbon dioxide during exhalation (mixed expired) can be used to determine the volume that corresponds to the anatomic, physiologic, and instrumental dead space by the following calculation {[end-tidal concentration of carbon dioxide in Torr][average concentration of carbon dioxide during exhalation in Torr]}/{ [end-tidal concentration of carbon dioxide in Torr]x[average tidal volume of each breath]}. This calculation assumes that the subject is breathing at steady-state. The concentration of any marker molecule that is measured in exhaled breath has been diluted by this volume. 1.4 Effects of exercise Discussion to this point has assumed that the subject from whom the breath is collected or sampled is seated and is breathing normally at rest. Under these circumstances steady-state conditions are achieved and pulmonary blood flow and minute ventilation are constant. The instantaneous molecular profile during each breath will vary with inspiration and expiration but the composite molecular profile for each breath will be similar. If the subject is then asked to exercise their ventilation and pulmonary blood flow will change as exercise progresses. Minute ventilation and pulmonary blood flow will no longer be at steady-state and the composite molecular profile of each breath will change. This is particularly evident when the cardiac output reaches a plateau and the minute ventilation continues to increase. Under these conditions, it is possible that molecules are excreted in the breath faster than they are being delivered to the alveolar-capillary membrane or produced in tissues and therefore their concentration in breath and blood will decrease. Similarly, if the lactate threshold (anaerobic threshold) is achieved during exercise, the breath profile will change and the relative abundances of specific breath markers will be different. If breath analysis is to be performed during exercise in order to study exercise physiology, it is preferable to normalize concentrations of breath molecules to oxygen consumption or carbon dioxide production. Using concentration of breath molecules directly or normalizing concentrations of breath molecules to minute ventilation will either over-estimate or under-estimate the production of breath markers, respectively.
2. Breath Markers of Normal and Abnormal Physiology 2.1 Breath hydrocarbons Isoprene (2-methy 1-1,3 -butadiene), the most abundant hydrocarbon in human breath, was first identified in the breath of adults in 1969 [4] and its presence in normal human
T.H. Risby / Volatile Organic Compounds as Markers
117
breath was confirmed subsequently by others [5,6]. However, the existence of detectable isoprene in human breath remained observational until 1984 when the in vivo biosynthesis of isoprene from DL-mevalonate was demonstrated in the cytosolic fraction of rat liver [7]. Subsequently, it was established that isoprene is produced by the decomposition of dimethylallyl pyrophosphate via a carbonium ion mechanism [8]. These studies were confirmed in humans by proving that levels of isoprene in exhaled breath can be lowered by administration of lovastatin, a pharmacological agent that blocks the enzyme 3-hydroxy-3methylglutaryl-CoA reductase (HMGCoA reductase) [9]. HMGCoA reductase catalyzes the production of mevalonic acid, which is the rate limiting intermediate in the pathway of cholesterol biosynthesis. Also, it was shown that feeding the study subjects a cholesterolrich diet caused a reduction in the level of breath isoprene [9]. These studies confirm that breath isoprene can be an excellent non-invasive marker of endogenous cholesterol status in humans. For example, breath isoprehe could be used diagnostically to identify human subjects that have increased risk for coronary artery disease as a result of increased biosynthesis of cholesterol. Breath isoprene has been found to be elevated in the breath of human subjects judged to have familial combined hyperlipidemia (FCH, Type IIA) and familial hypercholesterolemia (FH, Type IIB) as compared to gender, and age-matched subjects with normal lipid profiles (unpublished results). FCH is caused by a defect in the regulation of apolipoprotein B whereas FH is caused by a defect in the cell surface receptor that controls the degradation of plasma LDL. Humans that have these defects are at increased risk for coronary artery disease. One of the potential problems with the use of breath isoprene to identify individuals at risk is that the concentration of breath isoprene has a circadian rhythm. Breath isoprene has been shown to have a maximum concentration at around 6:00 A.M. and reaches a minimum at approximately 6:00 P.M. [10]. Additionally, the concentration of isoprene in breath is age dependent (unpublished results); it is non-detectable in the breath of neonates and increases linearly with age from approximately 6 months until it plateaus in middle age. The concentration of isoprene in breath decreases with old age. A similar age-dependence is known for serum cholesterol. Breath isoprene is also higher in the breath of males as compared to the breath of females but this gender difference disappears after menopause (unpublished results). If breath isoprene is to be used successfully to identify humans at risk for coronary artery disease as a result of high serum cholesterol, then an algorithm must be generated to account for natural variations due to time of day, age and gender. Cholesterol reduction therapy with pharmacological agents could be followed with breath isoprene. Levels of breath isoprene change more rapidly than serum levels of cholesterol and the subject would act as his/her own control. Breath isoprene has been used to follow the repair of cellular damage caused by exposure to ozone [11]. Reduced levels of breath isoprene have also been observed in patients with acute respiratory distress syndrome (ARDS) as compared to ventilation patients without ARDS [12]. In 1974, it was demonstrated that quantifiable increases in the amounts of ethane and ethylene were produced when mouse liver and brain tissue or mice were exposed to carbon tetrachloride [14]. These results lead to the proposition that ethane and ethylene could be used as markers of in vitro and in vivo lipid peroxidation since the metabolism of carbon tetrachloride, a known hepatotoxin, involves the generation of free radicals. Lipid peroxidation is a chain reaction with initiation, propagation, and chain termination steps. It is initiated by a reactive oxygen species, typically the hydroxyl radical, that abstracts an allylic hydrogen atom from an unsaturated lipid to produce a carbon centered radical and water. This radical is conjugated, peroxidized by molecular oxygen, and undergoes a variety of reactions. Their proposition was supported by the observation that the concentrations of ethane and ethylene could be correlated with concentration of malondialdehyde another marker of lipid peroxidation. Evidence of lipid peroxidation was confirmed by the reduction of the concentrations of these products by pretreatment of the tissue or mice with the antioxidant, vitamin E. The net result of lipid peroxidation is extensive damage to unsaturated lipids that can lead to the loss of integrity of cellular membranes. Structural and enzymatic proteins are also susceptible to damage by reactive oxygen species, particularly those proteins that contain thiol and amide functionalities. Reactive oxygen species have been implicated in the pathogenesis of a variety of diseases from cardiovascular, pulmonary.
118
T. H. Risby / Volatile Organic Compounds as Markers
autoimmunological, neurological, inflammatory, to connective tissue diseases. Moreover, reactive oxygen species have been proposed to contribute to the aging process. The reactivities of oxygen-centered free radicals demonstrate the need to quantify the presence of excess reactive oxygen species since such determinations would identify humans at risk for disease. Some of the stable end-products of lipid peroxidation such as ethane, ethylene, and 1-pentane are well suited for the estimation of cellular damage because these species are excreted in breath within minutes of their formation in tissues. In many ways, quantifying stable products of lipid peroxidation is superior to the direct measurement of free radicals since the quantification of damage is more relevant to the estimation of adverse effects. The degree of oxidative damage has been assigned the name oxidative stress status (OSS), which is the physiologic balance between the cellular levels of oxidants and antioxidants. Quantifying the concentrations of breath ethane and/or 1-pentane have been used extensively to monitor reactive oxygen mediated-damage in tissues, animals, and humans, for review see [14]. Our laboratory at Johns Hopkins has for more than a decade been investigating the role of oxygen free radicals in normal and diseased humans subjects. Evidence of acute damage to cellular lipids has been demonstrated in the operating room when blood flow was restored to ischemic tissue during organ transplantation, vascular surgery, and coronary artery bypass surgery. Confirmation that this damage was mediated by reactive oxygen species was provided in animal models using selective inhibitors. Additionally, acute damage was shown to occur when tissue was exposed to ionizing radiation during cancer therapy. Moreover, the effects of chronic exposure to reactive oxygen species were demonstrated in neonates, children and adults. The etiologies of these chronic exposures were diet, disease, or life styles. In many instances the progress of therapeutic interventions was followed using the concentrations of breath ethane. A recent review has discussed this body of work [15]. 2.2 Breath oxygen-containing compounds The following oxygen-containing compounds are the major compounds that have been identified and quantified in normal human breath in order of their abundances: acetone, ethanol, acetaldehyde, methanol and 2-propanoI. Breath acetone, which has a concentration comparable to that of isoprene, has been the most widely studied. Acetone is produced by hepatocytes from excess acetyl CoA. Acetoacetate and D-p-hydroxybutyrate are the other species that are also produced concomitantly with acetone, and these species are known collectively as ketone bodies. Ketone bodies diffuse from the hepatocytes into the blood stream and are oxidized via the Krebs cycle in peripheral tissue. Under normal conditions there is a steady-state low concentration of ketone bodies in the blood and hence in the exhaled breath. In times of stress, such as during dieting, fasting or starving (when fat tissue is used as an energy source instead of carbohydrates) the rate of production of ketone bodies exceed the rate of utilization by peripheral tissues and the subject becomes ketonemic. The blood concentrations of ketone bodies are increased with uncontrolled diabetes mellitus or chronic alcoholism. The concentrations of breath acetone have been proposed to be useful in the management of diabetes especially when used in conjunction to the determination of serum glucose [16]. The combination of these two were proposed since breath acetone was a more sensitive indicator of poor control of diabetes than of serum glucose. An interesting application of breath acetone would be to follow people who are dieting to see whether their breath contains high concentrations of ketone bodies. The "Atkins Diet" is a good example of this use. 2-propanol has been found in the breath of normal human subjects although at a lower concentration than acetone [17]. The origin of 2-propanol has been postulated to be the enzyme-mediated reduction of acetone. 2-propanol has been observed in ketonemic subjects who have elevated ratios of NADH/NAD*. The potential uses of breath acetone or 2-propanol are limited since there are many other ways to quantify ketonemia. Ethanol is normally found in human breath albeit at concentrations of orders of magnitude less that the levels of ethanol found in the breath of intoxicated subjects. The source of this ethanol is probably intestinal bacterial flora. Gut bacteria are known to synthesize and metabolize ethanol. In a recent study from this laboratory, the concentration of ethanol in the breath of mice has been related to obesity [18]. Specifically, the
T.H. Risby / Volatile Organic Compounds as Markers
\ 19
concentration of ethanol in the breath of genetically obese ob/ob mice was found to be significantly higher than the ethanol in the breath of their lean littermate controls (C57BL/6). This difference in the concentrations of breath ethanoi was negated when the ob/ob mice were treated orally to a poorly absorbed antibiotic. These results support the proposition that gut flora is producing the ethanol. Genetically obese mice have fatty livers that appear to be similar to the earliest stage of fatty liver disease in human subjects. Obesity has been shown to be a risk factor for the development of fatty liver disease in obese humans. An ob/ob mouse is a good model to study this problem. One feature common to obese humans and genetically obese mice is reduced gut motility. This reduced motility may increase the potential for the gut flora to produce ethanol or may increase gut permeability. Alternatively decreased gut motility may favor bacterial overgrowth. Since obesity-related liver disease has similar histological features to alcohol-induced liver damage it was postulated that endogenous low concentrations of ethanol may be a risk factor in the development of nonalcoholic steatohepatitis (NASH). This hypothesis was tested in a human study with biopsy-proven NASH patients and obese age-matched controls [19]. All subjects had quantifiable levels of breath ethanol, but the patients with NASH did not have elevated levels of breath ethanol compared to their obese controls. None of the study subjects had reported consuming alcohol for at least one year. The severity of liver disease was not influenced by the concentration of breath ethanol. However, there was a relationship between obesity and the concentration of breath ethanol for all study subjects and female subjects had a higher concentration of breath ethanol as compared to male subjects. Gender (female) is a risk factor for the development of NASH in obese subjects. This investigation is being continued with a larger population of normal and diseased subjects and if successful may provide important information on the pathogenesis of NASH, The origin of acetaldehyde found in normal human breath is probably the oxidation of endogenously produced ethanol since the concentration of acetaldehyde is always much lower than ethanol. An alternative reason for the observation that breath acetaldehyde is always much lower than breath ethanol is that low-molecular aldehydes are notoriously susceptible to oxidation to the corresponding acids. There is a report that abstinent men with the low activity polymorphism of alcohol dehydrogenase (ADH) or with low activity polymorphism of aldehyde dehydrogenase (ALDH) were found to have high endogenous concentration of ethanol or acetaldehyde in their blood [20]. Unfortunately, there are no studies reporting the relationship between polymorphisms in alcohol metabolism and breath markers although breath ethanol or acetaldehyde could be a simple method to identify specific polymorphisms. The origin of breath methanol may also be intestinal bacterial flora [21], although there was a report that suggested that methanol is produced in any tissue when the leaving methyl groups are hydrolyzed [22]. Examples are the conversion of S-adenosylmethionine to S-adenosylhomocysteine in various tissues. There are no studies that have reported breath profiles in human subjects with genetic defects in amino acid metabolisms although this is a potential application of a methanol breath test. 2.3 Breath sulfur-containing compounds It has been postulated since the early part of the 20th century that the breath sulfurcontaining compounds, methyl mercaptan, ethyl mercaptan, dimethyl sulfide and dimethyl disulfide, are responsible for the characteristic sweet, musty odor found on the breath of cirrhotic patients. This characteristic odor known as fetor hepaticus was first characterized chemically in 1970 [23]. In this classic paper the origin of these sulfur compounds was proposed to be the incomplete metabolism of methionine and this hypothesis was tested experimentally in humans. Others, who have also improved the analytical methods for the detection of these labile compounds, have confirmed this study. Although the degradation of methionine by liver mitochondria was first observed in 1953 [24,25], the complete transamination pathway in the liver has yet to be completely defined [26]. The production of methyl mercaptan and other volatile sulfur compounds has been shown to require the presence of either glyoxylic acid or 2-oxoglutaric acid and pyruvate [26]. The branched chain 2-oxyacid dehydrogenase complex probably controls the transaminative flux of these compounds. Degradation of methionine can also occur in the gut by the action of bacterial
120
T.H. Risby / Volatile Organic Compounds as Markers
methionine gamma-lyase [27], although it has been proposed that the gut is not the source of methyl mercaptan and dimethyl sulfide in liver disease [28]. Mercaptans are easily oxidized to their respective sulfides and that is the reason why breath sulfur-containing compounds are more abundant in breath. The production of methyl mercaptan depresses the synthesis of urea [29] with the result that circulating levels of ammonia, biogenic amines, and shortchain fatty acids are increased, thereby setting up the scenario for hepatic encephalopathy. Animals with compromised livers are demonstrably more sensitive to the CNS depressive effects of methyl mercaptan [30-32], thereby suggesting that the liver is the major organ responsible for the oxidation of methyl mercaptan [33]. It has been demonstrated that methyl mercaptan can be oxidized by erythrocytes to formic acid and sulfite or sulfate [34]. Similar oxidative pathways for the removal of volatile sulfur compounds are probably involved in both liver and erythrocytes. Under normal circumstances there are low concentrations of circulating sulfur-containing compounds present in the blood and breath of humans with normal, healthy livers. However, since impairment of liver function increases the level of reduced sulfur containing compounds, liver disease must affect the hepatic oxidation more than it affects transamination production. Recently the presence of chronic liver failure can be detected with sensitivity and specificity by means of analysis of breath carbonyl sulfide arising from the abnormal metabolism associated with liver diseases [35]. Moreover, monitoring breath carbonyl sulfide appears to distinguish between hepatocellular and biliary tract etiologies, and allows staging for disease severity. This breath marker may provide the clinician with a simple, non-invasive technique for screening large populations and follow-up for patients with chronic liver disease. This same breath marker has been used in other studies to identify lung transplant recipients who were experiencing acute rejection as compared to stable subjects. These preliminary studies suggest an additional diagnostic role for this noninvasive biomarker. The mechanism for the production of this marker in transplant recipients is probably tissue necrosis. Further exploration of breath analysis in lung transplant recipients is warranted with the view to obviate the need for fiberoptic bronchoscopy in some patients [36]. 2.4 Breath nitrogen-containing compounds In normal subjects 20% of the daily production of urea is secreted into the gut where the gut bacterial flora converts the urea to ammonia and carbon dioxide. The ammonia is subsequently reabsorbed from the intestine into the blood stream and converted by the liver back into urea. Under normal circumstances humans reuse most of the ammonia derived from catabolism of amino acids in the urea cycle although some urea, uric acid, and free ammonia is excreted in the urine. In end-stage renal disease, urine excretion is minimal and the concentrations of the catabolites of amino acids increase in the blood. The characteristic odor of uremic breath due toth elevated levels of dimethylamine and trimethylamine has been known for most of the 20 century, although it was not until 1977 that amines were conclusively identified and quantified in breath [37]. Ammonia will only appear in the blood if there is liver damage and the removal of ammonia by conversion to urea is decreased. Until recently the evidence that ammonia was present in breath was observational although it was known that if acidic vapors were inhaled then a portion of these vapors were neutralized in the nasal passage. This neutralization was postulated to be due to endogenously produced ammonia. In 1997 ammonia was positively identified and quantified in the breath of normal and uremic patients. These determinations were only possible as a result of the introduction of a novel mass spectrometer system [38]. Uremic patients had elevated levels of ammonia compared to normal subjects. The concentrations of breath ammonia were found to correlate with their respective plasma urea concentrations for all subjects examined. This correlation supports the hypothesis that hydrolysis of urea is the source for breath ammonia. Both of these studies have reported preliminary investigations on the use of exhaled breath to examine the efficacy of renal dialysis. This is an area where breath analysis has a major potential, particularly if a monitor is available that can quantify breath nitrogen compounds in real-time. Monitors that detect amines or ammonia in breath would be equally suitable for this important application. The development of these detectors will also allow biochemical pathways for the production of nitrogen-containing compounds to be investigated more fully.
T.H. Risby / Volatile Organic Compounds as Markers
\ 21
3. Conclusions Breath markers can be used to study the pathogenesis of a variety of disease states. Acute events are more easily studied since the subject can act as their own control. This approach is ideally suited to pharmacological interventions. Breath markers can also be used to identify individuals with metabolic defects. The ability to determine breath biomarkers in real-time will expand this approaches potential application in the future. This is significant, particularly in the surgical arena when the ability to measure changes in realtime and to ameliorate these changes on the basis of breath analysis could impact the surgical outcome. Such applications will only be possible if real-time monitors are developed for a variety of breath markers. Development of breath markers will expand as novel breath markers are identified that can be relate to the pathophysiology of disease progression. Current technology already allows molecular breath profiles to be generated for both normal and diseased humans subjects. Careful comparisons of these profiles may allow molecules to be identified that are early indicators of disease or disease progression. Once unique marker molecules have been identified then the biochemical pathways that produce these molecules must be proposed. The collection of breath is ideally suited to situations where blood is difficult to sample, e.g., in neonatology. Moreover, breath can be sampled multiple times with minimal invasion. References 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18.
G.E. Hayden, Olfactory diagnosis in medicine, Postgraduate Medicine, 67 (1980) 110-115. A. Manolis, The diagnostic potential of breath analysis, Clinical Chemistry, 29 (1983) 5-15. M. Phillips, Breath tests in medicine, Scientific American, July (1992) 74-79. B.O. Jansson and B.T. Larsson, Analysis of organic compounds in human breath by gas chromatographymass spectrometry, Journal of Laboratory & Clinical Medicine, 74, (1969), 961-966. J.P. Conkle et al., Trace composition of human respiratory gas, Archives of Environmental Health, 30, (1975), 290-295. B. Krotoszynski et al., Characterization of human expired air: a promising investigative and diagnostic technique. Journal of Chromatographic Science, 15, (1977), 239-244. E.S. Deneris et al., In vitro biosynthesis of isoprene from mevalonate utilizing a rat liver cytosolic fraction, Biochemical & Biophysical Research Communications, 123, (1984), 691-696. E.S. Deneris et al., Acid-catalyzed formation of isoprene from a mevalonate-derived product using a rat liver cytosolic fraction, Journal of Biological Chemistry, 260, (1985), 1382-1385. B.G. Stone et al,, Effects of regulating cholesterol biosynthesis on breath isoprene excretion in men, L/>w!s, 28, (1993), 705-708. A. Cailleux and P. Allain, Isoprene and sleep, Life Sciences, 441, (1989), 1877-1880. W.M. Foster et al., Breath isoprene: temporal changes in respiratory output after exposure to ozone. Journal of Applied Physiology, 80, (1996), 706-710. J.K. Schubert et al., Application of a new method for the analysis of exhaled gas in critically ill patients, Intensive Care Medicine, 24, (1998), 415-421. C.A. Riely et al., Ethane evolution: a new index of lipid peroxidation, Science, 183, (1974), 208-210. C.M. Kneppkens et al., The potential of the hydrocarbon breath test as a measure of lipid peroxidation. Free Radicals in Biology & Medicine, 17, (1994), 127-160. T.H. Risby and S.S. Sehnert, Clinical application of breath biomarkers of oxidative stress status. Free Radicals in Biology & Medicine, 27, (1999), 1182-1192. D. Barnett et al., Breath acetone and blood sugar measurements in diabetes, Clinical Sciences, 37. (3969), 570. P.L. Davis et al., Endogenous isopropanol: forensic and biochemical implications, Journal of Analytical Toxicology, 8, (1984), 209-212. K. Cope et al., Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis, Gasteroenterology, 119, (2000), 1340-1347.
122
T. H. Risby / Volatile Organic Compounds as Markers
19. S. Nair et al., Obesity and female gender increases breath ethanol concentration: potential implications for the pathogenesis of nonalcoholic steatohepatitis, American Journal ofGasteroenlerology, 96, (2001). 1200-1204. 20. W.F. Borson et al., Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases and their relationships to alcohol metabolism. Hepatology, 6, (1984), 502-510. 21. S. P. Eriksen and A.B. Kulkarni, Methanol in normal human breath, Science, 141, (1963), 639-640. 22. J. Axelrod and J. Daly, Pituitary gland: enzymic formation of methanol from S-adenosylmethionine. Science, 150, (1965), 892-893. 23. S. Chen et al., Mercaptans and dimethyl sulfide in the breath of patients with cirrhosis of the liver. Journal of Laboratory & Clinical Medicine, 75, (1970), 628-635. 24. E.S. Canellakis and H. Tarver, Studies on protein synthesis in vitro. IV. Concerning the apparent uptake of methionine by paniculate preparation from liver, Archives of Biochemistry & Biophysics, 42, (1953), 387-398. 25. E.S. Canellakis and H. Tarver, The metabolism of methyl mercaptan in the intact animal. Archives of Biochemistry & Biophysics, 42, (1953) 446-455. 26. P.W.D. Scislowski and K. Pickard, The regulation of transaminative flux of methionine in rat liver mitochondria, Archives of Biochemistry & Biophysics, 314, (1994), 412-416. 27. M. Johnston el al., Mechanistic studies on reactions of bacterial methionine gamma-lyase with olefinic amino acids, Biochemistry, 20, (1981), 4325-4333. 28. C.J. McClain et al., Blood methanethiol in alcoholic liver disease with and without hepatic encephalopathy. Gut, 21, (1980), 318-323. 29. R.F. Derr and L. Zieve, Methanethiol and fatty acids depress urea synthesis by the isolated perfused rat liver, Journal of Laboratory & Clinical Medicine, 100 (1982), 585-592. 30. A. Finkelstein and N.J. Benevenga, The effect of methanethiol and methionine toxicity on the activities of cytochrome c oxidase and enzymes involved in protection from peroxidative damage. Journal of Nutrition, 116, (1986), 204-215. 31. T. Vahlkamp et al., Inhibition of mitochrondrial electron transfer in rats by ethanethiol and methanethiol, Clinical Sciences, 56, (1979), 147-156. 32. L. Zieve et al., Ammonia, octanoate and a mercaptan depress regeneration of normal rat liver after partial hepatectomy, Hepatology, 5, (1985), 28-31. 33. L. Zieve et al., Effect of hepatic failure toxins on liver thymidine kinase activity and omithine decarboxylase after massive necrosis with acetaminophen in the rat, Journal of Laboratory & Clinical Medicine, 106, (1985), 583-588. 34. H.J. Blom and A. Tangerman, Methanethiol metabolism in whole blood, Journal of Laboratory & Clinical Medicine, 111, (1988), 606-610. 35. S.S. Sehnert et al., Breath biomarkers for detection of human liver diseases: a preliminary study. Biomarkers, in press, 2001. 36. S.M. Studer et al., Patterns and significance of exhaled-breath biomarkers in lung transplant rejection with acute allograft rejection, Journal of Heart Lung Transplantation, in press, 2001. 37. M.L. Simenhoff et al.. Biochemical profile of uremic breath, New England Journal of Medicine, 297. (1977), 132-135. 38. S. Davies et al.. Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. Kidney International, 52, (1997), 223-228.
Section 4. The "Living State"
This page intentionally left blank
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
125
The living state: intimate insights through personal discoveries Miklos KELLERMAYER Department of Clinical Chemistry, Medical School, University of Pecs, Hungary Abstract. Experimental findings on nuclei of living cells may be used as "indicators" of changes of the living state in healthy and in injured cells. Our experimental observations strongly indicate that neither the water molecules, nor the monovalent cations (K+ and Na4 ions) are freely moving, or solubilised inside normal living cells. In other words, the chromatin, the DNA, i.e. the genes are not exposed to a 150-200 mM free electrolyte solution inside the healthy living cells, however, in injured, agonizing and dead cells the freedom of water molecules and K+ - Na+ ions gradually and rapidly increases and DNA progressively becomes more and more exposed to this solute.
Cells of an SV40 virus induced tumor (H-50 cell line) were hybridized with chicken erythrocytes and the nuclei of the heterokaryons were analyzed in the first set of our experiments as herein presented [1]. In order to produce cell fusion UV inactivated Sendai virus extract was used and the tumor specific nuclear protein, the large T-antigen was detected by immune fluorescence microscopy. The first antibody was obtained from blood sera of tumor bearing hamsters. The second antibody was an anti-hamster globulin conjugated with fluorescein isothyocyanate (Progressive Laboratories, Baltimore, USA). The size of the nuclei was determined planimetrically. Dry-mass of the nuclei was measured using the interference microscopic technique (Zeiss, Oberkochen, Germany). The DNA synthetic activity in the nuclei was analyzed autoradiographically after H-thymidine incorporation. In some experiments the heterokaryons were treated with colchicin in order to determine whether the observed changes of the nuclei were or were not dependent upon the integrity of the cytoskeleton or specifically on the integrity of the micro tubular system. The first table summarizes our fluorescence microscopic and autoradiographic observations. Table 1. The effect of colchicin treatment on size, T-antigen positivity and 3Hthymidine incorporation of nuclei of H-50 tumor cells and chicken erythrocyte heterokaryons. Size of nuclei u2
J
T-antigen
H-thymidin inc.
30 h after fusion
H-50
erythr.
n=27
n=25
351.96
46.08
167 ]
-
±13.4
10"4 M colchicin
n=42
n=44
(6 h without and 24 h with colchicin)
384.47
17.91
+ 135.7
+ 3.7
Control
H-50
Erythr.
H-50
erythr.
++++
++++
++++
++++
++++
No
++
no
(no colchicin) ±
126
M. Kellermayer/The Living State: Intimate Insights
The small, pyknotic nuclei of chicken erythrocytes enlarged inside the heterokaryons were obtained by fusion of H-50 tumor cells and chicken red blood cells. This observation confirmed the original findings of H. Harris [2]. Parallel with the enlargement of these chicken erythrocyte nuclei they became positive for T antigen and incorporated 3Hthymidin. However, when the heterokaryons were treated 6 hours after fusion with colchicin, the chicken erythrocyte nuclei remained small, negative for T-antigen and inactive for DNA synthesis, even if they remained for a period of 24 hours in the cytoplasm of the giant fused cells. These observations confirmed the need for a specific intracellular environment for DNA synthesis which is always present in tumor cells as well as in normal cells processing their generation cycle (G]-S-G2-M phases), but missing in dormant cells like the erythrocytes circulating in chicken blood. The molecular composition (the homogenate) of the rapidly growing cells and dormant (inactive for DNA synthesis) cells are quite similar, which means that the fundamental difference in their DNA synthetic activity most probably originates from the differences in the organization, the arrangement of the molecules; naturally mainly proteins. The essence of the intracellular molecular organization, which creates an environment for genes to be active for DNA synthesis in tumor cells and in rapidly growing normal cells, but the fact that it becomes inhibitory in dormant cells like the nucleated red blood cells of chicken, is practically unknown. On the basis of the most accepted "intracellular free solution - membrane pump" cell view these observations, these experimental facts could never be truly explained. Instead these experimental observations force a change in the hypothetical intracellular free solution view to a more realistic fact-based cell hypothesis. The observed time delay (6 to 24 hours) that was needed to initiate the accumulation of the large T-antigen, the 80 kD size tumor specific protein, into the dormant chicken red blood cell nuclei demands a conceptual system in which a dynamic intracellular molecular rearrangement, recompartmentalization exists and at the same time, denies any kind of random molecular diffusion as the main feature of the interior of the living cell. If the interior of the living cells were a free solution, a cytosol and nuclear sap, as it is assumed in the widely accepted "solution - membrane pump" cell view, the random molecular collisions would be the only way for the intracellular molecular trafficking which is completely contradictory to our observed facts. The dependence of the accumulation of T-antigen into the dormant erythrocyte nuclei on the integrity of cytoskeleton, more specifically on the integrity of the micro tubular system strongly supports a dynamic self-compartmenting, self-rearranging system inside the living cells. Such a system could have its own memory, the so-called spatial memory and could be considered as a three dimensional "programmable" organization of "energized" proteins with the capability of adsorbing water molecules and inorganic ions. Our interference microscopic observations (Table 2) give further insight into such a dynamic protein-waterion co-compartment system. According to our opinion this organization itself can be considered as living state, the state which had been, has been and still being used to specify the life at the cellular level. Table 2. Interference microscopic measurements of nuclei of chicken erythrocytes in the heterokaryons of H-50 and chicken red blood cells.
n 2
Area (n ) 12
Dry mass (grx 10~ )
4h after fusion
24h after fusion
18
17
17.3+4.1
36.2+4.7
18.9 + 4.3
27.1 +3.6
1.10 + 0.08
0.75+0.10
Concentration (grxlO-'2/n2)
M. Kellermayer/ The Living State: Intimate Insights
] 27
In heterokaryons 24 hours after fusion the total dry mass content and the volume (area) of erythrocyte nuclei increased significantly. However, the increase of the nuclear volume was found to be much higher than the increase of the total dry mass content. In other words more water accumulated into the nuclei than mass. (The mass naturally means protein). If the interior of the living cell were a free solution, what is declared in the cytosol and nuclear sap view, our interference microscopic findings would indicate an increased gradient for water molecules inside the enlarged nuclei. Knowing the size of the water molecules and the structure of the nucleus with their large pores, an increasing water gradient between the nucleus and the rest of the cell would be impossible. The only explanation for our interference microscopic observations is an increased water-binding, water-structuring, water-holding capacity of proteins which had migrated into the nuclei and was associated with the different fixed chromatin structures inside the nucleus [3, 4, 5]. Interestingly, the transition of the condensed (inactive) heterochromatin to the loose (more hydrated) genetically active euchromatin (chromatin where the DNA and RNA synthesis occurs) could also only be explained by a higher water-structuring, water-binding capacity of those proteins which were accumulated in these regions and participated in the synthesis of the DNA and RNA. In a second set of the experiments, tissue culture cells (HeLa, Hep2 and human fibroblasts) were used. The cells were stained with Romhanyi's precipitation toluidin blue technique and analyzed with a polarization microscope [6, 7, 8, 9]. The DNA inside the nuclei of the interphase cells was always optically isotrop, while inside the mitotic chromosomes birefringent. Furthermore, it is important to note that the isolated DNA filaments have intensive negative birefringence. When the nuclei of monolayer cultured cells were isolated "in situ" with nonionic detergents (NP40, Triton X100) at 0.1%-0.2% concentration, the DNA inside the isolated nuclei was always birefringent if the cation concentration, i.e. the concentration of the free K+ and/or Na+ ions in the surrounding medium reached or exceeded 70 mmol/1 [6, 10, 11]. On the other hand, if the concentration of K+ and/or Na+ in the solution around the isolated nuclei was lower than 70 mmol/1 the DNA was always isotrop. The structural changes of DNA, i.e. the transition from the isotrop to the anisotrop (birefringent) state and vice versa was always reversible. Consequently, our polarization microscopic studies indicate that the DNA inside the nucleus of an interphase cell can not be exposed to a free 150-200 mmol/1 K+ - Na electrolyte solution, which is the widely accepted intracellular K+ - Na+ ion concentration for the living cells according to the "intracellular solution (cytosol, nuclear sap) membrane pump" cell view. In other words, our polarization microscopic observations are also strongly contradictory to the concept of intracellular free solution, i.e. to the cytosol and nuclear sap view. The reversible birefringence of DNA in mitotic chromosomes proves that the DNA undergoes not only a condensation but also certain structural changes during mitosis. It had been shown that the basic nucleosomal structure of DNA-histones is not broken up in mitotic chromosomes. Consequently, the structural changes of DNA we observed in mitotic chromosomes can only be explained by a local free ion (K+) driven reversible folding-unfolding transition of DNA in the linker region [9]. In other words our polarization microscopic findings on DNA of chromosomes and interphase cell nuclei support the concept of a local free ion regulatory system in the close vicinity of the genes [10, 12]. Naturally, such a local regulatory system can only work if both the water molecules and the inorganic ions are reversible bound to and released from proteins changing their configuration and energy levels in reversible manner. We might state that our polarization microscopic observations confirm our previously presented observations on cell hybrids of H-50 tumor cells and chicken erythrocytes and both of them are very supportive for a dynamic, "programmable", three dimensional spatial memory carrying "energized protein - water - ion co-compartment system" in all living cells.
128
M. Kellermayer / The Living State: Intimate Insights
The final set of our experiments (Table 3) are also supportive for such a system. HeLa cells growing in monolayers on glass and plastic surfaces were released with mild trypsinization and for the purpose of increasing the number of agonizing and dead cells, they were vigorously shaken for 1 and 2 hours. Parallel samples were stained with nigrosin (viability test) and with Romhanyi's precipitation toluidin blue technique. Ten preparations were analyzed from each sample and 200 cells were counted in every preparation.
Table 3. The nigrosin stainability and nuclear birefringence in mechanically injured HeLa culture cells. % N I"
2"
2000
24.1
38.5
(10x200)
+ 2.4
+ 2.9
Dead cells
2000
23.5
37.9
(nigrosin stained cells)
(10x200)
+ 2.6
+ 3.2
Nuclear birefringent
Comparing the nigrosin-stained cells with cells birefringent DNA in their nuclei, a very close correlation was found. This finding indicated that the cells that were agonizing, dying or already dead permit the nigrosin to diffuse inward and induces the DNA in their pyknotic nuclei to turn from the isotrop to the anisotrop state. On the basis of our previously described observations the change of the DNA from the isotrop to the anisotrop state can only be explained if the DNA in nuclei of agonizing and dead cells were becoming more and more exposed to an increasing (higher then 70 mmol/1) concentration of free K+ - Na+ ions. Therefore, we might conclude that at cell agony and cell death the water molecules and K* and Na"1" ions are gradually or rapidly released from their dynamic co-compartmentalization with proteins. It is important to note that the nuclear pycnosis itself, which is a well-known characteristics of cell agony and cell death at apoptosis and also at cell necrosis is probably caused by the release of water molecules and ions from their dynamic compartments with energized proteins in the close vicinity of DNA. In summary, all of our experimental observations on the nuclei of the living cells are strongly contradictory to the widely accepted free "intracellular solution-membrane pump" cell view. The DNA molecules, the genes within the nuclei of the healthy living cells are not exposed to a 150-200 mmol/1 K* - Na* solution. However, at cell agony and cell death, the DNA is gradually or rapidly becoming more and more exposed to such free electrolyte. All of this indicates that the living state, i.e. the life at cell level must be connected to certain energy driven dynamic associations of proteins with water molecules and inorganic ions. For the question: "What is life?" Szent-Gyorgyi Albert answered this: "The life is the water dancing Jo the tune of solids" [13]. As a corollary, we would answer thus: "The life is water and potassium dancing to the tune of energized proteins" [14, 15]. What are the energized proteins? To answer this question we need to listen to Gilbert N. Ling who speaks about the extended state of proteins with high electron density sites and water structuring capability [16, 17, 18, 19]. We may add to this that our newest strategy, the study of the release kinetics of K+, ATP and proteins from detergent "opened" cells provides promising insights into the major secrete, i.e. the living state [20, 21].
M. Kellermayer / The Living State: Intimate Insights
129
Acknowledgements: This work was supported by the OTKA T 032043 grant. Critical comments of Carlton F. Hazlewood and Gilbert N. Ling are highly appreciated.
References:
[I]
M. Kellermayer et al., Inhibiton of Intranuclear Transport of SU40-Induced T-antigen in Heterokaryons, Cell Biology International Reports 2(1978) 19-24.
[2]
H. Harris, Nucleus and Cytoplasm. Claredone Press, Oxford, 1967.
[3]
M. Kellermayer et al., Swelling of Nuclei and Decondensation of Chromatin in a Multinuclear Model, European Journal of Cell Biology 23(1980) 204-207.
[4]
M. Kellermayer, Soluble and "Loosely Bound" Nuclear Proteins in Regulation of the Ionic Environment in Living Cell Nuclei. In: H. G. Schweiger (eds.), International Cell Biology 1980-1981. Springer-Verlag, Berlin-Heidelberg, New York, 1981, pp 915-924.
[5]
M. Kellermayer et al., Platelet-derived Growth Factor (PDGF) Induces Intranuclear Protein Accumulation in 3T3 Fibroblats, Experimental Cell Research 152(1984) 255-259.
[6]
M. Kellermayer and K. Jobst, Ion-dependent Anisotropy of Deoxyribonucleoprotein Structures in Tissue Cultures, Experimental Cell Research 63(1970) 204-207.
[7]
M. Kellermayer et al. Polarization Optical Study of the Ultra Structure of Cell Nuclei in Tissue Cultures, Acta Morphologica Acad. Sci. Hung., 18(1970) 131-137.
[8]
K. Jobst and M. Kellermayer, Sodium-induced Changes in the Nuclei of Monolayer HeLa Cultures, Journal Cell Sciences 11(1972) 669-673.
[9]
M. Kellermayer and C. F. Hazlewood, Dynamic Inorganic Ion-Protein Interactions in Structural Organization of DNA of Living Cell Nuclei, Cancer Biochem. Biophys., 3(1979) 181-188. M. Kellermayer and K. Jobst, Isolation of Cell Nuclei in Coverslip Cultures, Beitr. Path 142(1971)321-323.
[10] [II]
M. Kellermayer and K. Jobst, Cytoplasmic Protein Network in HeLa Cells, Histochemistry 44(1975)193-195.
[12]
M. Kellermayer and C. F. Hazlewood, Dynamic Interaction of Water Molecules, Inorganic Ions and Chromatin Structures in Isolated Thymus Nuclei. In: A. Pullman, V. Vasilescu, L. Packer (eds.), Water and Ions in Biological Systems, Plenum Press, New York and London, 1985, pp 57-67.
[13]
A. Szent-Gytfrgyi, The Living State. Academic Press, New York and London, 1972.
[14]
M. Kellermayer, ATP Dependent Cocompartmentation of Proteins and K+ within the Living Cell. In: J. Tigyi, M. Kellermayer, C. F. Hazlewood (eds.), The Physical Aspect of the Living Cell, Akade"miai Kiado, Budapest, 1991, pp 165-180.
[15]
G. H. Pollack, Cells, Gels and the Engines of Life. A New, Unifying Approach to Cell Function. Ebner and Sons Publishers, Seattle, 2001.
[16]
G. N. Ling, A physical theory of the living state. The association-induction hypothesis. Blaisdell Publishing Co. New York and London, 1962.
[17]
G. N. Ling, In Search of the Physical Basis of Life. Plenum Press, New York and London, 1984.
[18]
G. N. Ling, A Revolution in the Physiology of the Living Cell. Krieger Publishing Co. Malabar, Florida, 1992.
[19]
G. N. Ling, Life at the Cell and Below-Cell Level. The Hidden History of a Fundamental Revolution in Biology. Pacific Press, New York, 2001.
[20]
M. Kellermayer et al., Potassium Retention in Membraneless Thymus Lymphocyte Nuclei, Physiol. Chem. Phys. and Med NMR., 16(1984) 503-511.
[21]
M. Kellermayer et al., Cocompartmentation of Proteins and K+ within the Living Cell, Proc. Nat. Acad Sci. USA 83(1986) 1011-1015.
This page intentionally left blank
Part II. Asthma
This page intentionally left blank
Disease Markers in Exhaled Breath N. Marczin andM.H. Yacoub (Eds.) IOS Press, 2002
133
Biology of Asthma Peter J BARNES National Heart and Lung Institute, Imperial College, London, UK
Abstract. Asthma is a chronic inflammatory disease of the airways, characterised by an infiltration of eosinophils, activation of T helper-2 lymphocytes and activation of mast cells. Structural cells of the airway, including epithelial cells and airway smooth muscle participate in the inflammatory process via the production of multiple mediators, including nitric oxide. Many inflammatory mediators, including cytokines and chemokines, are involved in asthma and lead to the characteristic pathophysiology, including contraction of airway smooth muscle, plasma exudation, mucus secretion and activation of sensory nerves. Chronic inflammation may result in structural changes, including proliferation of airway smooth muscle, new vessel formation and fibrosis that may lead to irreversible airway narrowing.
1. Introduction Asthma is a highly complex disease involving many different inflammatory cells, multiple mediators, and complex acute and chronic inflammatory responses in the airways [l](Figure 1). There have been important advances in our understanding of the molecular and cellular pathways involved, partly through the development of new molecular techniques and partly by application of novel inhibitors developed by the pharmaceutical industry [2]. Yet despite these considerable advances many fundamental questions about asthma that remain to be answered.
Figure 1. Many cells and mediators are involved in asthma and lead to several effects on the airways.
134
P.J. Barnes / Biology Of Asthma
Our understanding of asthma has been transformed by the recognition that chronic inflammation underlies the clinical syndrome. Previously it had commonly been assumed that the basic defect in asthma lay in abnormal contractility of airway smooth muscle, giving rise to variable airflow obstruction, and the common symptoms of intermittent wheeze and shortness of breath. However studies of airway smooth muscle from asthmatic patients have shown no consistent evidence for increased contractile responses to spasmogens such as histamine in vitro, indicating that asthmatic airway smooth muscle is not fundamentally abnormal and suggesting that it is the control of airway calibre in vivo which is abnormal. 2. Airway inflammation in asthma All patients with symptomatic asthma have inflamed airways. This has been confirmed by fibreoptic bronchial biopsies, by bronchoalveolar lavage, by induced sputum and by the use of exhaled markers of inflammation, such as exhaled nitric oxide (NO) and carbon monoxide (CO). This inflammation appears to involve all airways in asthma, from the trachea to terminal bronchioles, but does not extend to the lung parenchyma. The inflammatory pattern in asthma is characteristic, with an increase in activated eosinophils, degranulation of mast cells and activation of T helper (CD4+) lymphocytes. It differs markedly from the inflammation seen in chronic obstructive pulmonary disease and chromic bronchitis. The relationship between inflammation and clinical symptoms of asthma is still not clearly understood. The airway inflammation is related to airway hyperresponsiveness (AHR), as measured by histamine or methacholine challenge, but the degree of inflammation does not clearly correspond to asthma severity. This suggests that other factors, such as structural changes in the airway wall are important. The increased airway responsiveness in asthma is a striking physiological abnormality that is present even when airway function is normal. It is likely that there are several factors that underlie this increased responsiveness to contractor agents, particularly those that act indirectly by releasing bronchoconstrictor mediators form airway cells. Airway hyperresponsiveness may be due to increased release of mediators (such as histamine and leukotrienes from mast cells), abnormal behaviour of airway smooth muscle, thickening of the airway wall by reversible (oedema) and irreversible (airway smooth muscle thickening, fibrosis) elements. Airway sensory nerves may also contribute importantly to symptoms, such as cough and chest tightness, as the nerves become sensitised by the chronic inflammation in the airways. Although most attention has previously focused on the acute inflammatory changes seen in asthmatic airways (bronchoconstriction, plasma exudation, mucus secretion) asthma is a chronic inflammatory disease, with inflammation persisting over many years in most patients. Superimposed on this chronic inflammatory state are acute inflammatory episodes, which correspond to exacerbations of asthma. It is clearly important to understand the mechanisms of acute and chronic inflammation in asthmatic airways and to understand the long-term consequences of this chronic inflammation on airway function. 3. Inflammatory Cells Many different inflammatory cells are involved in asthma, although the precise role of each cell type is not yet certain. No single inflammatory cell is able to account for the complex pathophysiology of asthma, but some cells predominate in asthmatic inflammation. It is likely that there are important interactions between these cells. The pattern of inflammation is similar in all forms of asthma so far investigated with a predominance of activated eosinophils, mast cells and T helper lymphocytes. The inflammation in intrinsic asthma, with no evidence of atopy is identical to that of the common atopic asthma [3j.
P.J. Barnes/Biology Of Asthma
135
Mast cells Mast cells are important in initiating the acute bronchoconstrictor responses to allergen and probably to other indirect stimuli, such as exercise and hyperventilation (via osmolality or thermal changes) and fog. Mast cells also secrete certain cytokines, such as interleukin(IL)-4 that may be involved in maintaining the allergic inflammatory response. However, there are questions about the role of mast cells in more chronic inflammatory events, and it seems more probable that other cells such as macrophages, eosinophils and T-lymphocytes are more important in the chronic inflammatory process, including AHR. Classically mast cells are activated by allergens through an IgE-dependent mechanism and the critical importance of IgE in the pathophysiology of asthma has been highlighted by recent clinical studies with humanised anti-IgE antibodies, which block IgE-mediated effects [4]. Anti-IgE antibody results in a reduction in circulating IgE to undetectable levels and significant clinical improvement even in patients with severe steroid-dependent asthma. Macrophages Macrophages, which are derived from blood monocytes, traffic into the airways in asthma and may be activated by allergen via low affinity IgE receptors (FceRII) and may also be inhibited by anti-IgE therapy. The enormous repertoire of macrophages allows these cells to produce many different products, including a large variety of cytokines, which may orchestrate the inflammatory response. Macrophages have the capacity to initiate a particular type of inflammatory response via the release of certain patterns of inflammatory mediators. Macrophages may both increase and decrease inflammation, depending on the stimulus. Alveolar macrophages normally have a suppressive effect on lymphocyte function, but this may be impaired in asthma after allergen exposure. Macrophages may therefore play an important anti-inflammatory role, preventing the development of allergic inflammation, Macrophages may also act as antigen-presenting cells which process allergen for presentation to T-lymphocytes, although alveolar macrophages are far less effective in this respect than macrophages from other sites, such as the peritoneum. Dendritic cells Dendritic cells are specialised macrophage-like cells in the airway epithelium, that are very effective antigen-presenting cells, and may therefore play a very important role in the initiation of allergen-induced responses in asthma. Dendritic cells take up allergens, process then to peptides and migrate to local lymph nodes where they present the allergenic peptides to uncommitted T-lymphocytes, to programme the production of allergen-specific T cells. Eosinophils Eosinophil infiltration is a characteristic feature of asthmatic airways and differentiates asthma from other inflammatory conditions of the airway. Allergen inhalation results in a marked increase in eosinophils in bronchoalveolar lavage fluid at the time of the late reaction, and there is a close relationship between eosinophil counts in peripheral blood or bronchial lavage and AHR. Eosinophils are linked to the development of AHR through the release of basic proteins and oxygen-derived free radicals. The mechanisms involved in recruitment of eosinophils into asthmatic airways have been carefully investigated, as this may provide a specific target to inhibit inflammation in asthma. Eosinophils are derived from bone marrow precursors and their production is dependent on the cytokine IL-5. After allergen challenge eosinophils appear in BAL fluid during the late response, and this is associated with a decrease in peripheral eosinophil counts and with the appearance of eosinophil progenitors in the circulation. The signal for increased eosinophil production is presumably derived from the inflamed airway. Eosinophil recruitment initially involves adhesion of eosinophils to vascular
136
P.J. Barnes / Biology Of Asthma
endothelial cells in the airway circulation, their migration into the submucosa and their subsequent activation. The role of individual adhesion molecules, cytokines and mediators in orchestrating these responses has been extensively investigated. Adhesion of eosinophils involves the expression of specific glycoprotein molecules on the surface of eosinophils (integrins) and their expression of such molecules as intercellular adhesion molecule-1 (ICAM-1) on vascular endothelial cells. An antibody directed at ICAM-1 markedly inhibits eosinophil accumulation in the airways after allergen exposure and also blocks the accompanying hyperresponsiveness. However, ICAM-1 is not selective for eosinophils and cannot account for the selective recruitment of eosinophils in allergic inflammation. The adhesion molecules VLA4 expressed on eosinophils and VCAM-1 appear to be more selective for eosinophils and IL-4 increases the expression of VCAM-1 on endothelial cells. Eosinophil migration may be due to the effects of lipid mediators, such as platelet-activating factor (PAF), to the effects of cytokines, such as GM-CSF and IL-5, which may be very important for the survival of eosinophils in the airways, and may "prime" eosinophils to exhibit enhanced responsiveness. Eosinophils from asthmatic patients show exaggerated responses to PAF and phorbol esters, compared to eosinophils from atopic non-asthmatic individuals and this is further increased by allergen challenge, suggesting that they may have been primed by exposure to cytokines in the circulation. There are several mediators involved in the migration of eosinophils from the circulation to the surface of the airway. The most potent and selective agents appear to be CC-chemokines, such as eotaxin. RANTES, and MCP-4, that are expressed in epithelial cells. There appears to be a co-operative interaction between IL-5 and eotaxin, so that both cytokines are necessary for the eosinophilic response in airways. Once recruited to the airways eosinophils require the presence of various growth factors, of which GM-CSF appears to be the most important. In the absence of these growth factors eosinophils undergo programmed cell death (apoptosis). Recently a humanised monoclonal antibody to IL-5 has been administered to asthmatic patients and, as in animal studies, there is a profound and prolonged reduction in circulating eosinophils; the infiltration of eosinophils into the airway after inhaled allergen challenge is completely blocked [5]. However, there is no effect on the response to inhaled allergen and no reduction in AHR, questioning the pivotal role of eosinophils in asthma. Neutrophils The role of neutrophils in asthma is less clear. Neutrophils are found in the airways of patients with COPD and cystic fibrosis, who do not have the degree AHR found in asthma, but are rarely seen in the airways of patients with chronic asthma. However, in patients who die suddenly of asthma large numbers of neutrophils are found in the airways, although this may reflect the rapid kinetics of neutrophil recruitment compared to eosinophil inflammation. Increased numbers of neutrophils are also found in the airway sand induced sputum of patients with severe asthma. Whether these cells are present because of high does of inhaled corticosteroids or are contributing to the pathophysiology of severe asthma is currently unknown. T-lymphocytes T-lymphocytes play a pivotal role in orchestrating the inflammatory response in asthma through the release of specific patterns of cytokines, resulting in the recruitment and survival of eosinophils and in the maintenance of mast cells in the airways. T-lymphocytes are coded to express a distinctive pattern of cytokines, which may be similar to that described in the murine Th2 type of T-lymphocytes, which characteristically express IL-4, IL-5 and IL-9. This programming of T-lymphocytes is presumably due to antigen-presenting cells, such as dendritic cells, which may migrate from the epithelium to regional lymph nodes or which
P.J. Barnes / Biology Of Asthma
137
interact with lymphocytes resident in the airway mucosa. There appears to be an imbalance of Th cells in asthma with the balance tipped away from the normally predominant Thl cells in favour of Th2 cells. The balance between Thl cells and Th2 cells may be determined by locally released cytokines, such as IL-12 derived from dendritic cells and macrophages, which tips the balance in favour of Thl cells and IL-4 which favours Th2 cells. There is some evidence that early infections might promote Thl-mediated responses to predominate and that a lack of infection in childhood may favour Th2 cell expression and thus atopic diseases [6]. Basophils The role of basophils in asthma is uncertain, as these cells have previously been difficult to detect by immunocytochemistry. Using a basophil-specific marker a small increase in basophils has been documented in the airways of asthmatic patients, with an increased number after allergen challenge. However, these cells are far outnumbered by eosinophils. Structural cells Structural cells of the airways, including epithelial cells, fibroblasts and even airway smooth muscle cells may also be an important source of inflammatory mediators, such as cytokines and lipid mediators in asthma. Indeed, because structural cells far outnumber inflammatory cells they may become the major source of mediators driving chronic inflammation in asthmatic airways. In addition, epithelial cells may a key role in translating inhaled environmental signals into an airway inflammatory response and are probably a major target cell for inhaled corticosteroids. 4. Inflammatory Mediators Many different mediators have been implicated in asthma and they may have a variety of effects on the airways and together they account for the pathological features of asthma [7], Mediators such as histamine, prostaglandins, leukotrienes, bradykinin and endothelins contract airway smooth muscle, increase microvascular leakage, increase airway mucus secretion and attract other inflammatory cells. The multiplicity of mediators makes it unlikely that antagonising any single mediator will have a major impact in clinical asthma; this has been confirmed with clinical trials using specific antagonists and synthesis inhibitors of individual mediators. The cysteinyl-leukotrienes LTC4, LTD4 and LTE4 are potent constrictors of human airways and have been reported to increase AHR and may play an important role in asthma. The development of potent anti-leukotrienes has now made it possible to evaluate the role of these mediators in asthma. Potent LTD4 antagonists reduce exercise- and allergen-induced bronchoconstriction and chronic treatment improves lung function and symptoms in asthmatic patients, although the degree of improvement is not nearly as great as seen with an inhaled corticosteroids. It is only through the use of specific antagonists that the role of individual mediators of asthma may be defined. For example, PAF is a potent inflammatory mediator that mimics many of the features of asthma, including eosinophil recruitment and activation and induction of airway hyperresponsiveness, yet even potent PAF antagonists, such as modipafant, do not control asthma symptoms, at least in chronic asthma. Cytokines Cytokines are important in the chronic inflammation of asthma and play a critical role in orchestrating the nature of allergic inflammatory response [8]. Many inflammatory cells (macrophages, mast cells, eosinophils and lymphocytes) are capable of synthesising and releasing these proteins, and structural cells such as airway epithelial, smooth muscle and endothelial cells may also release a variety of cytokines and may therefore participate in the
138
P.J. Barnes / Biology Of Asthma
chronic inflammatory response. While inflammatory mediators like histamine and leukotrienes are important in the acute and subacute inflammatory responses and in exacerbations of asthma, it is likely that cytokines play a dominant role in chronic inflammation. Almost every cell is capable of producing cytokines under certain conditions. Research in this area is hampered by a lack of specific antagonists, although important observations have been made using specific neutralising antibodies. The cytokines which appear to be of particular importance in asthma include the lymphokines secreted by Th2 cells: IL-4 which is critical in switching B-lymphocytes to produce IgE, for expression of VCAM-1 on endothelial cells and for inducing the differentiation of Th2 cells, IL-13, which acts similarly to IL-4 in IgE switching, and IL-5 which is essential for the differentiation, of eosinophils. The critical role of an IL-5 in eosinophilia has been confirmed by the use of an anti-IL-5 antibody in asthmatic patients. Another Th2 cytokine IL-9 may play a critical role is sensitising responses the the cytokines IL-4 and IL-5. Other cytokines, such as IL-10 and tumour necrosis factor-a (TNF-a), may play an important role in amplifying the inflammatory response in asthma and are released from a variety of cells, including macrophages and epithelial cells. Both cytokines show an increased expression in asthma and activate the proinflammatory transcription factors, nuclear factor-icB (NF-KB) and activator protein-1 (AP-1), which then switch on many inflammatory genes. Inhalation of TNF-a increased airway responsiveness in normal individuals. Oxidative stress As in all inflammatory diseases, there is increased oxidative stress in asthma as activated inflammatory cells, such as macrophages and eosinophils produce reactive oxygen species. Evidence for increased oxidative stress in asthma is provided by the increased concentrations of 8-isoprostane (a product of oxidised arachidonic acid) in exhaled breath condensates and increased ethane (a product of oxidative lipoid peroxidation) in exhaled breath of asthmatic patients. Increased oxidative stress is related to disease severity and may amplify the inflammatory response and reduce responsiveness to corticosteroids. Nitric oxide NO is produced by several cells in the airway by NO synthases. An inducible form of the enzyme (iNOS) is expressed in epithelial cells of asthmatic patients and can be induced by cytokines in airway epithelial cells in vitro. This may account for the increased concentration of NO in the exhaled air of untreated asthmatic patients [9]. NO itself is a potent vasodilator and this may increase plasma exudation in the airways; it may also amplify the Th2lymphocyte mediated response and attract and prolong the survival of eosinophils. The combination of increased oxidative stress and NO may lead to the formation of the potent radical peroxynitrite, that may result in nitrosylation of proteins in the airways. 5. Effects of Inflammation on the Airways The chronic inflammatory response has several effects on the target cells of the airways, resulting in the characteristic pathophysiological changes associated with asthma. Asthma may be regarded as a disease with continuous inflammation and repair proceeding simultaneously. Several structural changes are recognisable in severe asthma and these may not be fully reversible with existing therapies. Airway epithelium Airway epithelial shedding may be important in contributing to AHR and may explain how several different mechanisms, such as ozone exposure, certain virus infections, chemical
P.J. Barnes / Biology Of Asthma
139
sensitisers and allergen exposure, can lead to its development, since all these stimuli may cause epithelial disruption. Epithelium may be shed as a consequence of inflammatory mediators, such as eosinophil basic proteins and oxygen-derived free radicals, together with various proteases released from inflammatory cells. Epithelial cells are commonly found in clumps in the BAL or sputum (Creola bodies) of asthmatics, suggesting that there has been a loss of attachment to the basal layer or basement membrane. Epithelial damage may contribute to AHR in a number of ways, including loss of its barrier function to allow penetration of allergens, loss of enzymes (such as neutral endopeptidase), which normally degrade inflammatory mediators, loss of a relaxant factor (so called epithelial-derived relaxant factor), and exposure of sensory nerves which may enhance reflex neural effects on the airway. Fibrosis Subepithelial fibrosis is a characteristic of asthmatic airways, and may even be seen in patients with episodic asthma who have no symptoms. The increased thickness is unrelated to asthma severity and its functional significance is uncertain. Type HI and V collagen appear to be laid down, and may be produced by myofibroblasts which are situated under the epithelium. However, there is also evidence for fibrosis deeper within the airway wall and within the airway smooth muscle layer that may have a greater functional significance. The mechanism of fibrosis is not yet clear but several cytokines, including transforming growth factor-p and platelet-derived growth factor may be produced by epithelial cells or macrophages in the inflamed airway. Air-way smooth muscle There is still debate about the role of abnormalities in airway smooth muscle is asthmatic airways. In vitro airway smooth muscle from asthmatic patients usually shows no increased responsiveness to spasmogens. Reduced responsiveness to 6-agonists has been reported in post-mortem or surgically removed bronchi from asthmatics, although the number of B-receptors is not reduced, suggesting that B-receptors have been uncoupled. These abnormalities of airway smooth muscle may be a reflection of the chronic inflammatory process. For example the reduced 13-adrenergic responses in airway smooth muscle could be due to phosphorylation of the stimulatory G-protein coupling fi-receptors to adenylyl cyclase, resulting from the activation of protein kinase C by the stimulation of airway smooth muscle cells by inflammatory mediators, to increased activity of the inhibitory G-protein (Gs) induced by proinflammatory cytokines. In asthmatic airways there is also a characteristic hypertrophy and hyperplasia of airway smooth muscle, which is presumably the result of stimulation of airway smooth muscle cells by various growth factors, such as PDGF, or endothelin-1 released from inflammatory cells. Vascular responses Vasodilatation occurs in inflammation, yet little is known about the role of the airway circulation in asthma, partly because of the difficulties involved in measuring airway blood flow. The bronchial circulation may play an important role in regulating airway calibre, since an increase in the vascular volume may contribute to airway narrowing. Increased airway blood flow may be important in removing inflammatory mediators from the airway, and may play a role in the development of exercise-induced asthma. There may also be an increase in the number of blood vessels in asthmatic airways as a result of angiogenesis in response to growth factors. Microvascular leakage is an essential component of the inflammatory response and many of the inflammatory mediators implicated in asthma produce this exudation of plasma
140
P.J. Barnes / Biology Of Asthma
from post-capillary venules. Plasma exudation in asthma may have several consequences on airway function, including increased airway secretions, impaired mucociliary clearance, formation of new mediators from plasma precursors (such as kinins) and mucosal oedema which may contribute to airway narrowing and AHR. Mucus hypersecretion Mucus hypersecretion is a common inflammatory response in secretory tissues. Increased mucus secretion contributes to the viscid mucus plugs, which occlude asthmatic airways, particularly in fatal asthma. There is evidence for hyperplasia of submucosal glands, which are confined to large airways and of increased numbers of epithelial goblet cells at all airway levels. This increased secretory response may be due to inflammatory mediators acting on submucosal glands and due to stimulation of neural elements. Little is understood about the control of goblet cells, which are the main source of mucus in peripheral airways, although cholinergic nerves and sensory neuropeptides may be important in stimulating secretion. Epidermal growth factor may also be an important mediator for goblet cell and mucus gland hyperplasia in asthma. Neural effects There has recently been a revival of interest in neural mechanisms in asthma. Autonomic nervous control of the airways is complex, for in addition to classical cholinergic and adrenergic mechanisms, non-adrenergic non-cholinergic (NANC) nerves and several neuropeptides have been identified in the respiratory tract. Several studies have investigated the possibility that defects in autonomic control may contribute to airway hyperresponsiveness and asthma, and abnormalities of autonomic function, such as enhanced cholinergic and ct-adrenergic responses or reduced 6-adrenergic responses, have been proposed. Current thinking suggests that these abnormalities are likely to be secondary to the disease, rather than primary defects. It is possible that airway inflammation may interact with autonomic control by several mechanisms. Cholinergic nerves are the major bronchoconstrictor neural pathway in human airways and abnormalities of cholinergic control of the airways have long been suspected to be involved in the pathophysiology of asthma. Animal studies have demonstrated defective function in M2 muscarinic receptors on cholinergic nerve endings, resulting in increased acetycholine release and increased reflex bronchoconstriction. Inflammatory mediators may act on various pre-junctional receptors on airway nerves to modulate the release of neurotransmitters. Inflammatory products may also sensitise sensory nerve endings in the airway epithelium, so that the nerves become hyperalgesic. Hyperalgesia and pain (dolor) are cardinal signs of inflammation, and in the asthmatic airway may mediate cough and chest tightness, which are such characteristic symptoms of asthma. The precise mechanisms of hyperalgesia are not yet certain, but mediators such as prostaglandins, certain cytokines and neurotrophins may be important. Neurotrophins, which may be released form various cell types in the airways, may cause proliferation and sensitisation of airway sensory nerves [10]. Bronchodilator nerves, which are non-adrenergic, are prominent in human airways, and it has been suggested that these nerves may be defective in asthma. In animal airways vasoactive intestinal peptide (VIP) has been shown to be a neurotransmitter of these nerves but no abnormalities in VIP-immunoreactive nerves have been seen in asthma. In human airways NO appears to be the sole transmitter of bronchodilator nerves. Airway nerves may also release neurotransmitters which have inflammatory effects. Thus neuropeptides such as substance P (SP), neurokinin A and calcitonin-gene related peptide may be released from sensitised inflammatory nerves in the airways which increase
P.J. Barnes / Biology Of Asthma
141
and extend the ongoing inflammatory response. There is some evidence for an increase in SPimmunoreactive nerves in airways of patients with severe asthma, although this has not been confirmed in milder asthmatic patients. There may also be a reduction in the activity of enzymes, such as neutral endopeptidase, which degrade neuropeptides such as SP. There is also evidence for increased gene expression of the neurokinin receptors (NK,, NK 2 ) that mediates the effects of tachykinins. Thus chronic asthma may be associated with increased neurogenic inflammation, which may provide a mechanism for perpetuating the inflammatory response, even in the absence of initiating inflammatory stimuli. However, there is still no direct evidence for this in asthma and the negative effects of tachykinin antagonists in asthma argue against an important role, at least in mild asthma. Acute and chronic inflammation Asthma is characterised by acute inflammatory episodes, which may occur after upper respiratory tract virus infections or exposure to a large amount of inhaled allergen, resulting in bronchoconstriction, plasma exudation and oedema and mucus secretion. However, asthma is also a chronic inflammatory process, partly driven by exposure to low level environmental allergens, such as house dust mite and moulds, and this may result in structural changes in the airway walls (remodelling) that lead to progressive and largely irreversible narrowing of airways. This may result in permanent structural changes that may underlie the irreversible reduction in airflow that occurs in some patients with asthma. It is likely that genetic factors will influence the extent of remodelling that occurs in individual patients. 6. Transcription Factors The chronic inflammation of asthma is due to increased expression of multiple inflammatory proteins (cytokines, enzymes, receptors, adhesion molecules). In many cases these inflammatory proteins are induced by transcription factors, DNA binding factors that increase the transcription of selected target genes. Several transcription factors, including NFKB, AP-1 and signal transduction activated transcription factors (STATs), are activated by inflammatory stimuli and switch on panels of pro-inflammatory genes [11]. NF-KB may play a critical role in asthma is, as it can be activated by multiple stimuli that exacerbate asthmatic inflammation, including oxidants, proinflammatory cytokines, allergen and rhinovirus infection. There is evidence for increased activation of NF-KB in asthmatic airways, particularly in epithelial cells and macrophages. NF-KB regulates the expression of several key genes that are over-expressed in asthmatic airways, including proinflammatory cytokines (IL-lp, TNF-a, GM-CSF), chemokines (RANTES, MlP-la, eotaxin), adhesion molecules (ICAM-1, VCAM-1) and inflammatory enzymes (cyclo-oxygenase-2 and iNOS). The c-Fos component of AP-1 is also activated in asthmatic airways and often co-operates with NF-KB in switching on inflammatory genes. 7. Anti-inflammatory Mechanisms in Asthma Although most emphasis has been placed on inflammatory mechanisms, there may be important anti-inflammatory mechanisms that may be defective in asthma, resulting increased inflammatory responses in the airways [12]. Various cytokines have anti-inflammatory actions. IL-1 receptor antagonist (IL-lra) inhibits the binding of IL-1 to its receptors and therefore has a potential anti-inflammatory potential in asthma. It is reported to be effective in an animal model of asthma. IL-12 and interferon-y (IFN-y) enhance Thl cells and inhibit Th2 cells and there is some evidence that IL-12 expression may be impaired in asthma. IL-10, which was originally described as cytokine synthesis inhibitory factor, inhibits the expression of multiple inflammatory cytokines (TNF-a, IL-lp, GM-CSF, IL-5), chemokines (eotaxin), and inflammatory enzymes (iNOS, COX-2) and also inhibits antigen presentation. There is
142
P.J. Barnes / Biology Of Asthma
evidence that IL-10 secretion and gene transcript are defective in macrophages and monocytes form asthmatic patients; this may lead to enhancement of inflammatory effects in asthma and may be a determinant of asthma severity. References 1. Busse WW, Lemanske RF. Asthma. N.EngU.Med. 2001; 344: 350-62. 2. Barnes PJ. Therapeutic strategies for allergic diseases. Nature 1999; 402: B31-B38 3. Humbert M, Menz G, Ying S, et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999; 20: 528-33. 4. Barnes PJ. Anti-IgE therapy in asthma: rationale and therapeutic potential. Int Arch Allergy Immunol 2000;123: 196-204. 5. Leckie MJ, ten Brincke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response. Lancet 2000; 356: 2144-8. 6. Holt PG, Sly PD. Prevention of adult asthma by early intervention during childhood: potential value of new generation immunomodulatory drugs. Thorax 2000; 55: 700-3. 7. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998; 50: 515-96. 8. Chung KF, Barnes PJ. Cytokines in asthma. Thorax 1999; 54: 825-57. 9. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1693-772. 10. Carr MJ, Hunter DD, Undem BJ. Neurotrophins and asthma. Curr Opin Pulm A/ec/2001; 7: 1-7. 11. Barnes PJ, Adcock IM. Transcription factors and asthma. Eur Respir J 1998; 12: 221-34. 12. Barnes PJ. Endogenous inhibitory mechanisms in asthma. Am J Respir Crit Care Med 2000; 161: S176S181
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
143
Transcriptional Regulation of Airway Inflammation Serpil C. ERZURUM Pulmonary and Critical Care Medicine Cancer Biology Lerner Research Institute Cleveland Clinic Foundation Cleveland Ohio 44195 U.S.A. Abstract. Airway inflammation occurs in response to numerous mediators/cytokines or infectious agents. Increased expression of inducible nitric oxide synthase (iNOS, or NOS2) occurs in association with the airway inflammation of asthma and/or viral infections. Signal transduction to NOS2 in the human airway epithelium occurs through various signaling pathways including signal transducers and activators of transcription 1 (STAT1) and double-stranded RNA dependent protein kinase (PKR). Airway inflammatory signal transduction pathways will be reviewed in the context of NOS2 gene activation.
1. Airway Inflammation Airway inflammation is a defining characteristic of asthma. In recognition of this, recent guidelines for asthma care advocate therapies targeted to decrease inflammation, such as inhaled corticosteroids [1]. Numerous mediators and cytokines contribute to the development and maintenance of inflammation in the asthmatic airway. Asthmatic inflammation has traditionally been associated with Th2 lymphocyte cytokines, such as IL-4. However, interferon gamma (IFNy)(a Thl cytokine) is increasingly implicated in the pathobiology leading to airway inflammation and hyperreactivity in asthma [2 - 5]. For example, animal models of ovalbumin sensitized mice develop airway hyperresponsiveness dependent upon IFNy [2]. Bronchoalveolar cell cultures derived from individuals with asthma spontaneously release increased amounts of IFNy. [3]. Further, adoptive transfer of Thl lymphocytes, which characteristically produce IFNy, increase airway inflammation [5]. Nitric oxides synthase 2 (NOS2) expression is critically dependent upon exposure of cells to IFNy, and may be one mechanism through which it contributes to airway inflammation. Viruses also lead to airway inflammation and are a major cause of asthma exacerbation. Nitric oxide synthase 2 (NOS2) is induced in airway epithelium by common respiratory viruses, including influenza, parainfluenza and respiratory syncytial virus. NOS2 induction occurs in the course of viral infection in part due to IFNy, but
144
S.C. Erzurum / Transcriptional Regulation of Airway Inflammation
early in infection gene expression may be induced by the viral replicative intermediate double-stranded RNA (dsRNA) through the dsRNA-activated protein kinase (PKR) [6]. In support of this, NOS2 gene expression in human airway epithelial cells occurs in response to influenza A vims or synthetic dsRNA in vitro. Specifically, dsRNA leads to rapid activation of PKR, followed by activation of signaling components including nuclear factor kappa B (NF-DB) and interferon regulatory factor 1 (IRF-1). Moreover, examination of the transcriptional events leading to NOS2 in the airway are reviewed to reveal how viruses and cytokines lead to airway inflammation.
2. Viral mechanisms of signal transduction to airway inflammation Influenza virus infection causes significant morbidity and mortality in human populations worldwide with a broad spectrum of clinical responses ranging from asymptomatic infection, rhinitis to viral pneumonia [7]. Although factors dictating the severity of virus disease are complex, interaction between inherent viral properties and host cellular response ultimately determines disease outcome [7 - 9]. The first site of viral contact with the host, and main target of infection and inflammation is the airway mucosal epithelium. Epithelial cells at the airway mucosal surface have a variety of inflammatory and immune defense mechanisms to deal with virus, including expression of cytokines with chemoattractant and proinflammatory functions [10 - 13], e.g. NOS2 [12, 14]. Nitric oxide (NO) produced by NOS2 has potent antiviral activity against a number of viruses [15 - 19]. However, NO also contributes to inflammation and injury through formation of toxic reactive nitrogen intermediates [12, 14, 20]. In this context, development of pneumonia in a murine model of influenza infection has been linked to hostNOS2 expression [14, 21]. Viral mechanisms regulating NOS2 expression in human airway epithelial cells IFNy produced by lymphocytes in the airway mucosa, is likely involved in NOS2 induction later in the course of viral infection. However, NOS2 induction by virus early in infection is mediated by proteins responsive to the viral replicative intermediate, double-stranded RNA (dsRNA). Influenza viruses are enveloped viruses with a segmented, single-stranded RNA genome, which generate dsRNA during replication [7, 22]. Intracellular dsRNA formed during viral replication [22], binds to and activates a serine/threonine kinase, dsRNA-activated protein kinase (PKR), which has been implicated in signal transduction [23 - 25]. In this context, PKR is a component of the signaling pathway to NOS2 gene induction following viral infection of human airway epithelium. NOS2 gene expression in human airway epithelial cells occurs after influenza A virus or synthetic dsRNA exposure [6]. Importantly, dsRNA leads to activation of PKR, followed by activation of signal transduction proteins including NFDB and interferon regulatory factor 1 (IRF-1) in airway epithelial cells. A role for PKR in the signal transduction pathway of viral-induced NOS2 expression is conclusively demonstrated in experiments using cells genetically-deficient in PKR (PKR-/-) [6]. Impairment of NOS2 induction in response to LPS is also found in PKR-/-cells, confirming a central role for PKR in the general signaling pathway to NOS2.
S. C. Erzurum / Transcriptianal Regulation of A irway Inflammation
145
Signal transduction through PKR PKR is important for host antiviral mechanisms, as evidenced by impaired antiviral responses in mice with a homozygous targeted deletion in the PKR gene [24] First identified as a component of interferon-inducible cellular antiviral defenses, PKR exhibits two distinct kinase activities upon activation by dsRNA, autophosphorylation/activation and phosphorylation of substrates [26]. One antiviral effect mediated by PKR is the phosphorylation of eukaryotic initiation factor-2G, effectively restricting viral protein translation and subsequent replication [26]. In addition to effects on translation, PKR regulates transcriptional events by phosphorylation of proteins related to signal transduction pathways. For example, PKR is required for the activation of NF-DB in immortal cell lines in response to different stimuli [23]. NF-KB activation by dsRNA in human airway epithelial cells is most likelydue to PKR activation and phosphorylation of the inhibitor of NF-KB (1KB). Thus, PKR appears to mediate signal transduction in human airway epithelial cells in part through NF-KB. In addition, PKR may impact upon the signaling pathways through transcriptional and/or post-translational effects on the transcription factor interferon regulatory factor 1 (IRF-1) [27]. In fact, expression of IRF-1 protein in cells does not manifest functional DNA binding activity unless a phosphorylation signal is provided [28], potentially by PKR [29, 30]. In support of this concept, IRF-1 protein is induced and activated by dsRNA in human airway epithelial cells. PKR's role in signaling is essential for activation of NOS2, as assessed by experiments in murine embryo fibroblast cells (MEF) derived from mice with homozygous deletions for PKR. PKR contributed significantly to activation of signaling pathways, including NF-KB and IRF-1, which are important for pro-inflammatory gene expression such as NOS2 [27]. Interestingly, PKR is also essential for LPS-induction of NOS2 in murine cells, confirming a central role for PKR in microbial-induced signaling pathway to NOS2. On the other hand, continued NOS2 expression in PKR -/- cells exposed to a combination of IFNy and LPS or poly 1C, albeit at lower levels than in PKR+/+ cells, points out the possibility of inducible alternative signaling pathways to NOS2, which are independent of PKR [6]. Taken together, a model for regulation of NOS2 in the airway early in the course of viral infection is derived. Upon infection of human airway epithelial cells, the viral replicative intermediate dsRNA binds to and activates PKR, which leads to activation of NF-KB. dsRNA also induces de novo synthesis and activation of IRF-1 through PKR activation. IRF-1 in cooperation with other factor(s), such as NF-KB, leads to NOS2 gene induction. Soon, release of IFNy by activated lymphocytes in the virus-infected airway induces prolonged NOS2 gene expression in human airway epithelium. Increases in airway NOS2 expression early in viral infection may be antimicrobial and limit spread of virus. However, IFNy mediated high-level NOS2 expression that persists for days to weeks most likely contributes to airway inflammation and injury, and associated clinical respiratory symptoms.
146
S. C. Erzurum / Transcriptional Regulation of Airway Inflammation
3. Signal transduction in the asthmatic airways NOS2 protein is present in healthy airway epithelial cells but is clearly increased in asthmatic airways in vivo. Although translational and post-translational mechanisms are important in the regulation of NO synthesis, NOS2 is substantially regulated at the level of transcription [32 - 34]. As we and others have previously shown, healthy human airway epithelium in vivo expresses the NOS2 gene continuously at abundant mRNA levels [35, 36]. NOS2 mRNA expression in asthmatic airway epithelium is higher than controls in vivo, but not increased in asthmatics receiving inhaled corticosteroid. Inhaled corticosteroids are the most effective therapies for reducing inflammation in asthma. While the use of inhaled corticosteroids as a first-line treatment in asthma has increased, little is known regarding the cellular and molecular mechanisms that contribute to the efficacy of inhaled corticosteroids in vivo. Several studies have shown that inhaled or intravenous corticosteroids reduce exhaled NO [37 - 39]. In situ analysis of the asthmatic airway suggested that NOS2 expression is reduced by corticosteroids [40]. In general, mechanisms by which corticosteroids regulate NOS2 gene expression in vivo are not known. In vitro, glucocorticoids inhibit NOS2 expression at multiple levels including inhibition of gene transcription, reduction of mRNA translation and increased degradation of NOS2 protein [41 - 43]. Increased NOS2 mRNA in asthma, which is downregulated by corticosteroid, supports an association between NOS2 expression and airway inflammation. NOS2 expression is lost in airway epithelial cells upon removal from the airway environment, which substantiates a critical link between airway conditions and/or factors in vivo and NOS2 expression. Induction of NOS2 expression in vitro varies in different cell types, but typically is increased by cytokines [32 - 34, 44]. IFNy is crucial for induction of NOS2 expression in airway epithelial cells in vitro [44]. IFNy signaling to gene expression begins with a specific receptor interaction and oligomerization of receptor chains, causing a tyrosine kinase cascade. STAT1 phosphorylation, dimerization and translocation to the nucleus, is followed by binding to regulatory DNA elements to activate transcription of interferon-stimulated-genes [45, 46]. IFNy leads to STAT1 activation in primary human airway epithelial cells in culture [44, 47]. Recently. STAT1 activation has been demonstrated in the asthmatic airway by nuclear localization of STAT1 in airway epithelial cells, and demonstration of phosphorylation of STAT1 by western analyses of epithelial cell lysates [48]. The STAT1 activation correlated with induction of IFNy/STATl-stimulated-genes, including IRF-1 which has been identified as essential for NOS2 activation in murine macrophages [49]. STAT1 activation quantitated by electrophoretic mobility shift assays is present in controls but increased in asthmatic airway epithelial cell lysates. In contrast to increased STAT1 activation in the asthmatic airway, other cell signaling proteins are not increasingly activated. STAT6 and NFkB activation are not increased in mild asthmatic airway as compared to healthy controls. Previous study has shown that STAT3 and activator protein (AP)-l activation is also not increased in asthma [48]. STAT1 tyrosine phosphorylation and translocation to the nucleus occurs in response to many growth factors and cytokines including IFNy, IL10, IFNa/p, epidermal growth factor, platelet derived growth factor, granulocytemacrophage colony stimulating factor, IL-6, IL-11, leukemia inhibitory factor, ciliary
S. C. Erzurum / Transcriptional Regulation of A irway Inflammation
! 47
neurotrophic factor, Oncostatin M, growth hormone, prolactin, and colony stimulating factor-1 [45, 46]. However, IFNy is higher in asthmatic epithelial lining fluid than control following a segmental bronchoprovocation with antigen [50]. The large number of IFNy/STATl-stimulated-genes, including IRF-1, ICAM-1 and NOS2, are likely involved in the airway inflammatory events of asthma. Collectively, these data provide strong support for STAT1 activation mediating NOS2 gene expression in human airway epithelial cells in vivo. NFkB activation and binding to kB DNA elements in the 5' flanking region of the NOS2 gene plays a role in the cytokine induction of NOS2 in the human lung epithelial cell line A549 in vitro [32 - 34]. However, studies of NFkB activation in asthma are conflicting, perhaps in part due to the types of sample analyzed [48, 51]. Expectorated sputum from asthmatics or pooled biopsies of asthmatic airways have shown increased NFkB activation in comparison to controls [51], while no increase in activation is noted by nuclear localization of NFkB in biopsies and electrophoretic mobility shift assays of whole cell extracts from bronchial brushings of asthmatic airway epithelium [48, 50]. Nevertheless, low level NFkB activation is present in control and asthmatic epithelium, and may contribute to the tonic expression of NOS2 in the airway. In conclusion, multiple mechanisms function coordinately to support high level NO synthesis in the inflamed asthmatic airway. Human airway epithelium has abundant expression of NOS2 due to continuous transcriptional activation of the gene in vivo. Increased NOS2 gene expression in asthmatic airways is related to increased STAT1 activation caused by increased cytokines e.g., IFNy.
4. Signal transduction mechanisms of corticosteroid effect The broad anti-inflammatory and immunomodulatory effects of corticosteroids are effective in treatment of most asthma. The anti-inflammatory mechanisms of corticosteroids have been detailed at the molecular level. At the cellular level, glucocorticoids (GC) freely penetrate the cell plasma membrane and bind to a specific intracellular receptor, the glucocorticoid receptor (OCR). This binding dissociates heatshock proteins and creates an active GC-GCR complex. The GC-GCR complex translocates to the nucleus and binds to specific GCR-responsive elements (GRE) on genomic DNA that induce gene expression, e.g. beta-adrenergic receptors [52]. The GCGCR complex may also suppress gene expression by interfering with the interaction of transcription factor proteins AP-1 and NF-KB with promoter regions of pro-inflammatory cytokines [53]. While AP-1 directly interacts with the glucocorticoid receptor leading to interference of AP-1 -dependent transcription, glucocorticoids prevent NFKB activation by inducing the inhibitor of NFKB (1KB) [53]. Through these mechanisms, glucocorticoids inhibit the production of a wide range of cytokines involved in asthma, including IL-1, IL-3, IL-4, IL-5, IL-6, IL-13, granulocyte monocyte colony stimulating factor (GM-CSF), and tumor necrosis factor-alpha (TNF-a). IL-3, IL-5, and GM-CSF differentiate, activate, and proliferate eosinophils. IL-4 and IL-13 cause the antibody isotype switch to IgE production. IL-1 and TNF-a upregulate adhesion molecules. IL-4, IL-5, and IL-6 promote IgE production and T-helper lymphocyte response [54].
148
S.C. Erzurum / Transcriptional Regulation of Airway Inflammation
In addition to inhibiting cytokine production, glucocorticoids also inhibit production of inflammatory leukotrienes and eicosanoids through effects on phospholipase A2 [54]. In contrast, genes for anti-inflammatory or bronchodilatory products are increased by corticocorticosteroids such as beta receptors and lipocortin. Lipocortin, a protein that inhibits phospholipase AI, further dampens inflammation. Neutral endopeptidase, which is expressed on bronchial epithelial cells and enhances degradation of proinflammatory tachykinins, is also increased by corticosteroids [52]. 5. Conclusion Multiple signal transduction pathways are specifically and coordinately activated in the airway in response to inflammation or infection. Identification of the transcription factors activated, such as NF-kB or STAT1, reveal some of the underlying pathogenic mechanisms of inflammation, which may be targets for anti-inflammatory therapy in the future. References [1] Guidelines for the diagnosis and the management of asthma, Expert panel report II. Bethesda, Md.: National Asthma Education and Prevention Program, April 1997. (NIH publication no. 97-4051.) [2] E.M. Hessel, A.J.M. Van Oosterhout, I.V. Ark, B.V. Esch, G. Hofinan, et al. Development of airway hyperresponsiveness is dependent on interferon-y and independent of eosinophil infiltration. Am. J. Respir. Cell Mol. Biol. 16 (1997) 325. [3] M. Cembrzynska-Nowak, E. Szklarz, A.D. Inglot, and J.A. Teodorczyk-Injeyan. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am. Rev. Respir. Dis. 147 (1993) 291. [4] X.M. Li, R.K. Chopra, T.Y. Chou, B.H. Schofield, M. Wills-Karp, et al. Mucosal IFN-y gene transfer inhibits pulmonary allergic responses in mice. J. Immunol. 157 (1996) 3216. [5] G. Hansen, G. Berry, R.H. DeKruyff, and D.T. Umetsu. Allergen-specific Thl cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J. Clin Invest. 103(1998) 175. [6] K. Uetani, S.D. Der, M. Zamanian-Daryoush, C. de la Motte, B. Lieberman, B.R.G. Williams, and S.C. Erzurum. Central Role of double-stranded RNA-Activated Protein Kinase in Microbial Induction ofNitric Oxide Synthase. J Immunol 165 (2000) 988. [7] R.B. Murphy, and R.G. Webster. 1996. Orthomyxoviruses. In Fields Virology, Vol. 1. B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, T. P. Monath, J. L. Melnick, B. Roizman, and S. E. Straus, eds. Lippincott-Raven Publishers, Philadelphia, PA, p. 1397. [8] A. Garcia-Sastre, R.K. Durbin, H. Zheng, P. Palese, R. Gertner, D. E. Levy, and J. E. Durbin.. The role of interferon in influenza virus tissue tropism. J. Virol. 72 (1998) 8550. [9] M. F. Kagnoff, and L. Eckmann.. Epithelial cells as sensors for microbial infection. J. Clin. Invest. 100 (1997)6. [10]S. Matsukura, F. Kokubu, H. Noda, H. Tokunaga, and M. Adachi. Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A. J Allergy. Clin. Immunol. 98 (1996) 1080. [11]Z. Zhu, W. Tang, A. Ray, Y. Wu, O. Einarsson, M. L. Landry, J. Gwaltney, Jr., and J. A. Elias. Rhinovirus stimulation of interleukin-6 in vivo and in vitro. Evidence for nuclear factor kappa Bdependent transcriptional activation. J. Clin. Invest. 97 (1996) 421. [12]K. Tanaka, H. Nakazawa, K. Okada, K. Umezawa, N. Fukuyama, and Y. Koga. Nitric oxide mediates murine cytomegalovirus-associated pneumonitis in lungs that are free of the virus. J. Clin. Invest. 100 (1997) 1822.
5. C. Enurum / Transcriptional Regulation of Airway Inflammation
149
[13] F. G. Hayden, R. Fritz, M. C. Lobo, W. Alvord, W. Strober, and S. E. Straus. Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense. J. Clin. Invest. 101 (1998) 643. [14]T. Akaike, Y. Noguchi, S. Ijiri, K. Setoguchi, M. Suga, Y.M. Zheng, B. Dietzschold, and H. Maeda. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. USA. 93 (1996) 2448. [15] G. Karapiah, Q. W. Xie, R. M. Buller, C. Nathan, C. Duarte, and J. D. MacMicking. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science. 261 (1993) 1445. [16] K. D. Croen. Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J. Clin. Invest. 91 (1993)2446. [17]J. B. Mannick, K. Asano, K. Izumi, E. Kieff, and J. S. Stamler. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell. 79 (1994) 1137. [18]C. Zaragoza, C. J. Ocampo, M. Saura, A. McMillan, and C. J. Lowenstein. Nitric oxide inhibition of coxsackievirus replication in vitro. J. Clin. Invest. 100 (1997) 1760. [19]F. C. Fang. Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. 99 (1997) 2818. [20]H. Adler, J. L. Beland, N. C. Del-Pan, L. Kobzik, J. P. Brewer, T. R. Martin, and I. J. Rimm. Suppression of herpes simplex virus type 1 (HSV-1)-induced pneumonia in mice by inhibition of inducible nitric oxide synthase (iNOS, NOS2). J. Exp. Med 185 (1997) 1533. [21]G. Karupiah, J. H. Chen, S. Mahalingam, C. F. Nathan, and J. D. MacMicking. Rapid interferon gamma-dependent clearance of influenza A virus and protection from consolidating pneumonitis in nitric oxide synthase 2- deficient mice. J. Exp. Med. 188 (1998) 1541. [22] Jacobs, B. L., and J. O. Langland. When two strands are better than one: the mediators and modulators of the cellular responses to double-stranded RNA. Virology. 219 (1996) 339. [23] A. Kumar, J. Haque, J. Lacoste, J. Hiscott, and B. R. Williams. Double-stranded RNA-dependent protein kinase activates transcription factor NF-kappa B by phosphorylating I kappa B. Proc. Natl. Acad. Sci. USA. 91 (1994) 6288. [24] Y. L. Yang, L. F. Reis, J. Pavlovic, A. Aguzzi, R. Schafer, A. Kumar, B. R. Williams, M. Aguet, and C. Weissmann. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO.J. 14(1995)6095. [25] M. Zamanian-Daryoush, S. D. Der, and B. R. Williams. Cell cycle regulation of the double stranded RNA activated protein kinase, PKR. Oncogene. 18 (1999) 315. [26] E. Meurs, K. Chong, J. Galabru, N. S. Thomas, I. M. Kerr, B. R. Williams, and A. G. Hovanessian. Molecular cloning and characterization of the human double-stranded RNA- activated protein kinase induced by interferon. Cell. 62 (1990) 379. [27] A. Kumar, Y. L. Yang, V. Flati, S. Der, S. Kadereit, A. Deb, J. Haque, L. Reis, C. Weissmann, and B R. Williams. Deficient cytokine signaling in mouse embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and NF-kappaB. EMBO J. 16 (1997) 406. [28] H. Harada, T. Fujita, M. Miyamoto, Y. Kimura, M. Maruyama, A. Furia, T. Miyata, and T. Taniguchi. Structurally similar but functionally distinct factors, IRF-1 and IRF- 2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell. 58 (1989) 729. [29]N. Watanabe, J. Sakakibara, A. G. Hovanessian, T. Taniguchi, and T. Fujita. Activation of IFN-beta element by IRF-1 requires a posttranslational event in addition to IRF-1 synthesis. Nucleic. Acids. Rex. 19(1991)4421. [30] S. Kirchhoff, A. E. Koromilas, F. Schaper, M. Grashoff, N. Sonenberg, and H. Hauser. IRF-1 induced cell growth inhibition and interferon induction requires the activity of the protein kinase PKR. Oncogene. 11(1995)439. [31]S. D. Der, Y. L. Yang, C. Weissmann, and B. R. Williams. A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc. Natl. Acad. Sci. USA. 94 (1997) 3279. [32] J. Marks-Konczalik, S. C. Chu, and J. Moss. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein I and nuclear factor kB-binding sites. J. Biol. Chem. 273 (1998) 22201. [33] B. S. Taylor, M. E. de Vera, R. W. Ganster, Q. Wang, R. A. Shapiro, et al. Multiple NF-kB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J. Biol. Chem. 273(1998) 15148.
150
S. C. Erzurum / Transcriptional Regulation of Airway Inflammation
[34] M. E. de Vera, R. A. Shapiro, A. K. Nussler, J. S. Mudgett, R. L. Simmons, et al. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: Initial analysis of the human NOS2 promoter. Proc. Natl. Acad. Sci. USA. 93 (1996) 1054. [35] F. H. Guo, H. R. De Raeve, T. W. Rice, D. J. Stuehr, F. B. J. M. Thunnissen, and S. C. Erzurum. Continuous nitic oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc. Natl. Acad. Sci. USA. 92 (1995) 7809. [36] L. Kobzik, D. S. Bredt, C. J. Lowenstein, J. Drazen, B. Gaston, et al. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am. J. Respir. Cell Mol. Biol 9 (1993)371. [37] A. F. Massaro, B. Gaston, D. Kita, C. Fanta, J. S. Stamler, and F. M. Drazen. Expired nitric oxide levels during treatment of acute asthma. Am. J. Respir. Crit. Care. Med. 152 (1995) 800 [38] S. A. Kharitonov, D. H.Yates, and P. J. Barnes. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am. J. Respir. Crit. Care. Med. 153 (1996) 454. [39] P. E. S. Silkoff, P. A.. McClean, A. S. Slutsky, M. Caramori, K. R. Chapman, C. Gutierrez, and N. Zamel. Exhaled nitric oxide and bronchial reactivity during and after inhaled beclomethasone in mild asthma. J. Asthma. 35 (1998) 473. [40] D. Saleh, P. Ernst, S. Lim, P. J. Barnes, and A. Giaid . Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid. FASEBJ. 12 (1998) 929. [41] D. A. Geller, A. K. Nussler, M. D. Silvio, C. J. Lowenstein, R. A. Shapiro, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl. Acad. Sci. USA. 90 (1993) 522. [42] M.W. Radomski, R. M. J. Palmer, and S. Moncada. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl. Acad. Sci. USA. 87(1990) 10043. [43] D. Kunz, G. Walker, W. Eberhardt, and J. Pfeilschifter. Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expression in interleukin I (^-stimulated mesangial cells: Evidence for the involvement of transcriptional and posttranscriptional regulation. Proc. Natl. Acad. Sci USA. 1996.93(1996)255. [44] F. H. Guo, K. Uetani, S. J. Haque, B. R. G. Williams, R. A. Dweik, F. B. J. M. Thunnissen, W. Calhoun, and S. C. Erzurum. Interferon y and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J. Clin. Invest. 100(1997)829. [45] S. J. Haque, and B. R. G. Williams. Signal transduction in the interferon system. Semin. Oncol. 25 (1998)14. [46] C. S. Hill, and R. Treisman. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell. 80 (1995) 199. [47] D. C. Look, M. R. Pelletier, and M. J. Holtzman. Selective interaction of a subset of interferon-g response element-binding proteins with the intercellualr adhesion molecule-1 (1CAM-1) gene promoter controls the pattern of expression on epithelial cells. Proc. Natl. Acad. Sci. USA. 269 (1994) 8952. [48] D. Sampath, M. Castro, D. C. Look, and M. J. Holtzman Constitutive activation of an epithelial-signal transducer and activation of transcription (STAT) pathway in asthma. J. Clin. Invest. 103 (1999) 1353. [49] R. Kamijo, H. Harada, T. Matsuyama, M. Bosland, J. Gerecitano, et al. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263 (1994) 1612. [50] F.H. Guo, S.A.A. Comhair, S. Zheng, R.A. Dweik, N.T. Eissa, M.J. Thomassen, W. Calhoun, and S.C. Erzurum. Molecular Mechanisms of Increased Nitric Oxide (NO) in Asthma: Evidence for Transcriptional and Post-translational Regulation of NO Synthesis. J Immunol 164 (2000) 5970. [51] L. A. Hart, V. L. Krishnan, I. M. Adcock, P. J. Barnes, and K. F. Chung. Activation and localization of transcription factor, nuclear factor-kB, in asthma. Am. J. Respir. Crit. Care Med. 158 (1998) 1585. [52] D.Y. Leung, and S.J. Szefler. New insights into steroid resistant asthma. Pediatr Allergy' and Immunol9(]99Z)3. [53] S.J. Lane, and T.H. Lee. Mechanism of corticosteroid resistance in asthmatic patients. Int Arch Allergy Immunol 113 (1997) 193. [54] J.D. Spahn, D.Y.M. Leung, S.J. Szefler. New insights into the pathogenesis and management of steroid-resistant asthma. J Asthma 34 (1997) 177.
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) 1OS Press, 2002
151
Molecular Mechanisms of Steroid Actions Ian M. ADCOCK and Kazuhiro ITO Thoracic Medicine, National Heart & Lung Institute, Imperial College of Science, Technology and Medicine, Dovehouse Street, London SW3 6LY Abstract. Steroids are the most effective treatment for chronic inflammatory diseases such as asthma. They act through binding to a cytosolic receptor (GR) which undergoes nuclear trans location. Within the nucleus, GR represses inflammatory gene induction by inhibiting the action of pro-inflammatory DMA binding proteins (transcription factors) such as AP-1 and NF-tcB. This occurs through alterations in the chromatin structure associated with changes in the histone acetylation status. This effect can be demonstrated both at the whole cell level but more importantly at specific promoters and is associated with specific gene induction. Under conditions of oxidative and nitrosyl stress GR function is impaired possibly as a result of nitrosylation and/or phosphorylation of GR-associated proteins.
1. Introduction Inflammation is a central feature of many lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The specific characteristics of the inflammatory response and the site of inflammation differ between these diseases, but all involve the recruitment and activation of inflammatory cells and changes in the structural cells of the lung. These diseases are characterised by an increased expression of many proteins involved in the complex inflammatory cascade. These inflammatory proteins include cytokines, chemokines, growth factors, enzymes, receptors and adhesion molecules. The increased expression of most of these proteins is the result of enhanced gene transcription since many of the genes are not expressed in normal cells under resting conditions but are induced in a cell-specific manner.
2. Over-expression of mediators Using in-situ hybridisation and immunohistochemistry increased gene expression of cytokines, chemokines, receptors and adhesion molecules have been reported [Ijand references therein). Included amongst these induced mediators are the Th2 cytokines interleukin (IL-)5 and GM-CSF [1]. IL-5 and GM-CSF are important cytokines involved in eosinophil survival with GM-CSF appearing to be the most important contributor, and is predominantly expressed in airway epithelium and macrophages [2]. IL-5 and GM-CSF can prime eosinophils such as to increase the release of granule-associated proteins such as eosinophil cationic protein (ECP) from stimulated eosinophils [2]. GM-CSF can also enhance the production of leukotrienes from eosinophils [2].
152
IM. Adcock and K. Ito /Molecular Mechanisms of Steroid Actions
3. Transcription Factors Changes in gene transcription are regulated by transcription factors. Transcription factors are proteins that bind to DNA-regulatory sequences (enhancers and silencers), usually localised in the 5' upstream region of target genes, to increase (or sometimes decrease) the rate of gene transcription. This may result in increased or decreased protein synthesis and subsequent altered cellular function. Many transcription factors are common to several cell types (ubiquitous) and may play a general role in the regulation of inflammatory genes, whereas others are cell specific and may determine the phenotypic characteristics of a cell [3]. Transcription factor activation is complex and may involve multiple intracellular signal transduction pathways, including kinases (such as tyrosine kinases of the mitogen activated protein kinases (MAPKs) and Janus kinases (JAKs) families) and the protein kinase C family (PKCs), stimulated by cell-surface receptors. Activation of MAPK pathways by inflammatory stimuli leads to activation of a number of ubiquitous transcription factors such C/EBPP, Elk-1, c-Fos, c-Jun, c-Myc, NF-KB and STATs. Transcription factors may therefore convert transient environmental signals at the cell surface into long-term changes in gene transcription, thus acting as "nuclear messengers". 3.1 NF-KB Activation of NF-KB leads to the co-ordinated induction of multiple genes that are expressed in inflammatory and immune responses. Many of these genes are induced in inflammatory and structural cells and play an important role in the inflammatory process [4]. While NF-KB is not the only transcription factor involved in regulation of the expression of these genes it often appears to have a decisive regulatory role [4]. NF-KB often functions in co-operation with other transcription factors, such as AP-1 and C/EBPp, which are also involved in regulation of inflammatory and immune genes. NF-KB is activated by many of the stimuli that exacerbate asthmatic inflammation (e.g rhinovirus infection, allergen exposure proinflammatory cytokines, oxidants)[5]. There is also evidence for activation of NF-KB in the bronchial epithelial cells of patients with asthma [6]. The role of NF-KB should be seen as an amplifying and perpetuating mechanism that will exaggerate the disease-specific inflammatory process through the co-ordinated activation of multiple inflammatory genes. One of the most important concepts to have emerged is the demonstration that maximal transcription factor activation is associated with co-incident activation of several intracellular pathways and other transcription factors. This may explain how transcription factors that are ubiquitous may regulate particular genes in certain types of cells. The complexity of the activation pathways and their ability to engage in cross-talk enables cells to overcome inhibition of one pathway and retain a capacity to activate specific transcription factors. 3.2 Histone acetylation Binding of transcription factors to their specific binding motifs in the promoter region may alter transcription by interacting directly with components of the basal transcription apparatus or via co-factors that link the specific transcription factor to the basal transcription apparatus [7]. Large proteins that bind to the basal transcription apparatus may bind many transcription factors and thus act as integrators of gene transcription. These co-activator
I.M. Adcock and K. ho / Molecular Mechanisms of Steroid Actions
153
molecules include CREB-binding protein (CBP), and the related p300, thus allowing complex interactions between different signalling pathways. DNA is wound around histone proteins to form nucleosomes and the chromatin fibre in chromosomes [7]. It has long been recognised at a microscopic level that chromatin may become dense or opaque due to the winding or unwinding of DNA around the histone core [8]. CBP and p300 have histone acetylase activity (HAT) which is activated by the binding of transcription factors, such as AP-1, NF-icB and STATs. The central role of CBP and associated proteins in controlling the inflammatory response may explain synergy between transcription factors such as NFKB and AP-1. Numerous pro-inflammatory transcription factors interact with, and activate, CBP-associated HAT activity including CREB, AP-1, NF-KB, SV40 promoter-1 (Spl), E26 (Ets), nuclear factor of activated T-cells (NF-AT) and STATs [9] (Figure 1).
Figure 1. The co-activator molecule CBP integrates transcription factor activity and regulates histone acetylation. Stimulation of intracellular signalling pathways (JNKs, JAKs and IKK) activates transcription factors (CREB, c-Jun, STATs and NF-icB). These can bind to CBP, singly or in combinations, to enhance CBPassociated histone acetylase (HAT) activity leading to histone acetylation (Ac") within the inflammatory gene promoter, chromatin modification, loosening of the nucleosome structure and recruitment of RNA polymerase II (RNA pol II) and enhanced inflammatory gene transcription.
Acetylation of histone residues results in unwinding of DNA coiled around the histone core, thus opening up the chromatin structure, which allows other transcription factors, accesory molecules (e.g. TAFs) and RNA polymerase II to bind more readily, thereby increasing transcription [7]. Acetylation is an active process that is held in balance by the action of histone deacetylases (HDACs). Deacetylation of histone, increases the winding of DNA round histone residues, resulting in dense chromatin structure and reduced access of transcription factors to their binding sites, thereby leading to repressed transcription of genes [7]. We have recently shown that IL-lp stimulates histone acetyltransferase activity in a time- and concentration-dependent manner [10]. This acetylation occurs predominantly on histone H4 rather than other histones H2A, H2B or H3. Histone H4 has four potential aceylation sites, lysine residues 5, 8, 12 and 16. IL-lp-activated NF-KB induces acetylation on K8 and K12 only [10]. These changes do not occur across the genome but are targeted to the promoter sites of inflammatory genes transcription factors such as NF-KB. Thus we have recently shown that IL-lp-activated NF-KB is directed to the GM-CSF promoter where histone acetylation on lysines 8 and 12, but not lysine 5, occur [10].
154
I.M. Adcock and K. Ito / Molecular Mechanisms of Steroid Actions
4. Repression of Inflammatory Gene expression by Glucocorticoids Glucocorticoids are the most effective therapy in the long-term control of asthma and appear to reduce inflammation in asthmatic airways largely by inhibiting abnormal gene expression [9]. Although it is not yet possible to be certain of the most critical aspects of glucocorticoid action in suppressing inflammation, it is likely that their inhibitory effects on cytokine synthesis are particularly important. Glucocorticoids inhibit the transcription of several cytokines and chemokines that are relevant in inflammatory lung diseases, including IL-lp, TNFa, GM-CSF, IL-4, IL-5, IL-8 and eotaxin [9] Glucocorticoids may not only block the synthesis of cytokines, but may also block their effects by inhibiting the synthesis of cytokine receptors, such as the IL-2 receptor [9] (Table 1). Glucocorticoids markedly reduce the survival of eosinophils and T-lymphocytes. Eosinophil survival is dependent upon the cytokines GM-CSF and IL-5 whose actions are blocked by glucocorticoids leading to programmed cell death or apoptosis [9]. Glucocorticoids also promote T-cell apoptosis although the mechanism of action is unclear it is thought to involve gene induction [9], Increased gene transcription Lipocortin-1 (annexin-1) p2-adrenoceptor Secretory Leucocyte Inhibitory Protein IL-RII Decreased gene transcription Cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8. IL-11, IL-13, TNfiz, GM-CSF Chemokines RANTES, Eotaxin, NHP1a.MCP-1, MCP-3 Enzymes iNOS, COX-2, cPLA, Adhesion Molecules ICAM-1.VCAM-1 Receptors IL-2R, NK,R
Table 1. Target genes for glucocorticoid action.
4.1 The glucocorticoid receptor Glucocorticoids exert their effects by binding to a single cytoplasmic receptor (GR) [11]. The inactive GR is bound to a protein complex that includes two subunits of the heat shock protein hsp90 which thus act as molecular chaperones preventing the nuclear localisation of unoccupied GR [11]. Once the ligand binds to GR, hsp90 dissociates allowing the nuclear localisation of the activated GR-steroid complex and its binding to specific DNA sequences (GREs, GGTACAnnnTGTTCT) or interaction with co-activator complexes [11]. 4.2 Induction of gene transcription Binding of the GR homodimer to GREs changes the rate of transcription, resulting in either induction of steroid-responsive genes. An increased number of GREs and proximity to the TATA box increases the inducibility of a gene [11]. Other transcription factors binding in the vicinity of GRE may also have a powerful influence on steroid inducibility and the relative abundance of different transcription factors may contribute to the responsiveness of a particular cell type. GR-DNA interactions changes DNAsel sensitivity, indicating that there may be a local change in DNA or chromatin configuration, which may expose previously masked areas, resulting in increased binding of other transcription factors and the formation of a more stable transcription initiation complex [11]. Recent data has
I.M. Adcock and K. Ito /Molecular Mechanisms of Steroid Actions
155
suggested that GR interactions with DNA are very dynamic such that once a GR molecule binds to DNA, it quickly dissociates and allows another to replace it. Thus although the DNA footprint will be present it is a result of many distinct GR proteins binding to the specific ORE [12]. Glucocorticoids also increase the synthesis of anti-inflammatory proteins, including lipocortin-1, serum leukoprotease inhibitor, Clara Cell protein 10 (CC-10) and IL-1 receptor antagonist (IL-lra) and these effects are presumably mediated via GREs in the promoter regions of these genes [9]. Glucocorticosteroids have also been reported to increase the expression of iKB-a in lymphocytes and thus to inhibit NF-KB, but this has not been seen in other cell types [9]. GRs, as with other transcription factors increase gene transcription through an action on chromatin remodelling and recruitment of RNA polymerase II to the site of local DNA unwinding as described above for pro-inflammatory transcription factors. GR interacts with CBP and other coactivator proteins, including steroid receptor coactivator-1 (SRC-1), transcription factor intermediary factor-2 (TIF2), p300/CBP co-integrator-associated protein (p/CIP) or glucocorticoid receptor interacting protein-1 (GRIP-1) which enhance local HAT activity [7]. High concentrations of dexamethasone (>10~8M) in A549 cells results in binding of activated GR to CBP and/or associated co-activators resulting in histone acetylation on ly sines 5 and 16 of histone H4 and increased gene transcription [10]. 5. Cross-talk between GR and other Transcription Factors In spite of the ability of glucocorticosteroids to induce gene transcription, the major antiinflammatory effects of glucocorticosteroids are through repression of inflammatory and immune genes. The inhibitory effect of glucocorticosteroids appears to be due largely to a protein-protein interaction between activated GR and transcription factors, such as AP-1 and NF-KB [13]. Direct protein-protein interactions have been demonstrated between GR and AP-1 and between GR and the p65 component of NF-KB [13],
Figure 2. Glucocorticoid receptor inhibition of NF-icB-induced histone acetylation. NF-KB (p65/p50 dimer) activates histone acetylation (HAT activity) at the NF-icB responsive site in inflammatory gene promoters. Activated glucocorticoid receptors (GR) inhibit NF-icB-activated HAT activity by a combination of direct inhibition of HAT activity and by recruitment of histone deacerylase (HDAC2) to the NFicB/HAT complex.
156
/. M. Adcock and K. ho / Molecular Mechanisms of Steroid Actions
The interplay between pro-inflammatory transcription factors and GR may reflect differing effects on histone acetylation/deacetylation. This may occur through one of several mechanisms that are probably not exclusive. The repressive action of glucocorticosteroids may be due to competition between GR and the binding sites on CBP for other transcription factors, including AP-1, NF-KB and STATs. Alternatively, activated GR may bind to one of several transcription co-repressor molecules, such as HDACs, RIP 140 NCoRl and GRIP1, which associate with proteins that have differing histone deacetylase activity [14]. Thus, IL-lp and TNFa can cause histone acetylation on lysines 8 and 12 of histone H4 and low concentrations of dexamethasone (>10~9 M) can represses this IL-lp-stimulated histone acetylation. This occurs partly by a direct inhibition of NF-icBassociated HAT activity and partly by active recruitment of HDAC proteins to the NF-icBactivated transcriptional complex [10]. In addition, high concentrations of dexamethasone can induce HDAC expression over longer time periods [10]. Overall, this results in the deacetylation of histones at the site of inflammatory gene transcription, increased tightening of DNA round histone residues and reduced access of transcription factors such as AP-1 and NF-KB to their binding sites and of RNA polymerase II to the activation complex. This results in repression of inflammatory genes [10] (Figure 2). Other models propose that GR interferes with p65 association with the TATA box environment thus inhibiting p65 actions [15] Recent data has suggested another mechanism for GR action. Serine phosphorylation of RNA polymerase II induced by NF-icB activity at the IL-8 promoter is reduced by GR without affecting the assembly of the pre-initiation complex. This suggests a downstream action for GR/p65 interactions [16]. 6. Failure to respond to glucocorticoids A small proportion of asthmatic patients are glucocorticoid-resistant and fail to respond to even high doses of oral steroids [17]. This impaired response appears to be specific to monocytes and T-lymphocytes. This resistance is seen at the site of inflammation where cytokines are produced - i.e. in the airways of asthmatic patients, but not at non-inflamed sites. GR function may be regulated by several factors acting on different components of the GR pathway including nuclear translocation and interaction with, or recruitment of. transcription complexes. Steroid-insensitive asthmatic subjects have a reduced number of activated GR (GRE binding) within the nucleus of mononuclear cells compared to controls after glucocorticoid treatment in vitro [18]. This suggests a reduction in GR nuclear translocation or modification of the GR DNA binding complex occurs. In a majority of asthmatic subjects there is a direct correlation between the GR nuclear translocation and induction of histone acetylation. In most severe steroid-dependent and -resistant asthmatics there is reduced nuclear translocation implying a specific defect in GR dissociation from the hsp90 chaperonine complex or passage through the nuclear membrane. As GR does not appear to redistribute into the nuclear membrane dissociation from the hsp90 complex is the more likely explanation. A similar effect has been reported in COS? and CHO cells by Okamoto and colleagues [19]. Here, oxidative stress (lOOuM HiO2) reduced GR nuclear transport. Nitrosyl stress induced by the NO donor S-nitroso-DL-penicillamine has also been shown to prevent GR dissociation from the hsp90 complex and a reduction in ligand binding [20]. Other potential causes of reduced GR function involve nuclear events. Since HDACs are important in GR function we have investigated HDAC expression and activity in the presence of oxidative stress. HDAC activity is decreased in BAL macrophages and biopsies of smokers and patients with COPD and this correlates with increased inflammatory gene
I.M. Adcock and K. Ito / Molecular Mechanisms of Steroid Actions
157
expression and reduced steroid-responsiveness [21]. This effect can also be mimicked by pre-treatment of U937 cells with I^hOi (lOOuM) and parallels the effects seen with the HDAC inhibitor trichostatin A [21]. This suggests that oxidative stress by repression of HDAC activity can modulate GR function in BAL macrophages and U937 cells. In order to examine the mechanism for this effect we investigated the action of H2O2 and SIN-1, an NO donor, on HDAC2 phosphorylation and nitration status and activity. H2O2 did not affect IL-1B stimulated NF-KB nuclear translocation but enhanced the ability of DNA bound NF-KB to cause histone acetylation. This suggests either activation of a specific HAT has occurred or repression of an HDAC activity. We have preliminary evidence to suggest that HiO2 induced tyrosine nitration of HDAC2 and that this is associated with a loss of HDAC2 enzymic activity [22]. Therefore, tyrosine nitration can modulate HDAC2 activity and thereby enhance inflammatory gene transcription. Furthermore, this will result in reduced steroid sensitivity as HDAC2 recruited to the NF-KB activation complex will also have reduced activity.
Figure 3. Pro-inflammatory cytokine production is induced by inflammatory stimuli following activation of kinase cascades. These same cascades act in a negative feedback manner to switch off cytokine mRNA production after an initial burst of production. This is due, at least in part, to phosphorylation of tyrosine residues in histone deacetylases (HDAC) increasing their activity and thus inducing a silenced chromatin structure. Oxidative stress overcomes this feedback activity of HDAC activity by inducing nitration of distinct tyrosine residues and repressing HDAC activity. Similar effects may occur on GR itself to modify its actions in response to oxidative stress.
In summary, histone acetylation is important in the control of inflammatory gene transcription and recruitment of HDAC2 to the activated NF-KB complex by GR mediates at least 50% of dexamethasone-induced repression of these genes. Furthermore, phosphorylation and nitration can modify GR function either directly by targeting GR or indirectly by targeting GR-associated proteins such as HDACs. Whether these effects occur within the cytoplasm or the nucleus the net effect is a reduction in GR function.
158
/. M. Adcock and K. Ito / Molecular Mechanisms of Steroid Actions
Acknowledgements This work was funded by the British Lung Foundation, The Clinical Research Committee (Brompton Hospital) and GlaxoSmithKline (UK). References [1] Barnes, P.J., Chung, K.F., & Page, C.P. (1998) Inflammatory mediators of asthma: an update. Pharmacot Rev, 50, 515-596. [2] Giembycz, M.A. & Lindsay, M.A. (1999) Pharmacology of the eosinophil. Pharmacol. Rev., 51,213-340. [3] Barnes, P.J. & Adcock, I.M. (1998) Transcription factors and asthma. Ear Respir J, 12,221-234. [4] Baldwin, A.S., Jr. (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev. Immunol., 14,649-683. [5] Barnes, P.J. & Karin, M. (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med, 336, 1066-1071. [6] Hart, L.A., Krishnan, V.L., Adcock, I.M., Barnes, P.J., & Chung, K.F. (1998) Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am J Respir Crit Care Med, 158, 1585-1592 [7] Imhof, A. & Wolffe, A.P. (1998) Transcription: gene control by targeted historic acetylation. Curr Biol, 8, R422-R424. [8] Allfrey, V.G., Faulkner, R., & Mirsky, A.E. (1964) Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. U. S. A., SI, 786-794. [9] Adcock, I.M. & Ito, K. (2000) Molecular mechanisms of corticosteroid actions. Monaldi Arch Chest Dis, 55, 256-266. [10]Ito, K., Barnes, P.J., & Adcock, I.M. (2000) Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1 beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol, 20, 68916903. [1 IJBeato, M., Truss, M., & Chavez, S. (1996) Control of transcription by steroid hormones. Ann. N. Y. Acad. Sci. ,784,-1996. [12]McNally, J.G., Muller, W.G., Walker, D., Wolford, R., & Hager, G.L. (2000) The glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science, 287, 1262-1265. [13] Karin, M. (1998) New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable? Cell, 93,487-490. [14] Ding, X.F., Anderson, C.M., Ma, H., Hong, H., Uht, R.M., Kushner, P.J., & Stallcup, M.R. (1998) Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): multiple motifs with different binding specificities. Mol Endocrinoi, 12,302-313. [15]Vanden Berghe, W., Vermeulen, L., De Wilde, G., De Bosscher, K., Boone, E., & Haegeman, G. (20"00) Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem. Pharmacol., 60, 1185-1195. [16]Nissen, R.M. & Yamamoto, K.R. (2000) The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 14, 2314-2329. [17] Leung, D.Y., de Castro, M., Szefler, S.J., & Chrousos, G.P. (1998) Mechanisms of glucocorticoidresistant asthma. Ann. N. Y. Acad. Sci., 840, 735-746. [18]Adcock, I.M. (1996) Steroid resistance in asthma. Molecular mechanisms. Am J Respir Crit Care Med. 154,S58-S61. [19]Okamoto, K., Tanaka, H., Ogawa, H., Makino, Y., Eguchi, H., Hayashi, S., Yoshikawa, N., Poellinger, L., Umesono, K., & Makino, I. (1999) Redox-dependent regulation of nuclear import of the glucocorticoid receptor. J. Biol. Chem.,274, 10363-10371. [20]Galigniana, M.D., Piwien-Pilipuk, G., & Assreuy, J. (1999) Inhibition of glucocorticoid receptor binding by nitric oxide. Mol Pharmacol, 55, 317-323. [21] Ito, K., Lim, S., Caramon, G., Chung, K.F., Barnes, P.J., & Adcock, I.M. (2001) Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEBJ, 15, 1110-1112. [22] Ito, K., Hanazawa, T., Kharitonov, S.A., Tomita, K., Barnes, P.J., & Adcock, I.M. Tyrosine nitration and oxidative stress inhibit histone deactylase 2 activity and function. American Journal of Respiratory and Critical Care Medicine 163, A575. 2001.
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
159
Nitric Oxide Reactions in the Asthmatic Airway Raed A. DWEIK Department of Pulmonary and Critical Care Medicine Cleveland Clinic Foundation 9500 Euclid Avenue Cleveland Ohio 44195 U.S.A. Abstract. The dynamics of nitric oxide metabolism during an asthmatic response reveal multiple and sequential reactions, and suggest a multifunctional role for NO in the airway. In comparison to healthy controls, mild well-controlled atopic asthmatics tend to have increased NO, NO3", and nitrotyrosine but undetectable SNO in the lower airways. Within 10 min of antigen-induced asthmatic response, NO3" increases markedly in all asthmatics, while NO2" or SNO do not change, and NO tends to decrease. By 48 h after antigen-induced asthmatic response, NO, SNO and NO3" are strikingly increased. Despite notable changes in asthmatic airways, healthy control individuals have no changes in levels of NO or NO reaction products. Thus, these changes are distinct to atopic asthmatic individuals. Careful evaluation of the temporal sequence of NO reactions in the lower airway of asthmatics reveals that while NO may have some harmful effects, it also serves a protective role in the asthmatic response.
1. Nitric Oxide (NO) in Asthma The exhaled air of asthmatic individuals contains higher levels of NO than found in exhalate of healthy non-smoking individuals (1-7). The role of NO in asthma is unclear but studies suggest that NO relaxes bronchial smooth muscle leading to bronchodilatation, inhibits pro-inflammatory signaling events (8, 9) or conversely contributes to airway inflammation and injury through formation of toxic reactive nitrogen species (RNS) (10). Ultimately, the functional role of NO, as any molecule, will depend on both its concentration and association with other biomolecules and proteins (11). In this context, NO is a highly reactive molecule and exhaled NO likely represents only a fraction of the total NO in the lung. NO reacts with oxygen or reactive oxygen species (ROS) to form oxidation products, such as NO2", NO3~, and RNS (8, 10-13). NO or RNS may lead to nitration of tyrosine residues in proteins, or nitrosylation of biologic constituents to form S-nitrosothiols (SNO); 100% of NO reaction products are partitioned in the liquid phase of the lung (8, 10, 11, 13). Studying the temporal sequence of these
160
R.A. Dweik/Nitric Oxide Reactions in the Asthmatic Airway
downstream reaction products within airways during an asthmatic attack has greatly improved our understanding of the role(s) played by NO in asthma. 2. Antigen Challenge in the Study of Asthma Airway antigen (Ag) challenge has been used in atopic individuals as an experimental model to study mechanisms/mediators that lead to asthmatic responses and airway inflammation (14-19). Exposure of asthmatic individuals to appropriate Ag results in both an immediate asthmatic response occurring within minutes and a similar but prolonged late response after many hours. The immediate response has been associated with release of bronchoconstrictor mediators and ROS, and the late response with thickening of the airway mucosa by edema and inflammatory cell influx (14-19).
3. NO and NO Metabolite Levels Before and After Antigen Challenge NO in exhaled and intrapulmonary gases Intrapulmonary NO levels in the gas phase achieve a steady-state plateau which can be quantitated. Baseline intrapulmonary (plateau) NO in asthmatic airways are higher than controls. NO at 10 min after Ag challenge are similar to baseline levels, with only a small tendency to decrease NO in asthmatic airways. In contrast, intrapulmonary NO at 48 h after Ag challenge increases 2-fold in asthma but not in controls (Table). Exhaled NO at the mouth underestimates intrapulmonary NO in asthma but it clearly reflects the changes in intrapulmonary NO.
Table: Nitric oxide reaction products in the lower airway in asthma before and after antigen challenge. (t increased, «-> unchanged, I decreased) Compared to Compared to asthma baseline controls (before challenge) Baseline
10 minutes
48 hrs
NO
t
i
ttt
NO2"
<->
«•
<^
NO3"
t
t
tt
SNO
44
«+
tt
R.A. Dweik/Nitric Oxide Reactions in the Asthmatic Airway
NO2, NOi, and SNO in Bronchoalveolar Lavage (BAL) Fluid Total NO reaction products in BAL fluid tend to be higher in asthma at baseline. NO reaction products increase in asthmatics but not controls, after Ag challenge. The major NO reaction product in the healthy control is NOz", while NOs" is predominant in the asthmatic BAL fluid. Levels of NOi~ are remarkably similar in asthmatic and controls, with no changes during Ag challenge. In contrast, NOa" in asthmatic BAL fluid increases at 10 min of Ag challenge with further increases at 48 h, whereas control NOs" does not change (Table) (3). In contrast to healthy controls, SNO are undetectable in BAL fluid from asthmatics at baseline or 10 minutes after Ag challenge. However 48 h after Ag challenge, SNO in asthmatic BAL fluid increases and to levels similar to control levels (Table) (3). Nitrotyrosine in Endobronchial Biopsies Biopsies of asthmatic airways demonstrate thickened basement membranes, epithelial shedding and increased numbers of goblet cells at baseline. Immunoreactivity for nitrotyrosine is positive in epithelial cells of the asthmatic airways as compared to healthy control epithelial cells (4, 22, 23). At 48 h after Ag challenge, epithelial cells are lost, with areas of denuded basement membrane. Furthermore, prominent influx of eosinophils is noted in Ag challenged segments. Epithelial cells and eosinophils stain positive for nitrotyrosine. Due to marked loss of epithelial cells with Ag challenge, quantitation of nitrotyrosine at 48 hr Ag challenge was not possible. Semiquantitative assessment of the basal cells in epithelial biopsies at baseline revealed a tendency to more intense staining for nitrotyrosine in asthmatic as compared to control epithelium (3).
4. Role of NO Metabolism in the Pathophysiology of Asthma The key difference between asthmatics and controls is that NOa" in the asthmatic lung is higher than in controls at baseline and increases further within minutes of an antigen challenge (Table). Based upon the known chemistry of NO and the known (oxidizing and acidic) chemistry in the lower airway of asthmatic individuals (19, 25), we can construct a model of the events in the asthmatic airway and determine the pathways that may account for the enhanced formation of MV in asthma (Figure). Role of Oxyhemoglobin In the presence of the rich supply of oxyhemoglobin in the lung, reaction of NO with oxyhemoglobin results in NO3" (reaction A in the figure) (26). Although oxyhemoglobin concentration is the same in well-controlled asthmatic and healthy control lungs, enhanced formation of NOs" in asthmatic lungs at baseline may result from the increased NO generated in asthma (4). The lack of any significant increase of NO
162
R.A. Dweik/Nitric Oxide Reactions in the Asthmatic Airway
during the immediate asthmatic response indicates that this pathway (reaction A) is not the etiology of the rapid rise in NOs" within minutes of Ag challenge. Indeed the lack of immediate increase of intrapulmonary NO, but rather a tendency to decrease, suggests that NO is being consumed by a more rapid reaction. Given the assumption that the amount of oxyhemoglobin does not change in the asthmatic lung after a challenge, then the increased formation of NOs" likely results from a different reaction.
02
NOS
H
ONOOCC
NO|-^ONOQ02
RSNO
ONOOH
Fe-O
Figure 1. Model of NO reactions in the lung during an antigen-induced asthmatic response (from reference 3 with permission)
Role ofSuperoxide and Peroxynitrite A more likely reaction is the rapid generation of peroxynitrite (ONOO") via reaction of superoxide and NO (reaction B) (27, 28). Indeed, spontaneous asthma attacks and models of experimental antigen challenge are both associated with immediate release of superoxide (Or') which persists throughout the late asthmatic response (15-18). As early as 10 min following local instillation of antigen into airways of atopic individuals, Or is generated by airspace cells, with uM levels of superoxide at sites of Ag challenge (15-18). The oxidative environment in the airway during asthmatic response is confirmed by a decrease in reduced glutathione and increase in oxidized glutathione at 10 min following Ag challenge (19). Notably, NO undergoes a direct bimolecular reaction with O2-~ yielding ONOO" at almost diffusion-limited rates (28, 31, 32). The rate constant is over 3.5 times faster than the dismutation of O2'~ by superoxide dismutases (SOD). Taken together with the rapid loss of SOD activity during the immediate antigeninduced asthmatic response (19), this reaction (B) is overwhelmingly favored in the asthmatic airway.
R.A. Dweik/Nitric Oxide Reactions in the Asthmatic Airwav
163
Following NO reaction with superoxide and generation of ONOO", stopped flow experiments demonstrate peroxynitrite decay depends upon both COi and pH (reactions C and D) (29-31). At physiologic CO2 and pH, the CC>2 catalyzed decomposition of ONOO" is faster than the proton catalyzed decomposition/isomerization to NOs" (28, 29, 31). COi levels are relatively high in the lung (1.76 mM), and the reaction rate with ONOO" is one of the fastest for ONOO" that likely occurs in biologic systems (29, 31, 33). ONOO" and CO2 lead to nitrosoperoxycarbonate adduct (ONOOCO2~), which has a lifetime of < 3 ms (28, 31). On the basis of kinetics, ONOOCO2~ has enhanced nitrating capabilities as compared to ONOO" or ONOOH, such that nonenzymatic nitration of tyrosines becomes a physiologically significant process in cells (29, 31). In the absence of target molecules, decomposition of ONOOCO2" to NOs" occurs rapidly with regeneration of CX>2 (3). Protonation of ONOO" (reaction D) is markedly enhanced by acidification (27, 28, 31), and increased acidity occurs in asthmatic airway during an attack (25). The H+ in the asthmatic airway may reach levels of 6.3 uM, as opposed to H+ levels in the healthy airway of 22 nM (25). Thus, enhanced NOa" formation in asthmatic response is likely due to increased ROS and acidity in the asthmatic airway (3). NO{ is not involved Importantly, NO2~ is not predicted to increase in this proposed reaction scheme (3). The third order reaction of NO and O2 is relatively very slow in comparison to the rapid consumption of -NO by superoxide (27). Depending on the reactions available for NO, some fraction of the -NO in vivo reacts with molecular oxygen to yield NOi, and subsequently NO2~. While MV can be produced from dimerization of NO2 to yield N2O4 followed by nitrosation of water to give NO2~ and NOs", this is an unlikely route in biological systems since -NO2 is formed slowly at -NO concentrations found in vivo (3, 27). SNO and NO in the late Asthmatic Response While studies have shown that humans with severe asthma have low airway SNO (25), this is the first report that SNO is undetectable in airways of mild well-controlled asthmatic individuals. Low levels of SNO in asthma have been attributed to increased catabolic processes (34). Two soluble protein fractions have been identified from homogenates of rodent lung which specifically breakdown SNO and prevent airway smooth muscle relaxation in vitro (34). Furthermore, increased catabolic activity has been identified in rodent lung homogenates following ovalbumin sensitization. While enzymatic processes for SNO catabolism exist in neutrophils (34), neutrophils are <1% of cells in asthmatic and control lungs at baseline, and do not increase significantly at 10 min after allergen challenge (24). Thus, neutrophils are a less likely mechanism for low SNO in the asthmatic lung. Nevertheless, these findings indicate that SNO catabolism is
164
R.A. Dweik /Nitric Oxide Reactions in the Asthmatic Airway
accelerated in mild stable asthma as well as in severe asthma. Interestingly, SNO increases to "normal" during the late asthmatic response. SNO may be formed in the lung by organic or inorganic reactions. NO, present at high levels in asthmatic airways (4), may produce SNO under conditions in which glutathione levels are high, as found in the airway (8, 16, 34). Specifically, ONOO" may be scavenged by high thiol concentrations producing a source of SNO formation by NOS (35). Reactions between oxygen, superoxide and NO may also form nitrosating species in the oxidative environment of the asthmatic airway. Nitrosylation of thiols has also been proposed to occur via reaction with ONOOCO2~ or by formation of thiyl radicals (13, 27-29, 31). Oxygen dependent pathways for SNO formation through thiol autooxidation or NO2 formation may also be relevant in the oxidizing environment of the asthmatic lung (13). However, the fact that SNO increase during the late asthmatic response, and not in the immediate response, implies a mechanism of formation that may depend upon an influx of inflammatory cells and/or enzymatic processes, e.g. peroxidases (24). Overall, these findings support that the ongoing inflammation upregulates SNO catabolism in mild asthma, but that SNO formation overwhelms catabolism in the late asthmatic response, perhaps through enzymatic acceleration of reactions or acidification, which favor SNO synthesis and stability. NO increases only during the late asthmatic response (6, 7, 14). NO is endogenously produced in the lung by NO synthases (NOS) 1-3 (4, 36-38). Of the three enzymes, NOS2 expression is regulated primarily at the transcriptional level by cytokines (4, 36). Specifically, upregulation of NOS2 gene expression in airway epithelial cells occurs in a delayed fashion at 8 to 24 h following exposure to interferon-gamma in vitro (36, 37). The increase of NO during the late asthmatic response is consistent with a mechanism that may include upregulation of NOS2 gene expression by cytokines generated by cells recruited into Ag-challenged airways.
5. Conclusions NO reactions in the asthmatic airway suggest several relevant biologic functions for NO in the airway. NO rapidly consumes cytotoxic reactive oxygen species produced during the immediate asthmatic response. The reaction product ONOO7ONOOH is far less reactive than superoxide and leads to the accumulation of the innocuous product NOa". This immediate detoxification role for NO is supported by animal models of asthma in which inhibition of NO synthesis leads to worsening toxic reaction to an antigen challenge (6, 39, 40). Nitrosylation reactions predominate during the late asthmatic response with accumulation of SNO, which have been proposed as safe reservoirs for removal of toxic NO derivatives (13). While NO may have some harmful effects in the airways, the temporal sequence of NO participation in asthmatic airway chemical events suggests that NO may also serve a protective role in the asthmatic response.
R.A. Dweik/Nitric Oxide Reactions in the Asthmatic Airway
165
References [I] Persson, M.G., Zetterstrom, O., Agrenius, V., Ihre E., Gustafsson, L.E. (1994) Lancet 343, 146-147. [2] Kharitonov, S. A., Yates, D., Robbins, R.A., Logan-Sinclair, R., Shinebourne, E.A., Barnes, P.J. (1994) Lancet 343, 133-135. [3] Dweik RA, Comhair SAA, Gaston B, Thunnissen FBJM, Farver C, Thomassen MJ, Kavuru M, Hammel J, Abu-Soud HM, Erzurum SC (2001) Proceedings of the National Academy of Sciences (USA) 98, 2622-27. [4] Guo. F.H., Comhair, S.A.A., Zheng, S., Dweik, R.A., Eissa, N.T., Thomassen, M.J., Calhoun, W., Erzurum, S.C. (2000) J. Immunol. 164, 5970-5980. [5] Silkoff, P., Sylvester, J., Zamel, N., Permutt, S. (2000) Am. J. Respir. Crit. Care Med. 161, 1218-1228. [6] Mehta, S., Lilly, C., rotlenhagen, J., Haley, K., Asano, K., Drazen, J. (1997) Am. J. Physiol. 272, L124L131. [7] Kharitonov, S., O'connor B., Evans D., Barnes, P. (1995) Am. J. Respir. Crit. Care Med. 151, 18941899. Sanders, S. P. (1999). ,4m. J. Respir. Cell Mol. Biol. 21, 147-149. Raychaudhuri, B., Dweik, R., Connors, M.J., Buhrow, L.T., Malur, A., Drazba, J., Erzurum, S.C.. Kavuru, M.S., Thomassen, M.J. (1999) Am. J. Respir. Cell Mol. Biol. 21, 311-316. [10] van der Vliet, A., Elserich, J. P., Shigenaga, M. K., Cross, C. E.. (1999) Am. J. Respir. Crit. Care. Med. 160, 1-9. [ I I ] Dweik, R.A., Laskowski, D., Abu-Soud, H.M., Kaneko, F.T., Hutte, R., Stuehr, D.J., Erzurum, S.C, (1998)J. Clin. Inv. 101,660-666. [12] Wink, D. A., I. Hanbauer, M. B. Grisham, F. Laval, R. W. Nims, et al. (1996) Curr. Top. Cell. Regul. 34, 159-187. [13] Gaston, B., Sears, S., Woods, J., Hunt, J., Ponaman, M., McMahon, T., and Stamler, J.S. (1998) Lancet S S I , 1317-1319, [14] Thomassen, M.J., Raychaudhuri, B., Dweik, R.A., Farver, C., Buhrow, L.T., Malur, A., Hammel, J., Erzurum, S.C., Kavuru, M.S. (1999) J. Allergy Clin. Immunol. 104, 1174-1182. [ 15] Calhoun, W.J., Reed H.E., Moest, D.R., Stevens, C.A. (1992) Am. Rev. Respir Dis. 145, 317-325. [16] Liu, M.C., Hubbard, W.C., Proud, D., Stealey B, Galli, S, Gagey-Sobotka, A., Bieeker, E, Lichtrenstein, L. (1991) Am. Rev. Respir Dis. 144, 51-58. [17]Jourjour, N., Calhoun, W., Kelley, E.A., Gleich, G., Schwartz, L., Busse, W. (1997) Am. J. Respir. Crit. Care Med. 155, 1515-1521. [18] Sanders, S., Zweier, J., Harrison, S., Trush, M., Rembish, S., Liu, M. (1995) Am. J. Respir. Crit. Care Med. 151, 1725-1733. [19]Comhair, S.A.A., Bhathena, P.R., Dweik, R.A., Kavuru, M., Erzurum, S.C. (2000) Lancet 355, 624. [20] Guidelines for the diagnosis and the management of asthma, Expert panel report II. Bethesda, Md.: National Asthma Education and Prevention Program, April 1997. (NIH publication no. 97-4051.) [21] Fang, K., Ragsdale, N.V., Carey, R.M., Macdonald, T., and Gaston, B. (1998) Biochem. Biophys. Rex. Commun. 252, 535-540, [22] Kaminsky, D., Mitchell, J., Carroll N., James, A, Soultanakis, R., Janssen, Y. (1999) J. Allergy Clin. Immunol. 104, 747-754. [23]Saleh, D., Ernst, P., Lim, S., Barnes, P.J., Giaid, A. (1998) FASEB Journal. 12, 929-937. [24]Wu, W., Samoszuk, M., Comhair, S., Thomassen, M.J., Farver, C., Dweik, R.A., Kavuru, M.. Erzurum, S.C., Hazen, S.L. (2000) J. Clin. Inv. 105, 1455-1463. [25] Hunt, J., Fang, K., Malik, R., Snyder, A. Malhotra, N., Platts-Mills, T., Gaston, B. (2000) Am. ./., Respir. Crit. Care Med. 161, 694-699. [26]Fukuto J.M. (1995) in Nitric Oxide: Biochemistry, Molecular Biology, and Therapeutic Implications. eds. Ignarro L & Murad F (Academic Press), pp. 1-15. [27] Crow J.P., and Beckman J.S. (1995) in Nitric Oxide: Biochemistry, Molecular Biology, and Therapeutic Implications, eds. Ignarro, L & Murad, F. (Academic Press), pp. 17-43.
166
R.A. Dweik/Nitric Oxide Reactions in the Asthmatic Airway
[28] Freeman B.A, White C.R., Gutierrez H., Paler-Martinez A, Trapey M.M., Rubbo H. (1995) in Nitric Oxide: Biochemistry, Molecular Biology, and Therapeutic Implications, eds. Ignarro, L. & Murad. F. (Academic Press), pp. 45-69. [29]Radi R., Denicola A, Freeman B. (1999) Methods Enzymol. 301, 353-367. [30]Padmaja, S., Kissner, R., Bounds, P, Koppenol, W. (1998> Helv. Chim. Ada 7, 1201-1206. [31]Koppenol, W. (1999) in Metal tons In Biological Systems, eds. Sigel, A. & Sigel, H. (Marcel Dekker. New York), pp. 597-619. [32]Rochelle, L., Fischer, B., Adler, K. (1998) Free Radio. Biol. Med. 24, 863-868. [33]Pryor, W.A., Lemercier, J.N., Zhang, H., Uppu, R.M., Squadrito, G.L. (1997) Free Radic. Biol. Med. 23,331-338. [34] Fang, K., Johns, R., Macdonald, T., Kinter, M., Gaston, B. (2000> Am J Physiol. Lung Cell Mol. Physiol.23,Lll6-L72\. [35] Schmidt, H.H.H.W., Hofrnan, H., Schindler, U., Shutenko, Z.S., Cunningham, D.D., Feeelisch, M. Proc. Natl. Acad. Sci. USA. 93, 14492-14497. [36]Guo, F.H., Uetani, K., Haque, J., Williams, B.R.G., Dweik, R.A., Thunnissen, F.B.J.M., Calhoun, W.. Erzurum, S.C. (1997) J. Clin. Inv. 100, 829-838. [37] Uetani, K., Der, S.D., Zamanian-Daryoush, M., de La Motte, C., Lieberman, B.Y., Williams, B.R.. Erzurum, S.C. (2000) J. Immunol. 165, 988-996. [38] De Sanctis, G.T., MacLean, J.A., Hamada, K., Mehta, S., Scott, J.A., Jiao, A., Yandava, C.N., Kobzik, L., Wolyniec, W.W., Fabian, A.J., Venugopal, C.S., Grasemann, H., Huang, P.L., Drazen, J.M. (1999) J. Exp. Med. 189, 1621-1630. [39] Schuiling, M., Meurs, H., Zuidhof, A.B., Venema, N., Zaagsma, J. (1998) Am. J. Respir.Crit Care. Med.158, 1442-1449. [40] Ricciardolo, F.L., Geppetti, P., Mistretta, A., Nadel, J.A., Sapienza, M.A., Belloflore, S., Di Maria, G.U. (1996) Lancet. 348, 374-377.
Disease Markers in Exhaled Breath N. Marczin and M.H. Yacoub (Eds.) IOS Press, 2002
167
Regulation of pH in the Human Airway: Mechanisms and Monitoring John F. HUNT Division ofPediatric Respiratory Medicine, Box 800386 The University of Virginia Health System, Charlottesville, VA 22908, USA Phone: 804-924-1820; Fax: 804-243-5392. Email: jfh2m @ Virginia, edu Abstract. The pH of exhaled breath condensate (EBC) is measurable and stable after deaeration with Argon and is found to be moderately alkaline in healthy subjects. In contrast, in patients with asthma, EBC is prominently acidic and normalizes during corticosteroid therapy. Depletion of ammonia (NH3) in exhaled air is necessary but not sufficient for EBC acidification. Human airway epithelial cells respond to extracellular acidic challenge with upregulation of glutaminase activity and resultant release of ammonia. This process serves a pH homeostatic role that may be dysregulated by pro-inflammatory cytokines, allowing airway pH disturbance in inflammatory lung diseases. The measurement of EBC pH and NH3 allows simple non-invasive assays of biochemical processes relevant to lung disease in humans.
1. Introduction Nebulized acidic challenge to the airway is used in the research setting to induce bronchoconstriction, cough and pulmonary function changes[l-7] . Gastro-esophageal reflux disease is causally associated with chronic asthma symptoms by a mechanism attributable to microaspiration of acidic gastric fluid[8]. Inhalation of acid fog has been reported to be a risk factor for asthma hospitalization, bronchial hyperreactivity and decreased pulmonary function[9-15]. In the process of clarifying potential adverse effects of environmental acidic insult, investigators have identified that acidic airway pH (below 6.8) diminishes ciliary function[16], causes epithelial damage and sloughing[17], and alters mucous viscosity[18]. Eosinophils subjected to acidic stress in vitro undergo necrosis and release of inflammatory granule products [19]. Importantly, the chemistry of diverse chemical reactions—including those involving nitrogen oxides[20, 21]—is altered by protonation of the reactants. These observations are consistent with recent findings concerning airway pathophysiology in several lung diseases—most specifically asthma—and led to the hypothesis that airway acidification might also occur endogenously within the lung. In this regard, multiple biochemical processes release acids in the airway, especially so jn the setting of inflammation [22-25]. The condensable portion of exhaled breath (EBC) can be assayed for pH, and in addition, specific acids and bases can be measured that together contribute to final fluid pH.
168
J.F. Hunt / Regulation ofpH in the Human Airway